UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 20-F
(Mark One)
☐
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
For the fiscal year ended December 31, 2018
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
for the transition period from to
OR
☒
☐
☐
Date of event requiring this shell company report
Commission file number 001-38475
ASLAN Pharmaceuticals Ltd
(Exact name of Registrant as specified in its charter)
Not Applicable
(Translation of Registrant’s name into English)
Cayman Islands
(Jurisdiction of incorporation)
83 Clemenceau Avenue #12-03 UE Square
Singapore 239920
(address of principal executive offices)
Carl Firth
Chief Executive Officer and Chairman
ASLAN Pharmaceuticals Limited
83 Clemenceau Avenue #12-03 UE Square
Singapore 239920
(Name, Telephone, E-mail and/or Facsimile number and Address of Company Contact Person)
Securities registered or to be registered, pursuant to Section 12(b) of the Act:
Title of each class
American Depositary Shares (ADSs), each representing five ordinary shares, par value NT$10 per
ordinary share
Ordinary shares, par value NT$10 per share *
* Not for trading, but only in connection with the registration of the American Depositary Shares.
Securities registered or to be registered pursuant to Section 12(g) of the Act:
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:
None
None
Name of each exchange on which registered
The Nasdaq Global Market
The Nasdaq Global Market *
Indicate the number of outstanding shares of each of the issuer’s classes of capital stock or common stock as of the close of business covered by the annual report.
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒
Ordinary shares, par value NT$10 per share: 160,248,940 as of December 31, 2018
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Yes ☐ No ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period
that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” and
“emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Non-accelerated filer
☐
☒
Accelerated filer
Emerging growth company
☐
☒
If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards † provided pursuant to Section 13(a) of the Exchange Act. ☐
† The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.
Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:
U.S. GAAP ☐
International Financial Reporting Standards as issued
by the International Accounting Standards Board ☒
Other ☐
If “Other” has been checked in response to the previous question indicate by check mark which financial statement item the registrant has elected to follow. Item 17 ☐ Item 18 ☐
If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
TABLE OF CONTENTS
Page
Presentation of Financial and Other Information
Cautionary Statement Regarding Forward-Looking Statements
PART I
ITEM 1.
IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS
ITEM 2.
OFFER STATISTICS AND EXPECTED TIMETABLE
ITEM 3.
ITEM 4.
KEY INFORMATION
A. Selected financial data
B. Capitalization and indebtedness
C. Reasons for the offer and use of proceeds
D. Risk factors
INFORMATION ON THE COMPANY
A. History and development of the company
B. Business overview
C. Organizational structure
D. Property, plant and equipment
ITEM 4A.
UNRESOLVED STAFF COMMENTS
ITEM 5.
ITEM 6.
ITEM 7.
ITEM 8.
OPERATING AND FINANCIAL REVIEW AND PROSPECTS
A. Operating results
B. Liquidity and capital resources
C. Research and development, patents and licenses, etc.
D. Trend information
E. Off-balance sheet arrangements
F. Tabular disclosure of contractual obligations
G. Safe Harbor
DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES
A. Directors and senior management
B. Compensation
C. Board practices
D. Employees
E. Share ownership
MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS
A. Major shareholders
B. Related party transactions
C. Interests of experts and counsel
FINANCIAL INFORMATION
A. Consolidated statements and other financial information
B. Significant Changes
1
4
5
7
7
7
7
7
8
8
8
54
54
55
104
105
105
105
105
115
121
121
121
121
122
122
122
126
131
135
136
136
136
138
139
139
139
140
THE OFFER AND LISTING
A. Offer and listing details
B. Plan of distribution
C. Markets
D. Selling shareholders
E. Dilution
F. Expense of the issue
ADDITIONAL INFORMATION
A. Share capital
B. Memorandum and articles of association
C. Material contracts
D. Exchange controls
E. Taxation
F. Dividends and paying agents
G. Statement by experts
H. Documents on display
I. Subsidiary information
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
A. Foreign Exchange Risk
B. Interest rate risk
DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES
A. Debt Securities
B. Warrants and Rights
C. Other Securities
D. American Depositary Shares
ITEM 9.
ITEM 10.
ITEM 11.
ITEM 12.
PART II
ITEM 13.
DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES
ITEM 14.
MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS
ITEM 15.
CONTROLS AND PROCEDURES
A. Audit committee financial expert
B. Code of Ethics
C. Principal Accountant Fees and Services
D. Exemptions from the Listing Standards for Audit Committees
E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers
F. Changes in Registrant’s Certifying Accountant
G. Corporate Governance
H. Mine Safety Disclosure
ITEM 16
PART III
ITEM 17.
FINANCIAL STATEMENTS
2
140
140
140
140
140
140
140
141
141
141
158
158
158
165
165
165
166
166
166
167
168
168
168
168
168
172
172
172
172
172
173
173
173
174
174
174
175
175
175
ITEM 18.
FINANCIAL STATEMENTS
ITEM 19.
EXHIBITS
175
175
3
GENERAL INFORMATION
Unless otherwise indicated or the context otherwise requires, all references in this Annual Report to the terms “ASLAN,” “ASLAN
Pharmaceuticals,” “the company,” “we,” “us” and “our” refer to ASLAN Pharmaceuticals Limited and its subsidiaries.
PRESENTATION OF FINANCIAL AND OTHER INFORMATION
Our consolidated financial statements have been prepared in accordance with International Financial Reporting Standards, or IFRS, as issued by
the International Accounting Standard Board, or IASB, which may differ in material respects from generally accepted accounting principles in
other jurisdictions, including the United States.
Our functional currency is the U.S. dollar. Unless otherwise specified, all monetary amounts presented are in U.S. dollars. All references in this
Annual Report to “$” mean U.S. dollars, all references in this Annual Report to “NT$” mean New Taiwan dollars, the legal currency of the
Republic of China, or ROC, and all references in this Annual Report to “SG$” mean Singapore dollars, the legal currency of Singapore. No
representation is made that the New Taiwan dollar amounts referred to herein could have been or could be converted into U.S. dollars at any
particular rate or at all. Any discrepancies in any table between totals and sums of the amounts listed are due to rounding.
We have made rounding adjustments to some of the figures included in this Annual Report . Accordingly, numerical figures shown as totals in
some tables may not be an arithmetic aggregation of the figures that preceded them.
4
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS
This Annual Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended (Exchange Act), that involve substantial risks and uncertainties. In some cases,
you can identify forward-looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,”
“objective,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and “ongoing,” or the negative of these terms, or other
comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and
other important factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the
information expressed or implied by these forward-looking statements. The forward-looking statements and opinions contained in this Annual
Report on Form 20-F are based upon information available to us as of the date of this Annual Report and, while we believe such information
forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate
that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. Forward-looking statements
include statements about:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
the outcome, cost and timing of our product development activities and clinical trials;
our plans and expected timing with respect to regulatory filings and approvals;
our ability to fund our operations;
our plans to develop and commercialize our product candidates and expand our development pipeline;
our ability to enter into a transaction with respect to commercialization of our products and product candidates;
the size and growth potential of the markets for our product candidates, and our ability to serve those markets;
our sales and marketing strategies and plans;
potential market acceptance of our product candidates;
potential regulatory developments in the United States and foreign countries;
the performance of our third party suppliers and manufacturers;
our ability to compete with other therapies that are or become available;
our expectations regarding the period during which we qualify as an emerging growth company (EGC) under the Jumpstart Our
Business Startups Act (JOBS Act);
our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and
our expectations regarding the terms of our patents and ability to obtain and maintain intellectual property protection for our product
candidates.
5
You should refer to the section titled “Item 3.D. Risk Factors” for a discussion of important factors that may cause our actual results to differ
materially from those expressed or implied by our forward-looking statements. As a result of these factors, we cannot assure you that the
forward-looking statements in this Annual Report will prove to be accurate. Furthermore, if our forward-looking statements prove to be
inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard
these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time
frame, or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future
events or otherwise, except as required by law. We claim the protection of the safe harbor for forward-looking statements contained in the
Private Securities Litigation Reform Act of 1995 for all forward-looking statements.
You should read this Annual Report and the documents that we reference in this Annual Report, completely and with the understanding that our
actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary
statements.
Unless otherwise indicated, information contained in this Annual Report on Form 20-F concerning our industry and the markets in which we
operate, including our general expectations and market position, market opportunity and market size estimates, is based on information from
independent industry analysts, third-party sources and management estimates. Management estimates are derived from publicly available
information released by independent industry analysts and third-party sources, as well as data from our internal research, and are based on
assumptions made by us based on such data and our knowledge of such industry and market, which we believe to be reasonable. In addition,
while we believe the market opportunity information included in this Annual Report on Form 20-F is generally reliable and is based on
reasonable assumptions, such data involve risks and uncertainties and are subject to change based on various factors, including those discussed
under the section of this Annual Report on Form 20-F titled “Item 3.D—Risk Factors.”
6
PART I
Item 1. Identity of Directors, Senior Management and Advisers
Not applicable.
Item 2. Offer Statistics and Expected Timetable
Not applicable.
Item 3. Key Information
A.
Selected financial data.
The following selected consolidated statement of comprehensive loss data for the years ended December 31, 2016, 2017 and 2018 and the
selected consolidated balance sheet data as of December 31, 2017 and 2018 have been derived from our audited consolidated financial
statements included elsewhere in this Annual Report on Form 20-F. Our historical results for any period are not necessarily indicative of results
to be expected for any future period. The selected consolidated financial data should be read in conjunction with, and are qualified in their
entirety by reference to, our audited consolidated financial statements and related notes and “Item 5. Operating and Financial Review and
Prospects” below.
2016
Year ended December 31,
2017
(in thousands, except share and per share data)
2018
Selected Consolidated Statement of
Comprehensive Loss Data:
Net revenues
Cost of revenues
Operating expenses
General and administrative expenses
Research and development expenses
Loss from operations
Non-operating income and expenses
Interest income
Other income
Other gains and losses
Finance costs
Total non-operating income and expenses
Loss before income tax
Income tax expense
Net loss
Weighted-Average shares used in
calculating net loss per ordinary shares,
basic
Net loss per share, basic
11,547
(125)
(6,956)
(13,165)
(8,699)
47
—
127
(524)
(350)
(9,049)
—
(9,049)
—
—
(8,759)
(30,381)
(39,140)
363
—
(698)
(417)
(752)
(39,892)
—
(39,892)
—
—
(10,514)
(31,834)
(42,348)
268
187
213
(492)
177
(42,171)
(14)
(42,186)
105,027,040
(0.09)
124,424,960
(0.32)
149,739,242
(0.28)
7
As of December 31,
2017
2018
(in thousands)
$
50,573 $
51,334
5,979
9,841
41,514
35,513
130,128,940
28,909
52,881
7,998
14,264
51,627
30,618
160,248,940
Selected Consolidated Balance Sheet Data:
Cash and cash equivalents
Total assets
Total current liabilities
Total non-current liabilities
Capital Stock - Ordinary Shares
Total equity
Number of shares issued
B.
Capitalization and indebtedness.
Not applicable
C.
Reasons for the offer and use of proceeds.
Not applicable
D.
Risk factors.
An investment in our American Depositary Shares (ADSs) involves a high degree of risk. You should carefully consider the following information
about these risks, together with the other information appearing elsewhere in this Annual Report, before deciding to invest in our ADSs. The
occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future
growth prospects. In these circumstances, the market price of our ADSs could decline, and you could lose all or part of your investment.
Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations and
price of our ADSs.
Risks Related to Our Financial Condition and Need for Additional Capital
We have incurred significant losses since our inception and anticipate that we will continue to incur significant losses for the foreseeable
future.
We are a clinical-stage oncology and inflammatory disease focused biopharmaceutical company based in Singapore developing novel
therapeutics for global markets. We target diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe.
Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and
significant risk that any potential product candidate will not demonstrate adequate effectiveness in the targeted indication or an acceptable safety
profile, gain regulatory approval or become commercially viable. All of our product candidates will require substantial additional development
time and resources before we would be able to apply for or receive regulatory approvals and begin generating revenue from product sales. We are
not profitable and have incurred significant net losses in each year since our inception, including net losses of $9.0 million, $39.9 million and
$42.2 million for fiscal years 2016, 2017 and 2018, respectively. As of December 31, 2018, we had an accumulated deficit of $132.5 million.
8
We have devoted substantially all our financial resources to developing our product candidates and targeted discovery work, including preclinical
development activities and clinical trials. We expect to continue to incur substantial and increased expenses, losses and negative cash flows as we
expand our development activities and advance our clinical programs, particularly with respect to our planned clinical development for varlitinib,
ASLAN003 and ASLAN004, as well as the ASLAN005 discovery program. If our product candidates are not successfully developed or
commercialized, including because of a lack of capital, or if we do not generate enough revenue following marketing approval, we will not
achieve profitability and our business may fail. Even if we successfully obtain regulatory approval to market our product candidates in the United
States and Europe, our revenue will also be heavily dependent upon the size of the markets outside of the United States and Europe, in particular
China and Japan, as well as our ability to obtain market approval and achieve commercial success in those markets.
We currently do not generate any revenue from product sales, have generated only limited revenue since inception, and may never be
profitable.
We do not anticipate generating revenue from sales of our proprietary product candidates for the foreseeable future. Our ability to generate future
revenue from product sales depends on our success in completing clinical development of, obtaining regulatory approval for, and launching and
successfully commercializing any product candidates.
Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to predict the timing or
amount of increased expenses, when, or if, we will begin to generate revenue from product sales, or when, or if, we will be able to achieve or
maintain profitability. In addition, our expenses could increase beyond planned levels if we are required by the U.S. FDA to perform studies in
addition to those that we currently anticipate or if such studies are larger, take longer or are otherwise more expensive to conduct than we expect.
Even if one or more of our product candidates is approved for commercial sale, to the extent we do not engage a third-party collaborator, we
anticipate incurring significant costs associated with commercializing any approved product candidate. Even if we are able to generate revenue
from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations.
We will need to obtain substantial additional financing for our operations, and if we fail to obtain additional financing, we may be forced to
delay, reduce or eliminate our product development programs or commercialization efforts.
Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive and we have consumed substantial
amounts of capital since inception. To date, we have financed our operations through government subsidies and grants, collaboration payments
and the sale of equity securities and convertible debt. We will need substantial additional financing to continue our operations and do not expect
revenues from product sales or potential licensing transactions to be sufficient to offset our development expenses as we advance our clinical
programs, including varlitinib.
9
As of December 31, 2018, we had cash and cash equivalents of approximately $28.9 million and working capital of $21.0 million. Based upon
our current operating plan, we believe that our existing cash and cash equivalents will enable us to fund our operating expenses and capital
requirements for at least the next 12 months. Regardless of our expectations as to how long our existing cash and cash equivalents will fund our
operations, changing circumstances beyond our control may cause us to consume capital more rapidly than we currently anticipate. For example,
our clinical trials may encounter technical, enrollment or other difficulties that could increase our development costs more than we expect. We
may also incur expenses as we create additional infrastructure to support our planned commercialization efforts and our operations as a U.S.
public company. In any event, we will require additional capital prior to completing pivotal studies of (except with respect to varlitinib in biliary
tract cancer), filing for regulatory approval for, or commercializing, varlitinib, ASLAN003, ASLAN004 or any of our other preclinical product
candidates.
We cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we are unable to raise
additional capital when required or on acceptable terms, we may be required to:
•
•
•
•
significantly delay, scale back or discontinue the development or commercialization of our product candidates;
seek corporate partners for our product candidates when we would otherwise develop our product candidates on our own, or at an
earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available;
relinquish or license on unfavorable terms, our rights to technologies or product candidates that we otherwise would seek to develop
or commercialize ourselves; or
significantly curtail or cease operations.
If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will be prevented from pursuing development
and commercialization efforts, which will have an adverse effect on our business, operating results and prospects.
Risks Related to Clinical Development and Regulatory Approval
We are heavily dependent on the success of varlitinib, as well as ASLAN003 and ASLAN004. We cannot give any assurance that any of
varlitinib, ASLAN003 or ASLAN004 will successfully complete clinical development or receive regulatory approval, which is necessary
before they can be commercialized.
Our business and future success is substantially dependent on our ability to successfully develop, obtain regulatory approval for, and successfully
commercialize our lead program, varlitinib, as well as ASLAN003 and ASLAN004. Any delay or setback in the development of any of our
product candidates, could adversely affect our business and cause the price of our ADSs or ordinary shares to decline. Should our planned
clinical development of our more advanced product candidates fail to be completed in a timely manner or at all, we will need to rely on our other
product candidates, which will require additional time and resources to obtain regulatory approval and proceed with commercialization. We
cannot assure you that our planned clinical development for varlitinib or our other product candidates will be completed in a timely manner, or at
all, or that we will be able to obtain approval for varlitinib or any of our product candidates from the U.S. FDA, the Chinese National Medical
Products Administration, or NMPA (formerly China Food and Drug Administration, or CFDA), or any comparable foreign regulatory authority.
10
Clinical development is a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be
predictive of future trial results. Failure can occur at any stage of clinical development. We have never completed a pivotal clinical trial for
our product candidates or submitted a New Drug Application, or NDA, or a Biologics License Application, or BLA, to the U.S. FDA or
similar drug approval filings to comparable foreign authorities.
Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during
the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results
of subsequent clinical trials. We have a limited operating history and to date have not demonstrated our ability to complete large scale pivotal
clinical trials.
Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through
preclinical studies and initial clinical trials. In addition to the safety and efficacy traits of any product candidate, clinical trial failures may result
from a multitude of factors including flaws in trial design, dose selection, placebo effect and patient enrollment criteria. A number of companies
in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles,
notwithstanding promising results in earlier trials. Based upon negative or inconclusive results, we or any potential future collaborator may
decide, or regulators may require us, to conduct additional clinical trials or preclinical studies. In addition, data obtained from trials and studies
are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do, which may delay, limit or prevent
regulatory approval. Our future clinical trials may not be successful.
If any product candidate is found to be unsafe or lack efficacy, we will not be able to obtain regulatory approval for it and our business may be
materially harmed. For example, if the results of our ongoing pivotal studies for varlitinib in biliary tract cancer, our ongoing Phase 2 clinical
trial of ASLAN003 in AML, our ongoing Phase 1 clinical trial of ASLAN004 in atopic dermatitis, or any other clinical trials for these product
candidates demonstrate unexpected safety findings or do not achieve the primary efficacy endpoints, the prospects for approval of these product
candidates, as well the price of our ADSs and ordinary shares and our ability to create shareholder value would be materially and adversely
affected.
In some instances, there can be significant variability in safety and/or efficacy results between different trials of the same product candidate due
to numerous factors, including changes in trial protocols, differences in composition of the patient populations, adherence to the dosing regimen
and other trial protocols and the dropout rate among clinical trial participants. For example, we could be required to use a primary endpoint in
our pivotal studies that is different from endpoints in our Phase 2 clinical trials, which could result in negative or less compelling efficacy results
in pivotal trials despite promising results in Phase 2 clinical trials. We do not know whether any future clinical trials we may conduct will
demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to market our product candidates. If we are unable to bring
any of our current or future product candidates to market, our ability to create long-term shareholder value will be limited.
11
Delays in clinical trials are common and have many causes, and any delay could result in increased costs to us and jeopardize or delay our
ability to obtain regulatory approval and commence product sales.
We may experience delays in clinical trials of our product candidates. Our planned clinical trials may not begin on time, have an effective design,
enroll a sufficient number of patients, or be completed on schedule, if at all. Our clinical trials can be delayed for a variety of reasons, including:
•
•
•
•
•
•
•
•
•
•
•
inability to raise funding necessary to initiate or continue a trial;
delays in obtaining regulatory approval to commence a trial;
delays in reaching agreement with the U.S. FDA, NMPA or other regulatory authorities on final trial design;
imposition of a clinical hold for safety reasons or following an inspection of our clinical trial operations or trial or manufacturing sites
by the U.S. FDA, NMPA or other regulatory authorities;
delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites;
delays in obtaining required institutional review board, or IRB, approval at each site;
delays in recruiting suitable patients to participate in a trial;
delays in having patients complete participation in a trial or return for post-treatment follow-up;
clinical sites dropping out of a trial to the detriment of enrollment;
time required to add new clinical sites; or
delays by our contract manufacturers to produce and deliver sufficient supply of clinical trial materials.
We could also experience delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our
product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be
suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted, any data monitoring committee for such
trial, or by the U.S. FDA, NMPA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in
accordance with regulatory requirements or our clinical protocols, inspection of clinical trial or manufacturing sites by the U.S. FDA, NMPA or
other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a
benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the
clinical trial. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and while we
have agreements governing their committed activities, we have limited influence over their actual performance. If we experience termination of,
or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed,
and our ability to generate product revenues will be delayed. In addition, any delays in completing our clinical trials will increase our costs and
slow down our product development and approval process. Any of these occurrences may harm our business, prospects, financial condition and
results of operations significantly. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may
also ultimately lead to the denial of regulatory approval for our product candidates.
12
Because we have multiple product candidates in our clinical pipeline and are considering a variety of target indications, we may expend our
limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may
be more profitable or for which there is a greater likelihood of success.
Because we have limited financial and managerial resources, we must focus our research and development efforts on those product candidates
and specific indications that we believe are the most promising. As a result, we may forego or delay pursuit of opportunities with other product
candidates or other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to
capitalize on viable commercial products or profitable market opportunities.
We may in the future spend our resources on other research programs and product candidates for specific indications that ultimately do not yield
any commercially viable products. For example, one component of our business strategy is to build a broad immuno-oncology portfolio based on
antibodies which inhibit specific immune checkpoints in ways that we believe will enable us to simultaneously target multiple pathways.
However, these antibodies have not been proven and we cannot assure you that they will be viable candidates for preclinical development, that
we will be able to target multiple pathways simultaneously or that our estimates for the resultant pipeline will prove accurate. In addition, the
costs, time and resources required to successfully move these antibodies into development may be greater than our estimates. Furthermore, if we
do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that
product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us
to retain sole development and commercialization rights.
Our product candidates may cause adverse events or have other properties that could delay or prevent their regulatory approval or limit the
scope of any approved label or market acceptance.
Adverse events, or AEs, caused by our product candidates or other potentially harmful characteristics of our product candidates could cause us,
other reviewing entities, clinical trial sites or regulatory authorities to interrupt, delay or halt clinical trials and could result in the denial of
regulatory approval. For example, across all varlitinib clinical trials, the most commonly occurring drug-related AEs as of December 31, 2018
were nausea (36% of patients with any grade, 1% with grade 3 or 4), diarrhea (32% of patients with any grade, 3% with grade 3 or 4) and fatigue
(32% of patients with any grade, 4% with grade 3 or 4). Grade refers to the severity of the AE, with grade 3 indicating a severe or medically
significant but not immediately life-threatening AE, grade 4 indicating an AE with potentially life-threatening consequences, and grade 5
meaning patient death.
Patients admitted to our varlitinib clinical trials are experiencing later stages of cancer and may be in a diminished physical state prior to entering
our clinical trials, which put them at increased risk of death. These patients may die while receiving our drug candidates. In such circumstances,
it may not be possible to exclude with certainty a causal relationship to varlitinib. For example, across our varlitinib clinical trials, seven patient
deaths (grade 5) that were possibly related to the varlitinib treatment occurred. One death was related to disease progression (worsening of
metastatic breast cancer), one death was related to acute kidney injury, one death was due to liver failure leading to multi-organ failure and
sepsis, one death was related to hemorrhage of upper gastrointestinal tract, one death was related to heart failure, one death was related to
polymicrobial bacteremia due to hepatobiliary sepsis and one death was related to condition deterioration with suspected cholangiogenic
infection. These deaths were reported to the appropriate regulatory authorities as “possibly related” to varlitinib because the immediate cause of
the patient’s death could not be determined, and therefore, a relationship to varlitinib could not be excluded.
13
Serious adverse events observed in any of our clinical trials may adversely impact our ability to obtain regulatory approval for our product
candidates. Further, if any of our approved products cause serious or unexpected side effects after receiving market approval, a number of
potentially significant negative consequences could result, including:
•
•
•
•
•
regulatory authorities may withdraw their approval of the product or impose restrictions on its distribution;
regulatory authorities may require the addition of labeling statements, such as warnings or contraindications;
we may be required to change the way the product is administered or conduct additional clinical studies;
we could be sued and held liable for harm caused to patients; or
our reputation may suffer.
Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidate and could substantially
increase the costs of commercializing our product candidates.
The regulatory approval processes of the U.S. FDA, NMPA and comparable foreign authorities are lengthy, time consuming and
inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be
substantially harmed.
The time required to obtain approval by the U.S. FDA, NMPA and comparable foreign authorities is unpredictable but typically takes many years
following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory
authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the
course of a product candidate’s clinical development and may vary among jurisdictions. For example, we cannot guarantee that our ongoing
pivotal clinical trials of varlitinib in biliary tract cancer will be sufficient to warrant accelerated approval or that our Phase 2 clinical trials of
ASLAN003 in AML or Phase 1 clinical trials of ASLAN004 in atopic dermatitis will be sufficient to allow subsequent development or that the
U.S. FDA or comparable foreign regulatory authorities will not require additional or different clinical trials prior to subsequent development of
ASLAN003 or ASLAN004 or that the required primary endpoints in subsequent pivotal trials or other clinical trials will be different than those
in Phase 2 clinical trials.
Our product candidates could fail to receive regulatory approval for many reasons, including the following:
•
•
•
•
•
the U.S. FDA or comparable foreign regulatory authorities may disagree with the design, scope or implementation of our clinical
trials;
we may be unable to demonstrate to the satisfaction of the U.S. FDA or comparable foreign regulatory authorities that a product
candidate is safe and effective for its proposed indication;
the results of clinical trials may not meet the level of statistical significance required by the U.S. FDA or comparable foreign
regulatory authorities for approval;
we may be unable to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks;
the U.S. FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or
clinical trials;
14
•
•
•
the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA, BLA or
other submission or to obtain regulatory approval in the United States or elsewhere;
the U.S. FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party
manufacturers with which we contract for clinical and commercial supplies; and
the approval policies or regulations of the U.S. FDA or comparable foreign regulatory authorities may change significantly in a
manner rendering our clinical data insufficient for approval.
This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval
to market our product candidates, which would harm our business, results of operations and prospects significantly.
In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited
indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance
of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or
desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could harm the commercial prospects
for our product candidates.
We have not previously submitted an NDA, BLA or any similar drug approval filing to the U.S. FDA or any comparable foreign authority for
any product candidate, and we cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory
approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive
regulatory approvals for our product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory
approvals to market one or more of our product candidates, our revenue will be dependent, to a significant extent, upon the size of the markets in
the territories for which we gain regulatory approval. If the markets for patients or indications that we are targeting are not as significant as we
estimate, we may not generate significant revenue from sales of such products, if approved.
Pharmaceutical companies in China are required to comply with extensive regulations and hold a number of permits and licenses to carry on
their business. Our ability to obtain and maintain these regulatory approvals is uncertain, and future government regulation may place
additional burdens on our efforts to commercialize our product candidates.
The pharmaceutical industry in China is subject to extensive government regulation and supervision. The regulatory framework addresses all
aspects of operating in the pharmaceutical industry, including approval, registration, production, distribution, packaging, labelling, storage and
shipment, advertising, licensing and certification requirements and procedures, periodic renewal and reassessment processes, registration of new
drugs and environmental protection. In order to commercialize our product candidates and manufacture and distribute pharmaceutical products in
China, we are required to:
•
•
obtain a pharmaceutical manufacturing permit and good manufacturing practices, or cGMP, certificate for each production facility
from the NMPA and its relevant branches for trading and distribution of drugs not manufactured by the drug registration certificate
holder;
obtain a drug registration certificate, which includes a drug approval number, from the NMPA for each drug manufactured by us;
15
•
•
obtain a pharmaceutical distribution permit and good supply practice, or GSP, certificate from the NMPA and its relevant branches;
and
renew the pharmaceutical manufacturing permits, the pharmaceutical distribution permits, drug registration certificates, cGMP
certificates and GSP certificates every five years, among other requirements.
If we are unable to obtain or renew such permits or any other permits or licenses required for our operations, will not be able to engage in the
commercialization, manufacture and distribution of our product candidates and our business may be adversely affected.
The regulatory framework governing the pharmaceutical industry in China is subject to change and amendment from time to time. The Chinese
government has introduced various reforms to the Chinese healthcare system in recent years and may continue to do so, with an overall objective
to expand basic medical insurance coverage and improve the quality and reliability of healthcare services. The specific regulatory changes under
the reform still remain uncertain. The implementing measures to be issued may not be sufficiently effective to achieve the stated goals, and as a
result, we may not be able to benefit from such reform to the level we expect, if at all. Moreover, the reform could give rise to regulatory
developments, such as more burdensome administrative procedures, which may have an adverse effect on our business and prospects.
Even if we obtain regulatory approval for our product candidates, we will still face extensive regulatory requirements and our products may
face future development and regulatory difficulties.
Even if we obtain regulatory approval in the United States, China or other markets, the U.S. FDA, NMPA or other regulatory authorities, as
applicable, may still impose significant restrictions on the indicated uses or marketing of our product candidates, or impose ongoing
requirements for potentially costly post-approval studies or post-market surveillance. Our product candidates, if approved, will also be subject to
ongoing U.S. FDA, NMPA and/ or other applicable regulatory requirements governing the labeling, packaging, storage, distribution, safety
surveillance, advertising, promotion, record-keeping and reporting of safety and other post-market information. The holder of an approved NDA
or BLA is obligated to monitor and report AEs and any failure of a product to meet the specifications in the NDA or BLA, as applicable. The
holder of an approved NDA or BLA must also submit new or supplemental applications and obtain U.S. FDA approval for certain changes to the
approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with U.S. FDA rules and are
subject to U.S. FDA review, in addition to other potentially applicable federal and state laws.
In addition, manufacturers of drug products and their facilities are subject to payment of user fees and continual review and periodic inspections
by the U.S. FDA, NMPA and other regulatory authorities for compliance with current good manufacturing practices, or cGMP, and adherence to
commitments made in the NDA. If we or a regulatory agency discovers previously unknown problems with a product, such as AEs of
unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose
restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or
suspension of manufacturing.
If we fail to comply with applicable regulatory requirements following approval of a product candidate, a regulatory agency may:
•
•
issue a warning letter asserting that we are in violation of the law;
seek an injunction or impose civil or criminal penalties or monetary fines;
16
•
•
•
•
•
suspend or withdraw regulatory approval;
suspend any ongoing clinical trials;
refuse to approve a pending NDA or supplements to an NDA submitted by us;
seize product; or
refuse to allow us to enter into supply contracts, including government contracts.
In particular, we may seek accelerated approval from the U.S. FDA for our product candidates which will likely require a further confirmatory
trial. If this confirmatory trial is not successful, we will be required to withdraw our product candidate from the U.S. market and potentially other
markets. For instance, we intend to seek accelerated approval for varlitinib in second-line biliary tract cancer.
Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could
generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our products and
generate revenue.
In addition, if any of our product candidates are approved and we are found to have improperly promoted off-label uses of those products, we
may become subject to significant liability. The U.S. FDA and other regulatory agencies strictly regulate the promotional claims that may be
made about prescription products, such as our product candidates, if approved. In particular, a product may not be promoted for uses that are not
approved by the U.S. FDA or such other regulatory agencies as reflected in the product’s approved labeling. However, companies may share
truthful and not misleading information that is otherwise consistent with the product’s FDA approved labeling. For example, if we receive
marketing approval for varlitinib as a treatment for biliary tract cancer, physicians may nevertheless use our product for their patients in a
manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant
liability, which would materially adversely affect our business and financial condition.
Even if we obtain U.S. FDA approval for our product candidates in the United States, we may never obtain approval to commercialize our
product candidates outside of the United States, which would limit our ability to realize their full market potential.
In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements
of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other
countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval
processes vary among countries and can involve additional product testing and validation and additional administrative review periods.
17
Seeking foreign regulatory approval could result in difficulties and costs for us and require additional non-clinical studies or clinical trials which
could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the
introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including
international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with
regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets
are delayed, our target market will be reduced and our ability to realize the full market potential of our products will be harmed.
If we fail to develop, acquire or in-license other product candidates or products, our business and prospects will be limited.
Our long-term growth strategy is to develop, acquire or in-license and commercialize a portfolio of product candidates in addition to varlitinib
and our other existing product candidates. Identifying, selecting and acquiring or licensing promising product candidates requires substantial
technical, financial and human resources expertise. Efforts to do so may not result in the actual development, acquisition or license of a particular
product candidate, potentially resulting in a diversion of our management’s time and the expenditure of our resources with no resulting benefit. If
we are unable to add additional product candidates to our pipeline, our long-term business and prospects will be limited.
We rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their
contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates
and our business could be substantially harmed.
We have relied upon and plan to continue to rely upon third-party CROs to conduct our preclinical studies and clinical trials, including
investigator-initiated studies sponsored by the investigator’s institution, and control only certain aspects of their activities. Nevertheless, we are
responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards
and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with U.S. FDA
laws and regulations regarding current good clinical practice, or cGCP, which are also required by the Competent Authorities of the Member
States of the European Economic Area and comparable foreign regulatory authorities in the form of International Council for Harmonization, or
ICH, guidelines for all of our products in clinical development. Regulatory authorities enforce cGCP through periodic inspections of trial
sponsors, principal investigators and trial sites. If we or any of our CROs fail to comply with applicable cGCP, the clinical data generated in our
clinical trials may be deemed unreliable and the U.S. FDA or comparable foreign regulatory authorities may require us to perform additional
clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such
regulatory authority will determine that any of our clinical trials comply with cGCP regulations. In addition, our U.S. clinical trials must be
conducted with product produced under cGMP regulations. While we have agreements governing activities of our CROs, we have limited
influence over their actual performance. In addition, portions of the clinical trials for our product candidates are expected to be conducted at
various locations great distances from where our principal operations are located in Singapore, which will make it more difficult for us to
monitor CROs and perform visits of our clinical trial sites and will force us to rely heavily on CROs to ensure the proper and timely conduct of
our clinical trials and compliance with applicable regulations, including cGCP. Failure to comply with applicable regulations in the conduct of
the clinical trials for our product candidates may require us to repeat clinical trials, which would delay the regulatory approval process.
18
Some of our CROs have an ability to terminate their respective agreements with us if, among other reasons, it can be reasonably demonstrated
that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our
creditors or if we are liquidated. If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements
with alternative CROs or to do so on commercially reasonable terms. In addition, our CROs are not our employees, and except for remedies
available to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our
preclinical and clinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they
need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical
protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to
obtain regulatory approval for or successfully commercialize our product candidates. Consequently, our results of operations and the commercial
prospects for our product candidates would be harmed, our costs could increase substantially and our ability to generate revenue could be
delayed significantly.
Switching or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition
period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical
development timelines. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter
challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition
and prospects.
Risks Related to Our Business Operations and Industry
Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.
We are highly dependent on the principal members of our executive team listed under “Management” located elsewhere in this Annual Report,
the loss of whose services may adversely impact the achievement of our objectives. While we have entered into employment agreements with
each of our executive officers, any of them could leave our employment at any time, subject to any applicable notice requirements. Recruiting
and retaining other qualified employees for our business, including scientific and technical personnel, will also be critical to our success.
Competition for skilled personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable
terms given the competition among numerous pharmaceutical companies for individuals with similar skill sets. In addition, failure to succeed in
clinical studies may make it more challenging to recruit and retain qualified personnel. The inability to recruit or loss of the services of any
executive or key employee might impede the progress of our development and commercialization objectives.
We will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.
As of December 31, 2018, we had 56 full-time employees. In connection with our January 2019 corporate restructuring plan, we reduced our
total workforce by approximately 30%. In the future we may expand our employee base to increase our managerial, scientific, clinical,
operational, financial and other resources, to add a sales and marketing function and to hire more consultants and contractors. Future growth
would impose significant additional responsibilities on our management, including the need to identify, recruit, maintain, motivate and integrate
additional employees, consultants and contractors. Also, our management may need to divert a disproportionate amount of its attention away
from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be
19
able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, give rise to operational
mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Future growth could require
significant capital expenditures and may divert financial resources from other projects, such as the development of our existing or future product
candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to
generate and grow revenue could be reduced, and we may not be able to implement our business strategy. Our future financial performance and
our ability to commercialize our product candidates, if approved, and compete effectively will depend, in part, on our ability to effectively
manage any future growth.
We may undertake internal restructuring activities in the future that could result in disruptions to our business or otherwise materially harm
our results of operations or financial condition.
From time to time we may undertake internal restructuring activities as we continue to evaluate and attempt to optimize our cost and operating
structure in light of developments in our business strategy and long-term operating plans. For example, we initiated a corporate restructuring in
January 2019 that resulted in a reduction in our workforce. Any such restructuring activities may result in write-offs or other restructuring
charges. There can be no assurance that any restructuring activities that we have undertaken or undertake in the future will achieve the cost
savings, operating efficiencies or other benefits that we may initially expect. Restructuring activities may also result in a loss of continuity,
accumulated knowledge and inefficiency during transitional periods and thereafter. In addition, internal restructurings can require a significant
amount of time and focus from management and other employees, which may divert attention from commercial operations. If any internal
restructuring activities we have undertaken or undertake in the future fail to achieve some or all of the expected benefits therefrom, our business,
results of operations and financial condition could be materially and adversely affected.
The terms of our Loan Agreement with CSL Finance place restrictions on our operating and financial flexibility. If we raise additional
capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.
In connection with the license agreement with CSL Limited related to ASLAN004, in May 2014 we entered into a loan agreement with CSL
Finance Pty Ltd, or CSL Finance, pursuant to which CSL Finance agreed to provide a ten-year facility for $4.5 million, or the CSL
Facility. Borrowings under the CSL Facility are unsecured and can be used to reimburse a portion of eligible invoices for certain research and
development costs or expenses incurred by us in connection with developing ASLAN004 and approved by CSL Finance at each drawdown
period. In addition, we are required to mandatorily prepay amounts outstanding if we receive any income or revenue in connection with the
commercialization or out-licensing of any intellectual property rights (other than under the license agreement with CSL Limited related to
ASLAN004), in which case we are required to apply at least a low double digit percentage of such income or revenue against any amounts then-
outstanding under the CSL Facility. Under the CSL Facility, we are subject to customary reporting and restrictive covenants. If an event of
default occurs, CSL Finance can terminate the commitment under the CSL Facility and accelerate all amounts outstanding.
Further, if we are liquidated, CSL Finance’s right to repayment would be senior to the rights of the holders of our ordinary shares to receive any
proceeds from the liquidation. Any declaration by CSL Finance of an event of default could significantly harm our business and prospects and
could cause the price of our ordinary shares to decline. If we raise any additional debt financing, the terms of such additional debt could further
restrict our operating and financial flexibility.
20
We face potential product liability, and, if successful claims are brought against us, we may incur substantial liability.
The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of
product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies or
others selling or otherwise coming into contact with our products and product candidates. If we cannot successfully defend against product
liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may
result in:
•
•
•
•
•
•
•
impairment of our business reputation;
withdrawal of clinical trial participants;
costs due to related litigation;
distraction of management’s attention from our primary business;
substantial monetary awards to patients or other claimants;
the inability to commercialize our product candidates; and
decreased demand for our product candidates, if approved for commercial sale.
Our current clinical trial liability insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover,
insurance coverage is becoming increasingly expensive and in the future we may not be able to maintain insurance coverage at a reasonable cost
or in sufficient amounts to protect us against losses due to liability. If and when we obtain marketing approval for our product candidates, we
intend to expand our insurance coverage to include the sale of commercial products; however, we may be unable to obtain product liability
insurance on commercially reasonable terms or in adequate amounts. On occasion, large judgments have been awarded in class action lawsuits
based on drugs that had unanticipated adverse effects. A successful product liability claim or series of claims brought against us could cause the
price of our ADSs or ordinary shares to decline and, if judgments exceed our insurance coverage, could adversely affect our results of operations
and business.
Our internal computer systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could
result in a material disruption of our operations.
Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are
vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical
failures. Such events could cause interruptions of our operations. For instance, the loss of preclinical study or clinical trial data involving our
product candidates could result in delays in our development and regulatory filing efforts and significantly increase our costs. In addition, theft or
other exposure of data may interfere with our ability to protect our intellectual property, trade secrets, and other information critical to our
operations. We can provide no assurances that certain sensitive and proprietary information relating to one or more of our product candidates has
not been, or will not in the future be, compromised. There can be no assurances we will not experience unauthorized intrusions into our computer
systems, or those of our CROs and other contractors and consultants, that we will successfully detect future unauthorized intrusions in a timely
manner, or that future unauthorized intrusions will not result in material adverse effects on our financial condition, reputation, or business
prospects.
21
Certain data breaches must also be reported to affected individuals and the government, and in some cases to the media, under provisions of the
U.S. Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic
and Clinical Health Act, or HITECH, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union
Data Protection Directive, and financial penalties may also apply.
Our insurance policies may not be adequate to compensate us for the potential losses arising from breaches, failures or disruptions of our
infrastructure, catastrophic events and disasters or otherwise. In addition, such insurance may not be available to us in the future on economically
reasonable terms, or at all. Further, our insurance may not cover all claims made against us and defending a suit, regardless of its merit, could be
costly and divert management’s attention.
Furthermore, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and
significantly increase our costs to recover or reproduce the data. Likewise, we rely on other third parties for the manufacture of our product
candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our
business.
In addition to in-licensing or acquiring product candidates, we may engage in future business acquisitions that could disrupt our business,
cause dilution to our ADS holders and harm our financial condition and operating results.
While we currently have no specific plans to acquire any other businesses, we have, from time to time, evaluated acquisition opportunities and
may, in the future, make acquisitions of, or investments in, companies that we believe have products or capabilities that are a strategic or
commercial fit with our current product candidates and business or otherwise offer opportunities for our company. In connection with these
acquisitions or investments, we may:
•
•
•
issue shares that would dilute our ADS holders’ percentage of ownership;
incur debt and assume liabilities; and
incur amortization expenses related to intangible assets or incur large write-offs.
We also may be unable to find suitable acquisition candidates and we may not be able to complete acquisitions on favorable terms, if at all. If we
do complete an acquisition, we cannot assure you that it will ultimately strengthen our competitive position or that it will not be viewed
negatively by customers, financial markets or investors. Further, future acquisitions could also pose numerous additional risks to our operations,
including:
•
•
•
•
•
•
•
problems integrating the purchased business, products or technologies;
increases to our expenses;
the failure to have discovered undisclosed liabilities of the acquired asset or company;
diversion of management’s attention from their day-to-day responsibilities;
harm to our operating results or financial condition;
entrance into markets in which we have limited or no prior experience; and
potential loss of key employees, particularly those of the acquired entity.
22
We may not be able to complete one or more acquisitions or effectively integrate the operations, products or personnel gained through any such
acquisition without a material adverse effect on our business, financial condition and results of operations.
Our Asia development platform is unproven and may not result in the competitive advantages we anticipate.
We have built a development platform centered in Asia that is designed to enable us to accelerate the development of drugs which target Asia
prevalent diseases and which we believe can generate data suitable for submission to regulators in the United States, Europe, China and Japan.
Although data collected in Asia from the varlitinib biliary tract cancer clinical trial as well as other varlitinib clinical data have been submitted to
a number of regulatory authorities, including the U.S. FDA, the NMPA, the Pharmaceutical and Medical Devices Agency, or PMDA, the Health
Sciences Authority in Singapore, the Taiwan Food and Drug Administration and the Ministry of Food and Drug Safety in South Korea, and after
reviewing the data these health authorities have each agreed to include patients from their respective countries in the varlitinib biliary tract
cancer clinical trials, we cannot guarantee this result will hold true in the future. Regulatory authorities could potentially reject Asia data if they
believe that the Asian disease population is substantially different from the disease population in their particular country. Furthermore, while we
have shown in certain cases that the pharmacokinetics in Asian and Caucasian patients are similar, we cannot guarantee that this will hold true
more generally or in the future, or with respect to other ethnicities. While we believe our platform in Asia offers us an opportunity to accelerate
the development of novel therapies in diseases where either the diseases are more prevalent or the availability of suitable patients in clinical trials
is greater, an Asia-focused development platform is a relatively novel approach to drug development and has not yet resulted in a proven track
record of accelerated development or regulatory approval.
Furthermore, drug development focused in Asia may be subject to a number of risks and uncertainties. We cannot assure you that governments of
Asian countries will not enact regulations or incentives that favor local pharmaceutical companies over foreign-owned pharmaceutical
companies. Any developments in Asia that make clinical development costlier or more time-consuming could delay our development timelines
and materially harm our business and results of operations.
Our operations across Asia could be subject to natural disasters, health epidemics and other business disruptions, which could have a
material adverse effect on our business, results of operation and financial condition.
Our operations, and in particular our clinical trials, are being conducted across areas of Asia that may be prone to natural disasters, such as
earthquakes, cyclones, monsoons and floods, which could cause interruptions to our operations. In addition, the areas in which our clinical trials
could be adversely affected by the outbreak of influenza A (H1N1), avian influenza (H7N9), severe acute respiratory syndrome (SARS) or other
pandemics.
Any occurrence of these natural disasters or pandemic diseases or other adverse public health developments in the areas in which we operate our
clinical trials could disrupt or delay our business operations or clinical development, which could materially adversely affect our business.
23
Our business is subject to economic, political, regulatory and other risks associated with international operations.
As a company based in Singapore with an Asia based development platform, our business is subject to risks associated with conducting business
outside of the United States. Many of our suppliers and collaborative and clinical trial relationships are located outside the United States.
Accordingly, our future results could be harmed by a variety of factors, including:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
economic weakness, including inflation, or political instability;
differing and changing regulatory requirements for drug approvals;
differing jurisdictions could present different issues for securing, maintaining or obtaining freedom to operate in such jurisdictions;
potentially reduced protection for intellectual property rights;
difficulties in compliance with local laws and regulations;
changes in local regulations and customs, tariffs and trade barriers;
changes in currency exchange rates, including the Singapore dollar, and currency controls;
changes in a specific country’s or region’s political or economic environment;
the relationship between Singapore and other countries, including China;
trade protection measures, import or export licensing requirements or other restrictive actions;
differing reimbursement regimes and price controls;
negative consequences from changes in tax laws;
compliance with tax, employment, immigration and labor laws for employees;
workforce uncertainty in countries where labor unrest is more common than in the United States;
difficulties associated with staffing and managing international operations, including differing labor relations;
production shortages resulting from any events affecting raw material supply or manufacturing capabilities; and
business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters including typhoons, floods
and fires.
More specifically, the economy in Asia differs from most developed markets in many respects, including the level of government involvement,
level of development, growth rate, control of foreign exchange, government policy on public order and allocation of resources. In some of the
Asian markets, governments continue to play a significant role in regulating industry development by imposing industrial policies. Moreover,
some local governments also exercise significant control over the economic growth and public order in their respective jurisdictions through
allocating resources, controlling payment of foreign currency-denominated obligations, setting monetary policies, and providing preferential
treatment to particular industries or companies. In addition, some Asian markets have experienced, and may in the future experience, political
instability, including strikes, demonstrations, protests, marches, coups d’état, guerilla activity or other types of civil disorder. These instabilities
and any adverse changes in the political environment could increase our costs, increase our exposure to legal and business risks, or disrupt our
clinical operations.
24
European data collection is governed by restrictive regulations governing the use, processing, and cross-border transfer of personal
information.
The collection and use of personal data in the European Union are governed by the General Data Protection Regulation, or GDPR. The GDPR
imposes stringent requirements for controllers and processors of personal data, including, for example, more robust disclosures to individuals and
a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention of information, increased
requirements pertaining to special categories of data, such as health data, and additional obligations when we contract with third-party processors
in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European
Union to the United States and other third countries. In addition, the GDPR provides that European Union member states may make their own
further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.
The GDPR applies extraterritorially, and we may be subject to the GDPR because of our data processing activities that involve the personal data
of individuals located in the European Union, such as in connection with any European Union clinical trials. Failure to comply with the
requirements of the GDPR and the applicable national data protection laws of the European Union member states may result in fines of up to
€20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative
penalties. GDPR regulations may impose additional responsibility and liability in relation to the personal data that we process and we may be
required to put in place additional mechanisms to ensure compliance with the new data protection rules. This may be onerous and may interrupt
or delay our development activities, and adversely affect our business, financial condition, results of operations and prospects.
Risks Related to Our Intellectual Property
If we are unable to obtain or protect intellectual property rights related to our current product candidates or any future product candidates
which we may develop, we may not be able to compete effectively in our market.
We rely upon a combination of patents, trade secret protection, confidentiality agreements and proprietary know-how, and intend to seek
marketing exclusivity for any approved product, in order to protect the intellectual property related to product candidates. The strength of patents
in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that
we own or in-license may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign
countries for a number of reasons, including because of a finding of lack of novelty or that the claimed inventions are already in the public
domain. If this were to occur, early generic competition could be expected against our product candidates. Even if patents do successfully issue,
third parties may challenge their validity, enforceability or scope, which may result in such patents being invalidated or deemed as not infringing.
Also, a third party may challenge our ownership of patents and patent applications assigned to us, or may challenge our exclusive rights to
patents and patent applications that we license from third parties. Furthermore, even if they are unchallenged, our patents and patent applications
may not adequately protect our intellectual property or prevent others from designing around our claims. If the patent applications we hold with
respect to our other product candidates fail to issue or if their breadth or strength of protection is threatened, it could dissuade companies from
collaborating with us to develop them, and threaten our ability to commercialize any resulting products. We cannot offer any assurances about
which, if any, applications will issue as patents or whether any issued patents will be found not invalid and not unenforceable or will go
unthreatened by third parties. Further, if we encounter delays in regulatory approvals, the period of time during which we could market our
product candidates under patent protection could be reduced. Furthermore, patent applications by third parties can result in an interference
proceeding in the United States being invoked by a third party or instituted by us to determine who was the first to invent any of the subject
matter covered by the patent claims of our applications or patents.
25
In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-
how that is not patentable, processes for which patents are difficult to enforce and any other elements of our drug development process that
involve proprietary know-how, information or technology that is not covered by patents. Although we generally require all of our employees to
assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how,
information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly
executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain
access to our trade secrets or independently develop substantially equivalent information and techniques. If we are unable to prevent material
disclosure of the non-patented intellectual property related to our technologies to third parties, and there is no guarantee that we will have any
such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could
materially adversely affect our business, results of operations and financial condition.
We may not be able to protect our intellectual property and proprietary rights throughout the world.
Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and the
laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Consequently, we may not be able to
prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using
our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not
obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have
patent protection but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or
other intellectual property rights may not be effective or sufficient to prevent them from competing.
Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The
legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other
intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products
in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in
foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents
at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to
assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be
commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be
inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.
Several countries have compulsory licensing laws under which, in certain circumstances, a patent owner may be compelled to grant licenses to
third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these
countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is
forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our
business, financial condition, results of operations, and prospects may be adversely affected.
26
In China, the validity, enforceability and scope of protection available under the relevant intellectual property laws are uncertain and still
evolving. Implementation and enforcement of Chinese intellectual property-related laws have historically been inconsistent. Accordingly,
intellectual property and confidentiality legal regimes in China may not afford protection to the same extent as in the United States or other
countries. Policing unauthorized use of proprietary technology is difficult and expensive, and we may need to resort to litigation to enforce or
defend patents issued to us or to determine the enforceability, scope and validity of our proprietary rights or those of others. The experience and
capabilities of Chinese courts in handling intellectual property litigation varies, and outcomes are unpredictable. Further, such litigation may
require a significant expenditure of cash and may divert management’s attention from our operations, which could harm our business, financial
condition and results of operations. An adverse determination in any such litigation could materially impair our intellectual property rights and
may harm our business, prospects and reputation in China.
If we fail to comply with our obligations in the agreements under which we license rights to technology from third parties, or if the license
agreements are terminated for other reasons, we could lose license rights that are important to our business.
We are a party to a number of technology licenses that are important to our business and expect to enter into additional licenses in the future. For
example, our rights to varlitinib are the subject of an exclusive license agreement with Array. If we fail to comply with our obligations under our
agreement with Array (including, among other things, if we fail to use commercially reasonable efforts to develop and commercialize varlitinib)
or our other license agreements, or we are subject to insolvency or liquidation, the licensor may have the right to terminate the license. In
addition, under our agreement with Array, in the event of a change of control, we may be required to make additional payment to Array if the
change of control meets specified conditions. In the event that any of our important technology licenses were to be terminated by the licensor, we
would likely cease further development of the related program. See “Item 4.B. Information on the Company - Business overview—License and
Collaboration Agreements” for a description of our license agreements, which includes a description of the termination provisions of these
agreements.
We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual
property that we own, which are described elsewhere under “Risks Related to Our Intellectual Property.” If we or our licensors fail to adequately
protect this intellectual property, our ability to commercialize products could suffer.
Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.
Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial
amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and
pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and inter party reexamination proceedings before
the U.S. Patent and Trademark Office, or the USPTO. Numerous U.S. and foreign issued patents and pending patent applications, which are
owned by third parties, exist in the fields in which we and our collaborators are developing product candidates. As the biotechnology and
pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of
infringement of the patent rights of third parties.
27
Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent
applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our
product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later
result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of
our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the
manufacturing process of any of our product candidates, any drug substance formed during the manufacturing process or any final product itself,
the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtain a license under the
applicable patents, or until such patents are invalidated or expire. Similarly, if any third-party patent were held by a court of competent
jurisdiction to cover aspects of our formulations or methods of use, the holders of any such patent may be able to block our ability to develop and
commercialize the applicable product candidate formulation or use unless we obtain a license or until such patent expires. In either case, such a
license may not be available on commercially reasonable terms or at all.
Parties making claims against us may request and/or obtain injunctive or other equitable relief, which could effectively block our ability to
further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve
substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of
infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, obtain
one or more licenses from third parties, pay royalties or redesign our infringing products or manufacturing processes, which may be impossible
or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would
be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties
to advance our research, manufacture clinical trial supplies or allow commercialization of our product candidates. We may fail to obtain any of
these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or
more of our product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not
exist which might be enforced against our products, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an
obligation on our part to pay royalties and/or other forms of compensation to third parties.
We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming
and unsuccessful.
Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file
infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of
ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that
our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our
patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.
28
Interference proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our
patents or patent applications or those of our collaborators or licensors. An unfavorable outcome could require us to cease using the related
technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a
license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in
substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation
of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.
Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some
of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of
the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be
negative, it could have a material adverse effect on the price of our ADSs.
Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and
other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance
with these requirements.
Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of
the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee
payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of
a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can (i) result in abandonment
or lapse of, or (ii) otherwise affect the patentability of, the patent or patent application, resulting in partial or complete loss of patent rights in the
relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not
limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit
formal documents. If we or our licensors that control the prosecution and maintenance of our licensed patents fail to maintain the patents and
patent applications covering our product candidates, our competitors might be able to enter the market, which would have a material adverse
effect on our business.
In addition, as licensees we may not be responsible for or have control over the prosecution or enforceability of our licensed patents. In such
cases, we have to rely on the licensor to comply with the requisite obligations of the patent offices, including the duty of disclosure, filing
assignments, etc. We cannot guarantee that all of these duties have been or will be complied with. As licensees, we may not be in a position to
assess if these duties have been complied with or have the ability to complete these duties on behalf of the licensor. Failure to comply with such
duties may affect the enforceability of the patent rights.
29
We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential
information of third parties.
We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that
we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our
employees’ former employers or other third parties. We may also be subject to claims that former employers or other third parties have an
ownership interest in our patents. Litigation may be necessary to defend against these claims. There is no guarantee of success in defending these
claims, and if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.
Although we have obtained orphan drug designation for varlitinib in gastric cancer and cholangiocarcinoma, a form of biliary tract cancer,
and for ASLAN003 in AML in the United States, we may not be able to obtain or maintain the benefits associated with orphan drug status,
including market exclusivity.
Regulatory authorities in some jurisdictions, including the United States and the European Union, may designate drugs for relatively small
patient populations as orphan drugs. Under the Orphan Drug Act, the U.S. FDA may designate a drug as an orphan drug if it is intended to treat a
rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States. We
have obtained orphan drug designation for varlitinib in gastric cancer and cholangiocarcinoma from the U.S. FDA, as well as for varlitinib in
biliary tract cancer from the Ministry of Food and Drug Safety in South Korea. We have also obtained orphan drug designation from the U.S.
FDA for ASLAN003 in AML. Generally, if a drug with an orphan drug designation subsequently receives the first marketing approval for the
indication for which it has such designation, the drug may be entitled to a period of marketing exclusivity, which precludes the U.S. FDA from
approving another marketing application for the same molecule for the same indication for that time period. We can provide no assurance that
another drug will not receive marketing approval prior to our product candidates. The applicable period is seven years in the United States and
ten years in Japan and the European Union. The exclusivity period in the European Union can be reduced to six years if a drug no longer meets
the criteria for orphan drug designation or if the drug is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug
exclusivity may be lost if the U.S. FDA determines that the request for designation was materially defective or if the manufacturer is unable to
assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. In addition, even after a drug is granted
orphan exclusivity and approved, the U.S. FDA can subsequently approve another drug for the same condition before the expiration of the seven
year exclusivity period if the U.S. FDA, concludes that the later drug is clinically superior in that it is shown to be safer, more effective or makes
a major contribution to patient care.
If our trademarks and tradenames are not adequately protected, then we may not be able to build name recognition in our markets and our
business may be adversely affected.
We have registered or applied to register certain trademarks to protect our company name and plan to apply to register trademarks to cover
product names in the future once our product candidates are closer to commercialization. We cannot assure you that our trademark applications
will be approved or that we will seek registered trademark protection for each of our product names in each jurisdiction in which we operate.
During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we
may be unable to overcome such rejections. In addition, in proceedings before the USPTO and in proceedings before comparable agencies in
many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek
30
to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive
such proceedings. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in
loss of brand recognition and could require us to devote resources toward advertising and marketing new brands. Further, we cannot assure you
that competitors will not infringe our trademarks or that we will have adequate resources to enforce our trademarks.
Risks Related to Commercialization of Our Product Candidates
Our commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians,
healthcare payors, patients and the medical community.
Even if we obtain regulatory approval for our product candidates, the product may not gain market acceptance among physicians, healthcare
payors, patients and the medical community, which is critical to commercial success. Market acceptance of any product candidate for which we
receive approval depends on a number of factors, including:
•
•
•
•
•
•
•
•
•
•
•
the efficacy and safety as demonstrated in clinical trials;
the timing of market introduction of the product candidate as well as competitive products;
the clinical indications for which the product candidate is approved;
acceptance by physicians, the medical community and patients of the product candidate as a safe and effective treatment and also the
willingness of physicians to prescribe a drug based on an active pharmaceutical ingredient, or API, that is less familiar to them than
other drug APIs;
the convenience of prescribing and initiating patients on the product candidate;
the potential and perceived advantages of such product candidate over alternative treatments;
the cost of treatment in relation to alternative treatments, including any similar generic treatments;
favorable pricing and the availability of coverage and adequate reimbursement by third-party payors, such as government authorities;
relative convenience and ease of administration;
the prevalence and severity of adverse side effects; and
the effectiveness of sales and marketing efforts.
If our product candidates are approved but fail to achieve an adequate level of acceptance by physicians, healthcare payors, patients and the
medical community, we will not be able to generate significant revenue, and we may not become or remain profitable. In addition, even if any of
our product candidates gain acceptance, the markets for the treatment of patients with our target indications may not be as significant as we
estimate.
31
Our organization has no prior sales and marketing experience and resources.
We have never, as an organization, commercialized a product and there is no guarantee that we will be able to do so successfully. We will need to
establish a commercial team and hire sales forces in the geographies where we are permitted and intend to market our drugs. We will also need to
develop a marketing team and strategy in order to successfully market and sell our product candidates, which will require significant time and
resources and the development of our ability to market and sell our product and generate revenues from our product candidates may be delayed
or limited. We cannot assure you that our sales efforts will be effective or produce the results we expect. We will be competing with other
pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. Further, we may face difficulties or
delays in obtaining and maintaining the required licenses and permits to sell our product candidates in individual states and jurisdictions. If our
commercialization of varlitinib or our other product candidates is unsuccessful or perceived as disappointing, the price of our ADSs could
decline significantly and the long-term success of the product and our company could be harmed.
We may also seek to establish collaborations with pharmaceutical companies to maximize the potential of our products in other markets. For
example, we are conducting a Phase 1 clinical trial to develop ASLAN004 in atopic dermatitis, and, in the future, we may seek a global partner
to support Phase 3 clinical trials and potential commercialization. We may not be successful in establishing development and commercialization
collaborations which could adversely affect, and potentially prohibit, our ability to develop our product candidates.
If our planned targeted commercial organization in the United States and selected Asian markets is not as successful as we anticipate, we
may be unable to generate any revenue.
Although we have started building a targeted commercial organization, we currently have a very limited commercial organization and capability,
and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any products
that may be approved, we must build sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to
perform these services. We may enter into strategic partnerships with third parties to commercialize our product candidates.
Part of our business strategy is to establish collaborative relationships to commercialize and fund development and approval of certain of our
product candidates. We may not succeed in establishing and maintaining collaborative relationships, which may significantly limit our ability
to develop and commercialize products, for which we pursue this commercialization strategy.
We will need to establish and maintain successful collaborative relationships to obtain sales, marketing and distribution capabilities for the
product candidates we do not intend to commercialize ourselves. The process of establishing and maintaining collaborative relationships is
difficult, time-consuming and involves significant uncertainty, including:
•
•
we may have limited control over the decisions of any partners and they may change the priority of any programs in a manner that
would result in termination or significant delays to a partnered program;
our ability to generate future payments and royalties from any partners will depend upon the ability of a partner to obtain regulatory
approvals and achieve market acceptance of products developed from our product candidates;
32
•
•
•
a partner may fail to properly initiate, maintain or defend our intellectual property rights, where applicable, or a party may use our
proprietary information in such a way as to invite litigation that could jeopardize or potentially invalidate our proprietary information
or expose us to potential liability;
a partner may not devote sufficient capital or resources towards our product candidates; and,
a partner may not comply with applicable government regulatory requirements necessary to successfully market and sell our products.
If any collaborator fails to fulfill its responsibilities in a timely manner, or at all, any clinical development, manufacturing or commercialization
efforts pursuant to that collaboration could be delayed or terminated, or it may be necessary for us to assume responsibility for expenses or
activities that would otherwise have been the responsibility of our collaborator. If we are unable to establish and maintain collaborative
relationships on acceptable terms or to successfully and timely transition terminated collaborative agreements, we may have to delay or
discontinue further development of one or more of our product candidates, undertake development and commercialization activities at our own
expense or find alternative sources of capital.
Attempting to secure additional financing for a product candidate may also lead to the risks discussed under the risk factor titled “We will need to
obtain substantial amounts of financing for our operations, and if we fail to obtain additional financing, we may be forced to delay, reduce or
eliminate our product development programs or commercialization efforts” described above.
We rely completely on third parties to manufacture our preclinical and clinical drug supplies and we intend to rely on third parties to produce
commercial supplies of any approved product candidate.
If we were to experience an unexpected loss of supply of our product candidates for any reason, whether as a result of manufacturing, supply or
storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, clinical
trials. We do not currently have nor do we plan to acquire the infrastructure or capability internally to manufacture our preclinical and clinical
drug supplies and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. The
facilities used by our contract manufacturers or other third-party manufacturers to manufacture our product candidates must be approved by the
U.S. FDA, NMPA or other regulators pursuant to inspections. While we work closely with our third-party manufacturers on the manufacturing
process for our product candidates, including quality audits, we generally do not control the implementation of the manufacturing process of, and
are completely dependent on, our contract manufacturers or other third-party manufacturers for compliance with cGMP regulatory requirements
and for manufacture of both active drug substances and finished drug products. If our contract manufacturers or other third-party manufacturers
cannot successfully manufacture material that conforms to applicable specifications and the strict regulatory requirements of the U.S. FDA,
NMPA or other regulators, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we
have no control over the ability of our contract manufacturers or other third-party manufacturers to maintain adequate quality control, quality
assurance and qualified personnel. If the U.S. FDA, NMPA or other regulators do not approve these facilities for the manufacture of our product
candidates or if they withdraw any such approval in the future, we may need to find alternative manufacturing facilities, which could take several
years and would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved.
33
We rely on our manufacturers to purchase from third-party suppliers the materials necessary to produce our product candidates for our clinical
trials. There are a limited number of suppliers for raw materials that we use to manufacture our product candidates and there may be a need to
assess alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our product candidates for our
clinical trials, and if approved, for commercial sale. We do not have any control over the process or timing of the acquisition of these raw
materials by our manufacturers. Although we generally do not begin a clinical trial unless we believe we have a sufficient supply of a product
candidate to complete the clinical trial, any significant delay in the supply of a product candidate, or the raw material components thereof, for an
ongoing clinical trial due to the need to replace a contract manufacturer or other third-party manufacturer could considerably delay completion of
our clinical trials, product testing and potential regulatory approval of our product candidates. If our manufacturers or we are unable to purchase
these raw materials after regulatory approval has been obtained for our product candidates, the commercial launch of our product candidates
would be delayed or there would be a shortage in supply, which would impair our ability to generate revenue from the sale of our product
candidates.
We expect to continue to depend on contract manufacturers or other third-party manufacturers for the foreseeable future, and our requirements
for and dependence upon these third-party manufacturers will increase when and if one or more of our product candidates is approved and
commercialized. We have not entered into any long-term commercial supply agreements with our current contract manufacturers or with any
alternate contract manufacturers. Although we intend to do so prior to any commercial launch of our product candidates, if approved by the U.S.
FDA, in order to ensure that we maintain adequate supplies of finished drug product, we may be unable to enter into such an agreement or do so
on commercially reasonable terms, which could have a material adverse impact upon our business, including delaying a product launch or
subjecting our commercialization efforts to significant supply risk. Even if we are able to enter into long-term agreements with manufacturers for
commercial supply on reasonable terms, we may be unable to do so with sufficient time prior to the launch of our product candidates, which
would expose us to substantial supply risk and potentially jeopardize our launch. See “Item 4.B. Information on the Company - Business
overview—Manufacturing” for additional information.
Manufacturing issues may arise that could increase product and regulatory approval costs or delay commercialization.
As we scale up manufacturing of our product candidates and conduct required stability testing, product, packaging, equipment and process-
related issues may require refinement or resolution in order to proceed with our planned clinical trials and obtain regulatory approval for
commercial marketing. In the future, we may identify impurities, which could result in increased scrutiny by the regulatory agencies, delays in
our clinical program and regulatory approval, increases in our operating expenses, or failure to obtain or maintain approval for our product
candidates.
Guidelines and recommendations published by various organizations can reduce the use of our product candidates.
Government agencies promulgate regulations and guidelines directly applicable to us and to our product candidates. In addition, professional
societies, such as practice management groups, private health and science foundations and organizations involved in various diseases from time
to time may also publish guidelines or recommendations to the healthcare and patient communities. Recommendations of government agencies
or these other groups or organizations may relate to such matters as usage, dosage, route of administration and use of concomitant therapies.
Recommendations or guidelines suggesting the reduced use of our product candidates or the use of competitive or alternative products as the
standard of care to be followed by patients and healthcare providers could result in decreased use of our product candidates.
34
We face significant competition from other biopharmaceutical companies, and our operating results will suffer if we fail to compete
effectively.
Our industry is intensely competitive and subject to rapid and significant technological change. While we believe that our Asia based
development platform, knowledge, experience and scientific resources provide us with competitive advantages, we face substantial competition
from multinational pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies, universities and other research
institutions worldwide. For example, there are several targeted therapies currently in clinical development targeting specific subsets of biliary
tract cancer, including ivosidenib being developed by Agios Pharmaceuticals, Inc., ARQ087 being developed by Arqule, Inc. and lenvatinib
being developed by Eisai Inc.
Many of our competitors have significantly greater financial, clinical and human resources. Additionally, small and early-stage companies may
also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. As a result, our
competitors may discover, develop, license or commercialize products before or more successfully than we do. Competition may increase further
as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our
competitors may succeed in developing, acquiring or licensing on an exclusive basis drug products or drug delivery technologies that are more
effective or less costly than our product candidates that we are currently developing or that we may develop.
We believe that our ability to successfully compete will depend on, among other things:
•
•
•
•
•
•
•
•
the efficacy and safety of our product candidates, especially as compared to marketed products and product candidates in development
by third parties;
the time it takes for our product candidates to complete clinical development and receive marketing approval;
the ability to commercialize and market any of our product candidates that receive regulatory approval;
the price of our products;
whether coverage and adequate levels of reimbursement are available from third-party payors, such as private and governmental
health insurance plans, including Medicare;
the ability to protect intellectual property rights related to our product candidates;
the ability to manufacture on a cost-effective basis and sell commercial quantities of any of our product candidates that receive
regulatory approval; and
acceptance of any of our product candidates that receive regulatory approval by physicians and other healthcare providers.
If our competitors market products that are more effective, safer or less expensive than our future products, if any, or that reach the market sooner
than our future products, if any, we may not achieve commercial success. Because we have limited research and development capabilities, it may
be difficult for us to stay abreast of the rapid changes in technology. If we fail to stay at the forefront of technological change, we may be unable
to compete effectively. Technological advances or products developed by our competitors may render our technologies or product candidates
obsolete, less competitive or not economical.
35
Price controls may adversely affect our future profitability.
In certain countries, prescription drug pricing and reimbursement is subject to governmental control. In those countries that impose price
controls, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To
obtain reimbursement or pricing approval in some countries, we or our strategic partners may be required to conduct a clinical trial that compares
the cost-effectiveness of our product candidates to other available therapies.
Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after
marketing or product licensing approval is granted. In certain markets, prescription pharmaceutical pricing remains subject to continuing
governmental control even after initial approval is granted. As a result, we or our strategic partners might obtain marketing approval for a
product candidate in a particular country, but then be subject to price regulations that delay commercial launch of the product candidate, possibly
for lengthy time periods, and negatively impact the revenue that we generate from the sale of the product in that country. If reimbursement of
such product candidates is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, or if there is competition from
lower priced cross-border sales, our profitability will be negatively affected.
Legislative or regulatory healthcare reforms may make it more difficult and costly for us to obtain regulatory clearance or approval of our
product candidates and to produce, market and distribute our products after clearance or approval is obtained.
From time to time, legislation is drafted and introduced that could significantly change the statutory provisions governing the regulatory
clearance or approval, manufacture and marketing of regulated products or the reimbursement thereof. In addition, U.S. FDA regulations and
guidance are often revised or reinterpreted by the U.S. FDA in ways that may significantly affect our business and our products. Any new
regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of our product
candidates. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or
adopted may have on our business in the future. Such changes could, among other things, require:
•
•
•
•
changes to manufacturing methods;
change in clinical trial design, including additional treatment arm (control);
recall, replacement or discontinuance of one or more of our products; and
additional recordkeeping.
Each of these would likely entail substantial time and cost and could harm our business and our financial results.
In addition, in the United States, there have been a number of legislative and regulatory proposals to change the health care system in ways that
could affect our ability to sell our products profitably. The pharmaceutical industry in the United States, as an example, has been affected by the
passage of the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010,
collectively PPACA, which, among other things, imposed new fees on entities that manufacture or import certain branded prescription drugs and
expanded pharmaceutical manufacturer obligations to provide discounts and rebates to certain government programs. Since its enactment, there
have been judicial and Congressional challenges to certain aspects of PPACA, as well as recent efforts by the Trump administration to repeal or
replace certain aspects of PPACA. Since January 2017, President Trump has signed two Executive Orders and other directives designed to delay
the implementation of
36
certain provisions of PPACA or otherwise circumvent some of the requirements for health insurance mandated by PPACA. In addition, The
Centers for Medicare and Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS, recently
published a final rule that will give states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces,
which may have the effect of relaxing the essential health benefits required under the PPACA marketplaces. Further, Congress has considered
legislation that would repeal or repeal and replace all or part of the PPACA. While Congress has not passed comprehensive repeal legislation,
two bills affecting the implementation of certain taxes under the PPACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or Tax
Act, includes a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain
individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate”. On
January 22, 2018, President Trump signed a continuing resolution on appropriations for the year ended 2018 that delayed the implementation of
certain PPACA-mandated fees, including the so-called “Cadillac” tax on certain high cost employer-sponsored insurance plans, the annual fee
imposed on certain health insurance providers based on market share, and the medical device excise tax on non-exempt medical devices. The
Bipartisan Budget Act of 2018, or the BBA, among other things, amended the PPACA, effective January 1, 2019, to increase from 50 percent to
70 percent the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage
gap in most Medicare drug plans, commonly referred to as the “donut hole.” In July 2018, CMS published a final rule permitting further
collections and payments to and from certain PPACA qualified health plans and health insurance issuers under the PPACA risk adjustment
program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. On
December 14, 2018, a U.S. District Court Judge in the Northern District of Texas, or Texas District Court Judge, ruled that the individual
mandate is a critical and inseverable feature of the PPACA, and therefore, because it was repealed as part of the Tax Act, the remaining
provisions of the PPACA are invalid as well. While the Texas District Court Judge, as well as the Trump Administration and CMS, have stated
that the ruling will have no immediate effect, it is unclear how this decision, subsequent appeals, , and other efforts to repeal and replace the
PPACA will impact the PPACA and our business.
Other legislative changes have been proposed and adopted in the United States since the PPACA was enacted. For example, in August 2011, the
Budget Control Act of 2011, among other things, created measures for spending reductions by U.S. Congress. A Joint Select Committee on
Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2012 through 2021, was unable to
reach required goals, thereby triggering the legislation’s automatic reduction to several government programs. This includes aggregate reductions
of Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and, due to subsequent legislative
amendments to the statute, including the BBA, will remain in effect through 2027 unless additional Congressional action is taken. In January
2013, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to certain providers, and increased the
statute of limitations period for the government to recover overpayments to providers from three to five years.
Further, there has been particular and increasing legislative and enforcement interest in the United States with respect to drug pricing practices in
recent years, particularly with respect to drugs that have been subject to relatively large price increases over relatively short time periods. There
have been several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring
more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program
reimbursement methodologies for drugs. At the federal level, the Trump administration’s budget proposal for the year ended 2019 contains
further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example,
measures to permit Medicare Part D plans to negotiate the price of
37
certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic
drugs for low-income patients. Additionally, the Trump administration released a “Blueprint” to lower drug prices and reduce out of pocket costs
of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare
programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by
consumers. HHS has already started the process of soliciting feedback on some of these measures and, at the same, is immediately implementing
others under its existing authority. For example, in September 2018, CMS announced that it will allow Medicare Advantage Plans the option to
use step therapy for Part B drugs beginning January 1, 2019, and in October 2018, CMS proposed a new rule that would require direct-to-
consumer television advertisements of prescription drugs and biological products, for which payment is available through or under Medicare or
Medicaid, to include in the advertisement the Wholesale Acquisition Cost, or list price, of that drug or biological product.
In addition, on January 31, 2019, the HHS Office of Inspector General, proposed modifications to the U.S. Anti-Kickback Statute discount safe
harbor for the purpose of reducing the cost of drug products to consumers which, among other things, if finalized, will affect discounts paid by
manufacturers to Medicare Part D plans, Medicaid managed care organizations and pharmacy benefit managers working with these
organizations. Although a number of these, and other proposed, measures will require additional authorization to become effective, Congress and
the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs.
At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and
biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing
cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.
Additionally, on May 30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, or the
Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain
investigational new drug products that have completed a Phase I clinical trial and that are undergoing investigation for FDA approval. Under
certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the
FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients
as a result of the Right to Try Act.
In the future, there will likely continue to be proposals relating to the reform of the U.S. healthcare system, some of which could further limit
coverage and reimbursement of drug products, including our product candidates.
Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private
payors. Our results of operations could be adversely affected by PPACA and by other health care reforms that may be enacted or adopted in the
future.
38
It may be difficult for us to profitably sell any future products that may be approved if coverage and reimbursement for these products is
limited by government authorities and/or third-party payor policies.
In addition to any healthcare reform measures which may affect reimbursement, market acceptance and sales of our product candidates, if
approved, will depend on, in part, the extent to which our products, and the procedures which utilize our products, will be covered by third-party
payors, such as government health care programs, commercial insurance and managed care organizations. These third-party payors determine the
extent to which new drugs, and the procedures which utilize new drugs, will be covered as a benefit under their plans and the level of
reimbursement for any covered product and procedures utilizing such products. It is difficult to predict at this time what third-party payors will
decide with respect to the coverage and reimbursement for our product candidates, and the procedures which utilize our product candidates.
A primary trend in the healthcare industry has been cost containment, including price controls, restrictions on coverage and reimbursement and
requirements for substitution of generic products and/or biosimilars. Third-party payors decide which drugs, and procedures using such drugs,
they will pay for and establish reimbursement and co-payment levels. Government and other third-party payors are increasingly challenging the
prices charged for health care products and services, examining the cost effectiveness of drugs in addition to their safety and efficacy, and
limiting or attempting to limit both coverage and the level of reimbursement for prescription drugs and the procedures which utilize prescription
drugs. We cannot be sure that coverage will be available for our product candidates, and the procedures which utilize our product candidates, if
approved, or, if coverage is available, the level of reimbursement.
There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products, and the procedures which
utilize such products. In the United States, the principal decisions about reimbursement for new medicines, and the procedures which utilize new
medicines, are typically made by CMS, as CMS decides whether and to what extent a new medicine, and procedures which utilize a new
medicine, will be covered and reimbursed under Medicare. Private payors may follow CMS, but have their own methods and approval processes
for determining reimbursement for new medicines, and the procedures that utilize new medicines. It is difficult to predict what CMS or other
payors will decide with respect to reimbursement for fundamentally novel products such as ours, as there is no body of established practices and
precedents for these new products.
Reimbursement may impact the demand for, and/or the price of, any product for which we obtain marketing approval. Assuming we obtain
coverage for a given product, or a procedure which utilizes a given product, by a third-party payor, the resulting reimbursement payment rates
may not be adequate or may require co-payments that patients find unacceptably high. Patients who are prescribed medications and procedures
for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs
associated with those prescription drugs and procedures. Patients are unlikely to use our products, or agree to procedures utilizing our products,
unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the associated costs. Therefore, coverage and
adequate reimbursement is critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards that
disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available.
There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and the procedures which utilize newly
approved drugs, and coverage may be more limited than the purposes for which such drug is approved by the U.S. FDA or comparable foreign
regulatory authorities.
Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs,
including research, development, manufacture, sale and distribution.
39
We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed
healthcare, the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on
healthcare costs in general, particularly prescription drugs, medical devices and surgical procedures and other treatments, has become very
intense. As a result, increasingly high barriers are being erected to the successful commercialization of new products. Further, the adoption and
implementation of any future governmental cost containment or other health reform initiative may result in additional downward pressure on the
price that we may receive for any approved product. Reimbursement by a third-party payor may depend upon a number of factors including the
third-party payor’s determination that use of a product is:
•
•
•
•
•
a covered benefit under its health plan;
safe, effective and medically necessary;
appropriate for the specific patient;
cost-effective; and
neither experimental nor investigational.
Obtaining coverage and reimbursement approval for a product, or a procedure which utilizes a product, from a government or other third-party
payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost effectiveness data for the use
of our products, and the procedures which utilize our products, to the payor. Further, no uniform policy requirement for coverage and
reimbursement for drug products, and procedures which utilize drug products, exists among third-party payors in the United States. Therefore,
coverage and reimbursement for drug products, and the procedures which utilize drug products, can differ significantly from payor to payor. As a
result, the coverage determination process may require us to provide scientific and clinical support for the use of our products to each payor
separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. We may not
be able to provide data sufficient to gain acceptance with respect to coverage and/or sufficient reimbursement levels. We cannot be sure that
coverage or adequate reimbursement will be available for our product candidates, or the procedures which utilize our product candidates, if
approved. Also, we cannot be sure that reimbursement amounts will not reduce the demand for, or the price of, our future products. If
reimbursement is not available, or is available only to limited levels, we may not be able to commercialize our product candidates, or achieve
profitably at all, even if approved.
Reimbursement may not be immediately available for our product candidates in China, which could diminish our sales or affect our
profitability.
In China, the Ministry of Human Resources and Social Security of China or provincial or local human resources and social security authorities,
together with other government authorities, review the inclusion or removal of drugs from China’s National Drug Catalog for Basic Medical
Insurance, Work-related Injury Insurance and Maternity Insurance, or the National Reimbursement Drug List, or the NRDL, or provincial or
local medical insurance catalogues for the National Medical Insurance Program regularly, and the tier under which a drug will be classified, both
of which affect the amounts reimbursable to program participants for their purchases of those drugs. These determinations are made based on a
number of factors, including price and efficacy.
40
We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws and health information
privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.
Our current and future operations may be directly or indirectly through our relationships with healthcare providers, patients and other persons
and entities, subject to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial
arrangements and relationships through which we research, market, sell and distribute our products. In addition, we may be subject to patient
privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to
operate include:
The U.S. Anti-Kickback Statute prohibits, among other things, any person or entity from knowingly and willfully offering, paying, soliciting,
receiving or providing any remuneration, directly or indirectly, overtly or covertly, to induce or in return for purchasing, leasing, ordering or
arranging for or recommending the purchase, lease or order of any item or service reimbursable, in whole or in part, under Medicare, Medicaid
or other U.S. federal healthcare programs. The U.S. Anti-Kickback Statute has been interpreted to apply to arrangements between
pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers, among others, on the other. There are a
number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution.
The U.S. federal false claims and civil monetary penalties laws, including the False Claims Act, or FCA, which prohibit any person or entity
from, among other things, knowingly presenting, or causing to be presented, a false, fictitious or fraudulent claim for payment to, or approval by,
the U.S. federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or
fraudulent claim to the U.S. federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a
claim includes “any request or demand” for money or property presented to the U.S. government. In addition, manufacturers can be held liable
under the FCA even when they do not submit claims directly to government third-party payors if they are deemed to “cause” the submission of
false or fraudulent claims. The FCA also permits a private individual acting as a “whistleblower” to bring actions on behalf of the federal
government alleging violations of the FCA and to share in any monetary recovery. FCA liability is potentially significant in the healthcare
industry because the statute provides for treble damages and mandatory penalties per false claim or statement. Government enforcement agencies
and private whistleblowers have investigated pharmaceutical companies for or asserted liability under the FCA for a variety of alleged
promotional and marketing activities, such as providing free product to customers with the expectation that the customers would bill federal
programs for the product; providing consulting fees and other benefits to physicians to induce them to prescribe products; engaging in promotion
for “off-label” uses; and submitting inflated best price information to the Medicaid Rebate Program.
HIPAA prohibits, among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit
program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully
obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or
making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or
services.
The Physician Payments Sunshine Act, enacted as part of PPACA, imposes, among other things, annual reporting requirements for covered
manufacturers for certain payments and “transfers of value” provided to physicians and teaching hospitals, as well as ownership and investment
interests held by physicians and their immediate family members.
41
HIPAA, as amended by HITECH, and their respective implementing regulations, impose, among other things, specified requirements relating to
the privacy, security and transmission of individually identifiable health information held by covered entities, which include certain healthcare
providers, health plans and healthcare clearinghouses, and their business associates, which include individuals or entities that perform services
for covered entities that involve the creation, use, maintenance or disclosure of, individually identifiable health information. HITECH also
created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and
gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce the federal HIPAA
laws and seek attorneys’ fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of
health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus
complicating compliance efforts.
Many U.S. states and other foreign jurisdictions have analogous laws and regulations, such as state anti-kickback and false claims laws, that may
apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors,
including private insurers. In addition, certain states require drug manufacturers to report information related to payments and other transfers of
value to physicians and other healthcare providers or marketing expenditures and certain states and local jurisdictions require the registration of
pharmaceutical sales representatives.
Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some
of our business activities could be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has
strengthened these laws. For example, recent health care reform legislation, has among other things, amended the intent requirement of the U.S.
Anti-Kickback Statute and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or
specific intent to violate it in order to have committed a violation. Moreover, recent health care reform legislation provides that the government
may assert that a claim including items or services resulting from a violation of the U.S. Anti-Kickback Statute constitutes a false or fraudulent
claim for purposes of the FCA.
Ensuring that our business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. It is
possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations or case
law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations were found to be in violation of any of these
laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties,
damages, fines, disgorgement, imprisonment, possible exclusion from government funded healthcare programs, contractual damages,
reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate
integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations, any of which
could substantially disrupt our operations. If the physicians or other providers or entities with whom we expect to do business are found not to be
in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government
funded healthcare programs.
42
We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with
such laws can subject us to criminal and/or civil liability and harm our business.
We are subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended, or the FCPA, the U.S. domestic bribery statute contained in 18
U.S.C. § 201, the U.S. Travel Act, the USA PATRIOT Act, and possibly other state and national anti-bribery and anti-money laundering laws in
countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, third-
party intermediaries, joint venture partners and collaborators from authorizing, promising, offering, or providing, directly or indirectly, improper
payments or benefits to recipients in the public or private sector. We engage third party investigators, CROs, and other consultants to design and
perform preclinical studies of our product candidates, and will do the same for any clinical trials. Also, once a product candidate has been
approved and commercialized, we may engage third party intermediaries to promote and sell our products abroad and/or to obtain necessary
permits, licenses, and other regulatory approvals. We or our third-party intermediaries may have direct or indirect interactions with officials and
employees of government agencies or state-owned or affiliated entities. We can be held liable for the corrupt or other illegal activities of these
third-party intermediaries, our employees, representatives, contractors, collaborators, partners, and agents, even if we do not explicitly authorize
or have actual knowledge of such activities.
Noncompliance with anti-corruption and anti-money laundering laws could subject us to whistleblower complaints, investigations, sanctions,
settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or
injunctions, suspension and/or debarment from contracting with certain persons, the loss of export privileges, reputational harm, adverse media
coverage, and other collateral consequences. If any subpoenas, investigations, or other enforcement actions are launched, or governmental or
other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations and financial
condition could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of
management’s attention and resources and significant defense and compliance costs and other professional fees. In certain cases, enforcement
authorities may even cause us to appoint an independent compliance monitor which can result in added costs and administrative burdens.
The incidence and prevalence for target patient populations of our product candidates are based on estimates and third-party sources. If the
market opportunities for our product candidates are smaller than we estimate or if any approval that we obtain is based on a narrower
definition of the patient population, our revenue and ability to achieve profitability might be materially and adversely affected.
Periodically, we make estimates regarding the incidence and prevalence of target patient populations for particular diseases based on various
third-party sources and internally generated analysis and use such estimates in making decisions regarding our drug development strategy,
including acquiring or in-licensing product candidates and determining indications on which to focus in preclinical or clinical trials.
These estimates may be inaccurate or based on imprecise data. For example, the total addressable market opportunity will depend on, among
other things, acceptance of our drugs by the medical community and patient access, drug pricing and reimbursement. The number of patients in
the addressable markets may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our drugs, or new
patients may become increasingly difficult to identify or gain access to, all of which may significantly harm our business, financial condition,
results of operations and prospects.
43
Risks Related to our ADSs
The price of our ADSs may be volatile and may fluctuate due to factors beyond our control.
The trading market for publicly traded emerging biopharmaceutical and drug discovery and development companies has been highly volatile and
is likely to remain highly volatile in the future. The market price of our ADSs may fluctuate significantly due to a variety of factors, including:
•
•
•
•
•
•
•
•
•
•
•
•
•
positive or negative results from, or delays in, testing and clinical trials by us, collaborators or competitors;
technological innovations or commercial product introductions by us or competitors;
changes in government regulations;
changes in the structure of healthcare payment systems;
developments concerning proprietary rights, including patents and litigation matters;
public concern relating to the commercial value or safety of our product candidates;
financing, collaborations or other corporate transactions;
publication of research reports or comments by securities or industry analysts;
general market conditions in the pharmaceutical industry or in the economy as a whole;
the loss of any of our key scientific or senior management personnel;
the perceived values of our ordinary shares trading on the TPEx and our ADSs trading on Nasdaq relative to one another;
sales of our ADSs or ordinary shares by us, our senior management and board members or holders of our ADSs or our ordinary shares
in the future; or
other events and factors, many of which are beyond our control.
These and other market and industry factors may cause the market price and demand for our ADSs to fluctuate substantially, regardless of our
actual operating performance, which may limit or prevent investors from readily selling their ADSs and may otherwise negatively affect the
liquidity of our ADSs. In addition, the stock market in general, and biopharmaceutical companies in particular, have experienced extreme price
and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. In the past, when
the market price of a security has been volatile, holders of that security have sometimes instituted securities class action litigation against the
issuer. If any of the holders of our ADSs were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and the
attention of our senior management would be diverted from the operation of our business. Any adverse determination in litigation could also
subject us to significant liabilities.
44
Restrictions on the ability to deposit our ordinary shares into our American depositary receipt facility may adversely affect the liquidity of our
ADSs.
The ability to deposit our ordinary shares into our American depositary receipt facility for the issuance of ADSs is restricted by Republic of
China, or ROC, law, which may adversely affect the liquidity of our ADSs. Under current ROC law and the Deposit Agreement, no person or
entity, including the holders of ADSs and us, may deposit our ordinary shares in our American depositary receipt facility for the issuance of
ADRs without specific approval of the Financial Supervisory Commission, or FSC, unless:
(i) we pay stock dividends on, or make a free distribution of, our ordinary shares;
(ii)
the ADS holder exercises pre-emptive rights in the event of capital increases for cash; or
(iii)
investors purchase our ordinary shares, directly or through the depositary, on the TPEx, and deliver our ordinary shares to the
custodian for deposit into our American depositary receipt facility, or our existing shareholders deliver our ordinary shares to the
custodian for deposit into our American depositary receipt facility.
With respect to (iii) above, the depositary may issue ADSs against the deposit of those shares only if the total number of ADSs outstanding
following the deposit will not exceed the number of ADSs previously approved by the FSC, plus any ADSs issued pursuant to the events
described in items (i) and (ii) above. Issuance of additional ADSs under item (iii) above will be permitted to the extent that a corresponding
number of previous ADSs have been cancelled.
The price of our ADSs may be limited by the trading price of our ordinary shares on the TPEx.
Our ordinary shares have been listed on the TPEx since June 1, 2017 under the code “6497.” From May 4, 2018 through April 22, 2019, the
closing price of our ordinary shares on the TPEx ranged from NT$20.25 per share to NT$49.85 per share (which would be approximately $0.66
per share to $1.62 per share, based on the exchange rate in effect as of April 22, 2019). During the same period, the closing price of our ADSs
on The Nasdaq Global Market ranged from $2.86 per ADS to $10.24 per ADS. The TPEx sets certain limitations on the trading volatility of our
ordinary shares and there is currently a ten percent limit on the daily price movement on the TPEx. As a result of these limitations, the potential
increase in trading price of any ADSs may be materially limited based on the perceived value of our ordinary shares on the TPEx. Similarly,
decreases in the trading price of our ordinary shares on the TPEx due to the perceptions of investors in that market, which may be different from
your own, may impact the value of your investment.
The cross listing of our ordinary shares and our ADSs may adversely affect the liquidity and value of our ADSs.
The cross listing of our ordinary shares and our ADSs may dilute the liquidity of these securities in one or both markets and may adversely affect
the development of an active trading market for our ADSs in the United States. The price of our ADSs could also be adversely affected by
trading in our ordinary shares on the TPEx. In addition, currency fluctuations as between the New Taiwan dollar and U.S. dollar may have an
adverse impact on the value of our ADSs.
45
We have incurred and will incur increased costs as a result of operating as a public company in the United States, and our senior
management will be required to devote substantial time to new compliance initiatives and corporate governance practices.
Our ADSs began trading on The Nasdaq Global Market on May 4, 2018 under the trading symbol “ASLN”. As a U.S. public company, we have
incurred significant legal, accounting and other expenses that we did not incur previously, and we will incur additional expenses after we no
longer qualify as an “emerging growth company,” or EGC. The Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer
Protection Act, the listing requirements of The Nasdaq Stock Market LLC, or Nasdaq, and other applicable securities rules and regulations
impose various requirements on non-U.S. reporting public companies, including the establishment and maintenance of effective disclosure and
financial controls and corporate governance practices. Our senior management and other personnel will need to devote a substantial amount of
time to these compliance initiatives. Moreover, these rules and regulations will increase our legal and financial compliance costs and will make
some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more
expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified
senior management personnel or members for our board of directors.
However, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result,
their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in
continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.
Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002, or Section 404, we will be required to furnish a report by our senior management on
our internal control over financial reporting and an attestation report on internal control over financial reporting issued by our independent
registered public accounting firm. However, while we remain an EGC we will not be required to include an attestation report on internal control
over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the
prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly
and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants, adopt a detailed
work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as
appropriate, validate through testing that controls are functioning as documented, and implement a continuous reporting and improvement
process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed
timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material
weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.
You may face difficulties in protecting your interests, and your ability to protect your rights through U.S. courts may be limited, because we
are incorporated under Cayman Islands law, we conduct substantially all of our operations and all of our directors and executive officers
reside outside of the United States.
We are an exempted company incorporated under the laws of the Cayman Islands. Our corporate affairs are governed by our Sixth Amended and
Restated Memorandum and Articles of Association, or our Articles, the Companies Law (2018 Revision) of the Cayman Islands and the common
law of the Cayman Islands. The rights of shareholders to take action against the directors, actions by minority shareholders and the fiduciary
duties of our directors to us under Cayman Islands law are to a large extent governed by
46
the common law of the Cayman Islands. The common law of the Cayman Islands is derived in part from comparatively limited judicial precedent
in the Cayman Islands as well as from the common law of England and Wales, the decisions of whose courts are of persuasive authority, but are
not binding, on a court in the Cayman Islands. Similarly, the rights of our shareholders and the fiduciary duties of our directors under Cayman
Islands law are not as clearly established as they would be under statutes or judicial precedent in some jurisdictions in the United States. In
particular, the Cayman Islands has a less developed body of securities laws than the United States, and some U.S. states, such as Delaware, have
more fully developed and judicially interpreted bodies of corporate law than the Cayman Islands. In addition, Cayman Islands companies do not
have standing to sue before the federal court of the United States.
Shareholders of Cayman Islands exempted companies like us have no general rights under Cayman Islands law to inspect corporate records or to
obtain copies of lists of shareholders of these companies. Although our shareholders are permitted by our Articles to request access to our books
and records, our directors have discretion under our Articles to determine whether or not, and under what conditions, our corporate records may
be inspected by our shareholders, but are not obliged to make them available to our shareholders. This may make it more difficult for you to
obtain the information needed to establish any facts necessary for a shareholder motion or to solicit proxies from other shareholders in
connection with a proxy contest.
Certain corporate governance practices in the Cayman Islands, which is our home country, differ significantly from requirements for companies
incorporated in other jurisdictions such as the United States. To the extent we choose to follow home country practice with respect to corporate
governance matters, our shareholders may be afforded less protection than they otherwise would under rules and regulations applicable to U.S.
domestic issuers.
As a result of all of the above, our public shareholders may have more difficulty in protecting their interests in the face of actions taken by
management, members of the board of directors or controlling shareholders than they would as public shareholders of a company incorporated in
the United States. For a discussion of significant differences between the provisions of the Companies Law of the Cayman Islands and the laws
applicable to companies incorporated in the United States and their shareholders, see “Item 10. Additional Information—B. Memorandum and
articles of association—Material Differences in Corporate Law”
Future sales, or the possibility of future sales, of a substantial number of our ADSs or ordinary shares could adversely affect the price of our
ADSs.
Future sales of a substantial number of our ADSs or ordinary shares, or the perception that such sales will occur, could cause a decline in the
market price of our ADSs. If any of our large shareholders or members of our management team sell substantial amounts of our securities in the
public markets, or the market perceives that such sales may occur, the market price of our ADSs and our ability to raise capital through an issue
of equity securities in the future could be adversely affected.
47
We may sell additional equity or debt securities or enter into other financing arrangements to fund our operations, which may result in
dilution to our shareholders and holders of our ADSs and impose restrictions on our business.
In order to raise additional funds to support our operations, we may sell additional equity or debt securities, which could adversely impact our
existing shareholders and new investors, as well as our business. The sale of additional equity or debt securities, or a combination of both, would
result in the issuance of additional shares capital and dilution to our shareholders and holders of our ADSs.
The incurrence of indebtedness would result in increased fixed payment obligations and could also result in certain restrictive covenants, such as
limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other
operating restrictions that could adversely impact our ability to conduct our business. In the event that we enter into collaborations or licensing
arrangements to raise capital, we may be required to accept unfavorable terms, including relinquishing or licensing to a third party on
unfavorable terms our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves or
potentially reserve for future potential arrangements when we might be able to achieve more favorable terms.
Because we do not anticipate paying any cash dividends on our ADSs or ordinary shares in the foreseeable future, capital appreciation, if
any, will be your sole source of potential gains and you may never receive a return on your investment.
We have not paid cash dividends in the past on our ordinary shares. We intend to retain earnings, if any, for use in our business and do not
anticipate paying any cash dividends in the foreseeable future. As a result, capital appreciation, if any, on our ADSs or ordinary shares will be
your sole source of potential gains for the foreseeable future, and you will suffer a loss on your investment if you are unable to sell your ADSs or
the underlying ordinary shares at or above the price you pay for our ADSs or ordinary shares. Investors seeking cash dividends should not
purchase our ADSs.
Holders of our ADSs may not have the same voting rights as the holders of our ordinary shares and may not receive voting materials in time
to be able to exercise their right to vote.
As a holder of our ADSs, you will only be able to exercise the voting rights with respect to the underlying ordinary shares in accordance with the
provisions of the deposit agreement. Under the deposit agreement, you must vote by giving voting instructions to the depositary. Upon receipt of
your voting instructions, the depositary will try to vote the underlying ordinary shares in accordance with these instructions. You will not be able
to directly exercise your right to vote with respect to the underlying shares unless you withdraw the shares. When a general meeting is convened,
you may not receive sufficient advance notice to withdraw the shares underlying your ADSs to allow you to vote with respect to any specific
matter. After we notify the depositary of the agenda for the shareholders’ meeting, the depositary will notify you of the upcoming vote and will
arrange to deliver our voting materials to you once they are available. We have agreed to give the depositary at least 30 days’ prior notice of
shareholder meetings. Nevertheless, we cannot assure you that you will receive the voting materials in time to ensure that you can instruct the
depositary to vote your shares. In addition, the depositary and its agents are not responsible for failing to carry out voting instructions or for their
manner of carrying out your voting instructions. This means that you may not be able to exercise your right to vote and you may have no legal
remedy if the shares underlying your ADSs are not voted as you requested.
48
Except in limited circumstances, the depositary for our ADSs will give us a discretionary proxy to vote our ordinary shares underlying your
ADSs if you do not vote at shareholders’ meetings, which could adversely affect your interests.
Under the deposit agreement for our ADSs, to the extent we have provided the depositary with at least 45 days’ notice of a proposed meeting, if
voting instructions are not timely received by the depositary from you, you shall be deemed to have instructed the depositary to give a
discretionary proxy to a person designated by us to vote the shares represented by your ADSs as desired. However, no such instruction shall be
deemed given and no discretionary proxy shall be given (a) if we inform the depositary in writing that (i) we do not wish such proxy to be given,
(ii) substantial opposition exists with respect to any agenda item for which the proxy would be given or (iii) the agenda item in question, if
approved, would materially or adversely affect the rights of holders of shares and (b) unless we have provided the depositary with an opinion of
our counsel to the effect that (a) the granting of such discretionary proxy does not subject the depositary to any reporting obligations in the
Cayman Islands or the ROC, or by the ROC FSC, or TPEx, (b) the granting of such proxy will not result in a violation of the laws, rules,
regulations or permits of the Cayman Islands, the ROC, the ROC FSC or TPEx, (c) the voting arrangement and deemed instruction will be given
effect under the laws, rules, regulations and permits of the Cayman Islands, the ROC, the ROC FSC and TPEx and (d) the granting of such proxy
will not under any circumstances result in the depositary being treated as the beneficial owner of ADSs under the laws, rules, regulations or
permits of the Cayman Islands, the ROC, the ROC FSC and TPEx.
The effect of this discretionary proxy is that, if you fail to give voting instructions to the depositary as to how to vote the ordinary shares
underlying your ADSs at any particular shareholders’ meeting, you cannot prevent our ordinary shares underlying your ADSs from being voted
at that meeting, absent the situations described above, and it may make it more difficult for shareholders to influence our management. Holders
of our ordinary shares are not subject to this discretionary proxy.
You may not be able to withdraw the underlying ordinary shares of our ADSs.
Pursuant to ROC law, an ADS holder who is a non-ROC person wishing to withdraw and hold deposited ordinary shares from the ADS facility is
required to appoint an eligible agent in the ROC for filing tax returns and making tax payments, or a Tax Guarantor. Such Tax Guarantor will be
required to meet the qualifications set by the Ministry of Finance of the ROC and will act as the guarantor of the withdrawing ADS holder’s tax
payment obligations. In addition, subject to certain limited exceptions, under current ROC law, repatriation of profits by a non-ROC withdrawing
ADS holder is subject to the submission of evidence by the withdrawing ADS holder of the appointment of a Tax Guarantor to, and approval thereof
by, the ROC tax authority and of tax clearance certificates or evidentiary documents issued by the Tax Guarantor. We cannot provide any assurances
that a withdrawing ADS holder will be able to appoint and obtain approval from the tax authority in a timely manner or at all.
Pursuant to ROC law, an ADS holder who is not an ROC person or ROC entity wishing to present ADSs to the depositary for cancellation and
withdrawal and holding of the Deposited Securities from the depositary receipt facility is required to register as a foreign investor with the
Taiwan Stock Exchange, or TWSE, if the ADS holder has never been registered as foreign investor with the TWSE previously, for making
investments in the ROC securities market prior to withdrawing and holding the underlying ordinary shares from the depositary receipts facility.
49
Additionally, pursuant to ROC law, such withdrawing ADS holder is required to appoint a local agent in the ROC to, on such ADS holder’s
behalf, open a securities trading account with prior approval granted by the TWSE with a local securities brokerage firm (with qualification set
by the FSC) and a bank account, pay ROC taxes, remit funds, exercise shareholder rights and perform such other functions as the ADS holder
may designate upon such withdrawal. In addition, such withdrawing ADS holder is also required to appoint a custodian bank and open a
custodian account to hold the securities and cash in safekeeping, make confirmations, settle trades and report all relevant information. Without
making such appointment and the opening of such custodian account, the withdrawing ADS holder would be unable to hold or subsequently sell
the deposited ordinary shares withdrawn from the ADR facility on the TPEx. The laws of the ROC applicable to the withdrawal of the
underlying ordinary shares may change from time to time. We cannot provide any assurances that current law will remain in effect or that future
changes of ROC law will not adversely affect the ability of ADS holders to withdraw deposited ordinary shares.
Holders of our ADSs may not receive distributions on our ordinary shares in the form of ADSs or any value for them if it is illegal or
impractical to make them available to holders of ADSs.
The depositary for our ADSs has agreed to pay to holder of our ADSs the cash dividends or other distributions it or the custodian receives on our
ordinary shares or other deposited securities after deducting its fees and expenses and certain taxes. Holders of our ADSs will receive these
distributions in proportion to the number of our ordinary shares their ADSs represent. However, in accordance with the limitations set forth in the
deposit agreement, it may be unlawful or impractical to make a distribution available to holders of ADSs. We have no obligation to take any
other action to permit the distribution of our ADSs, ordinary shares, rights or anything else to holders of our ADSs. This means that holders of
our ADSs may not receive the distributions we make on our ordinary shares or any value from them if it is unlawful or impractical to make them
available to ADS holders. These restrictions may have a negative impact on the market value of our ADSs.
Holders of our ADSs may be subject to limitations on transfer of their ADSs.
ADSs are transferable on the books of the depositary. However, the depositary may close its transfer books at any time or from time to time when
it deems expedient in connection with the performance of its duties. In addition, the depositary may refuse to deliver, transfer or register transfers
of ADSs generally when our books or the books of the depositary are closed, or at any time if we or the depositary deems it advisable to do so
because of any requirement of law or of any government or governmental body, or under any provision of the deposit agreement, or for any other
reason in accordance with the terms of the deposit agreement. The rights of our shareholders may differ from the rights typically offered to
shareholders of a U.S. corporation.
Our corporate affairs are governed by our Articles and by the laws governing Cayman Islands corporations and companies engaging in drug
development, marketing and sales businesses, as well as by the common law of the Cayman Islands. Certain rights and responsibilities of our
shareholders, ADS holders and members of our board of directors under Cayman law are different from those that apply to a Delaware
corporation. For example, Directors of Cayman Islands exempted companies are required to observe certain fiduciary duties. These duties are
owed to the Cayman Islands company and include the duty to act in the best interests of the company and the shareholders as a whole. However, the
fiduciary duties of a director of a Cayman Islands exempted company may not be the same as the fiduciary duty of a director of a U.S. corporation.
In addition, controlling shareholders of U.S. corporations owe fiduciary duties to minority shareholders, while shareholders (including controlling
shareholders) of Cayman Islands companies owe no fiduciary duties to either to the company or to other shareholders. Further, the
50
rights of our shareholders to bring shareholders’ suits against us or our board of directors under Cayman Islands law are much more limited than
those of shareholders of a U.S. corporation. For example, under Cayman Islands law, a shareholder who wishes to bring a claim against a director
would generally need to obtain permission from the courts to bring a derivative action, in the name of the company, against the director. This is
because the director of a Cayman Islands exempted company owes duties to the company and not to individual shareholders. As a result, our
shareholders may have more difficulty protecting their rights in connection with actions taken by our directors than they would as shareholders of a
U.S. corporation. In addition, minority shareholders in a Cayman Islands exempted company have more limited rights than minority shareholders
in a U.S. corporation in relation to mergers and similar transactions that the company may carry out. For example, if a merger under the Companies
Law involving a Cayman Islands exempted company is approved by the requisite majority of shareholders, a dissenting minority shareholder
would have the right to be paid the fair value of their shares (which, if not agreed between the parties, will be determined by the Cayman Islands
court) if they follow the required procedures, subject to certain exceptions. Such dissenter rights differ substantially from the appraisal rights,
which would ordinarily be available to dissenting shareholders of Delaware corporations. Further, if a takeover offer is made to the shareholders
of a Cayman Islands exempted company and accepted by holders of 90% of the shares affected, the offeror may require the holders of the remaining
shares to transfer such shares on the terms of the offer. An objection can be made to the Grand Court of the Cayman Islands but this is unlikely to
succeed in the case of an offer which has been so approved unless there is evidence of fraud, bad faith or collusion. A minority shareholder in
this scenario would have no rights comparable to the appraisal rights which would generally be available to a dissenting shareholder of a U.S.
corporation in similar circumstances. See the section of this Annual Report titled “Item 10. Additional Information—B. Memorandum and articles
of association—Material Differences in Corporate Law” for a description of the principal differences between the provisions of Cayman law
applicable to us and the U.S. Delaware General Corporate Law relating to shareholders’ rights and protections.
We qualify as a foreign private issuer and, as a result, we are not subject to U.S. proxy rules and are subject to Exchange Act reporting
obligations that permit less detailed and less frequent reporting than that of a U.S. domestic public company.
We report under the Exchange Act as a non-U.S. company with foreign private issuer status. Because we qualify as a foreign private issuer under
the Exchange Act, we are exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including
(i) the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the
Exchange Act; (ii) the sections of the Exchange Act requiring insiders to file public reports of their stock ownership and trading activities and
liability for insiders who profit from trades made in a short period of time; and (iii) the rules under the Exchange Act requiring the filing with the
SEC of quarterly reports on
Form 10-Q containing unaudited financial and other specified information, or current reports on Form 8-K upon the occurrence of specified
significant events. In addition, our officers, directors and principal shareholders are exempt from the reporting and “short-swing” profit recovery
provisions of Section 16 of the Exchange Act and the rules thereunder. Therefore, our shareholders may not know on a timely basis when our
officers, directors and principal shareholders purchase or sell our ordinary shares or ADSs. In addition, foreign private issuers are not required to file
their annual report on Form 20-F until the date that is four months after the end of each fiscal year, while U.S. domestic issuers that are accelerated
filers are required to file their annual report on Form 10-K within 75 days after the end of each fiscal year. Foreign private issuers also are exempt
from Regulation Fair Disclosure, aimed at preventing issuers from making selective disclosures of material information. As a result of the above,
you may not have the same protections afforded to shareholders of companies that are not foreign private issuers.
51
As a foreign private issuer, we are permitted to adopt certain home country practices in relation to corporate governance matters that differ
significantly from Nasdaq corporate governance listing standards. These practices may afford less protection to shareholders than they would
enjoy if we complied fully with corporate governance listing standards.
As a foreign private issuer, we are permitted to take advantage of certain provisions in the Nasdaq listing rules that allow us to follow ROC law
for certain governance matters. Certain corporate governance practices in the ROC may differ significantly from corporate governance listing
standards. When our ADSs are listed on The Nasdaq Global Market, we intend to continue to follow ROC corporate governance practices in lieu
of certain corporate governance requirements of Nasdaq. See “Management—Foreign Private Issuer Exemption.” Therefore, our shareholders
may be afforded less protection than they otherwise would have under corporate governance listing standards applicable to U.S. domestic issuers.
We may lose our foreign private issuer status in the future, which could result in significant additional costs and expenses.
As discussed above, we are a foreign private issuer, and therefore, we are not required to comply with all of the periodic disclosure and current
reporting requirements of the Exchange Act. The determination of foreign private issuer status is made annually on the last business day of an
issuer’s most recently completed second fiscal quarter. We would lose our foreign private issuer status if, for example, more than 50% of our
ordinary shares are directly or indirectly held by residents of the United States and we fail to meet additional requirements necessary to maintain
our foreign private issuer status. If we lose our foreign private issuer status on this date, we will be required to file with the SEC periodic reports
and registration statements on U.S. domestic issuer forms, which are more detailed and extensive than the forms available to a foreign private
issuer. We will also have to mandatorily comply with U.S. federal proxy requirements, and our officers, directors and principal shareholders will
become subject to the short-swing profit disclosure and recovery provisions of Section 16 of the Exchange Act. In addition, we will lose our
ability to rely upon exemptions from certain corporate governance requirements under the Nasdaq listing rules. As a U.S. listed public company
that is not a foreign private issuer, we will incur significant additional legal, accounting and other expenses that we will not incur as a foreign
private issuer, and accounting, reporting and other expenses in order to maintain a listing on a U.S. securities exchange. These rules and
regulations could also make it more difficult for us to attract and retain qualified members of our board of directors and more expensive to
procure director and officer liability insurance.
We are an EGC and we cannot be certain if the reduced reporting requirements applicable to “emerging growth companies” will make our
ADSs less attractive to investors.
We are an EGC as defined in the JOBS Act. For as long as we continue to be an EGC, we may take advantage of exemptions from various
reporting requirements that are applicable to other public companies that are not EGCs, including not being required to comply with the auditor
attestation requirements of Section 404, exemptions from the requirements of holding a nonbinding advisory vote on executive compensation
and shareholder approval of any golden parachute payments not previously approved. We may take advantage of these exemptions until we are
no longer an EGC. We could be an EGC until December 31, 2023, although circumstances could cause us to lose that status earlier, including if
the aggregate market value of our ADSs and ordinary shares held by non-affiliates exceeds $700 million as of the end of our second fiscal
quarter before that time, in which case we would no longer be an EGC as of the following December 31st (the last day of our fiscal year). We
cannot predict if investors will find our ADSs less attractive because we may rely on these exemptions. If some investors find our ADSs less
attractive as a result, there may be a less active trading market for our ADSs and the price of our ADSs may be more volatile.
52
If we fail to maintain an effective system of internal controls over financial reporting, we may not be able to accurately report our financial
results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our
business and the trading price of our ADSs.
Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure
controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered
in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with
Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over
financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements
or identify other areas for further attention or improvement. Inadequate internal controls could also cause investors to lose confidence in our
reported financial information, which could have a negative effect on the trading price of our ADSs.
Management will be required to assess the effectiveness of our internal controls annually, starting with our Annual Report on Form 20-F for the
year ended December 31, 2019. However, for as long as we are an EGC under the JOBS Act, our independent registered public accounting firm
will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404. An independent
assessment of the effectiveness of our internal controls could detect problems that our management’s assessment might not. Undetected material
weaknesses in our internal controls could lead to financial statement restatements requiring us to incur the expense of remediation and could also
result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements.
If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, the price of our
ADSs and our trading volume could decline.
The trading market for our ADSs depends in part on the research and reports that securities or industry analysts publish about us or our business.
If no or too few securities or industry analysts provide coverage or if one or more of the analysts who cover us downgrade our ADSs or publish
inaccurate or unfavorable research about our business, the price of our ADSs would likely decline. If one or more of these analysts cease
coverage of us or fail to publish reports on us regularly, demand for our ADSs could decrease, which might cause the price of our ADSs and
trading volume to decline.
Our U.S. ADS Holders may suffer adverse tax consequences if we are characterized as a passive foreign investment company.
Generally, if for any taxable year (i) 75% or more of our gross income is passive income, or (ii) at least 50% of the average quarterly value of our
assets are held for the production of, or produce, passive income, we would be characterized as a passive foreign investment company, or PFIC,
for U.S. federal income tax purposes. For purposes of the above calculations, a non-U.S. corporation that directly or indirectly owns at least 25%
by value of the shares of another corporation is treated as if it held its proportionate share of the assets of the other corporation and received
directly its proportionate share of the income of the other corporation. Passive income generally includes dividends, interest, rents, royalties and
capital gains. Based on estimates of our gross income and gross assets (including tangible assets and intangible assets based on the anticipated
market value of our ordinary shares), and the nature of our business, we expect to be classified as a PFIC for the taxable year ending December
31, 2018 and for future taxable years. There can be no assurance, however, regarding our PFIC status for any taxable year.
53
If we are characterized as a PFIC, our U.S. shareholders may suffer adverse tax consequences, including having gains realized on the sale of our
ordinary shares treated as ordinary income, rather than as capital gain, the loss of the preferential rate applicable to dividends received on our
ordinary shares by individuals who are U.S. Holders (as defined in “Material Income Tax Considerations—Material U.S. Federal Income Tax
Considerations for U.S. Holders”), and having interest charges apply to distributions by us and the proceeds of share sales and having to comply
with certain reporting requirements. Certain elections exist that may alleviate some of the adverse consequences of PFIC status and would result
in an alternative treatment (such as mark-to-market treatment) of our ordinary shares; however, we do not intend to provide the information
necessary for U.S. holders to make qualified electing fund elections if we are classified as a PFIC.
Item 4. Information on the Company
A. History and development of the company.
ASLAN Pharmaceuticals Pte. Ltd. was incorporated in Singapore in April 2010 and ASLAN Pharmaceuticals Limited was incorporated in
Cayman Islands in June 2014 as the listing vehicle for our initial public offering and listing on the TPEx. Our subsidiaries, ASLAN
Pharmaceuticals Taiwan Limited, ASLAN Pharmaceuticals Australia Pty Ltd., ASLAN Pharmaceuticals Hong Kong Limited, ASLAN
Pharmaceuticals (Shanghai) Co. Ltd. and ASLAN Pharmaceuticals (USA) Inc., were incorporated in the Republic of China, Australia, Hong
Kong, China and the United States in November 2013, July 2014, July 2015, May 2016 and October 2018, respectively.
Our principal executive offices are located at 83 Clemenceau Avenue, #12-03 UE Square, Singapore 239920. Our telephone number at that
address is +65 6222 4235. Our registered office in the Cayman Islands is at the offices of Intertrust Corporate Services (Cayman) Limited at 190
Elgin Avenue, George Town, Grand Cayman KY1-9005, Cayman Islands. Our agent for service of process in the United States is Cogency
Global Inc. 10 East 40th Street 10th Floor, New York, New York 10016, +1 212 947 7200. The SEC maintains an internet site that contains
reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at http://www.sec.gov.
We also maintain a corporate website at www.aslanpharma.com. Information contained in, or that can be accessed through, our website is not a
part of, and shall not be incorporated by reference into, this document. We have included our website address in this document solely as an
inactive textual reference.
Since our inception in 2010, we have devoted substantially all of our resources to acquiring rights to, and developing our product candidates,
including preclinical studies and clinical trials and providing general and administrative support for our operations. We have not generated any
revenue from product sales and we do not currently have any products approved for commercialization. We have financed our operations through
a combination of debt and equity financings and government grants.
Our actual capital expenditures for the years ended December 31, 2016, 2017 and 2018 amounted to $374,425, $291,432 and $80,262
respectively. These capital expenditures primarily consisted of our continued investment in construction of additional facilities to support the
development of our products and technologies. We expect our capital expenditures to increase in absolute terms in the near term as we continue
to advance our research and development programs and grow our operations. We anticipate our capital expenditures in 2019 to be financed from
the proceeds from our existing cash and cash equivalents, including the net proceeds from our initial public offering of American Depositary
Shares on the Nasdaq Global Market.
54
B. Business overview.
We are a clinical-stage oncology and inflammatory disease focused biopharmaceutical company based in Singapore developing novel
therapeutics for global markets. We target diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe.
Our Asia development platform is designed to enable us to accelerate the development of drugs to treat these diseases. Our portfolio is comprised
of four product candidates which target: validated growth pathways applied to new patient segments; novel immune checkpoints; and novel
cancer metabolic pathways.
Our lead program, varlitinib, is a reversible small molecule pan-HER inhibitor that targets the human epidermal growth factor receptors HER1,
HER2 and HER4. Varlitinib is currently being studied in a global pivotal clinical trial for biliary tract cancer for which we expect to report
topline data in the second half of 2019.
We focus on cancers, such as biliary tract cancer, that are orphan diseases in the United States and Europe for which there are few, if any,
approved therapies. Although registration trials for orphan diseases may require fewer patients, recruitment for such trials in the United States
and Europe is often challenging given the limited availability of suitable patients. Asia offers a unique opportunity to accelerate the development
of novel therapies in diseases where either the cancers are more prevalent or the availability of suitable patients is greater.
•
•
The cancers are more prevalent. As an example, there are approximately 12,600 new cases of biliary tract cancer every year in the
United States. In Asia, the incidence of biliary tract cancer is approximately 200,000 new cases every year, of which up to 145,000 are
in China. The higher incidence in Asia is believed to be driven by both genetic and environmental factors.
The availability of suitable patients is greater. As an example, in acute myeloid leukemia, or AML, there are a large number of
clinical trials in the United States and Europe competing for a relatively small patient population. By conducting clinical development
primarily in Asia, we are able to access a larger population of patients more easily and cost-effectively, with fewer competing trials.
Our Product Candidates
The following table summarizes our product candidate pipeline:
55
We hold global rights to all of our product candidates with the exception of varlitinib and ASLAN003, for both of which BioGenetics Co., Ltd.,
or BioGenetics, acquired certain rights for South Korea.
Our lead program, varlitinib, is a highly potent, oral, reversible small molecule pan-HER inhibitor. Targeting individual members of the human
epidermal growth factor receptor, or HER, family is a well-validated approach to cancer treatment. In some cancers, HER1-selective or HER2-
selective agents, such as Herceptin, appear to be effective for a large number of patients. However, in other cancers such as gastric cancer, only a
small number of patients have tumors driven by a single receptor, such as HER2. We believe there are larger subsets of patients with cancers
driven by a combination of HER1, HER2, HER3 and HER4. We have demonstrated that varlitinib has activity in biliary tract cancer, where HER
family expression is known to be high, as well as in HER2-positive breast cancer and in subsets of colorectal cancer. Following discussions with
the United States Food and Drug Administration, or U.S. FDA, and other regulators, we have initiated a global pivotal clinical trial of varlitinib
for biliary tract cancer. We believe varlitinib has the potential to be the first targeted therapy approved for biliary tract cancer.
In addition to varlitinib, we have several other product candidates in development. We are developing ASLAN003, an inhibitor of human
dihydroorotate dehydrogenase, or DHODH, in AML and are exploring development in other solid tumors where this mechanism has been shown
to be relevant. ASLAN003 has the potential to induce differentiation in blast cells and our observed signs of clinical activity and tolerance leads
us to believe that ASLAN003 could be applicable in a broad range of AML patients.
ASLAN004 is an IL-4/IL-13 receptor antibody, which we believe has the potential to be a best-in-class therapy for moderate-to-severe atopic
dermatitis and asthma, due to greater selectivity in binding target cells via the IL-13 receptor. We have initiated a Phase 1 clinical trial
investigating ASLAN004 as a therapeutic antibody for atopic dermatitis. The single ascending dose study is expected to be completed in the first
half of 2019.
ASLAN005 is an antibody in preclinical development targeting recepteur d’origine nantais, or RON, an immune checkpoint inhibitor.
Our Product Candidates
Varlitinib (ASLAN001)
Varlitinib is a highly potent, oral, reversible, small molecule inhibitor of the human epidermal growth factor receptor, or HER, family of receptor
tyrosine kinases, or RTKs. Approved drugs that selectively target HER1 (also known as EGFR) or HER2 have been effective in some patients.
However, patients may relapse on or may not respond to these therapies because the growth of their cancers is driven by other HER family
receptors.
Varlitinib targets multiple members of the HER family of receptors and therefore we believe it may be effective in a broader range of tumor types
and effective in patients that have progressed on prior HER1-selective or HER2-selective therapies. Following guidance from the U.S. FDA, we
initiated a randomized global pivotal clinical trial testing varlitinib in second-line biliary tract cancer. We expect to report topline data for this
trial in the second half of 2019.
56
We licensed varlitinib from Array BioPharma Inc., or Array, in 2011 after successful completion of five Phase 1 clinical trials in a range of solid
tumors, which showed activity in breast cancer. To date, we have completed four additional Phase 1b clinical trials and two Phase 2 clinical trials
for this product candidate. Over 600 patients have been dosed with varlitinib as monotherapy or in combination with other agents. In these
clinical trials, varlitinib was well-tolerated in Caucasian and Asian patients. Varlitinib has demonstrated activity in a range of tumor types
including biliary tract, gastric, breast and colorectal cancer. In January 2018, we entered into a new license agreement with Array, which replaces
and supersedes our previous collaboration and license agreement, pursuant to which we obtained an exclusive, worldwide license to develop,
manufacture and commercialize varlitinib for all human and animal therapeutic, diagnostic and prophylactic uses.
We have obtained orphan drug designation from the U.S. FDA for varlitinib in gastric cancer and cholangiocarcinoma, which represents
approximately 60% of biliary tract cancer cases. The IND for varlitinib in biliary tract cancer was originally submitted by Array in 2005 and
subsequently inactivated in February 2012.
The IND for varlitinib in biliary tract cancer was then reactivated on April 21, 2017. We also have obtained orphan drug designation from the
Ministry of Food and Drug Safety in South Korea for varlitinib in biliary tract cancer.
Mechanism of Action
Varlitinib targets the HER family of receptors, comprised of four members, HER1, HER2, HER3 and HER4, which is responsible for driving
growth in human epithelial cells. These receptors can be mutated or overexpressed in many tumors, which can cause excessive proliferative
activity and uncontrolled growth. For instance, HER2 is often overexpressed or amplified in breast cancer. Many of these tumors are dependent
on continued HER2 activity for growth and are therefore sensitive to HER2 targeted agents such as Herceptin (trastuzumab). We believe that a
pan-HER inhibitor such as varlitinib, which targets HER1, HER2 and HER4, could inhibit proliferation and control tumor growth. HER3
requires active HER1, HER2 or HER4 to function and therefore varlitinib indirectly inhibits HER3.
Varlitinib has been designed to have favorable properties with low nanomolar, or nM, potency for the HER family. Varlitinib selectively inhibits
the HER family and therefore has the potential for fewer off-target effects. It was well-tolerated in the clinic, with reduced gastrointestinal, or GI,
toxicity compared to other pan-HER inhibitors.
Varlitinib Mechanism of Action
57
As a reversible pan-HER inhibitor, varlitinib binds temporarily to the HER family of receptors when the drug concentration is high, but
dissociates when the drug concentration falls. Irreversible pan-HER inhibitors bind permanently to the receptor so when they are absorbed in the
GI tract, the receptors in the gut epithelium are irreversibly inhibited and prevented from proliferating, which may lead to high rates of diarrhea
in patients. In contrast, the gut epithelium of patients taking a reversible inhibitor like varlitinib can proliferate when the local concentration in
the gut falls between dosing, which should result in lower frequency and severity of diarrhea. Importantly, we believe the concentration of
varlitinib in the tumor remains stable between dosing leading to sustained target inhibition predicted to be in excess of 90%.
Advantages
We believe that varlitinib has the potential to be the first targeted therapy approved for biliary tract cancer. We believe varlitinib has the
following potential competitive advantages:
•
•
•
Potent inhibition of HER1, HER2 and HER4 potentially enables it to be used in a broader range of tumors than HER1-
selective and HER2-selective agents. Drugs such as Herceptin only target HER2, which is only effective in tumors driven
specifically by HER2. We believe there are other patients whose tumors are driven by different combinations of HER1, HER2, HER3
and HER4, that may respond to pan-HER inhibitors.
HER4 inhibition may lead to a more durable response. The upregulation of HER4 has been shown to act as an escape mechanism
in breast cancer cell lines treated with lapatinib, which has no activity against HER4, leading to resistance. These cell lines remain
sensitive to varlitinib, suggesting that varlitinib may lead to a more durable response. We believe that this response may also be seen
in other tumor types.
Low levels of GI toxicity in comparison to other pan-HER inhibitors. Varlitinib has demonstrated a low level of GI toxicity, which
we believe is because it is a reversible inhibitor. Other pan-HER inhibitors are irreversible inhibitors and patients in those trials have
exhibited as much as 40% grades 3/4 diarrhea. In contrast, across all varlitinib clinical trials as of December 31, 2018, only 3% of
patients experienced grades 3/4 diarrhea.
• Well-tolerated in conjunction with different chemotherapy regimens. Varlitinib has been tested in combination with seven
different chemotherapy regimens including doublet chemotherapy and doses have been established for all of these regimens. We
believe this is important as chemotherapy protocols used for diseases like biliary tract cancer can vary from country to country.
Biliary Tract Cancer
Market Opportunity
Annually, there are approximately 200,000 new cases of biliary tract cancer in Asia, of which up to 145,000 are in China, and approximately
12,600 new cases in the United States. Biliary tract cancer has a five-year survival rate of less than 10% and there has been little improvement in
prognosis or treatment outcomes over the last two decades.
Biliary tract cancer consists of intra-hepatic and extra-hepatic cholangiocarcinoma (cancer of the bile duct), cancer of the gall bladder and papilla
of Vater (the final portion of the bile duct emptying into the small bowel). Though biliary tract cancer is considered to be a subset of liver cancer,
therapies approved for liver cancer are not approved for biliary tract cancer. There are no therapies approved for biliary tract cancer in the United
States.
58
Approximately 35% of patients undergo surgical resection, but recurrence is common, with the disease returning in 50% to 60% of patients.
Late-stage patients typically receive chemotherapy. In the first-line setting, the doublet combination of gemcitabine and cisplatin is commonly
used and has demonstrated a response rate of 26% and overall survival of 11.7 months.
Specific pathways driving biliary tract cancer have not been identified, however recent data from Japan and China show that approximately 70%
of biliary tract cancer tumors exhibit HER family overexpression, with HER4 expressed most widely.
Preclinical and Clinical Development
In a pooled analysis of biliary tract cancer patients from three Phase 1 clinical trials of varlitinib in combination with platinum-based regimens
assessing efficacy and safety, 43 patients who have had up to four prior treatments have been enrolled as of the data cut-off date of November 26,
2018. Of the 27 patients evaluable for efficacy, 9 patients achieved a partial response (33%) and 13 patients had stable disease, corresponding to
an ORR of 33% and disease control rate of 81%.
Maximum change in tumor size in biliary tract cancer patients from three Phase 1 clinical trials: Varlitinib in combination with
platinum-based regimens
Ongoing Clinical Trials
First-Line Biliary Tract Cancer
We have initiated a Phase 1b clinical trial to test the safety, tolerability and efficacy of varlitinib in first-line biliary tract cancer in combination
with gemcitabine/cisplatin. In the Phase 1b clinical trial, increasing doses of varlitinib are combined with gemcitabine/cisplatin to determine the
maximum tolerated dose, or MTD, in first-line biliary tract cancer. When the MTD is declared, the clinical trial is expected to progress to Phase
2.
59
In the ongoing Phase 1b clinical trial, 21 biliary tract cancer patients who had not received prior systemic therapy had been enrolled as of the data
cut-off date of November 26, 2018. Of the 16 patients evaluable for efficacy (11 in the 200mg cohort and five in the 300mg cohort), seven
patients achieved a partial response and eight had stable disease greater or equal to 12 weeks, corresponding to an ORR of 44% and DCR of
94%. In the higher 300mg dose cohort, three of five patients achieved a partial response and two had stable disease greater or equal to 12 weeks,
corresponding to a higher ORR of 60% and DCR of 100%. These preliminary results demonstrate increased activity of varlitinib in combination
with gemcitabine/cisplatin compared to the commonly used doublet chemotherapy combination of gemcitabine/cisplatin alone, where ORR and
DCR are 26% and 81%, respectively.
Maximum change in tumor size in first-line biliary tract cancer patients from Phase 1b clinical trials: Varlitinib in combination with
gemcitabine/cisplatin
TREETOPP Trial in Second-Line Biliary Tract Cancer
Based on the results in biliary tract cancer from the Phase 1b clinical trials, we met with the U.S. FDA in October 2016 regarding the design of a
registration trial and the overall development pathway for varlitinib in this indication. If this registration trial demonstrates a significant effect on
overall response rate, varlitinib could be granted accelerated approval subject to a second confirmatory trial being run after approval to
demonstrate an improvement in overall survival. TREETOPP is a randomized, double-blind, placebo-controlled clinical trial in second-line
biliary tract cancer comparing varlitinib and capecitabine to placebo and capecitabine. This clinical trial is being led by Dr. Milind Javle at the
MD Anderson Cancer Center. The co-primary endpoints are ORR and PFS and will be assessed by ICR according to RECIST. The secondary
endpoints are OS, DOR, DCR and tumor size percentage change at week 12, as defined by RECIST. In order to maintain an overall one-sided
10% type I error rate for the trial, we plan to use a Hochberg procedure, meaning that the trial would be deemed to have met its primary objective
if either endpoint is significant at the one-sided 5% level or if both endpoints are significant at the one-sided 10% significance level. We
completed recruitment of 127 patients in December 2018 and expect to report topline data from this trial in the second half of 2019. If the
endpoints are met, we intend to submit a New Drug Application, or NDA, to the U.S. FDA for accelerated approval in second-line biliary tract
cancer.
60
Pivotal Biliary Tract Cancer Trial Design (ongoing)
Metastatic Breast Cancer
The prevalence of breast cancer in Asia was approximately 2.3 million patients in 2012, while the prevalence in the United States was
approximately 1.0 million, of which approximately 5% was metastatic in both cases.
Metastatic breast cancer has a five-year survival rate of 26%. Approximately 20% of these patients have tumors with HER2 amplification and
will typically receive the anti-HER2 monoclonal antibody therapies Herceptin and pertuzumab in first-line treatment and then ado-trastuzumab
emtansine in second-line treatment. In third-line treatment, patients receive the HER1/HER2 small molecule inhibitor lapatinib plus
capecitabine. Varlitinib has demonstrated an improved objective response rate and with lower levels of diarrhea compared to lapatinib in a Phase
2 clinical trial.
We have completed a randomized open label Phase 2 clinical trial in HER2 amplified patients who have progressed on Herceptin. The open label
clinical trial enrolled 50 patients with two arms comparing varlitinib and capecitabine to lapatinib and capecitabine, with a primary endpoint of
tumor shrinkage at week 12, as assessed by ICR according to RECIST. Six patients withdrew consent within the first 30 days following
enrollment, of which only one patient experienced a grade 4 serious adverse event, which was diarrhea and assessed as being drug-related. One
patient died due to liver failure leading to multi-organ failure and sepsis after 11 days on treatment with varlitinib and capecitabine and was
reported as “possibly related” to varlitinib because the immediate cause of the patient’s death could not be determined, and therefore, a
relationship to varlitinib could not be excluded. These patients were excluded from the subsequent efficacy analysis. For the patients who
remained in the clinical trial, the average tumor shrinkage in the varlitinib arm was 36% compared to 18% in the lapatinib arm, with p=0.075,
which met the preset statistical criterion for significance for this clinical trial. (For reference, the U.S. FDA would typically require p≤0.05 to
demonstrate statistical significance in a pivotal clinical trial.) The ORR was 60% for patients in the varlitinib arm compared to 46% for those in
the lapatinib arm. Varlitinib and capecitabine was well-tolerated with 12.5% grades 3/4 diarrhea that was controlled on standard doses of
loperamide. The incidence of diarrhea observed in the varlitinib and capecitabine arm also compared favorably to an observed incidence of 40%
grades 3/4 diarrhea in published data for neratinib, an irreversible pan-HER inhibitor. In addition, the 60% ORR seen with varlitinib and
capecitabine is comparable to the 64% ORR seen in neratinib studies. We also have ongoing investigator-led clinical trials in neoadjuvant breast
cancer and breast cancer with brain metastasis.
61
Phase 2 Metastatic Breast Cancer Trial Design (completed)
Safety
Varlitinib has been dosed as monotherapy and in combination with singlet and doublet chemotherapies commonly used in biliary tract, gastric,
metastatic breast and colorectal cancer. The maximum tolerated doses varied from 300mg twice daily to 500mg twice daily (BID).
Varlitinib Maximum Tolerated Dose in Phase 1/1b Clinical Trials
Across all varlitinib clinical trials, the most commonly occurring drug-related adverse events, or AEs, as of December 31, 2018 were nausea
(36% of patients with any grade, 1% with grade 3 or 4), diarrhea (32% of patients with any grade, 3% with grade 3 or 4) and fatigue (32% of
patients with any grade, 4% with grade 3 or 4). Grade refers to the severity of the AE, with grade 3 indicating a severe or medically significant
but not immediately life-threatening AE and grade 4 indicating an AE with potentially life-threatening consequences.
ASLAN003
ASLAN003 is an orally active, potent inhibitor of DHODH that has the potential to be first-in-class in AML. AML is a cancer of the myeloid
line of blood cells, characterized primarily by the rapid growth of abnormal white blood cells that build up in the bone marrow and interfere with
the production of normal blood cells. We are conducting a Phase 2 clinical trial to develop ASLAN003 in AML. We reported interim data from
the first 14 patients in December 2018 and we expect to report data from the dose optimization portion in the first half of 2019. Our plan is to
meet with regulatory authorities to discuss expedited regulatory strategies, such as accelerated approval. We are also exploring other solid and
liquid
62
tumor types where DHODH may be relevant, such as myelodysplastic syndrome, TNBC and HCC. We licensed ASLAN003 from Almirall in
2012 after Almirall’s completion of a Phase 1 single ascending dose clinical trial, in which the drug was well-tolerated in healthy volunteers. We
then conducted two additional Phase 1 clinical trials, exploring multiple ascending doses and fed/fasted comparison in healthy volunteers. These
trials demonstrated that the drug was well-tolerated and plasma concentrations following dosing were similar in Caucasians and Asians. In
August 2018, we obtained orphan drug designation from the U.S. FDA for ASLAN003 in AML.
Mechanism of Action
In cancer, increased levels of adenosine triphosphate, or ATP, and pyrimidines are required for tumor growth and survival. ASLAN003 is an
inhibitor of DHODH, which is the enzyme controlling the rate limiting step in the de novo synthesis of pyrimidines. Pyrimidines are nucleotides
and are essential building blocks for the production of DNA and RNA in mammalian cells. DHODH is located in the mitochondria and during
manufacture of nucleotides it also contributes to the production of ATP. Inhibition of DHODH depletes the intracellular pool of pyrimidines and
contributes to lower levels of ATP. This leads to the induction of the tumor suppressor p53, which at high levels of induction triggers apoptosis,
or programmed cell death.
In AML, blast cells are unable to differentiate and form granulocytes, such as neutrophils and eosinophils, causing depletion of white blood cells.
All-trans retinoic acid, or ATRA, which is approved to treat certain types of AML representing up to 15% of all AML patients, is able to
differentiate these AML blast cells. Over 90% of patients with these types of AML experience a complete response and have a five-year survival
of 75% when treated with ATRA. In other subsets of AML, DHODH inhibitors have been shown to promote differentiation of these blast cells in
vitro, allowing them to turn into granulocytes, which potentially may reverse the condition.
Teriflunomide and leflunomide, which is a prodrug of teriflunomide, are first generation DHODH inhibitors, approved in the United States,
Europe and Asia for the treatment of rheumatoid arthritis and multiple sclerosis, respectively. These molecules are less potent inhibitors of
DHODH as compared to ASLAN003 and are sufficient to slow the proliferation of inflammatory cells and therefore adequate in chronic
inflammatory disorders. However, these molecules have limited use in oncology because the inhibition of tumor growth requires more potent and
sustained inhibition of DHODH. Previous efforts to develop high potency DHODH inhibitors for oncology indications were unsuccessful.
Candidate drugs had unacceptable levels of toxicity due to off-target binding and would accumulate in the body, requiring up to two years to
clear below pharmacologically active levels after dosing was stopped. As a result, development of these inhibitors did not progress. In contrast,
ASLAN003 is not chemically related to first generation DHODH inhibitors. ASLAN003 is up to two orders of magnitude more potent at
inhibiting DHODH than leflunomide and teriflunomide, and has a half-life of 18 hours, which should allow once daily dosing. We assessed the
potency of ASLAN003 using three standard assays: cell free, human primary cell and human whole blood. The table below shows that
ASLAN003 is more potent than teriflunomide. The IC50 value is the concentration of the drug required to produce 50% inhibition of response in
the assay.
63
ASLAN003 Cellular and Biochemical Potency
Advantages
We believe that ASLAN003 has the potential to be a first-in-class DHODH inhibitor in oncology due to the following competitive advantages:
•
•
•
•
Potent inhibition of DHODH. The binding affinity of ASLAN003 to DHODH is up to two orders of magnitude stronger than first
generation DHODH inhibitors, such as leflunomide and teriflunomide. This highly specific and potent inhibition of human DHODH
has the potential to reach the levels required to be efficacious in oncology.
Lack of toxicities associated with first generation inhibitors and other novel AML therapies. Existing DHODH inhibitors, such
as leflunomide and teriflunomide, are associated with significant liver toxicity. Both of these drugs take between three and four weeks
to build to therapeutic levels and two years to clear completely after dosing is stopped. In contrast, ASLAN003 reaches full exposure
in 24 hours with a half-life of 18 hours allowing rapid clearance following cessation of treatment. Furthermore, recently launched
AML therapies, such as midostaurin and enasidenib, are associated with significant hematological and liver toxicities. Many AML
patients are elderly or cannot otherwise tolerate significant toxicities. As a result, we believe the safety profile of ASLAN003 could
allow its use in these patients.
Enables AML blast cells to differentiate into granulocytes and may be applicable in a broad range of AML patients.
ASLAN003 has demonstrated the ability to differentiate AML blast cells into granulocytes in a variety of AML cell lines that do not
respond to ATRA. ASLAN003 may have applicability in patients that do not respond to ATRA, which represent approximately 85%
of AML patients.
Evidence of activity in TNBC. Recent data suggest that DHODH inhibition is active in animal models of TNBC, an aggressive type
of breast cancer with few effective treatment options.
Market Opportunity
AML patients that have failed on standard of care chemotherapy in AML or do not respond to chemotherapy are termed relapsed/refractory, and
represent the majority of the total AML population. In 2016, the annual incidence of relapsed/refractory patients is approximately 13,000 patients
in the United States, 8,000 in Europe, 5,000 in Japan and 24,000 in China. Survival is age-dependent and survival rates are extremely poor for
the elderly. The five-year relative survival rate for AML patients aged 19 years and below is 65%, but declines to 50% for patients aged 20 to 49
years, and the survival rate for patients aged 65 years or older is only 6%.
64
The first-line treatment for patients with AML is a combination of aggressive chemotherapies. However, elderly patients with AML typically are
ineligible for aggressive treatment regiments due to the significant toxicity associated with these therapies. The survival of these patients is
usually less than one year. Over the past two decades, many compounds have been evaluated in AML patients, however, only three targeted
drugs have been approved. Furthermore, these drugs target relatively small subsets of patients, leaving a significant unmet need.
Preclinical and Clinical Development
Our Phase 1 single and multiple ascending dose clinical trials of ASLAN003, which were conducted with 95 healthy subjects, demonstrated dose
proportional pharmacokinetics and no accumulation in the body. The exposure profile of the drug was highly similar in Asian and Caucasian
subjects, and demonstrated stable drug levels in plasma at multiple doses.
After a single 100mg oral dose of ASLAN003, the plasma levels of the drug in Caucasians and Asians were highly similar. ASLAN003 also
reached steady state after the second day of dosing and did not accumulate in the body.
ASLAN003 Pharmacokinetic Profile
We predict the exposure of ASLAN003 to result in approximately 90% inhibition of DHODH, with 400mg taken once daily, in comparison to
the maximum dose of teriflunomide, which leads to only 30% inhibition, as shown in the graph below:
65
DHODH Binding with ASLAN003 Compared to Teriflunomide
ASLAN003 in AML
In AML, cancerous blast cells fail to differentiate into mature blood cells and do not follow normal processes controlling cell death due to
genetic mutations. As a result, the number of blast cells increases to very high levels, crowding out normal red and white blood cell production in
the bone marrow, which can eventually result in patient death. Normal differentiated blast cells express specific cell surface markers, such as
CD11b, and contain granules, which are active compartments inside the cell that store molecules for killing invading pathogens.
ASLAN003 has demonstrated the ability to cause differentiation of AML blast cells leading to mature cells that correctly express CD11b and
contain active granules.
Data published in 2016 identified inhibition of DHODH as a key mechanism that can trigger differentiation of blast cells in AML. Inhibition of
DHODH and the resultant depletion of the pyrimidine pool in AML resulted in extensive differentiation in in vitro and in vivo mouse bone
marrow transplant models. In preclinical studies, we have demonstrated that ASLAN003 can differentiate AML blast cells in vitro and in vivo in
a variety of AML cell lines and primary AML cells.
Differentiation of AML Cell Lines with ASLAN003
The human AML blast cell line, THP-1, demonstrated differentiation when exposed to low doses of ASLAN003 characterized by expression of
cell surface markers of normal immune cells, such as CD11b, condensation of the nuclei and formation of active granules that are indicative of
normal human white blood cells. Low concentrations of ASLAN003, approximately equivalent to a 50mg once daily dose in patients, led to over
95% upregulation of CD11b which is indicative of differentiation of AML blast cells to granulocytes.
66
ASLAN003 exposure also resulted in blast cells developing condensed, lobed nuclei, characteristic of normal human granulocytes, and in the
appearance of active granules in the cytoplasm, as demonstrated by the reduction of Nitro Blue Tetrazolium, or NBT, a standard assay for
granulocytes, as shown below:
In addition to THP-1, the differentiation effect of ASLAN003 has also been demonstrated in other AML cell lines, namely KG-1 and MOLM-14
with similar nanomolar potency.
AML cell line
THP-1
KG-1
MOLM-14
ASLAN003 in vitro differentiation activity
ED50 (nM) for differentiation
28
56
85
We have also demonstrated that ASLAN003 reduces leukemic burden and prolongs survival in vivo in mice bearing AML cell lines THP-1 and
MOLM-14. ASLAN003 also reduced leukemic burden in an AML PDX model.
67
Survival advantage of ASLAN003 in vivo
Reduction of leukemic burden in AML PDX model by ASLAN003
AML Phase 2 Clinical Trial
We have initiated a Phase 2 clinical trial with ASLAN003 in patients with advanced relapsed/refractory AML in Australia and Singapore. We
intend to initially recruit 24 patients in the first part of this trial and test at least four doses of ASLAN003 (100mg QD, 200mg QD, 100mg BID
and 200mg BID) in the AML population as monotherapy for 28 days or until progression with a primary endpoint of the rates of complete
remission, or CR, and complete remission with incomplete bone marrow recovery, or CRi, followed by an expansion cohort of an additional 20
patients to study the optimum dose selected by the steering committee. In addition, we are planning an additional clinical trial recruiting up to 10
patients to explore the efficacy of ASLAN003 in combination with azacitidine.
68
Phase 2 AML Trial Design (ongoing)
As of November 16 2018, 14 patients with AML ineligible for standard treatment, including relapsed, refractory and treatment naïve patients,
had been enrolled in the multicenter dose optimization study to evaluate ASLAN003 monotherapy administered as a 28-day cycle. Eight patients
had received at least one post-treatment assessment at the cut-off date and were evaluable for efficacy. Of the eight evaluable patients, four
patients showed clinical signs of efficacy: two patients exhibited evidence of myeloid differentiation; and, one patient in the 100mg BID cohort
developed suspected differentiation syndrome. Overall, four patients had stable disease for more than three months. One AML patient that
entered suspected differentiation syndrome demonstrated a reduction in peripheral blood blast cells from 66% to 6% with a concomitant increase
in neutrophils. Despite this significant reduction in blood blast cells, we were unable to confirm whether this patient had a complete remission
(which would require bone marrow blast cells to be 5% or less) because the patient had bone marrow fibrosis and it was therefore not possible to
take a viable bone marrow biopsy.
Efficacy summary of ongoing ASLAN003 AML Phase 2 clinical trial
Cohort
Patients treated
Patients evaluable for efficacy
Patients with signs of efficacy
100mg QD
200mg QD
100mg BID
Total
6
2
1
6
5
3
2
1
0
14
8
4
As of March 2019, we have completed recruitment for the 100mg BID cohort (cohort 3) and continue to see further evidence of activity. Dosing
for the 200mg BID cohort (cohort 4) has started and is expected to complete in the first half of 2019. In addition, we intend to open a cohort to
explore the safety, tolerability and efficacy of ASLAN003 in combination with azacitidine. In December 2018, we submitted an IND to the U.S.
FDA for ASLAN003 to allow the current Phase 2 clinical trial to open additional centers in the United States.
69
Potential Development Opportunity for ASLAN003 in Solid Tumors
Recent publications have demonstrated that phosphatase and tensin homolog (PTEN) (Mathur et. al., Cancer Discovery 2017) and KRAS
(Koundinya et. al., Cell Chemical Biology 2018) mutant cancers are both highly sensitive to DHODH inhibition. Additional evidence suggests
that DHODH inhibitors may have synergistic efficacy in TNBC in combination with commonly used chemotherapies (Brown et. al., Cancer
Discovery 2017). We have reproduced this data, and our data in PTEN mutant TNBC PDX models with ASLAN003 confirms inhibition of
DHODH leads to efficacy comparable to chemotherapy (doxorubicin). Finally, an upcoming publication demonstrates that tumorigenesis is
dependent on de novo synthesis of pyrimidines via DHODH and that DHODH activity is conserved in multiple cancer types, therefore inhibition
of DHODH can be efficacious in a wide variety of cancers (Bajzikova et. al., Cell Metabolism 2019).
Safety
ASLAN003 has been well-tolerated in AML patients treated to date with only two patients out of 14 experiencing a grade 3/4 adverse event. The
most commonly occurring adverse events in AML were leukocytosis, nausea and rash, with grade 3/4 leukocytosis in one patient.
Adverse event
Leukocytosis
Nausea
Rash maculo-papular
Pleural effusion
Abdominal pain
Fatigue
Conjunctivitis
Decreased appetite
Hypokalaemia
Epistaxis
Rash generalised
ASLAN004
N=14
Any grade
Grade ≥ 3
N
2
2
2
1
1
1
1
1
1
1
1
(%)
14
14
14
7
7
7
7
7
7
7
7
N
1
0
0
1
0
0
0
0
0
0
0
(%)
7
0
0
7
0
0
0
0
0
0
0
ASLAN004 is a fully human monoclonal antibody that targets the IL-13 receptor α1 subunit, or IL-13Rα1. ASLAN004 is currently in preclinical
development, and we are not aware of any other antibodies in clinical development targeting IL-13Rα1. By targeting IL-13Rα1, ASLAN004
potently inhibits signaling of both interleukin 4, or IL-4, and interleukin 13, or IL-13. IL-4 and IL-13 are central to triggering symptoms of
allergy in atopic dermatitis, such as redness and itching of the skin, as well as asthma symptoms such as shortness of breath, wheezing and
coughing. Dupilumab is marketed for both moderate-to-severe atopic dermatitis and moderate-to-severe asthma. As we target the same pathways
as
70
dupilumab, we believe ASLAN004 can follow a similar regulatory path. We believe ASLAN004 has the potential to become a first-in-class IL-
13Rα1 inhibitor. By targeting IL-13Rα1, a receptor with a narrower cellular distribution than the IL-4 receptor, we believe ASLAN004 has the
potential to offer a lower dosing frequency, which are important features for subcutaneous injections, providing greater patient convenience. In
addition, ASLAN004 has more selective binding than dupilumab, which we believe could give ASLAN004 a more favorable side effect profile
than dupilumab. We are conducting a Phase 1 clinical trial for ASLAN004 in atopic dermatitis. The single ascending dose portion of the study
recruited healthy volunteers and the multiple ascending dose component will recruit moderate to severe atopic dermatitis patients. The single
ascending dose study is expected to complete in the first half of 2019. In the future, we may also develop ASLAN004 in other inflammatory
indications, such as chronic obstructive pulmonary disorder, or COPD. We licensed worldwide rights for ASLAN004 from CSL Limited, or
CSL, in May 2014.
Mechanism of Action
ASLAN004 is a fully human monoclonal antibody with high affinity binding that inhibits both IL-4 and IL-13 signaling by binding to IL-13Rα1.
The cytokines IL-4 and IL-13 are the main drivers of allergic inflammation and have mutually redundant functions. They selectively bind and
stimulate the type 2 receptor, which is a complex composed of IL4Rα and IL-13Rα1. Stimulation of the common receptor for IL-4 or IL-13
triggers a signaling cascade that can result in severe atopic dermatitis or asthma. The pivotal role for this pathway in these disease indications has
been exemplified by the monoclonal antibody dupilumab which binds to IL-4Rα to block signaling by IL-4 and IL-13. We are not aware of any
other monoclonal antibody in development that can inhibit both IL-4 and IL-13 signaling. IL-13Rα1 has a narrower cellular distribution than IL-
4Rα. We believe this can offer potential benefits that include a lower dosing frequency than dupilumab, which requires subcutaneous injections
every two weeks with a 2 milliliter injection volume. These potential benefits of ASLAN004 would represent meaningful advantages for patient
treatment. An additional benefit of ASLAN004 is its lack of binding to the type 1 receptor, which is expressed on a broader range of
hematological cell types. We believe that by avoiding inhibition of the type 1 receptor, ASLAN004 may have fewer side effects than dupilumab,
which does bind the type 1 receptor.
The figure below demonstrates the binding of ASLAN004 and dupilumab to the type 2 receptor:
IL-4 / IL-13 Receptor Antibody Mechanism of Action
71
Advantages
We believe that ASLAN004 has the potential to be a best-in-class therapy:
•
•
•
Validated mechanism with the potential for greater efficacy than IL-13 selective and IL-4 selective inhibitors. IL-13 selective
and IL-4 selective inhibitors, such as lebrikizumab, have shown limited efficacy in treating allergic inflammation, with several agents
recently failing to demonstrate efficacy in Phase 2 and Phase 3 clinical trials. We believe that agents that can block the activity of both
IL-4 and IL-13 will be more efficacious. Dupilumab was shown to be effective in treating moderate-to- severe atopic dermatitis by
blocking IL-4 and IL-13 activity. Similar to dupilumab, ASLAN004 also blocks the activity of IL-4 and IL-13.
Potential for less frequent dosing. Dupilumab is dosed once every two weeks with a 2 milliliter subcutaneous injection. We may be
able to offer a once monthly injection with ASLAN004. This potential reduced injection frequency would provide patients with
greater convenience.
Potential for improved safety profile. ASLAN004 targets the IL-13Ra1 subunit of the IL-4/IL-13 receptor, whereas dupilumab
blocks IL-4Ra. As a result, both ASLAN004 and dupilumab block the type 2 receptor, which contains IL-4Ra and IL-13Ra1, however
only dupilumab blocks the type 1 receptor, which contains IL-4Ra but not IL-13Ra1, and is present on B-cells and macrophages. We
believe that by avoiding inhibition of the type 1 receptor, ASLAN004 may have fewer side effects.
Market Opportunity
Market Opportunity in Severe Atopic Dermatitis
Atopic dermatitis is the most common dermatological disease, affecting over 200 million patients worldwide, characterized by red inflamed skin
and severe daytime and nighttime itching, which can severely impact patients’ quality of life. Up to one-third of adult atopic dermatitis patients
are considered moderate-to-severe, for which currently available therapeutics are limited and management is challenging in the majority of cases.
Treatment options have focused on topical therapies. In December 2016, the U.S. FDA granted approval for Eucrisa (developed by Pfizer Inc.), a
topical treatment for mild to moderate atopic dermatitis. More recently in March 2017, the U.S. FDA granted approval for dupilumab (developed
by Sanofi S.A. and Regeneron Pharmaceuticals, Inc.) for adults with moderate-to-severe atopic dermatitis.
Market Opportunity in Asthma
Asthma affects approximately 300 million patients worldwide. Chronic inflammation of the airway, combined with bronchial hyper-reactivity
causes shortness of breath, wheezing and coughing, potentially leading to exacerbations that may result in hospitalization or death. Over 4.5
million severe asthmatics have symptoms which cannot be controlled with conventional therapies, such as bronchodilators or inhaled
corticosteroids.
Xolair (anti-IgE) and Nucala (anti-IL5) are the two leading biological therapies by sales. Novel therapies like dupilumab are anticipated to
compete with biological therapies and inhaled therapies.
72
Preclinical and Clinical Development
ASLAN004 is a fully human IgG4 monoclonal antibody that specifically binds to the human IL-13Ra1 protein and was originally made using the
Medarex mouse technology. The antibody was isolated and optimized to have picomolar binding affinity by CSL Behring, a member of the CSL
group of companies.
ASLAN004 is a potent inhibitor of both IL-4 and IL-13 signaling with a binding affinity in the picomolar range for human IL-13Ra1. In in vitro
assays, ASLAN004 inhibits the release of mediators that trigger allergic reactions with an IC50 in the low nM range.
We have constructed manufacturing cell lines that deliver a yield of over two grams per liter of therapeutic antibody. ASLAN004 has been
successfully manufactured at the 500-liter production scale in accordance with current good manufacturing practices, or cGMP. ASLAN004 has
been tested in four-week good laboratory practices, or GLP, compliant toxicology studies in primates.
We initiated a Phase 1 dose escalation clinical trial for ASLAN004 and enrolled the first subject in October 2018. The single ascending dose
(SAD) portion of the study will recruit healthy volunteers, and is followed by a multiple ascending dose (MAD) study conducted in moderate-to-
severe atopic dermatitis patients. In the first part of the SAD study, we demonstrated that ASLAN004 was well-tolerated at all doses when
administered to healthy volunteers intravenously. There were no adverse events that led to discontinuations. Analysis of downstream mediators
including phosphorylation of STAT6 (pSTAT6), a critical mediator of allergic inflammation, demonstrated complete inhibition within one hour of
dosing, which was then maintained for more than 29 days, suggesting monthly dosing may be achievable. In the second part of the ongoing SAD
study, we are testing a subcutaneous formulation. We dosed the last patient in March 2019 and the SAD study is expected to complete in the first
half of 2019. The MAD study will provide early efficacy data in severe atopic dermatitis, allowing dose selection and an early comparison to
currently available standards of care.
Preclinical Pipeline
We have been building an immuno-oncology portfolio to provide a pipeline of innovative drug candidates that could be used as monotherapy or
in combination with other drug candidates in our portfolio.
•
ASLAN005—an immuno-oncology target expressed on the macrophage, whose inhibition could enhance T-cell activity. We
have an ongoing collaboration with the Huntsman Institute in Utah studying the effects of RON inhibition. RON kinase activation
may lead to the formation of macrophages with an M2 phenotype, which are tumor supportive. By inhibiting RON, the macrophage
type 1 phenotype may be preferred and this phenotype is tumor suppressive, releasing cytokines that can potentially enhance the
activity of T-cells. This may lead to synergistic activity when combined with PD1 or CTLA4 inhibitors. We have started development
of a fully human monoclonal antibody against the extracellular domain of RON kinase.
Competition
Our industry is intensely competitive and subject to rapid and significant technological change. While we believe that our knowledge, experience
and scientific resources provide us with competitive advantages, we face substantial competition from major pharmaceutical companies,
specialty pharmaceutical companies and biotechnology companies worldwide. Many of our competitors have significantly greater financial,
technical and human resources. Small and early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. As a result, our competitors may discover, develop, license or commercialize products
before or more successfully than we do.
73
We face competition with respect to our current product candidates, and will face competition with respect to future product candidates, from
segments of the pharmaceutical, biotechnology and other related sectors, as well as from academic institutions.
The acquisition or licensing of pharmaceutical products is also very competitive. If we seek to acquire or license products, we will face
substantial competition from a number of more established companies, some of which have acknowledged strategies to license or acquire
products and many of which are bigger than us and have more institutional experience and greater cash flows than we have. These more
established companies may have competitive advantages over us, as may other emerging companies taking similar or different approaches to
product licenses or acquisitions. In addition, a number of established research-based pharmaceutical and biotechnology companies may acquire
products in late stages of development to augment their internal product lines, which may provide those companies with an even greater
competitive advantage.
If our product candidates are approved, they may compete with currently marketed drugs and therapies used for treatment of the same
indications, and potentially with drug candidates currently in development. The key competitive factors affecting the success of any approved
product include its efficacy, safety profile, price, method of administration and level of promotional activity.
Varlitinib
•
There are no approved targeted therapies for biliary tract cancer; however, there are several targeted therapies currently in clinical
development targeting specific subsets of biliary tract cancer, including ivosidenib being developed by Agios Pharmaceuticals, Inc.,
ARQ087 being developed by Arqule, Inc. and lenvatinib being developed by Eisai Inc.
ASLAN003
• We do not consider chemotherapy to be a competitor as we expect ASLAN003 to be used either in patients that are not eligible for
chemotherapy or in combination with chemotherapy.
•
•
•
Enasidenib was recently approved to treat adults with AML whose tumors have mutations in IDH2, which represents around 10-15%
of AML patients. In the single-arm registration study, 40% of patients responded to enasidenib; however, differentiation syndrome,
which can be fatal if not treated, occurred in 14% of patients.
Midostaurin was also recently approved to treat newly diagnosed AML patients with a FLT3 mutation, which represents around 30%
of AML patients.
There are a large number of drugs currently in development for AML. Most of these target specific subsets of disease.
ASLAN004
• We are not aware of any other drugs targeting IL-13Rα1 and we believe our intellectual property would preclude such development.
•
•
Dupilumab from Sanofi S.A. and Regeneron Pharmaceuticals, Inc. is approved to treat both moderate-to-severe atopic dermatitis and
moderate-to-severe asthma.
There are several IL-13 selective inhibitors in development, including lebrikizumab being developed by Dermira, Inc., and tralokinumab
being developed by AstraZeneca. Both of these drugs have recently failed in Phase 3 clinical trials in asthma, however they may be
successful in other indications, such as atopic dermatitis.
74
Manufacturing
We do not have internal manufacturing capabilities for small molecules or biological drugs and we do not intend to build or acquire infrastructure
for manufacturing our drugs for clinical or commercial supply. All of our clinical supplies are manufactured in accordance with cGMP using
high quality contract manufacturing organizations based in the United States, Europe and Asia.
We are currently developing a validated commercial process for the manufacture of varlitinib. We have contracted with three cGMP compliant
third-party manufacturers in the United Kingdom and China to manufacture the active pharmaceutical ingredient and final tablet. The first
batches of varlitinib drug substance manufactured using the validated commercial process are expected to be available in mid-2019.
We have worked with one contract manufacturing organization to manufacture ASLAN004 at a 500 liter scale and are currently in the process of
selecting a long term late-stage clinical commercial manufacturer for this drug.
Varlitinib
Varlitinib drug substance is manufactured in accordance with cGMP by Sterling Pharma Solutions Limited in the United Kingdom. We have
manufactured at the 200kg scale and are currently in process validation at the 350kg scale. Varlitinib drug product (tablet) is manufactured in
accordance with cGMP by PCI Pharma Services in the United Kingdom. Both drug substance and drug product can be scaled to over four tons
per year. A second site manufacture for varlitinib in accordance with cGMP has been established at WuXi Apptec Co., Ltd., or WuXi, in China
for both drug substance and drug product. Currently, WuXi has successfully manufactured at the 30kg scale.
ASLAN003
ASLAN003 drug substance has been manufactured by Sigma-Aldrich Company LTD in Switzerland at the 30kg scale in accordance with cGMP.
ASLAN003 drug product in the form of capsules has been manufactured by WuXi in China in accordance with cGMP. We expect to develop an
ASLAN003 tablet in 2019 and plan to conduct further scale up and process optimization of both drug substance and drug product.
ASLAN004
Manufacturing cell lines for ASLAN004 have been created by Selexis SA. Process development for ASLAN004 drug substance has been
successful and was developed by JHL Biotech, Inc. Manufacture at 500 liter scale for both non-GMP (for toxicology) and cGMP compliant (for
clinical trials) has been completed.
75
License and Collaboration Agreements
Collaboration and License Agreements with BioGenetics
License of varlitinib for South Korea
On February 27, 2019, we entered into a collaboration and license agreement with BioGenetics pursuant to which we granted BioGenetics the
exclusive right to commercialize, and if agreed, manufacture, varlitinib for the treatment of all indications in South Korea. In consideration of the
rights granted to BioGenetics under the agreement, we received an upfront payment of $2 million from BioGenetics and are eligible to receive up
to $11 million in sales and development milestones (the threshold for the sales milestones being subsequently amended by the ASLAN003
license summarized below). We are also eligible to receive tiered double-digit royalties on net sales up to a percentage within the mid-
twenties. BioGenetics will be responsible for obtaining initial and all subsequent regulatory approvals of varlitinib in South Korea. We may
provide clinical drug supplies to BioGenetics required for regulatory filings and for commercialization of products, pursuant to a separate
manufacturing and supply agreement which the parties shall use commercially reasonable efforts to enter into no later than June 30, 2020.
During the license period and for one year thereafter, neither BioGenetics, nor any of its affiliates, will participate in or fund, directly or
indirectly, the development, manufacture or commercialization of a product which competes with varlitinib. The license period commences on
the effective date of the agreement and, unless terminated earlier pursuant to the terms of the agreement, or is mutually agreed to be extended,
expires on the tenth anniversary of first commercial sale, subject to a right of automatic renewal for a further year upon ether party’s notice.
Either party may terminate the agreement in the event of material breach by, or insolvency of, the other party, or in the event of a material safety
risk associated with the product. On any termination of the agreement, the license granted to BioGenetics will terminate, subject to certain
transitional provisions.
License of ASLAN003 for South Korea
On March 11, 2019, we entered into a collaboration and license agreement with BioGenetics, pursuant to which we granted BioGenetics the
exclusive right to commercialize, and if agreed, manufacture, ASLAN003 for the treatment of all indications in South Korea. In consideration of
the rights granted to BioGenetics under the agreement, we received an upfront payment of $1 million from BioGenetics and are eligible to
receive up to $8 million in sales and development milestones, the thresholds for payment of such sales milestones being the aggregate of sales of
varlitinib under the license summarized above and sales of ASLAN003 products. We are also eligible to receive tiered double-digit royalties on
net sales up to a percentage within the mid-twenties. BioGenetics agreed to contribute to the global research and development costs incurred by
ASLAN in the clinical development of ASLAN003 in acute myeloid leukemia. BioGenetics will be responsible for obtaining initial and all
subsequent regulatory approvals of ASLAN003 in South Korea. We may provide clinical drug supplies to BioGenetics required for regulatory
filings and for commercialization of products, pursuant to a separate manufacturing and supply agreement which the parties shall use
commercially reasonable efforts to enter into no later than June 30, 2020.
76
During the license period and for one year thereafter, neither BioGenetics, nor any of its affiliates, will participate in or fund, directly or
indirectly, the development, manufacture or commercialization of a product which competes with ASLAN003. The license period commences on
the effective date of the agreement and, unless terminated earlier pursuant to the terms of the agreement, or is mutually agreed to be extended,
expires on the tenth anniversary of first commercial sale, subject to a right of automatic renewal for a further year upon ether party’s notice.
Either party may terminate the agreement in the event of material breach by, or insolvency of, the other party, or in the event of a material safety
risk associated with the product. On any termination of the agreement, the license granted to BioGenetics will terminate, subject to certain
transitional provisions.
License Agreement with Array
On January 3, 2018, we entered into a new license agreement with Array pursuant to which we obtained an exclusive, worldwide license to
develop, manufacture and commercialize varlitinib for all human and animal therapeutic, diagnostic and prophylactic uses. This new license
agreement replaces and supersedes our previous collaboration and license agreement with Array dated July 12, 2011.
Under the new license agreement, we agreed to use commercially reasonable efforts to obtain approval by the U.S. FDA or the applicable health
regulatory authority and commercialize varlitinib.
In consideration of the rights granted to us under the agreement, we made an initial upfront payment to Array of $12 million and an additional
upfront payment of $11 million in July 2018. In addition, we will be required to pay up to $30 million if certain development milestones are
achieved, $20 million if certain regulatory milestones are achieved, and up to $55 million if certain commercial milestones are achieved. We are
also required to pay Array tiered royalties in the low tens on net sales of varlitinib. Our royalty obligations will continue on a country-by-country
basis through the later of the expiration of the last valid patent claim for varlitinib or ten years after the first commercial sale of varlitinib in a
given country.
If within two years of the date of the new license agreement we sublicense varlitinib and are paid an upfront payment, Array will further be
entitled to receive one-half of the portion of any such upfront payment that exceeds a specified amount. In the event that the base royalty under a
sublicense agreement is 20% or less, we will only be required to share with Array one-half of the amount actually received by us under such
sublicense agreement in lieu of the tiered royalties described above, provided that the royalty paid in such case shall in no event be less than a
royalty in the high single digit range. If we undergo a change in control during a defined period following execution of the new license agreement,
Array will also be entitled to receive a low to mid single-digit percentage of the proceeds resulting from the change in control. Unless earlier
terminated, the agreement will continue on a country-by-country basis until the expiration of the respective royalty obligations in such country.
Upon such expiration in such country, Array will grant to us a perpetual, royalty-free, non-terminable, non-revocable, non-exclusive license to
exploit certain know-how in connection with the development, manufacturing and/or commercialization of varlitinib for all human and animal
therapeutic, diagnostic and prophylactic uses in such country. Either party may terminate the agreement (i) in the event of the other party’s
material breach of the agreement that remains uncured for a specified period of time or (ii) the insolvency of the other party. We may also terminate
the agreement without cause at any time upon 180 days advance notice to Array.
77
Development and License Agreement with Almirall
On May 16, 2012, we entered into a development and license agreement with Almirall, pursuant to which we obtained an exclusive, worldwide
license to certain patents, know-how and other intellectual property controlled by Almirall to a DHODH inhibitor, LAS186323, which we refer to as
ASLAN003. The licensed field covered by this agreement was limited to the treatment or prevention of rheumatoid arthritis, excluding any topical
formulation.
On December 21, 2015, we entered into an amended development and license agreement with Almirall which replaced the previous agreement,
further amended by an amendment agreement entered into on March 16, 2018. Under the agreement as so amended, we obtained from Almirall
an expanded exclusive, worldwide license to develop, manufacture and commercialize ASLAN003 products for all human diseases with primary
focus on oncology diseases, excluding topically-administered products embodying the compound for keratinocyte hyperproliferative disorders,
and the non-melanoma skin cancers basal cell carcinoma, squamous cell carcinomas and Gorlin Syndrome, or collectively, the KHD/NMSC
products. We generally have the right to sublicense our rights under the agreement. If Almirall wishes to use a third party to develop KHD/NMSC
products, we have a right of first negotiation to obtain a license from Almirall to carry out those developments.
Under the amended agreement, we are generally obligated to use commercially reasonable efforts to develop ASLAN003 products in accordance
with the development plan, and to commercialize ASLAN003 products, either by ourselves or through sublicensees. We agreed not to develop or
commercialize any competing product that has the same mechanism of action as ASLAN003 while the intellectual property licensed from
Almirall remains in force or for ten years after the launch of ASLAN003 products on a country-by-country basis, whichever is longer. In addition,
we granted to Almirall the right to use certain developed know-how for Almirall’s internal and commercial programs for KHD/NMSC products,
and Almirall granted us the right to use certain know-how developed by or on behalf of Almirall in the course of its programs for KHD/NMSC
products in the field licensed to ASLAN.
In consideration of the rights granted to us under the amended agreement, we will be required to pay an aggregate of up to $30 million if certain
development milestones are achieved and an aggregate of up to $50 million if certain regulatory milestones are achieved, in each case across
different indications. If we commercialize any ASLAN003 products, we will be required to pay Almirall tiered royalties in the mid single-digit
range on net sales of ASLAN003 products, subject to adjustments in certain circumstances. In the event we sublicense any of our rights under the
agreement relating to the ASLAN003 technology, we will be obligated to pay Almirall 10% of sublicensee income we may receive under such
sublicenses.
Unless earlier terminated, the amended agreement continues indefinitely. Either party may terminate the agreement (i) in the event of the other
party’s material breach of the agreement that remains uncured for a specified period of time, (ii) if significant safety issues arise which make
development or commercialization of the product unlawful or in violation of standard industry practices, (iii) if the other party becomes insolvent
or (iv) if the continuation of the agreement is no longer commercially viable, as proven by us based on supporting objective data reasonably
acceptable to Almirall and us. Almirall may terminate the agreement (i) if we fail to provide evidence of having used commercially reasonable
efforts to pursue development or commercialization, (ii) if we challenge or assist third parties in challenging any intellectual property rights
licensed from Almirall under the amended agreement, (iii) if there is a general withdrawal or recall of ASLAN003 products from any country, on
a product-by-product and/or country-by-country basis or (iv) upon a change of control of ASLAN if such change of control could reasonably be
expected to lead to an impairment to Almirall, subject to certain conditions. Under the agreement, an impairment in connection with a change of
control will only be deemed to occur if Almirall
78
can demonstrate that (i) a competitor of Almirall will control us, (ii) the commercial value of ASLAN003 products may be damaged, (iii) the
commercial value of Almirall’s KHD/NMSC products may be adversely affected, (iv) Almirall’s reputation or the reputation of any of Almirall’s
products or compounds in the marketplace may be damaged and/or (v) the party that will control us lacks the resources to maximize commercial
sales of ASLAN003 products.
License Agreement with CSL
On May 12, 2014, we entered into a license agreement with CSL, pursuant to which we obtained an exclusive, worldwide license to certain
patents, know-how and other intellectual property owned or controlled by CSL related to CSL’s anti-IL13 receptor monoclonal antibody,
CSL334, which we refer to as ASLAN004, and antigen binding fragments thereof. Under the agreement, we have the exclusive right to develop
ASLAN004 products through clinical proof of concept for the treatment, diagnosis or prevention of diseases or conditions in humans. Although
we do not have the right to commercialize ASLAN004 products ourselves, we have the right to grant the commercial rights to third parties after
we achieve clinical proof of concept subject to certain conditions.
On September 18, 2018, we amended the license agreement with CSL, primarily to change the focus of the development program from asthma to
atopic dermatitis.
We are obligated to develop ASLAN004 products through clinical proof of concept at our own expense, and we are required to achieve certain
development milestones by specified dates.
In consideration of the rights granted to us under the agreement, we are required to pay to CSL a share in the range of 40 to 50 percent of all
licensing revenue we receive. We are also responsible for all payments to third-party licensors to CSL, to the extent such obligations relate to our
exploitation of the rights licensed under CSL’s agreement with those parties.
The agreement continues until 12 months after the final development milestone date. However, if we have entered into a sublicense granting the
right to commercialize ASLAN004 products to a third party before such date, then the agreement will be extended until the expiration or
termination of such third-party sublicense.
Either party may terminate the agreement (i) in the event of the other party’s material breach of the agreement that remains uncured for a
specified period of time, (ii) under certain circumstances related to the safety of ASLAN004 or (iii) if the other party becomes insolvent. In
addition, we may terminate the agreement under certain circumstances related to the development and commercialization of ASLAN004.
In the event that we enter into an agreement with a third party for the commercialization of ASLAN004 products, and such agreement
subsequently expires by its terms, the license of CSL patents and know-how granted under the license agreement will become fully paid-up and
perpetual as they relate to the agreement with the third party. If the agreement is terminated or expires and CSL subsequently commercializes
ASLAN004 products or grants a third party rights to commercialize ASLAN004 products, then CSL will pay us royalties on the net sales of
ASLAN004 products or share license revenue with us (whichever is applicable).
79
Intellectual Property
Patents
Our commercial success depends in part on our ability to identify, obtain and seek protection for our products, drug candidates and our core
technologies employing a combination of patent rights, trade secrets, confidentiality agreements and contractual obligations and to operate
without infringing, misappropriating or otherwise violating on the proprietary rights of third parties. It is also important we prevent others from
infringing, misappropriating or otherwise violating our proprietary or intellectual property rights.
Our intellectual property strategy is, where appropriate, to file new patent applications on inventions, including improvements to existing
products/candidates and processes to improve our competitive edge or to improve business opportunities. We continually assess and refine our
intellectual property strategy to endeavor to ensure it is fit for purpose.
Our strategy requires us to license assets from third parties with suitable protection and to identify and seek patent protection for our inventions,
when possible. This process is expensive and time consuming and we may not be able to file and prosecute all necessary or desirable patent
applications at a reasonable cost, in a timely manner or in all jurisdictions where protection may be commercially advantageous, or we may
financially not be able to protect our proprietary rights at all. Despite our efforts to protect our proprietary rights, unauthorized parties may be
able to obtain and use information we regard as proprietary. Generally, many therapeutic indications currently being pursued have a focus in Asia
markets. Where possible, we seek to file in at least major commercial jurisdictions relevant to the product or technology, however, this is
assessed on a case by case basis.
Licensing assets from third parties involves technical and scientific due diligence to assess the opportunity, the strength of the intellectual
property protection for the asset and the ability to commercialize the asset. This due diligence is usually conducted over a relatively short period
of time. It can be difficult to identify all the issues relevant to the assessment. Failure to identify all the relevant issues can impact negatively on
the value of the asset.
The issuance of a patent does not ensure that it is valid or enforceable. Therefore, even if we are issued a patent, it may not be valid or
enforceable against third parties. Issued patents may be challenged, narrowed, invalidated or circumvented. In addition, court decisions may
introduce uncertainty in the enforceability or scope of patents owned by pharmaceutical and biotechnology companies. Thus, any of our patents,
including patents that we may rely on to protect our market for approved drugs, may be held invalid or unenforceable by a court of final
jurisdiction.
Because patent applications in the United States, Europe and many other jurisdictions are typically not published until 18 months after filing, and
because publications of discoveries in scientific literature lag behind actual discoveries, we cannot be certain that we were the first to make the
inventions claimed in our issued patents or pending patent applications, or that we were the first to file for protection of the inventions set forth in
our patents or patent applications. As a result, we may not be able to obtain or maintain protection for certain inventions. Therefore, the
enforceability and scope of our patents in the United States, Europe and in many other jurisdictions cannot be predicted with certainty and, as a
result, any patents that we own or license may not provide sufficient protection against competitors. We may not be able to obtain or maintain
patent protection from our pending patent applications, from those we may file in the future, or from those we may license from third parties.
Moreover, even if we are able to obtain patent protection, such patent protection may be of insufficient scope to achieve our business objectives.
80
In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that
prevent marketing of our products or working our own technology. We endeavor to identify early third party patents and patent applications
which may be blocking to a product or technology, to minimize this risk. However, relevant documents may be overlooked or missed, which may
in turn impact of the freedom to commercialize the relevant asset.
The term of a patent depends upon the laws of the country in which it is issued. In most jurisdictions, including the United States, Europe, China
and Japan, the basic patent term is 20 years from the earliest filing date of a non-provisional patent application. In the United States, Europe and
Japan, patents relating to inventions are effective for 20 years, subject to the payment of renewal fees. Some jurisdictions, such as the United
States, Europe and Japan provide for up to an additional five years patent term extension for therapeutics products that require marketing
approval. The requirements for this supplementary protection are set by the relevant authorities in the given jurisdiction. Products approved
before the expiry of the basic patent term may benefit from such a patent term extension. It is our strategy to apply for such supplementary
protection, where possible.
In addition to patent protection, statutory provisions in the United States, Europe and other countries may provide a period of clinical data
exclusivity which may be followed by an additional period of market exclusivity to compensate for the time required for regulatory approval of
our drug products. Once the relevant criteria are satisfied, the protection applies automatically. The length of protection depends on the
jurisdiction and may also depend on the type of therapy.
Third parties may seek to market “similar” versions of our approved products. Alternatively, third parties may seek approval to market their own
products, similar or otherwise, competitive with our products. We may not be able to block the commercialization of these products, which may
erode our commercial position in the market place.
If disputes over intellectual property and other rights that we have licensed or co-own prevent or impair our ability to maintain our current
licensing or exclusivity arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product
candidates. In addition, under certain of our collaboration agreements, our licensors may retain the right to grant non-exclusive licenses to the
licensed patents and technology to other academic or research institutions for non-commercial research purposes.
Certain provisions in the agreements under which we currently license intellectual property or technology to and from third parties may be
susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to
be the scope of our rights to the relevant intellectual property or technology, increase what we believe to be our financial or other obligations
under the relevant agreement or decrease the third party’s financial or other obligations under the relevant agreement, any of which could have a
material adverse effect on our business, financial condition, results of operations and prospects.
81
Varlitinib
Licensed from Array
On July 12, 2011, we entered into a collaboration and license agreement with Array, relating to Array’s pan-HER inhibitor, ARRY-543, which we
refer to as ASLAN001 or varlitinib, pursuant to which we obtained an exclusive, worldwide license to develop products incorporating varlitinib
as an active ingredient for the treatment or prevention of any diseases or conditions in humans, pursuant to an agreed development plan, and an
exclusive, worldwide license to pursue a commercial licensing program in relation to such products. On January 3, 2018, we entered into a new
license agreement with Array, which replaces and supersedes our previous collaboration and license agreement, pursuant to which we obtained
an exclusive, worldwide license to develop, manufacture and commercialize varlitinib for all human and animal therapeutic, diagnostic and
prophylactic uses.
The basic protection for varlitinib is provided by a family of composition of matter patents. These patents disclose a genus and also explicitly
discloses varlitinib (example number 52 in WO2005/016346).
As of December 31, 2018, this family of patents included patents issued in the United States (at least three patents, some relating to intermediates
and processes), Argentina, Australia, Canada, China (at least three patents), Chile, Colombia, Europe, Hong Kong, Indonesia, India, Iceland,
Israel, Japan, South Korea, Macau, Mexico, Norway, New Zealand, Philippines, Russia, Singapore, Ukraine, South Africa, and Taiwan. In
addition, as of December 31, 2018, this family of patents included patent applications filed in Brazil, Egypt and Venezuela. The scope of the
claims may differ in the various countries. The normal expiration of this family of patents is November 2024 in the United States and August
2024 outside the United States, subject to the payment of renewal fees.
The first patent application filed in China was not granted based on a technicality of Chinese practice. Subsequently filed divisional patent
applications were granted. If the validity of one or more of the granted divisional patents is challenged then one or more of these patents may
ultimately be considered invalid. In China typically branded medicines may still grow their market share, even after patent expiration. This trend
along with subsequently filed patent applications and the Chinese data exclusivity provisions may minimize the impact of negative decisions that
may be received in respect of one or more of the divisional patents.
Protection for the synthetic process of making varlitinib and a key intermediate in that process may be provided from the family of patents
derived from WO2007/059257, filed November 15, 2006. As of December 31, 2018, this family of patents includes issued patents in Australia,
Canada, China, Colombia, Europe, Hong Kong, Iceland, Israel, Japan, South Korea, Mexico, Norway, Philippines, Russia, Singapore, Taiwan,
Ukraine and the United States. In addition, as of December 31, 2018, this family of patents included patent applications filed in Brazil and India.
The scope of the claims may differ in the various countries. The normal expiration of this family of patents is November 2026.
Owned by Us
We are the applicant on a number of pending patents mostly relating to medical uses or combination therapies. These include the following
pending patent applications:
•
•
published PCT application WO2017/037298 filed September 5, 2016 relates to use of varlitinib in sensitizing a patient to
chemotherapy;
published PCT application WO2017/037299 filed September 5, 2016 relates to use of varlitinib in the treatment of biliary tract cancer;
82
•
•
•
published PCT application WO2017/037300 filed September 5, 2016 relates to use of varlitinib in treatment of resistant cancers;
published PCT application WO2017/184086 filed April 21, 2017 relates to use of the varlitinib in the treatment of HCC; and
published PCT application WO2018/004465 filed June 30, 2017, related to use of varlitinib as a maintenance therapy.
Normal expiration of these patents, if granted, is 2036, 2037 or 2038 subject to the payment of renewal fees. It is not clear what claims may be
granted, if any, when these patents are pursued at the national and regional phase.
There are four unpublished PCT applications and at least five unpublished Singapore priority patent applications relating to use of varlitinib.
These patent applications are at an early stage of filing and it is not possible to predict what claims may be ultimately granted, if any from these
patent applications.
ASLAN003
Licensed from Almirall
On May 16, 2012, we entered into a development and license agreement with Almirall, pursuant to which we obtained an exclusive, worldwide
license to certain patents, know-how and other intellectual property controlled by Almirall to a DHODH inhibitor, LAS186323, which we refer
to as ASLAN003. On December 21, 2015, we entered into an amended development and license agreement with Almirall which replaced the
previous agreement. This was further amended by an amendment agreement entered into on March 16, 2018. Under the amended agreement as
so amended, we obtained from Almirall an expanded exclusive, worldwide license to develop, manufacture and commercialize ASLAN003
products for all human diseases with primary focus on oncology diseases, excluding topically-administered products embodying the compound
for keratinocyte hyperproliferative disorders, and the non-melanoma skin cancers basal cell carcinoma, squamous cell carcinomas and Gorlin
Syndrome.
The basic compound protection for ASLAN003 is provided by the composition of matter family of patents derived from WO2008/077639. As of
December 31, 2018, this family of patents included patents issued in Australia, Canada, China, Europe, Hong Kong, Israel, Japan, Mexico, New
Zealand, Nigeria, Norway, Peru, Russia, Singapore South Africa, South Korea, Taiwan, and the United States (two patents). In addition, as of
December 31, 2018, this family of patents included patent applications filed in Argentina, Bolivia, Chile, Colombia, Ecuador, Egypt, Pakistan,
Philippines, Thailand, Ukraine, Uruguay, Venezuela and Vietnam. The scope of the claims may differ in different countries. The normal
expiration of this family of patents is December 2027, subject to the payment of renewal fees.
Owned by Us
We are the applicant on a number of pending patents mostly relating to medical uses or combination therapies. These include the following
pending patent applications:
•
•
published PCT application WO2018/136009 filed January 19, 2018 relates to use of ASLAN003 in a combination therapy;
published PCT application WO2018/136010 filed January 19, 2018 relates to use of ASLAN003 in a combination therapy;
83
•
•
•
published PCT application WO2018/160138 filed Mar 1, 2018 relates to use of ASLAN003 in treatment of hematological cancers;
published PCT application WO2018/222134 filed April 30, 2018 relates to use of the ASLAN003 in the treatment of a new indication;
and
published PCT application WO2018/222135 filed April 30, 2018 relates to use of the ASLAN003 in the treatment of a specific patient
population.
We also have two unpublished Singapore priority patent applications related to specific uses of ASLAN003.
ASLAN004
On May 12, 2014, we entered into a license agreement with CSL, pursuant to which we obtained an exclusive, worldwide license to certain
patents, know-how and other intellectual property owned or controlled by CSL related to CSL’s anti-IL13 receptor monoclonal antibody,
CSL334, which we refer to as ASLAN004, and antigen binding fragments thereof. This was further amended by an amendment agreement
entered into on September 18, 2018, primarily to change the focus of the development program from asthma to atopic dermatitis.
The basic compound protection for ASLAN004 is provided by a species (specific sequence) composition of matter family of patents is derived
from WO2008/060813, filed October 19, 2007. As of December 31, 2018, this family of patents included patents issued in Australia (two
patents), Canada, China, Europe (two patents), Hong Kong (two patents), Japan (two patents), and the United States (four patents). The normal
expiration of this family of patents is October 2027, subject to the payment of renewal fees. The situation for patent term extensions for
biological molecules, such as antibodies, may be more complicated than for small molecules, because generally the original legislation was
written with reference to small molecules. Having said that, the period of data exclusivity available in the United States may be 12 years.
We have two unpublished Singapore priority patent applications filed in the joint names of ASLAN and CSL, one related to a specific therapeutic
use for ASLAN004, and the other for a formulation of ASLAN004. These applications are at an early stage of filing and it is not possible to
predict what claims may be ultimately granted. We expect that there may opportunities to file further new jointly owned patent applications on
aspects of the manufacturing process and ASLAN004 formulation.
Trade Secrets
In addition to patents, we rely upon unpatented trade secrets and know-how and continuing technological innovation to develop and maintain our
competitive position. However, trade secrets and know-how can be difficult to protect. We seek to protect our proprietary information, in part, by
executing confidentiality agreements with our partners, collaborators, scientific advisors, employees, consultants and other third parties, and
invention assignment agreements which are included in the engagement and employment contracts we have with our consultants and employees.
The confidentiality agreements we enter into are designed to protect our proprietary information and the agreements or clauses requiring
assignment of inventions to us are designed to grant us ownership of technologies that are developed through our relationship with the respective
counterparty. We cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade
secrets or proprietary technology and processes or that these agreements will afford us adequate protection of our intellectual property and
proprietary information rights. If any of the partners, collaborators, scientific advisors,
84
employees and consultants who are parties to these agreements breaches or violates the terms of any of these agreements or otherwise discloses
our proprietary information, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result.
If we are unable to maintain the confidentiality of our trade secrets, our business and competitive position may be harmed.
Trademarks and Domain Names
We conduct our business using the trademark “ASLAN,” “ASLAN PHARMACEUTICALS” and our lion logo, as well as domain names
incorporating either or both of these trademarks. “ASLAN PHARMACEUTICALS” has been registered in Singapore. In terms of Chinese
character versions of our trademarks, in Taiwan, we have a trade mark registration for: “
”. In China, we have a trademark registration
”. We also have a trade mark registration in China to protect the following Chinese character version of the word
for “
varlitinib: “ (cid:0) (cid:0) (cid:0) (cid:0) ” (wei li ti ni). We have a portfolio of 20 domain names, which includes: aslanpharma.com, aslanpharma.com.sg,
aslanpharma.com.tw, aslanpharma.asia, aslanpharma.org, and aslanpharma.biz.
Government Regulation
The U.S. FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon
the clinical development, manufacture and marketing of pharmaceutical products. These agencies and other federal, state and local entities
regulate research and development activities and the testing, manufacture, quality control, safety, effectiveness, labeling, storage, packaging,
recordkeeping, tracking, approval, import, export, distribution, advertising and promotion of our products.
U.S. Government Regulation of Drug Products
In the United States, the U.S. FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FFDCA, and its implementing
regulations. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign
statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S.
requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of
administrative or judicial sanctions, such as the U.S. FDA’s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical
hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines,
refusals of government contracts, restitution, disgorgement or civil or criminal penalties.
The process required by the U.S. FDA before product candidates may be marketed in the United States generally involves the following:
•
•
•
•
nonclinical laboratory and animal tests that must be conducted in accordance with GLP;
submission of an IND, which must become effective before clinical trials may begin;
approval by an independent institutional review board, or IRB, for each clinical site or centrally before each trial may be initiated;
adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed product candidate for its
intended use, performed in accordance with current clinical practices, or cGCP;
85
•
•
•
•
•
•
submission to the U.S. FDA of an NDA and payment of user fees;
satisfactory completion of a U.S. FDA advisory committee review, if applicable;
pre-approval inspection of manufacturing facilities and selected clinical investigators for their compliance with cGMP, and cGCP;
satisfactory completion of U.S. FDA audits of clinical trial sites to assure compliance with cGCP and the integrity of the clinical data;
FDA approval of an NDA to permit commercial marketing for particular indications for use; and
compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation
Strategy, or REMS, and the potential requirement to conduct post-approval studies.
The testing and approval process requires substantial time, effort and financial resources. Preclinical studies include laboratory evaluation of
drug substance chemistry, pharmacology, toxicity and drug product formulation, as well as animal studies to assess potential safety and efficacy.
Prior to commencing the first clinical trial with a product candidate, we must submit the results of the preclinical tests and preclinical literature,
together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the U.S. FDA as part
of an IND. Some preclinical studies may continue even after the IND is submitted. The IND automatically becomes effective 30 days after
receipt by the U.S. FDA, unless the U.S. FDA, within the 30-day time period, raises safety concerns or questions about the conduct of the
clinical trial by imposing a clinical hold. In such a case, the IND sponsor and the U.S. FDA must resolve any outstanding concerns before the
clinical trial can begin. Submission of an IND may not result in U.S. FDA authorization to commence a clinical trial.
Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in
accordance with cGCP requirements. A separate submission to the existing IND must be made for each successive clinical trial conducted during
product development, as well as amendments to previously submitted clinical trials. Further, an independent IRB for each study site proposing to
conduct the clinical trial must review and approve the plan for any clinical trial, its informed consent form and other communications to study
subjects before the clinical trial commences at that site. The IRB must continue to oversee the clinical trial while it is being conducted, including
any changes to the study plans.
Regulatory authorities, an IRB or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that
the subjects are being exposed to an unacceptable health risk, the clinical trial is not being conducted in accordance with the U.S. FDA’s or the
IRB’s requirements, if the drug has been associated with unexpected serious harm to subjects, or based on evolving business objectives or
competitive climate. Some studies also include a data safety monitoring board, which receives special access to unblinded data during the clinical
trial and may advise us to halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no
demonstration of efficacy.
In general, for purposes of NDA approval, human clinical trials are typically conducted in three sequential phases that may overlap.
Phase 1—Studies are initially conducted to test the product candidate for safety, dosage tolerance, structure-activity relationships, mechanism of
action, absorption, metabolism, distribution and excretion in healthy volunteers or subjects with the target disease or condition. If possible, Phase
1 trials may also be used to gain an initial indication of product effectiveness.
86
Phase 2—Controlled studies are conducted with groups of subjects with a specified disease or condition to provide enough data to evaluate the
preliminary efficacy, optimal dosages and dosing schedule and expanded evidence of safety. Multiple Phase 2 clinical trials may be conducted to
obtain information prior to beginning larger and more expensive Phase 3 clinical trials.
Phase 3—These clinical trials are undertaken in larger subject populations to provide statistically significant evidence of clinical efficacy and to
further test for safety in an expanded subject population at multiple clinical trial sites. These clinical trials are intended to establish the overall
risk/benefit ratio of the product and provide an adequate basis for product labeling. These trials may be done globally to support global
registrations so long as the global sites are also representative of the U.S. population and the conduct of the study at global sites comports with
U.S. FDA regulations and guidance, such as compliance with cGCP.
The U.S. FDA may require, or companies may pursue, additional clinical trials after a product is approved. These so-called Phase 4 studies may
be made a condition to be satisfied after approval. The results of Phase 4 studies can confirm the effectiveness of a product candidate and can
provide important safety information.
Clinical trials must be conducted under the supervision of qualified investigators in accordance with cGCP requirements, which includes the
requirements that all research subjects provide their informed consent in writing for their participation in any clinical trial, and the review and
approval of the study by an IRB. Investigators must also provide information to the clinical trial sponsors to allow the sponsors to make specified
financial disclosures to the U.S. FDA. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the
trial procedures, the parameters to be used in monitoring safety and the efficacy criteria to be evaluated and a statistical analysis plan.
Information about some clinical trials, including a description of the trial and trial results, must be submitted within specific timeframes to the
National Institutes of Health, or NIH, for public dissemination on their ClinicalTrials.gov website.
The manufacture of investigational drugs for the conduct of human clinical trials is subject to cGMP requirements. Investigational drugs and
active pharmaceutical ingredients imported into the United States are also subject to regulation by the U.S. FDA relating to their labeling and
distribution. Further, the export of investigational drug products outside of the United States is subject to regulatory requirements of the receiving
country as well as U.S. export requirements under the FFDCA. Progress reports detailing the results of the clinical trials must be submitted at
least annually to the U.S. FDA and the IRB and more frequently if serious adverse events occur.
Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the
chemistry and physical characteristics of the product candidate as well as finalize a process for manufacturing the product in commercial
quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the
product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product.
Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product
candidate does not undergo unacceptable deterioration over its shelf life.
87
Orphan Drug Designation
Under the Orphan Drug Act, the U.S. FDA may designate a drug as an orphan drug if it is intended to treat a rare disease or condition (generally
meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the
cost of developing and making a drug available in the United States for treatment of the disease or condition will be recovered from sales of the
product). Orphan product designation must be requested before submitting an NDA or Biologics License Application. After the
U.S. FDA grants orphan product designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the U.S.
FDA. Orphan product designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.
If a product with orphan status receives the first U.S. FDA approval for the disease or condition for which it has such designation, the product is
entitled to orphan product exclusivity, meaning that the U.S. FDA may not approve any other applications to market the same drug for the same
indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity or if
the party holding the exclusivity fails to assure the availability of sufficient quantities of the drug to meet the needs of patients with the disease or
condition for which the drug was designated. Competitors, however, may receive approval of different products for the same indication for which
the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has
exclusivity. Orphan medicinal product status in the European Union has similar, but not identical, benefits. For example, the European Union
grants ten years of product exclusivity for orphan medicinal products.
Special U.S. FDA Expedited Review and Approval Programs
The U.S. FDA has various programs, including fast track designation, breakthrough therapy designation, accelerated approval, and priority
review, which are intended to expedite or simplify the process for the development and U.S. FDA review of drugs that are intended for the
treatment of serious or life threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these
programs is to provide important new drugs to patients earlier than under standard U.S. FDA review procedures.
Under the fast track program, the sponsor of a new drug candidate may request that U.S. FDA designate the drug candidate for a specific
indication as a fast track drug concurrent with, or after, the filing of the IND for the drug candidate. To be eligible for a fast track designation, the
U.S. FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life threatening disease or condition
and demonstrates the potential to address an unmet medical need, or that the drug qualifies as a qualified infectious disease product, or QIDP,
under the GAIN Act. The U.S. FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or
provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. Fast track designation provides
additional opportunities for interaction with the U.S. FDA’s review team and may allow for rolling review of NDA components before the
completed application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the U.S. FDA agrees to
accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the
first section of the NDA. However, U.S. FDA’s time period goal for reviewing an application does not begin until the last section of the NDA is
submitted. The U.S. FDA may decide to rescind the fast track designation if it determines that the qualifying criteria no longer apply.
88
In addition, a sponsor can request breakthrough therapy designation for a drug if it is intended, alone or in combination with one or more other
drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate
substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed
early in clinical development. Drugs designated as breakthrough therapies are eligible for intensive guidance from U.S. FDA on an efficient drug
development program, organizational commitment to the development and review of the product including involvement of senior managers, and,
like fast track products, are also eligible for rolling review of the NDA. Both fast track and breakthrough therapy products are also eligible for
accelerated approval and/or priority review, if relevant criteria are met.
Under the U.S. FDA’s accelerated approval regulations, the U.S. FDA may approve a drug for a serious or life threatening illness that provides
meaningful therapeutic benefit to patients over existing treatments based upon a surrogate endpoint that is reasonably likely to predict clinical
benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect
on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the
availability or lack of alternative treatments. A drug candidate approved on this basis is subject to rigorous post marketing compliance
requirements, including the completion of Phase 4 or post approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct
required post approval studies, or confirm a clinical benefit during post marketing studies, will allow U.S. FDA to withdraw the drug from the
market on an expedited basis. All promotional materials for drug candidates approved under accelerated approval regulations are subject to prior
review by U.S. FDA.
Once an NDA is submitted for a product intended to treat a serious condition, the U.S. FDA may assign a priority review designation if U.S.
FDA determines that the product, if approved, would provide a significant improvement in safety or effectiveness. A priority review means that
the goal for the U.S. FDA to review an application is six months, rather than the standard review of ten months under current Prescription Drug
User Fee Act, or PDUFA, guidelines. Under the current PDUFA agreement, these six and ten month review periods are measured from the 60-
day filing date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline
for review from the date of submission. Most products that are eligible for fast track breakthrough therapy designation are also likely to be
considered appropriate to receive a priority review.
Even if a product qualifies for one or more of these programs, the U.S. FDA may later decide that the product no longer meets the conditions for
qualification or decide that the time period for U.S. FDA review or approval will not be shortened. In addition, the manufacturer of an
investigational drug for a serious or life threatening disease is required to make available, such as by posting on its website, its policy on
responding to requests for expanded access. Furthermore, fast track designation, breakthrough therapy designation, accelerated approval and
priority review do not change the standards for approval and may not ultimately expedite the development or approval process.
89
NDA Submission and Review by the U.S. FDA
Assuming successful completion of the required clinical and preclinical testing, among other items, the results of product development, including
chemistry, manufacture and controls, nonclinical studies and clinical trials are submitted to the U.S. FDA, along with proposed labeling, as part
of an U.S. NDA. The submission of an NDA requires payment of a substantial user fee to the U.S. FDA. These user fees must be filed at the time
of the first submission of the application, even if the application is being submitted on a rolling basis. Fee waivers or reductions are available in
some circumstances. One basis for a waiver of the application user fee is if the applicant employs fewer than 500 employees, including
employees of affiliates, the applicant does not have an approved marketing application for a product that has been introduced or delivered for
introduction into interstate commerce, and the applicant, including its affiliates, is submitting its first marketing application.
In addition, under the Pediatric Research Equity Act, or PREA, an NDA or supplement to an NDA for a new active ingredient, indication, dosage
form, dosage regimen or route of administration must contain data that are adequate to assess the safety and efficacy of the drug for the claimed
indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the
product is safe and effective.
The U.S. FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after
approval of the product for use in adults or full or partial waivers from the pediatric data requirements.
The U.S. FDA must refer applications for drugs that contain active ingredients, including any ester or salt of the active ingredients, which have
not previously been approved by the U.S. FDA to an advisory committee or provide in an action letter a summary of the reasons for not referring
it to an advisory committee. The U.S. FDA may also refer drugs which present difficult questions of safety, purity or potency to an advisory
committee. An advisory committee is typically a panel that includes clinicians and other experts who review, evaluate and make a
recommendation as to whether the application should be approved and under what conditions. The U.S. FDA is not bound by the
recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.
The U.S. FDA reviews applications to determine, among other things, whether a product is safe and effective for its intended use and whether the
manufacturing controls are adequate to assure and preserve the product’s identity, strength, quality and purity. Before approving an NDA, the
U.S. FDA will inspect the facility or facilities where the product is manufactured. The U.S. FDA will not approve an application unless it
determines that the manufacturing processes and facilities, including contract manufacturers and subcontracts, are in compliance with cGMP
requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA,
the U.S. FDA will typically inspect one or more clinical trial sites to assure compliance with cGCP.
Once the U.S. FDA receives an application, it has 60 days to review the NDA to determine if it is substantially complete to permit a substantive
review, before it accepts the application for filing. Once the submission is accepted for filing, the U.S. FDA begins an in-depth review of the
NDA. The U.S. FDA’s NDA review times may differ based on whether the application is a standard review or priority review application. The
U.S. FDA may give a priority review designation to drugs that are intended to treat serious conditions and provide significant improvements in
the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions. Under the goals and policies agreed to by the U.S.
FDA under the PDUFA, the U.S. FDA has set the review goal of 10 months from the 60-day filing date to complete its initial review of a
standard NDA for a new molecular entity, or NME, and make a decision on the application. For non-NME standard applications, the U.S. FDA
has set the review goal of 10
90
months from the submission date to complete its initial review and to make a decision on the application. For priority review applications, the
U.S. FDA has set the review goal of reviewing NME NDAs within six months of the 60-day filing date and non-NME applications within six
months of the submission date. Such deadlines are referred to as the PDUFA date. The PDUFA date is only a goal and the U.S. FDA does not
always meet its PDUFA dates. The review process and the PDUFA date may also be extended if the U.S. FDA requests or the NDA sponsor
otherwise provides additional information or clarification regarding the submission.
Once the U.S. FDA’s review of the application is complete, the U.S. FDA will issue either a Complete Response Letter, or CRL, or approval
letter. A CRL indicates that the review cycle of the application is complete and the application is not ready for approval. A CRL generally
contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or
preclinical testing, or other information or analyses in order for the U.S. FDA to reconsider the application. The U.S. FDA has the goal of
reviewing 90% of application resubmissions in either two or six months of the resubmission date, depending on the kind of resubmission. Even
with the submission of additional information, the U.S. FDA ultimately may decide that the application does not satisfy the regulatory criteria for
approval. If and when those conditions have been met to the U.S. FDA’s satisfaction, the U.S. FDA may issue an approval letter. An approval
letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. The U.S. FDA may delay or
refuse approval of an NDA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require post-
marketing testing and surveillance to monitor safety or efficacy of a product, or impose other conditions, including distribution restrictions or
other risk management mechanisms. For example, the U.S. FDA may require a REMS as a condition of approval or following approval to
mitigate any identified or suspected serious risks and ensure safe use of the drug. The U.S. FDA may prevent or limit further marketing of a
product, or impose additional post-marketing requirements, based on the results of post-marketing studies or surveillance programs. After
approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims,
are subject to further testing requirements, U.S. FDA notification and U.S. FDA review and approval. Further, should new safety information
arise, additional testing, product labeling or U.S. FDA notification may be required.
If regulatory approval of a product is granted, such approval may entail limitations on the indicated uses for which such product may be
marketed or may include contraindications, warnings or precautions in the product labeling, which has resulted in a Black Box warning. The U.S.
FDA also may not approve the inclusion of labeling claims necessary for successful marketing. Once approved, the U.S. FDA may withdraw the
product approval if compliance with pre- and post-marketing regulatory standards is not maintained or if problems occur after the product
reaches the marketplace. In addition, the U.S. FDA may require Phase 4 post-marketing studies to monitor the effect of approved products, and
may limit further marketing of the product based on the results of these post-marketing studies.
Post-Approval Requirements
Any products manufactured or distributed by us pursuant to U.S. FDA approvals are subject to continuing regulation by the U.S. FDA, including
manufacturing, periodic reporting, product sampling and distribution, advertising, promotion, drug shortage reporting, compliance with any post-
approval requirements imposed as a conditional of approval such as Phase 4 clinical trials, REMS and surveillance, recordkeeping and reporting
requirements, including adverse experiences.
91
After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior U.S. FDA
review and approval. There also are continuing, annual user fee requirements for any approved products and the establishments at which such
products are manufactured, as well as new application fees for supplemental applications with clinical data. Drug manufacturers and their
subcontractors are required to register their establishments with the U.S. FDA and certain state agencies and to list their drug products, and are
subject to periodic announced and unannounced inspections by the U.S. FDA and these state agencies for compliance with cGMP and other
requirements, which impose procedural and documentation requirements upon us and our third-party manufacturers.
Changes to the manufacturing process are strictly regulated and often require prior U.S. FDA approval before being implemented, or U.S. FDA
notification. U.S. FDA regulations also require investigation and correction of any deviations from cGMP and specifications, and impose
reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly,
manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance.
Later discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing
processes, or failure to comply with regulatory requirements, may result in withdrawal of marketing approval, mandatory revisions to the
approved labeling to add new safety information or other limitations, imposition of post-market studies or clinical trials to assess new safety
risks, or imposition of distribution or other restrictions under a REMS program, among other consequences.
The U.S. FDA closely regulates the marketing and promotion of drugs. A company can make only those claims relating to safety and efficacy,
purity and potency that are approved by the U.S. FDA. Physicians, in their independent professional medical judgement, may prescribe legally
available products for uses that are not described in the product’s labeling and that differ from those tested by us and approved by the U.S. FDA.
We, however, are prohibited from marketing or promoting drugs for uses outside of the approved labeling.
In addition, the distribution of prescription pharmaceutical products, including samples, is subject to the Prescription Drug Marketing Act, or
PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and
regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples
and impose requirements to ensure accountability in distribution. The Drug Supply Chain Security Act also imposes obligations on
manufacturers of pharmaceutical products related to product and tracking and tracing.
Failure to comply with any of the U.S. FDA’s requirements could result in significant adverse enforcement actions. These include a variety of
administrative or judicial sanctions, such as refusal to approve pending applications, license suspension or revocation, withdrawal of an approval,
imposition of a clinical hold or termination of clinical trials, warning letters, untitled letters, cyber letters, modification of promotional materials
or labeling, product recalls, product seizures or detentions, refusal to allow imports or exports, total or partial suspension of production or
distribution, debarment, injunctions, fines, consent decrees, corporate integrity agreements, refusals of government contracts and new orders
under existing contracts, exclusion from participation in federal and state healthcare programs, restitution, disgorgement or civil or criminal
penalties, including fines and imprisonment. It is also possible that failure to comply with the U.S. FDA’s requirements relating to the promotion
of prescription drugs may lead to investigations alleging violations of federal and state healthcare fraud and abuse and other laws, as well as state
consumer protection laws. Any of these sanctions could result in adverse publicity, among other adverse consequences.
92
Other U.S. Healthcare Laws and Regulations
Healthcare providers, physicians and third-party payors play a primary role in the recommendation and use of medical products and drug
formulations that are granted marketing approval. Arrangements with third-party payors, existing or potential customers and referral sources,
including healthcare providers, are subject to broadly applicable fraud and abuse and other healthcare laws and regulations, and these laws and
regulations may constrain the business or financial arrangements and relationships through which manufacturers conduct clinical research,
market, sell and distribute the products for which they obtain marketing approval. Such restrictions under applicable federal and state healthcare
laws and regulations include the following:
•
•
•
the U.S. Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting,
receiving, offering or paying remuneration, directly or indirectly, in cash or kind, in exchange for, or to induce, either the referral of an
individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal
healthcare programs such as the Medicare and Medicaid programs. This statute has been interpreted to apply to arrangements between
pharmaceutical manufacturers, on the one hand, and prescribers, purchasers and formulary managers, among others, on the other hand.
The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or
PPACA, amended the intent requirement of the U.S. Anti-Kickback Statute. A person or entity no longer needs to have actual
knowledge of this statute or specific intent to violate it in order to commit a violation. There are a number of statutory exceptions and
regulatory safe harbors protecting some common activities from prosecution;
the federal false claims and civil monetary penalties laws, including the False Claims Act, or FCA, which prohibit, among other
things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid or
other third-party payors that are false or fraudulent, or making a false statement to avoid, decrease, or conceal an obligation to pay
money to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim
includes “any request or demand” for money or property presented to the U.S. government. In addition, manufacturers can be held
liable under the FCA even when they do not submit claims directly to government payors if they are deemed to “cause” the
submission of false or fraudulent claims. The FCA also permits a private individual acting as a “whistleblower” to bring actions on
behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. Government enforcement
agencies and private whistleblowers have investigated pharmaceutical companies for or asserted liability under the FCA for a variety
of alleged promotional and marketing activities, such as providing free product to customers with the expectation that the customers
would bill federal programs for the product; providing consulting fees and other benefits to physicians to induce them to prescribe
products; engaging in promotion for “off-label” uses; and submitting inflated best price information to the Medicaid Rebate Program.
In addition, the PPACA codified case law that a claim including items or services resulting from a violation of the U.S. Anti-Kickback
Statute constitutes a false or fraudulent claim for purposes of the FCA.
The Health Insurance Portability and Accountability Act of 1996, or HIPAA, prohibits, among other actions, knowingly and willfully
executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors,
knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a
healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false,
fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services;
93
•
•
•
the federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies
for which payment is available under Medicare, Medicaid, or the Children’s Health Insurance Program, with specific exceptions, to
report annually to the Centers for Medicare & Medicaid Services, or CMS, information related to payments and other transfers of
value to physicians, certain other healthcare providers and teaching hospitals, and ownership and investment interests held by
physicians and other healthcare providers and their immediate family members;
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their respective
implementing regulations, imposes, among other things, specified requirements relating to the security, privacy and transmission of
individually identifiable health information held by entities subject to HIPAA, such as health plans, health care clearinghouses and
certain healthcare providers, known as covered entities, and their respective business associates, persons or entities that create, use,
maintain or disclose individually identifiable health information on behalf of covered entities. HITECH also created new tiers of civil
monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state
attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce the federal HIPAA laws
and seek attorneys’ fees and costs associated with pursuing federal civil actions; and
state and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to
items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies
to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by
the federal government or otherwise restrict payments that may be made to healthcare providers and other potential referral sources;
state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other
healthcare providers or marketing expenditures; state and local laws that require the registration of pharmaceutical sales and
representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ
from each other in significant ways and may not have the same effect, thus complicating compliance efforts.
Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that
certain business activities can be subject to challenge under one or more of such laws. In addition, recent health care reform legislation has
strengthened these laws.
Violation of the laws described above or any other governmental laws and regulations may result in civil, criminal and administrative penalties,
damages, fines, the curtailment or restructuring of operations, the exclusion from participation in federal and state healthcare programs,
disgorgement, contractual damages, reputational harm, diminished profits and future earnings, imprisonment, and additional reporting
requirements and oversight if a manufacturer becomes subject to a corporate integrity agreement or similar agreement to resolve allegations of
non-compliance with these laws. Furthermore, efforts to ensure that business activities and business arrangements comply with applicable
healthcare laws and regulations can be costly for manufacturers of branded prescription products.
94
Coverage and Reimbursement
Significant uncertainty exists as to the coverage and reimbursement status of any products, for which we may obtain regulatory approval, and the
procedures utilizing such products. In the United States, sales of any product candidates for which regulatory approval for commercial sale is
obtained will depend in part on the availability of coverage and adequate reimbursement from third-party payors for the approved products, and
procedures which utilize such products. Third-party payors include government authorities and health programs in the United States such as
Medicare and Medicaid, managed care providers, private health insurers and other organizations. These third-party payors are increasingly
reducing reimbursements for medical products and services. The process for determining whether a payor will provide coverage for a product, or
procedures which utilizes such product, may be separate from the process for setting the reimbursement rate that the payor will pay for the
product, or procedures which utilize such product. Third-party payors may limit coverage to specific products on an approved list, or formulary,
which might not include all of U.S. FDA-approved products for a particular indication.
Additionally, the containment of healthcare costs has become a priority of federal and state governments. The U.S. government, state legislatures
and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on
coverage and reimbursement and requirements for substitution of less expensive products and procedures. Adoption of price controls and cost-
containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit our net
revenue and results.
A payor’s decision to provide coverage for a product, or procedures which utilize such product, does not imply that an adequate reimbursement
rate will be approved. Further, coverage and reimbursement for products, and procedure which utilize such products, can differ significantly from
payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide
scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement
will be applied consistently or obtained in the first instance.
Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and
services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for sale,
or any procedure which utilizes such product, it may be necessary to conduct expensive pharmacoeconomic studies in order to demonstrate the
medical necessity and cost-effectiveness of the products, and procedures which utilize such products, in addition to the costs required to obtain
regulatory approvals. If third-party payors do not consider a product, or procedures which utilize such product, to be cost-effective compared to
other available therapies, they may not cover the product, or procedures which utilize such product, after approval as a benefit under their plans
or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit.
The marketability of any product candidates for which we or our collaborators receive regulatory approval for commercial sale may suffer if the
government and third-party payors fail to provide adequate coverage and reimbursement for the product, or any procedure which utilizes such
product. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on
medical products and services pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable
coverage and reimbursement status is attained for one or more products for which we or our collaborators receive regulatory approval, less
favorable coverage policies and reimbursement rates may be implemented in the future.
95
In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be
marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the
cost-effectiveness of a particular product candidate to currently available therapies. European Union Member States may approve a specific price
for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market.
Other member states allow companies to fix their own prices for products, but monitor and control company profits. The downward pressure on
health care costs has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some
countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. Any country that
has price controls or reimbursement limitations may not allow favorable reimbursement and pricing arrangements.
Health Reform
The United States and some foreign jurisdictions are considering or have enacted a number of reform proposals to change the healthcare system.
There is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality or
expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected
by federal and state legislative initiatives, including those designed to limit the pricing, coverage, and reimbursement of pharmaceutical and
biopharmaceutical products as well as the procedures which utilize such products, especially under government-funded health care programs,
and increased governmental control of health care costs.
By way of example, in March 2010, the PPACA was signed into law, which is intended to broaden access to health insurance, reduce or constrain
the growth of healthcare spending, enhance remedies against fraud and abuse, add transparency requirements for the healthcare and health
insurance industries, impose taxes and fees on the healthcare industry and impose additional health policy reforms. Among the provisions of the
PPACA of importance to our business are:
•
•
•
•
•
•
•
an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents,
apportioned among these entities according to their market share in certain government healthcare programs;
an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0%
of the average manufacturer price for branded and generic drugs, respectively;
a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that
are inhaled, infused, instilled, implanted or injected;
expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain
individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer’s Medicaid
rebate liability;
expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;
a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness
research, along with funding for such research;
a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (and 70% as of January 1,
2019) point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period,
as a condition for the manufacturer’s outpatient drugs to be covered under Medicare Part D;
96
•
•
establishment of a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to
lower Medicare and Medicaid spending, potentially including prescription drug spending; and
a licensure framework for follow on biologic products.
Since its enactment, there have been judicial and Congressional challenges to certain aspects of the PPACA, as well as recent efforts by the
Trump administration to repeal or replace certain aspects of the PPACA. Since January 2017, President Trump has signed two Executive Orders
and other directives designed to delay the implementation of certain provisions of the PPACA or otherwise circumvent some of the requirements
for health insurance mandated by the PPACA. In addition, CMS recently published a final rule that will give states greater flexibility in setting
benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits
required under the PPACA for plans sold through such marketplaces. Further, Congress has considered legislation that would repeal or repeal and
replace all or part of the PPACA. While Congress has not passed comprehensive repeal legislation, two bills affecting the implementation of
certain taxes under the PPACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or Tax Act, includes a provision that repealed,
effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain
qualifying health coverage for all or part of a year that is commonly referred to as the “individual mandate”. On January 22, 2018, President
Trump signed a continuing resolution on appropriations for the year ended 2018 that delayed the implementation of certain PPACA-mandated
fees, including the so-called “Cadillac” tax on certain high cost employer-sponsored insurance plans, the annual fee imposed on certain health
insurance providers based on market share, and the medical device excise tax on non-exempt medical devices. The Bipartisan Budget Act of
2018, or the BBA, among other things, amended the PPACA, effective January 1, 2019, to close the coverage gap in most Medicare drug plans,
commonly referred to as the “donut hole.” In July 2018, CMS published a final rule permitting further collections and payments to and from
certain PPACA qualified health plans and health insurance issuers under the PPACA risk adjustment program in response to the outcome of
federal district court litigation regarding the method CMS uses to determine this risk adjustment. On December 14, 2018, a U.S. District Court
Judge in the Northern District of Texas, or Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of
the PPACA, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the PPACA are invalid as well. While the
Texas District Court Judge, as well as the Trump Administration and CMS, have stated that the ruling will have no immediate effect, it is unclear
how this decision, subsequent appeals, and other efforts to repeal and replace the PPACA will impact the PPACA.
Other legislative changes have been proposed and adopted in the United States since the PPACA was enacted. For example, in August 2011, the
Budget Control Act of 2011, among other things, created measures for spending reductions by U.S. Congress. A Joint Select Committee on
Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2012 through 2021, was unable to
reach required goals, thereby triggering the legislation’s automatic reduction to several government programs.
This includes aggregate reductions of Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and, due
to subsequent legislative amendments to the statute, including the BBA, will remain in effect through 2027 unless additional Congressional
action is taken. In January 2013, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to certain
providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.
97
Additionally, there have been several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among
other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between
pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. At the federal level, the
Trump administration’s budget proposal for the year ended 2019 contains further drug price control measures that could be enacted during the
2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of
certain drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid, and to eliminate cost sharing for generic
drugs for low-income patients. Additionally, the Trump administration released a “Blueprint” to lower drug prices and reduce out of pocket costs
of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal healthcare
programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by
consumers. HHS has already started the process of soliciting feedback on some of these measures and, at the same, is immediately implementing
others under its existing authority. For example, in September 2018, CMS announced that it will allow Medicare Advantage Plans the option to
use step therapy for Part B drugs beginning January 1, 2019, and in October 2018, CMS proposed a new rule that would require direct-to-
consumer television advertisements of prescription drugs and biological products, for which payment is available through or under Medicare or
Medicaid, to include in the advertisement the Wholesale Acquisition Cost, or list price, of that drug or biological product. In addition, on January
31, 2019, the HHS Office of Inspector General, proposed modifications to the U.S. Anti-Kickback Statute discount safe harbor for the purpose of
reducing the cost of drug products to consumers which, among other things, if finalized, will affect discounts paid by manufacturers to Medicare
Part D plans, Medicaid managed care organizations and pharmacy benefit managers working with these organizations. Although a number of
these, and other proposed, measures will require additional authorization to become effective, Congress and the Trump administration have each
indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have
increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price
or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures,
and, in some cases, designed to encourage importation from other countries and bulk purchasing.
Further, on May 30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, or the Right to
Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new
drug products that have completed a Phase I clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances,
eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access
program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right
to Try Act.
Additional Regulation
In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational
Safety and Health Act, the Resource Conservation and Recovery Act and the Toxic Substances Control Act, affect our business. These and other
laws govern the use, handling and disposal of various biologic, chemical and radioactive substances used in, and wastes generated by, operations.
If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and
governmental fines. Equivalent laws have been adopted in other countries that impose similar obligations.
98
U.S. Foreign Corrupt Practices Act
The U.S. Foreign Corrupt Practices Act of 1977, as amended, or FCPA, prohibits corporations and individuals from engaging in certain activities
to obtain or retain business or secure any improper advantage, or to influence a person working in an official capacity. It is illegal to pay, offer to
pay or authorize the payment of anything of value to any employee or official of a foreign government or public international organization, or
political party, political party official, or political candidate in an attempt to obtain or retain business or to otherwise influence a person working
in an official capacity. The scope of the FCPA also includes employees and official of state-owned or controlled enterprises, which may include
healthcare professionals in many countries. Equivalent laws have been adopted in other foreign countries that impose similar obligations.
European Union General Data Protection Regulation
In addition to European Union regulations related to the approval and commercialization of our products, we may be subject to the European
Union’s General Data Protection Regulation, or GDPR. The GDPR imposes stringent requirements for controllers and processors of personal
data of persons in the European Union, including, for example, more robust disclosures to individuals and a strengthened individual data rights
regime, shortened timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to special
categories of data, such as health data, and additional obligations when we contract with third-party processors in connection with the processing
of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States and
other third countries. In addition, the GDPR provides that European Union member states may make their own further laws and regulations
limiting the processing of personal data, including genetic, biometric or health data.
The GDPR applies extraterritorially, and we may be subject to the GDPR because of our data processing activities that involve the personal data
of individuals located in the European Union, such as in connection with any European Union clinical trials. Failure to comply with the
requirements of the GDPR and the applicable national data protection laws of the European Union member states may result in fines of up to
€20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative
penalties. GDPR regulations may impose additional responsibility and liability in relation to the personal data that we process and we may be
required to put in place additional mechanisms to ensure compliance with the new data protection rules.
China Government Regulation of Drug Products
In China, we operate in an increasingly complex legal and regulatory environment. We are subject to a variety of Chinese laws, rules and
regulations affecting many aspects of our business. This section summarizes the principal Chinese laws, rules and regulations relevant to our
business and operations.
Foreign Investment in the Pharmaceutical Industry
Investment activities in China by foreign investors are principally governed by the Guidance Catalogue of Industries for Foreign Investment, or
the Catalogue, which was promulgated and is amended from time to time by the Ministry of Commerce, or MOFCOM, and the National
Development and Reform Commission, or NRDC. Pursuant to the latest Catalogue, amended and issued on June 28, 2017 and effective on July
28, 2017, or the 2017 Catalogue, industries listed therein are divided into two categories: encouraged industries and the industries within the
catalogue of special entry administrative measures, or the Negative List, amended and issued separately on June 28, 2018 and effective on July
28, 2018.
99
Establishment of wholly foreign-owned enterprises is generally allowed in industries outside of the Negative List. Foreign investors are not
allowed to invest in industries that are expressly prohibited in the Negative List. The industries that are not expressly prohibited in the Negative
List are subject to government approvals and certain special requirements. For instance, some are limited to equity or contractual joint ventures,
while in some cases Chinese partners are required to hold the majority interests in such joint ventures. Industries not listed in the Catalogue are
generally open to foreign investment unless specifically restricted by other People’s Republic of China, or PRC, regulations.
Pursuant to the Negative List updated in June 2018, the manufacture of pharmaceutical products mostly falls outside of the Negative List.
Under Chinese law, the establishment of a wholly foreign-owned enterprise is subject to the approval of, or the requirement for record filing
with, MOFCOM or its local counterparts and the wholly foreign owned enterprise must register with the competent administrative bureau of
market regulation. We have completed the record filing with MOFCOM or its local counterparts for our interest in our wholly-owned PRC
subsidiary and completed the registration of our PRC subsidiary with the competent administrative bureau of market regulation.
In October 2016, MOFCOM issued the Interim Measures for Record-filing Administration of the Establishment and Change of Foreign-invested
Enterprises, or FIE Record-filing Interim Measures. Pursuant to FIE Record-filing Interim Measures, the establishment and change of foreign-
invested enterprises are subject to record-filing procedures, instead of prior approval requirements, provided that the establishment or change
does not involve special entry administrative measures. If the establishment or change of FIE matters involve the special entry administrative
measures, the approval of MOFCOM or its local counterparts is still required.
General Regulations of the NMPA
In China, the NMPA monitors and supervises the administration of pharmaceutical products, as well as medical devices and equipment. The
NMPA’s primary responsibility includes evaluating, registering and approving new drugs, generic drugs, imported drugs and traditional Chinese
medicines; approving and issuing permits for the manufacture, export and import of pharmaceutical products and medical appliances; approving
the establishment of enterprises for pharmaceutical manufacture and distribution; formulating administrative rules and policies concerning the
supervision and administration of food, cosmetics and pharmaceuticals; and handling significant accidents involving these products. Local
provincial drug administrative authorities are responsible for supervision and administration of drugs within their respective administrative
regions.
The Drug Administration Law of China promulgated by the Standing Committee of the National People’s Congress in 1984 and the
Implementing Measures of the Drug Administration Law of China promulgated by the Ministry of Health, or MOH in 1989 set forth the legal
framework for the administration of pharmaceutical products, including the research, development and manufacturing of drugs.
The Drug Administration Law of China went through several revisions and was last revised in April 2015. The purpose of the revisions was to
strengthen the supervision and administration of pharmaceutical products and to ensure the quality and safety of those products for human use.
The Drug Administration Law of China regulates and prescribes a framework for the administration of pharmaceutical preparations of medical
institutions and for the development, research, manufacturing, distribution, packaging, pricing and advertisement of pharmaceutical products.
The Implementing Measures of the Drug Administration Law of China promulgated by the State Council and most recently revised in February
2016 provide detailed implementing regulations for the revised Drug Administration Law of China.
100
Approval for Clinical Trials and Production of New Drugs
According to the Provisions for Drug Registration promulgated by the CFDA (now the NMPA) in 2007, the Drug Administration Law of China,
the Provisions on the Administration of Special Examination and Approval of Registration of New Drugs, the Special Examination and Approval
Provisions issued by the CFDA in 2009, and the Circular on Information Publish Platform for Pharmaceutical Clinical Trials issued by the
CFDA in 2013, we must comply with the following procedures and obtain several approvals for clinical trials and production of new drugs.
New Drug Application
When clinical trials have been completed, an applicant shall apply to the NMPA for approval of a new drug application. The NMPA, the Center
for Drug Evaluation, or the CDE, and the Drug Inspection Institution will conduct reviews and on-site inspections. The NMPA determines
whether to approve the application according to the comprehensive evaluation opinions produced by the reviews and on-site inspections. We
must obtain approval of our new drug applications before our drugs can be manufactured and sold in the Chinese market.
According to the Provisions for Drug Registration, drug registration applications are divided into three different types, namely Domestic New
Drug Application, Domestic Generic Drug Application, and Imported Drug Application.
Drug Registration Classification
In March 2016, the CFDA (now NMPA) promulgated the Work Plan for Reforming the Chemical Medicines Registration Classification System,
under which, the registrations of chemical medicines are divided into five categories as follows:
•
•
•
•
•
Category 1: Innovative drugs that are not marketed anywhere in the world. These drugs contain new compounds with clear structures
and pharmacological effects and they have clinical value.
Category 2: Modified new drugs that are not marketed anywhere in the world. With known active components, the drug’s structure,
phase, prescription manufacturing process, administration route and indication are optimized and it has obvious clinical advantage.
Category 3: Generic drugs, that have equivalent quality and efficacy to the originator’s drugs have been marketed abroad, but not yet
in China.
Category 4: Generic drugs, that have equivalent quality and efficacy to the originator’s drugs and have been marketed in China.
Category 5: Drugs that have been marketed abroad are applied to be marketed domestically in China.
The registration of Category 1 or Category 2 drugs above will be subject to the requirements of the Domestic New Drug Application, Category 3
or Category 4 drugs will be subject to the Domestic Generic Drug Application, and Category 5 drugs will be subject to the Imported Drug
Application.
101
Special Examination and Approval Procedures for Innovative Drugs
According to the Special Examination and Approval Provisions, the NMPA will conduct special examination and approval for new drugs
registration application when:
(1)
(2)
(3)
(4)
the effective constituent of drug extracted from plants, animals, minerals, etc. as well as the preparations thereof have never been
marketed in China, and the material medicines and the preparations thereof are newly discovered;
the chemical raw material medicines as well as the preparations and biological products thereof haven’t been approved for marketing
home and abroad;
the new drugs are for treating AIDS, malignant tumors and rare diseases, etc., and have obvious advantages in clinic treatment; or
the new drugs are for treating diseases with no effective methods of treatment.
The Special Examination and Approval Provisions provide that the applicant may file for special examination and approval at the stage of
Clinical Trial Application if the drug candidate falls within items (1) or (2). For drug candidates that fall within items (3) or (4), the application
for special examination and approval must be made when filing for production.
In addition, under the Special Examination and Approval Provisions, where a special examination and approval treatment is granted, the
application for clinical trial and manufacturing will be handled with priority and with enhanced communication with the CDE of the NMPA,
which will establish a working mechanism for communicating with the applicants. If it becomes necessary to revise the clinical trial scheme or
make other major alterations during the clinical trial, the applicant may file an application for communication. When an application for
communication is approved, the CDE will arrange the communication with the applicant within one month.
We believe that certain of our products fall within items (2) and (3) above. Therefore, we may file an application for special examination and
approval at the Clinical Trial Application stage, which may enable us to pursue a more expedited path to approval in China and bring therapies to
patients more quickly.
Reform of the Review and Approval Process for Drug Registration
In order to address a number of issues relating to the current drug registration system, in particular, long registration time, significant application
backlog, low-quality drug application clinical data, and a difficult registration system for innovative drugs, the State Council and the NMPA have
issued and implemented a numbers of opinions and orders.
In November 2015, the CFDA (now NMPA) released the Circular Concerning Several Policies on Drug Registration Review and Approval,
which further clarified the following policies potentially simplifying and accelerating the approval process of clinical trials:
•
•
A one-time umbrella approval procedure allowing approval of all phases of a new drug’s clinical trials at once, rather than the current
phase-by-phase approval procedure, will be adopted for new drugs’ clinical trial applications.
A fast track drug registration or clinical trial approval pathway will be available for the following applications: (i) registration of
innovative new drugs treating HIV, cancer, serious infectious diseases and orphan diseases; (ii) registration of pediatric drugs; (iii)
registration of geriatric drugs and drugs treating China-prevalent diseases; (iv) registration of drugs sponsored by national
102
science and technology grants; (v) registration of innovative drugs using advanced technology, using innovative treatment methods, or
having distinctive clinical benefits; (vi) registration of foreign innovative drugs to be manufactured locally in China; (vii) concurrent
applications for new drug clinical trials which are already approved in the U.S. or European Union, or concurrent drug registration
applications for drugs which have applied for marketing authorization and passed onsite inspections in the U.S. or European Union
and are manufactured using the same production line in China; and (viii) clinical trial applications for drugs with urgent clinical need
and patent expiry within three years, and marketing authorization applications for drugs with urgent clinical need and patent expiry
within one year.
In March 2016, the CFDA (now NMPA) issued the Interim Provisions on the Procedures for Drug Clinical Trial Data Verification that provides
procedural rules for NMPA’s on-site verification of clinical data before drug approvals.
In December 2017, the NMPA published the Opinions on Encouraging the Prioritized Evaluation and Approval for Drug Innovations, which
introduces a prioritized review and approval pathway to clinical trial applications and registration applications of certain drugs as part of NMPA’s
ongoing reform of its current drug review and approval system.
Recent Regulatory Changes for Foreign New Drugs
Recent regulatory developments in late 2017 have evolved new drug applications for foreign new drugs in China. According to the Decision on
Adjusting Relevant Matters Concerning the Administration of Imported Drug Registration issued by NMPA on October 10, 2017, for foreign
new drugs that have never been marketed both domestically in China and abroad that fall into Category 1 and Category 2 drugs, an application
for clinical trials and new drug registration may be submitted directly to the NMPA without a market approval issued in their home countries.
Whereas in the past, overseas applicants had to wait until the new drug was first approved in an overseas country before it could file for new
drug registration in China. Second, for those new drugs that have applied to conduct a Multi-Regional Clinical Trial, or MRCT, in China, Phase 1
clinical trials as required by NMPA may be conducted concurrently. Whereas in the past, MRCTs conducted in China could only be conducted
after the drugs had obtained a market approval or passed Phase 2 or Phase 3 in an overseas country.
Third, after such MRCTs have been completed in China, a new drug application may be submitted to the NMPA directly for their review with no
additional waiver of local clinical trial requirements is required. This may effectively shorten the registration period for Category 5 new drugs in
China.
According to the Opinions on Deepening the Reform of the Evaluation and Approval System and Inspiring Innovation of Drugs and Medical
Devices issued by the State Council on October 9, 2017, the clinical trial data obtained from foreign clinical trial institutions may be acceptable
if they meet the relevant requirements in new drug applications in China, for which the supplement of clinical trial data on racial difference may
be necessary. However, the relevant implementation guidelines have not been issued by the NMPA.
Last, the three-year pilot program of marketing authorization holders system that otherwise would expire on November 4, 2018, has been
extended for one additional year. The marketing authorization holders system allows drug research and development institutions to obtain and
hold the marketing authorization and have the ability to outsource manufacturing and distribution to third parties.
103
Good Manufacturing Practice
All facilities and techniques used in the manufacture of products for clinical use or for sale in China must be operated in conformity with good
manufacturing practice guidelines as established by the NMPA. Failure to comply with applicable requirements could result in the termination of
manufacturing and significant fines.
C. Organizational structure.
Name
ASLAN Pharmaceuticals Limited
ASLAN Pharmaceuticals Pte. Ltd.
Place of Incorporation
Cayman Islands
Singapore
Date of
Incorporation
June 2014
April 2010
ASLAN Pharmaceuticals Taiwan Limited
Taiwan
November 2013
ASLAN Pharmaceuticals Australia Pty Ltd.
Australia
ASLAN Pharmaceuticals Hong Kong
Limited
ASLAN Pharmaceuticals (Shanghai) Co. Ltd. China
Hong Kong
July 2014
July 2015
May 2016
ASLAN Pharmaceuticals (USA) Inc.
United States of America
October 2018
Main Business
Investment holding
New drug
development
New drug
development
New drug
development
New drug
development
New drug
development
New drug
development
research
and
research
and
research
and
research
and
research
and
research
and
104
D. Property, plants and equipment.
Our corporate headquarters are located in Singapore, where we occupy approximately 4,500 square feet of office space, the lease for which
expires in 2019. We also have offices in Taipei, Taiwan, and Shanghai, China. We lease all of our facilities and believe that our facilities are
adequate to meet our needs for the immediate future, and that, should it be needed, suitable additional space will be available on commercially
reasonable terms to accommodate any such expansion of our operations.
Item 4A. Unresolved Staff Comments
Not Applicable.
Item 5. Operating and Financial Review and Prospects
The following discussion and analysis of our financial condition and results of operations should be read together with Item 3.A. “Selected
financial data” and our consolidated financial statements and related notes appearing elsewhere in this Annual Report. Some of the information
contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and
strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many
factors, including those set forth in the Item 3.D. “Risk Factors” section of this Annual Report, our actual results could differ materially from the
results described in or implied by these forward-looking statements. Please also see the section titled “Cautionary Statement Regarding
Forward-Looking Statements.”
A.
Operating results.
Overview
We are a clinical-stage oncology and inflammatory focused biopharmaceutical company based in Singapore developing novel therapeutics for
global markets. We target diseases that are both highly prevalent in Asia and orphan indications in the United States and Europe. Our Asia
development platform is designed to enable us to accelerate the development of drugs to treat these diseases. Our portfolio is comprised of four
product candidates which target: validated growth pathways applied to new patient segments; novel immune checkpoints; and novel cancer
metabolic pathways.
Our lead program, varlitinib, is a reversible small molecule pan-HER inhibitor that targets the human epidermal growth factor receptors HER1,
HER2 and HER4. Varlitinib is currently being studied in a global pivotal clinical trial for biliary tract cancer for which we expect to report
topline data in in the second half of 2019. We focus on cancers, such as biliary tract cancer, that are orphan diseases in the United States and
Europe for which there are few, if any, approved therapies. Although registration trials for orphan diseases may require fewer patients,
recruitment for such trials in the United States and Europe is often challenging given the limited availability of suitable patients. Asia offers a
unique opportunity to accelerate the development of novel therapies in diseases where either the cancers are more prevalent or the availability of
suitable patients is greater.
105
Since our inception in 2010, we have devoted substantially all of our resources to acquiring rights to, and developing our product candidates,
including preclinical studies and clinical trials and providing general and administrative support for our operations. We have not generated any
revenue from product sales and we do not currently have any products approved for commercialization. We have financed our operations through
a combination of debt and equity financings and government grants. Since inception we have raised $167.2 million from the sale of our ordinary
shares including $33.0 million in a public offering conducted in Taiwan on June 1, 2017, $42.2 million in a public offering conducted in the
United Stated on May 4, 2018. Our ordinary shares are listed on the TPEx and our ADSs are listed on The Nasdaq Global Market. We recorded
$11.5 million of revenue for the year ended December 31, 2016, which was generated primarily through out-licensing activities. We did not
generate revenue for the years ended December 31, 2017 and 2018. To date we have outsourced our manufacturing and clinical operations to
third parties. We do not intend to operate our own clinical trials or build or acquire infrastructure for manufacturing our drugs for clinical or
commercial supply. All of our clinical supplies are manufactured in accordance with cGMP using high quality contract manufacturing
organizations based in the United States, Europe and Asia.
As of December 31, 2018, we had cash and cash equivalents of $28.9 million. We have never been profitable and have incurred significant net
losses in each period since our inception. Our consolidated net loss attributable to ordinary shareholders for the year ended December 31, 2016,
2017 and 2018 was $9.0 million, $39.9 million and $42.2 million, respectively. We incurred net losses of $9.0 million, $39.9 million and $42.2
million for the years ended December 31, 2016, 2017 and 2018, respectively. As of December 31, 2018, we had an accumulated deficit of $132.5
million. Our primary use of cash is to fund research and development costs. Our operating activities used $5.8 million, $34.1 million and $39.5
million of cash flows during the years ended December 31, 2016, 2017 and 2018, respectively. We expect to continue to incur significant
expenses and operating losses for the foreseeable future.
We expect expenses to be incurred in connection with our ongoing activities as we:
•
•
•
•
•
•
continue to invest in the clinical development of our product candidates, including in connection with the following planned and
ongoing clinical trials:
o
o
o
o
global pivotal clinical trial for varlitinib in biliary tract cancer;
global Phase 2 clinical trials for ASLAN003 in AML;
ASLAN004 Phase 1 clinical trials in atopic dermatitis; and
any additional clinical trials that we may conduct for product candidates;
identify and acquire new product candidates;
engage third parties to manufacture product candidates for clinical trials and, if any product candidates are approved, for
commercialization;
establish a sales, marketing and distribution infrastructure;
maintain, expand and protect our intellectual property portfolio; and
incur additional costs with operating as a U.S. public company.
We will continue to require additional capital to support our operating activities as we advance our product candidates through clinical
development, regulatory approval and, if any of our product candidates are approved, commercialization. The amount and timing of our future
funding requirements will depend on many factors, including the pace and results of our product development efforts.
106
Out-licensing Agreements
To date, we have out-licensing arrangements with BMS and BioGenetics.
BMS
On November 2, 2011, we entered into a license agreement with BMS, pursuant to which we received exclusive rights to develop and
commercialize ASLAN002 in China, Australia, South Korea, Taiwan and other selected Asian countries, and BMS retained exclusive rights in
the rest of the world. On July 19, 2016, BMS initiated their rights pursuant to the agreement to buy back the exclusive rights from us to develop
and commercialize ASLAN002. In connection with the buy-back, we received an upfront payment of $10.0 million in 2016, and are eligible to
receive additional payments upon BMS’s achievement of development and regulatory milestones in the future. Furthermore, we are eligible to
receive royalty payments on future worldwide sales generated by BMS. BMS also purchased from us research materials, supplies, research
documentation and clinical trial results related to ASLAN002 for $1.2 million, which was paid in 2016. As BMS has assumed the responsibility
for all development and commercialization activities and expenses and we have no further obligations under the license agreement, we have
recognized $11.2 million in revenue for the year ended December 31, 2016. Since the conditions enabling capitalization of research and
development costs related to ASLAN002 as an asset were not met and the research supplies related to ASLAN002 had no alternative future uses
if the project is abandoned, all research and development expenditures were recognized in profit or loss when incurred. As a result, no cost of
revenue was recorded in connection with the revenue recognized for the year ended December 31, 2016.
BioGenetics – License of varlitinib for South Korea
On February 27, 2019, we entered into a collaboration and license agreement with BioGenetics, pursuant to which we granted BioGenetics the
exclusive right to commercialize, and if agreed, manufacture, varlitinib for the treatment of all indications in South Korea. In consideration of the
rights granted to BioGenetics under the agreement, we received an upfront payment of $2 million from BioGenetics and are eligible to receive up
to $11 million in sales and development milestones (the threshold for the sales milestones being subsequently amended by the ASLAN003
license summarized below). We are also eligible to receive tiered double-digit royalties on net sales up to a percentage within the mid-
twenties. BioGenetics will be responsible for obtaining initial and all subsequent regulatory approvals of varlitinib in South Korea. We may
provide clinical drug supplies to BioGenetics required for regulatory filings and for commercialization of products, pursuant to a separate
manufacturing and supply agreement which the parties shall use commercially reasonable efforts to enter into no later than June 30, 2020.
BioGenetics – License of ASLAN003 for South Korea
On March 11, 2019, we entered into a collaboration and license agreement with BioGenetics, pursuant to which we granted BioGenetics the
exclusive right to commercialize, and if agreed, manufacture, ASLAN003 for the treatment of all indications in South Korea. In consideration of
the rights granted to BioGenetics under the agreement, we received an upfront payment of $1 million from BioGenetics and are eligible to
receive up to $8 million in sales and development milestones, the thresholds for payment of such sales milestones being the aggregate of sales of
varlitinib under the license summarized above and sales of ASLAN003 products. We are also eligible to receive tiered double-digit royalties on
net sales up to a percentage within the mid-twenties. BioGenetics agreed to contribute to the global R&D costs incurred by ASLAN in the
clinical development of ASLAN003 in acute myeloid leukemia. BioGenetics will be responsible for obtaining initial and all subsequent
regulatory approvals of ASLAN003 in South Korea. We
107
may provide clinical drug supplies to BioGenetics required for regulatory filings and for commercialization of products, pursuant to a separate
manufacturing and supply agreement which the parties shall use commercially reasonable efforts to enter into no later than June 30, 2020.
Hyundai
On October 30, 2015, we entered into a collaboration and license agreement with Hyundai, pursuant to which we granted Hyundai the right to
develop and an option to commercialize varlitinib for the treatment of cholangiocarcinoma (subsequently amended to be for the treatment of
BTC) in South Korea. In consideration of the rights granted to Hyundai under the agreement, we received an upfront payment of $0.3 million
from Hyundai in 2016. On February 26, 2019, prior to executing the broader agreement for varlitinib with BioGenetics above, we made a
payment of $325,000 to Hyundai to buy back the rights to varlitinib in BTC in South Korea and terminated the out-license to Hyundai.
In-licensing Agreements
We are required to make milestone payments upon the achievement of certain development, regulatory and commercial milestones and royalties
based on the net sales of the licensed products and therefore, we expect our results of operations will continue to be affected by these
agreements. In 2016, we made a payment of less than $0.1 million to Exploit Technologies Pte Ltd to acquire their license that was capitalized
as intangible assets. In 2018, we paid an aggregate of $23 million to Array Biopharma Inc. to acquire an exclusive, worldwide license to develop,
manufacture and commercialize varlitinib, which was capitalized as intangible assets. In June 2018, we paid $0.5 million to CSL Limited upon
the filing of our clinical trial authorization submission with the Singapore Health Sciences Authority, as required under the terms of our license
agreement with CSL Limited. For the year ended December 31, 2018, we have not made any other payments related to the in-license agreements.
See “Item 4.B. Information on the Company - Business overview—License and Collaboration Agreements” for a description of our license
agreements, which includes a description of the termination provisions of these agreements.
Key Components of Results of Operations
Revenues
To date, we have not generated any revenue from product sales and do not expect to generate any revenue from product sales until our product
candidates receive regulatory approval. For the year ended December 31, 2016, revenues consisted primarily of upfront payments received under
out-licensing arrangements, as described above. We did not generate revenue for the years ended December 31, 2017 and 2018.
Cost of Revenue
In connection with the upfront payment that we received from Hyundai in 2016, we made a $0.1 million payment to one of the third parties with
whom we have a licensing agreement, and such payment was recognized as costs of revenue for the year ended December 31, 2016. We did not
recognize costs of revenue for the years ended December 31, 2017 and 2018.
108
Research and Development Expenses
The largest component of our operating expenses since inception has been research and development activities, including the preclinical and
clinical development of our product candidates. Research and development costs are expensed as incurred. Our research and development
expenses primarily consist of:
•
•
•
•
•
•
costs incurred under agreements with contract research organizations and investigative sites that conduct preclinical studies and
clinical trials;
costs related to manufacturing pharmaceutical active ingredients and product candidates for preclinical studies and clinical trials;
salaries and personnel-related costs, including bonuses, related benefits and share-based compensation expense for our scientific
personnel performing or managing out-sourced research and development activities;
fees paid to consultants and other third parties who support our product candidate development;
other costs incurred in seeking regulatory approval of our product candidates; and
allocated facility-related costs and overhead.
Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical
development, primarily due to the increased size and duration of later-stage clinical trials. Accordingly, we expect research and development
costs to increase significantly for the foreseeable future as our programs progress. However, we do not believe that it is possible at this time to
accurately project total program-specific expenses through commercialization. Our expenditures on current and future preclinical and clinical
development programs are subject to numerous uncertainties in timing and cost to completion. In addition, we may enter into additional
collaboration arrangements for our product candidates, which could affect our development plans or capital requirements.
We allocate direct costs to product candidates when they enter into clinical development. For product candidates in clinical development, we
allocate development and manufacturing costs to our product candidates on a program-specific basis, and we include these costs in the program-
specific expenses. Our direct research and development expenses tracked by program consist primarily of external costs, such as fees paid to
outside consultants, CROs, and CMOs in connection with our preclinical development, manufacturing and clinical development activities. We do
not allocate employee costs or facility expenses, including other indirect costs, to specific programs because these costs are deployed across
multiple programs and, as such, are not separately presented. We use internal resources primarily to oversee research and discovery as well as for
managing our preclinical development, process development, manufacturing and clinical development activities. These employees work across
multiple programs and, therefore, we do not track their costs by program.
109
The table below summarizes our research and development expenses incurred by program for the periods presented:
Direct research and development expense by product:
Varlitinib
ASLAN003
ASLAN004
Other
Indirect research and development expense:
Employee benefit and travel expense
Other indirect research and development expense
Total research and development expense
General and Administrative Expenses
2016
Year ended December 31,
2017
(in thousands)
2018
$
$
7,270 $
312
1,104
839
3,230
410
13,165 $
19,578 $
778
3,265
1,368
4,381
1,011
30,381 $
17,474
1,623
5,897
2,241
4,320
279
31,834
General and administrative expenses consist of personnel costs, allocated expenses and other expenses for outside professional services,
including legal, audit and accounting services. Personnel costs consist of salaries, bonuses, benefits and stock-based compensation. Other general
and administrative expenses include facility-related costs not otherwise allocated to research and development expense, professional fees,
expenses associated with obtaining and maintaining patents and costs of our information systems. We anticipate that our general and
administrative expenses will continue to increase in the future as we increase our headcount to support our continued research and development
and potential commercialization of our product candidates, as well as expenses related to compliance with the rules and regulations of the
Securities and Exchange Commission, additional insurance expenses, investor relation activities and other administrative and professional fees.
Non-Operating Income and Expenses
Other Income
Other income is the gain recognized on the disposal of the licensed intellectual property and other rights arising from a third-party license
agreement.
Other Gains and Losses, Net
Other gains and losses are primarily net gains and losses from realized and unrealized currency exchange differences incurred during the period.
110
Finance Costs
Finance costs are interest expenses primarily from the Singapore Economic Development Board, or EDB, repayable grant and the CSL Facility,
as well as dividend accruals for preference shares from January to May 2016, all of which were converted into ordinary shares on May 27, 2016
in connection with our initial public offering in Taiwan. As of December 31, 2016, 2017 and 2018, the amount of funds disbursed under the EDB
repayable grant plus accrued interest was $8.3 million, $9.7 million, and $9.9 million, respectively. As of December 31, 2016 and 2017, there
were no amounts outstanding under the CSL Facility, and $4.1 million in principal and accrued interest outstanding as of December 31, 2018.
Results of Operations
The following table sets forth a summary of our consolidated results of operations for the periods indicated. This information should be read
together with our consolidated financial statements and related notes included elsewhere in this Form 20-F. Our operating results in any period
are not necessarily indicative of the results that may be expected for any future period.
2016
Year Ended December 31,
2017
(in thousands)
2018
11,547
(125)
(6,956)
(13,165)
(8,699)
47
—
127
(524)
(9,049)
—
(9,049)
—
—
(8,759)
(30,381)
(39,140)
363
—
(698)
(417)
(39,892)
—
(39,892)
—
—
(10,514)
(31,834)
(42,348)
268
187
213
(492)
(42,172)
(14)
(42,186)
105,027,040
(0.09)
124,424,960
(0.32)
149,739,242
(0.28)
Net revenues
Cost of revenues
General and administrative expenses
Research and development expenses
Loss from operations
Interest income
Other income
Other gains and losses
Finance costs
Loss from before income tax
Income tax expense
Net loss attributable to ordinary shareholders
Weighted-Average shares used in calculating
net loss per ordinary shares, basic and diluted
Net loss per share, basic and diluted
Comparison of the Years Ended December 31, 2017 and 2018
Revenue
We did not generate revenue for the years ended December 31, 2017 and 2018.
111
General and Administrative Expenses
The following table sets forth the components of our general and administrative expenses for the years indicated.
(In thousands)
General and administrative expenses
Employee benefit and travel expenses
Professional fees
Rent relating to operating leases
Other costs
Total general and administrative expense
Year Ended December 31,
2017
%
2018
%
5,044
2,103
882
730
8,759
58%
24%
10%
8%
100%
6,527
2,263
1,045
679
10,514
62%
22%
10%
6%
100%
General and administrative expenses increased by $1.7 million from $8.8 million for the year ended December 31, 2017 to $10.5 million for the
year ended December 31, 2018. The increase in general and administrative expenses was primarily due to an increase in employee benefit and
travel expenses, including an increase in headcount and staffing costs, and office administration costs.
Research and Development Expenses
The following table sets forth the components of our research and development expenses for the years indicated.
(In thousands)
Research and development expenses
Preclinical and clinical development expenses
Manufacturing expenses
Employee benefit and travel expenses
Total research and development expenses
Year Ended December 31,
2017
%
2018
%
19,459
6,541
4,381
30,381
64%
22%
14%
100%
21,361
6,153
4,320
31,834
67%
19%
14%
100%
Research and development expenses increased by $1.4 million from $30.4 million for the year ended December 31, 2017 to $31.8 million for the
year ended December 31, 2018. The increase in research and development expenses was primarily due to an increase in preclinical and clinical
development work as we advanced our drug candidate pipeline.
Other Gains and Losses, Net
Other net losses for the year ended December 31, 2017 were $0.7 million and other net gains for the year ended December 31, 2018 were $0.2
million, consisting primarily of realized and unrealized foreign exchange losses. The increase in net gains was primarily attributable to foreign
currency translation gains as a result of the translation of our assets, liabilities and results of operations into U.S. dollars using the relevant
foreign currency exchange rates. This was caused by the strengthening of the U.S. dollar against the Singapore dollar during those years.
112
Interest Income
Interest income for the years ended December 31, 2017 and 2018 were $0.4 million and $0.3 million, respectively. The decrease was primarily
due to a decrease in deposits in banks in 2018.
Other Income
Other income for the year ended December 31, 2017 and 2018 were $0 and $0.2 million, respectively. The increase was primarily due to a gain
on the disposal of intellectual property.
Net Loss Attributable to Ordinary Shareholders
For the years ended December 31, 2017 and 2018, we had a net loss attributable to ordinary shareholders of $39.9 million and $42.2 million,
respectively. The increases in general and administrative expenses, and research and development expenses were the key drivers of the increased
expenditure in 2018.
Comparison of the Years Ended December 31, 2016 and 2017
The following table sets forth a summary of our consolidated results of operations for the periods indicated. This information should be read
together with our consolidated financial statements and related notes included elsewhere in this Form 20-F. Our operating results in any period
are not necessarily indicative of the results that may be expected for any future period.
Net revenue
Cost of revenue
Operating expenses
General and administrative expenses
Research and development expenses
Loss from operations
Non-operating income and expenses
Other gains and losses, net
Finance costs
Interest income
Total non-operating income (expenses)
Loss before income tax
Income tax expense
Net loss
Total comprehensive loss
113
Year ended December 31,
2017
2016
$
(in thousands)
11,547 $
(125)
(6,956)
(13,165)
(8,699)
127
(524)
47
(350)
(9,049)
—
(9,049)
(9,049)
—
—
(8,759)
(30,381)
(39,140)
(698)
(417)
363
(752)
(39,892)
—
(39,892)
(39,892)
Revenue
Revenue was $11.5 million for the year ended December 31, 2016, consisting primarily of an upfront milestone payment of $10.0 million from
BMS, a payment of $1.2 million from BMS for the sale of research materials, supplies, research documentation and clinical trial results related to
ASLAN002, as well as a payment of $0.3 million from Hyundai related to the out-licensing of varlitinib in South Korea. We did not generate
revenue for the year ended December 31, 2017.
General and Administrative
The following table sets forth a summary of our general and administrative expenses for the periods indicated.
General and administrative expenses for the years ended December 31, 2016 and 2017 were $6.9 million and $9.1 million, respectively. The
increase in general and administrative expenses was primarily due to an increase in headcount and staffing costs, fund raising activity costs and
office administration costs.
General and administrative expense
Employee benefit and travel expenses
Professional fees
Rent expense related to operating leases
Other costs
Total general and administrative expense
Research and Development
Year ended December 31,
2017
2016
(in thousands)
$
$
4,678 $
1,316
280
683
6,957 $
5,044
2,103
882
730
8,759
The following table sets forth a summary of our research and development expenses for the periods indicated.
Research and development expenses for the years ended December 31, 2016 and 2017 were $13.2 million and $30.0 million, respectively,
consisting of expenditures relating to clinical development and clinical manufacturing work performed for our various product candidates. This
was primarily due to the increased spending on the clinical trial activities and product manufacturing in connection with the development of our
lead product candidate, varlitinib.
Research and development expense
Preclinical and clinical development expense
Manufacturing expense
Employee benefit and travel expenses
Total research and development expense
114
Year ended December 31,
2017
2016
(in thousands)
$
$
6,440 $
3,495
3,230
13,165 $
19,459
6,541
4,381
30,381
Other Gains and Losses, Net
Other net gains for the year ended December 31, 2016 were $0.1 million and other net losses for the year ended December 31, 2017 were $0.7
million, consisting primarily of realized and unrealized foreign exchange losses. The increase in net losses was primarily attributable to foreign
currency translation losses as a result of the translation of our assets, liabilities and results of operations into U.S. dollars using the relevant
foreign currency exchange rates. This was caused by the strengthening of the Singapore dollar against the U.S. dollar during those years.
Finance Costs
Finance costs for the years ended December 31, 2016 and 2017 were $0.5 million and $0.4 million, respectively, consisting primarily of interest
expense related to interest accrued on long-term borrowings. The decrease was primarily due to the repayment of the CSL Facility in 2016 that
resulted in less interest expenditure generated in 2017.
Interest Income
Interest income for the years ended December 31, 2016 and 2017 were $0.1 million and $0.4 million, respectively. The increase was primarily
due to an increase in deposits in banks in 2017 that resulted in more interest income generated in 2017.
Net Loss Attributable to Ordinary Shareholders
For the years ended December 31, 2016 and 2017, we had a net loss attributable to ordinary shareholders of $9.0 million and $39.9 million,
respectively. The increases in research and development expenses, general and administrative expenses and non-operating expenses were the key
drivers of the increased expenditure in 2017.
B.
Liquidity and Capital Resources
Since inception, we have invested most of our resources in the development of our product candidates, building our intellectual property
portfolio, developing our supply chain, conducting business planning, raising capital and providing support for our operations. To date we have
funded our operations through public and private placements of equity securities, upfront and milestone payments received from our
collaborators, funding from governmental bodies and interest income from banks. Through December 31, 2018, we had raised aggregate gross
proceeds of $167.2 million from private and public offerings, we had received aggregate gross upfront payments of $10.3 million from our
collaborators and received an aggregate of $7.4 million in grants from government bodies. Since our inception, we have incurred net losses and
negative cash flows from our operations. Substantially all of our losses have resulted from funding our research and development programs and
general and administrative costs associated with our operations. We incurred net losses of $9.0 million, $39.9 million and $42.2 million for the
years ended December 31, 2016, 2017 and 2018, respectively. As of December 31, 2018, we had an accumulated deficit of $132.5 million. Our
operating activities used $5.8 million, $34.1 million and $39.5 million of cash outflows during the years ended December 31, 2016, 2017 and
2018 respectively. As of December 31, 2018, we had cash and cash equivalents of $28.9 million.
We have not achieved profitability since our inception and we expect to continue to incur net losses for the foreseeable future. In January 2019,
we implemented a corporate restructuring plan to focus our
115
resources on its lead clinical programs: varlitinib in biliary tract cancer (BTC), ASLAN003 in acute myeloid leukaemia (AML) and ASLAN004
in atopic dermatitis.As part of the corporate restructuring plan, we substantially reduced research and development costs and administrative
expenses by closing certain studies and reducing our workforce. Based on our current operating plan, we believe that our existing cash and cash
equivalents will enable us to fund our operating expenses and capital requirements for at least the next 12 months. We have based this estimate
on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. If our planned
preclinical and clinical trials are successful, or our other product candidates enter clinical trials or advance beyond the discovery stage, we will
need to raise substantial additional financing in the future to fund our operations. In order to meet these additional cash requirements, we may
incur debt, out-license certain intellectual property and seek to sell additional equity or convertible securities that may result in dilution to our
stockholders. If we raise additional funds through the issuance of equity or convertible securities, these securities could have rights or
preferences senior to those of our ADSs and ordinary shares and any indebtedness could contain covenants that restrict our operations. There can
be no assurance that we will be able to obtain additional equity or debt financing on terms acceptable to us, if at all.
CSL Loan Facility
In connection with the license agreement with CSL Limited related to ASLAN004, in May 2014 we entered into the CSL Facility with CSL
Finance, pursuant to which CSL Finance agreed to provide a ten-year facility for $4.5 million. Borrowings under the CSL Facility are unsecured
and can be used to reimburse a portion of eligible invoices for certain research and development costs or expenses incurred by us in connection
with developing ASLAN004 and approved by CSL Finance at each drawdown period. Interest on the loan is computed at 6% plus LIBOR and is
payable on a quarterly basis. Any outstanding principal on the loan must be repaid 10 years from the date of the CSL Facility. Amounts
outstanding can be voluntarily prepaid. In addition, we are required to mandatorily prepay amounts outstanding if we receive any income or
revenue in connection with the commercialization or out-licensing of any intellectual property rights (other than under the license agreement
with CSL Limited related to ASLAN004), in which case we are required to apply at least a low double digit percentage of such income or
revenue against any amounts then-outstanding under the CSL Facility.
Under the CSL Facility, we are subject to customary reporting and restrictive covenants. In addition, if Carl Firth, our chief executive officer,
were to resign or be removed, we are obligated to find and hire within 12 months a replacement with the same level of experience, seniority and
expertise commensurate with that of a CEO of a company in the same field of activity and similar size and resources as ours. If an event of
default occurs, CSL Finance can terminate the commitment under the CSL Facility and accelerate all amounts outstanding.
As of December 31, 2016 and 2017, there were there were no amounts outstanding under the CSL Facility, and $4.1 million in principal and
accrued interest outstanding under the CSL Facility as of December 31, 2018.
116
Cash Flows
The following table provides information regarding our cash flows for the years ended December 31, 2016, 2017 and 2018:
(In thousands)
Net cash used in operating activities
Net cash used in investing activities
Net cash provided by financing activities
Net increase/(decrease) in cash and cash equivalents
Net cash used in operating activities
Year Ended December 31,
2017
2018
2016
(5,789)
(523)
30,987
24,675
(34,117)
(336)
33,289
(1,164)
(39,470)
(23,094)
40,899
(21,665)
The use of cash resulted primarily from our net losses adjusted for non-cash charges and changes in components of our operating assets and
liabilities. The primary cash inflow was generated from the consideration received for the out-licensing of experimental drugs. The primary use
of our cash was to fund the development of our research and development activities, regulatory and other clinical trial costs, and related
supporting administration. Our prepayments and other current assets, accounts payable and other payables balances were affected by the timing
of vendor invoicing and payments.
Net cash used in operating activities were $34.1 million and $39.5 million for the years ended December 31, 2017 and 2018, respectively. The
increase of net cash used in operating activities for 2018 was primarily due to an increase of $1.7 million related to general and administrative
expenses, and an increase of $1.4 million related to research and development expenses from 2017 to 2018, as we incurred more expenditures for
our clinical trial activities.
Net cash used in operating activities were $5.8 million and $34.1 million for the years ended December 31, 2016 and 2017, respectively. The
increase of net cash used in operating activities for 2017 was primarily due to the fact that no revenue was generated in 2017, compared to
revenue of $11.5 million generated from out-licensing activities in 2016, and an increase of $17.2 million related to research and development
expenses from 2016 to 2017 as we incurred more expenditures for our clinical trial activities of varlitinib and manufacturing activities in
connection with the development of our various product candidates.
Net cash used in investing activities
Net cash used in investing activities was $0.3 million and $23.1 million for the years ended December 31, 2017 and 2018, respectively. The
increase in cash used in investing activities for 2018 was primarily due to the purchase of the worldwide commercial rights for varlitinib.
Net cash used in investing activities was $0.5 million and $0.3 million for the years ended December 31, 2016 and 2017, respectively. The
decrease of net cash used in investing activities for 2017 was primarily due to lower expenditures related to office equipment and leasehold
improvements and intangible assets.
117
Net cash provided by financing activities
Net cash provided by financing activities was $31.0 million, $33.3 million, and $40.9 million for the years ended December 31, 2016, 2017 and
2018, respectively, which consisted primarily of the net proceeds from our private financings in 2016, net proceeds from our initial public
offering in Taiwan in 2017, and net proceeds from our issuance of ADSs in our initial public offering in the United States in 2018.
Critical Accounting Policies and Significant Judgments and Estimates
Critical Accounting Policies
Summarized below are our accounting policies that we believe are important to the portrayal of our financial results and also involve the need for
management to make estimates about the effect of matters that are uncertain in nature. Actual results may differ from these estimates, judgments
and assumptions. Certain accounting policies are particularly critical because of their significance to our reported financial results and the
possibility that future events may differ significantly from the conditions and assumptions underlying the estimates used and judgments made by
our management in preparing our financial statements. The following discussion should be read in conjunction with our consolidated financial
statements and related notes, which are included in this Annual Report.
Revenue Recognition
Revenue comprises the fair value of the consideration received or receivable for the out-licensing of experimental drugs that have reached ‘proof
of concept’ to business partners for ongoing global development and launch, in the ordinary course of our activities. Revenue is presented, net of
goods and services tax, rebates and discounts.
We recognize revenue when we have completed the out-licensing of the experimental drug to business partners, such partners have accepted the
products, and collectability of the related receivables is reasonably assured.
Typically the consideration received from out-licensing may take the form of upfront payments, option payments, milestone payments, and
royalty payments on licensed products. To determine revenue recognition for contracts with customers, we perform the following five steps: (i)
identify the contracts with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate
the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) we satisfy the performance
obligations. At contract inception, we assess the goods or services promised within each contract, assess whether each promised good or service
is distinct and identify those that are performance obligations. We recognize as revenue the amount of the transaction price that is allocated to the
respective performance obligation when (or as) the performance obligation is satisfied.
Upfront License Fees
If a license to our intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, we
recognize revenues from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is
able to use and benefit from the license. For licenses that are bundled with other performance obligations, we use judgment to assess the nature
of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if over time, the appropriate
method of measuring progress for purposes of recognizing revenue. We evaluate the measure of progress each reporting period and, if necessary,
adjust the measure of performance and related revenue recognition.
118
Milestone Payments
At the inception of each contract with customers that includes development or regulatory milestone payments (i.e., the variable consideration),
we include some or all of an amount of variable consideration in the transaction price estimated only to the extent that it is highly probable that a
significant reversal in the amount of cumulative revenue recognized would not occur when the uncertainty related to the variable consideration is
subsequently resolved. Milestone payments that are contingent upon the achievement of events that are uncertain or not controllable, such as
regulatory approvals, are generally not considered highly probable of being achieved until those approvals are received, and therefore not
included in the transaction price. At the end of each reporting period, we evaluate the probability of achievement of such milestones and any
related constraints, and if necessary, may adjust our estimate of the overall transaction price.
Royalties
For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, and for which the
license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (i) when the subsequent sales
occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To
date, we have not recognized any royalty revenue resulting from any of out-licensing arrangements.
Acquired in-process research and development product candidate
In January 2018, we entered into a new license agreement with Array Biopharma Inc. to acquire an exclusive, worldwide license to develop,
manufacture and commercialize varlitinib for all human and animal therapeutic, diagnostic and prophylactic uses. Since varlitinib is still under
development and not yet approved for commercialization, the acquired in-process research and development costs related to varlitinib are
capitalized as an indefinite-lived intangible asset until the completion or abandonment of the related research and development activities. When
the related research and development is completed or a change in circumstance occurs that defines the useful life, the asset is reclassified to a
definite-lived intangible asset and amortized over its estimated useful life.
Indefinite-lived intangible asset is not subject to amortization, but is tested annually for impairment or more frequently if there are indicators of
impairment. In respect of the impairment indicators, we consider both internal and external sources of information to determine whether an asset
may be impaired, which may include significant underperformance of the business in relation to expectations, significant negative industry or
economic trends, and significant changes or planned changes with adverse effects in the use of the assets, as well as the internal reporting which
indicates the economic performance of an asset is worse than expected. If any such indicators exist, we will estimate the recoverable amount of
such indefinite-lived intangible asset and compare it with its carrying amount. Same as what is performed in the annual impairment testing, if the
recoverable amount is less than its carrying amount, an impairment charge is recognized in the consolidated statements of comprehensive income
accordingly. For the year ended December 31, 2018, we did not recognize any impairment charges related to the indefinite-lived intangible asset.
119
Realization of Deferred Income Tax Assets
When we have net operating loss carry forwards or temporary differences in the amount of tax recorded for tax purposes and accounting
purposes, we may be able to reduce the amount of tax that we would otherwise be required to pay in future periods. We generally recognize
deferred tax assets to the extent that it is probable that sufficient taxable benefits will be available to utilize. The income tax benefit or expense is
recorded when there is a net change in our total deferred tax assets and liabilities in a period. The ultimate realization of the deferred tax assets
depends upon the generation of future taxable income during the periods in which the net operating losses and temporary differences become
deductible may be utilized. Since the determination of the amount of realization of the deferred tax assets is based, in part, on our forecast of
future profitability, it is inherently uncertain and subjective. In cases where the actual profits generated are less than expected, a material
adjustment of deferred tax assets may arise, which would be recognized in profit or loss for the period in which such adjustment takes place. As
of December 31, 2017 and December 31, 2018, no deferred tax asset has been recognized on tax losses due to the unpredictability of future profit
streams.
Research and Development Expenses
Research and development expenditures are capitalized only if development costs can be measured reliably, the product or process is technically
and commercially feasible, future economic benefits are probable, and we intends to and has sufficient resources to complete development and to
use or sell the asset. The conditions enabling capitalization of development costs as an asset have not yet been met and, therefore, all
development expenditures are recognized in the consolidated statement of operations when incurred.
Share-Based Compensation
As of December 31, 2017 and 2018, there were options outstanding to purchase 14,530,879 and 14,343,213 ordinary shares, respectively. The
options granted pursuant to our 2014 Employee Share Option Scheme Plan are either vested in full as of the date of grant or are 25% vested as of
the date of grant, with the remaining 75% vesting in equal annual installments over the three years following the date of grant. Options granted
pursuant to our 2017 Employee Share Option Plan 1 vest in full upon the second anniversary of the date of grant.
Equity-settled share-based payments to employees are measured at the fair value of the equity instruments at the grant date. The fair value
determined at the grant date of the employee share options is expensed on a straight-line basis over the vesting period, based on the estimate of
employee share options that will eventually vest, with a corresponding increase in capital surplus—employee share options. The fair value
determined at the grant date of the employee share options is recognized as an expense in full at the grant date when the share options granted
vest immediately.
At the end of each reporting period, we revise our estimate of the number of employee share options expected to vest. The impact of the revision
of the original estimates is recognized in profit or loss such that the cumulative expense reflects the revised estimate, with a corresponding
adjustment to the capital surplus—employee share options.
We are responsible for determining the fair value of the stock options granted to employees following the regulatory requirements of the TPEx
and using various information, including information provided by an independent third party valuation firm. The binomial option pricing model
is applied in determining the estimated fair value of the options granted to employees. See footnote 18 to the consolidated financial statements
included elsewhere in this Annual Report for further details on the assumptions used to estimate the fair value of share-based awards granted in
prior periods.
120
JOBS Act
Subject to certain conditions set forth in the JOBS Act, we are entitled to rely on certain exemptions and reduced reporting requirements as an
EGC. We are not required to, among other things, (i) provide an auditor’s attestation report on our system of internal controls over financial
reporting pursuant to Section 404(b), (ii) provide all of the compensation disclosure that may be required of non-emerging growth public
companies under the Dodd-Frank Wall Street Reform and Consumer Protection Act, (iii) comply with any requirement that may be adopted by
the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing
additional information about the audit and the financial statements (including critical audit matters), and (iv) disclose certain executive
compensation-related items such as the correlation between executive compensation and performance and comparisons of the chief executive
officer’s compensation to median employee compensation. These exemptions will apply until December 31, 2023 or until we no longer meet the
requirements of being an EGC, whichever is earlier.
Recently Issued Accounting Pronouncements
A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is
disclosed in Note 3, “Application of new standards, amendments and interpretations,” to our consolidated financial statements and related notes
appearing elsewhere in this Annual Report.
C.
Research and Development, Patents and Licenses, etc.
Full details of our research and development activities and expenditures are given in “Item 4.B. Information on the Company - Business
overview” and “Item 5.A. Operating Results” within this Annual Report.
D.
Trend Information.
See “Item 5.A. Operating Results” and “Item 5.B. Liquidity and Capital Resources” within this Annual Report.
E.
Off-balance Sheet Arrangements.
We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined in the rules and
regulations of the SEC.
F.
Tabular Disclosure of Contractual Obligations.
The following table sets forth our contractual obligations as of December 31, 2018 (in thousands). Amounts we pay in future periods may vary
from those reflected in the table.
Operating lease obligations(1)
CSL loan facility(2)
Total
$
$
$
599 $
4,060 $
4,659 $
493 $
— $
493 $
106 $
— $
106 $
— $
— $
— $
—
4,060
4,060
Total
Less than
1 year
2 – 3 years
4 – 5 years
More than
5 years
(1) Operating lease obligations reflect lease payments for our office space in Singapore, Taipei, Taiwan and Shanghai, China.
121
(2)
Reflects the principal amount outstanding under the CSL Facility as of December 31, 2018. Any outstanding principal on the loan must be repaid 10
years from the date of the CSL Facility. In addition, we are required to mandatorily prepay amounts outstanding if we receive any income or revenue in
connection with the commercialization or out-licensing of any intellectual property rights (other than under the license agreement with CSL Limited
related to ASLAN004), in which case we are required to apply at least a low double digit percentage of such income or revenue against any amounts
then-outstanding under the CSL Facility.
The table above does not include:
•
•
our repayment obligations under the loan from EDB, which are contingent on future events, and which as of December 31, 2018 was
approximately $9.9 million; and
we also have obligations to make future payments to third party licensors that become due and payable on the achievement of certain
development, regulatory and commercial milestones as well as tiered royalties on net sales. We have not included these commitments
on our balance sheet or in the table above because the commitments are cancellable if the milestones are not complete and
achievement and timing of these obligations are not fixed or determinable.
G.
Safe Harbor
This Annual Report on Form 20-F contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E
of the Exchange Act and as defined in the Private Securities Litigation Reform Act of 1995. See the section titled “Cautionary Statement
Regarding Forward-Looking Statements” at the beginning of this Annual Report.
Item 6. Directors, Senior Management and Employees
A.
Directors and senior management.
The following table sets forth information regarding our executive officers and directors, including their ages, as of March 31, 2019.
Name
Executive Officers:
Carl Firth, Ph.D.
Mark McHale, Ph.D.
Ben Goodger
Kiran Asarpota
Stephen Doyle
Age
Position(s)
46
Chief Executive Officer and
Chairman
Chief Development Officer and Head
of R&D
54
56 General Counsel
40 Vice President Finance
46 Chief Business Officer
Non-Executive Directors:
Abel Ang (representing Advanced Medtech Holdings
Pte Ltd.)
Jun Wu, Ph.D. (representing Alnair Investment)
Lim Chin Hwee Damien (representing BV Healthcare II
Pte Ltd.)
Andrew Howden
Kelvin Sun
Robert E. Hoffman.
45 Director
52 Director
56 Director
59 Director
56 Director
53 Director
122
Executive Officers
Carl Firth, Ph.D. Dr. Firth founded our company in 2010 and has served as our Chairman of the board of directors since June 2014, as our Chief
Executive Officer since January 2011 and as a director since July 2010. Prior to founding our company, Dr. Firth was Head of Asia Healthcare at
Bank of America Merrill Lynch, supporting public and private financing of healthcare companies and advising on M&A transactions, from
January 2008 to June 2010. Prior to joining the banking industry, Dr. Firth worked for AstraZeneca from October 1998 to December 2007 in
various commercial and R&D roles, including Regional Business Development Director, Asia Pacific, and Director of New Product
Development, China. Dr. Firth is currently a member of Singapore’s Health and Biomedical Sciences International Advisory Council, where he
has served in such capacity since September 2017, and an independent director at Singapore’s Exploit Technologies, a commercialization arm of
A*STAR, which supports A*STAR in its efforts to transform the economy by driving innovation and commercializing its research outcomes,
where he has served in such capacity since April 2014. Previously, Dr. Firth was an independent director of Hong Kong listed Uni-Bio Sciences,
a leading Chinese biopharmaceutical company engaged in the research, development, production and commercialization of biopharmaceuticals
for the Chinese healthcare market, where he served in such capacity from April 2014 to November 2017. Dr. Firth is an Adjunct Professor at
Duke-NUS Medical School, a position he has held since June 2014. He holds a Ph.D. in Molecular Biology from Cambridge University (Trinity
College), an Executive M.B.A. from London Business School, and a B.A. in Molecular Biology from Cambridge University.
Mark McHale, Ph.D. Dr. McHale helped found our company in 2010 and has served as our Chief Operating Officer since February 2011, and
was appointed Chief Development Officer and Head of R&D for ASLAN in January 2019. Prior to joining us, Dr. McHale was the Head of
Molecular Sciences at AstraZeneca, Respiratory & Inflammation, from 1997 to 2010. Dr. McHale was a core member of the respiratory strategy
research team for half a decade where he led all new target identifications in asthma. Dr. McHale also previously worked from 1991 to 1997 at
SmithKline Beecham (now GlaxoSmithKline Plc.), where he supported lead optimization projects in serotonin and dopamine receptors. Dr.
McHale has a Ph.D. in Molecular Biology from the University of East Anglia in the United Kingdom, and a B.S. in Genetics and Molecular
Biology from the University of London.
Ben Goodger. Mr. Goodger has served as our General Counsel since November 2016. Prior to joining us, Mr. Goodger was the Partner and Head
of Intellectual Property (IP) Licensing and Transactions with Osborne Clarke in the United Kingdom, a multinational law firm, from November
2014 to October 2016. Mr. Goodger also previously served as Partner, Head of IP Commercialization, at Edwards Wildman in the United
Kingdom, a multinational law firm, from November 2010 to October 2014, as Executive, Head of IP Commercial, at Rouse & Co. International
in London, Oxford, and Shanghai, a multinational law firm, from December 1997 to October 2010, and as the President of Licensing Executives
Society, a not for profit, non-political, umbrella organization, from 1998 to 1999. Mr. Goodger received his M.A. in English Literature &
Language from Oxford University (Exhibitioner, Keble College) and he is a Solicitor of England & Wales, enrolled October 1986.
Kiran Asarpota. Mr. Asarpota has served as our Vice President Finance since November 2010. Prior to joining us, Mr. Asarpota was Group
Finance Director at Global Brands Group Holding Limited, a public branded apparel company, from 2006 to 2010, where he was responsible for
the group’s corporate and commercial finance functions. Mr. Asarpota received his M.B.A. from London South Bank University in the United
Kingdom, and a B.B.M. from Oxford Brookes.
123
Stephen Doyle. Mr. Doyle has served as our Vice President Commercial and Head of China since February 2018, and was appointed Chief
Business Officer in January 2019. Prior to joining us, Mr. Doyle was the Vice President and Head of Specialty Care for China at Boehringer
Ingelheim GmbH, a global pharmaceutical company, from January 2014 to February 2018. Mr. Doyle also previously served as the Vice
President of Oncology, Haematology and Transplantation Business Unit with Sanofi S.A. in Shanghai, a global pharmaceutical company, from
October 2010 to October 2013, as Regional Commercial Director for Oncology for Asia Pacific, Russia and India with Sanofi-aventis in
Singapore, from 2007 to 2010, and as Director and Head of Scientific Communications, Global Marketing, Oncology Franchise with Sanofi-
aventis in Paris from 2005 to 2007. Mr. Doyle holds a B.S. in Pharmacy from The Robert Gordon University in the United Kingdom and an M.S.
in Clinical Pharmacy from the University of Derby in the United Kingdom.
Non-Executive Directors
Abel Ang. Mr. Ang has served as a member of our board of directors and representative for Advanced Medtech Holdings Pte Ltd. since April
2016. Mr. Ang currently serves as the Chief Operating Officer of Accuron Technologies Ltd., a precision engineering and technology company,
and the acting Chief Executive Officer of Dornier MedTech Group, a urological medical equipment manufacturer, positions he has held since
July 2014. He currently serves as a director of the Board of Economic Development Innovations Singapore Pte. Ltd., a privately-owned
international economic development company, a position he has held since March 2013, as an independent director of Exploit Technologies Pte
Ltd, the technology transfer arm of the Agency for Science, Technology and Research in Singapore, a position he has held since October 2012,
and as a director of Advanced Materials Technologies Pte Ltd., a position he has held since July 2014. Mr. Ang served as the Senior Advisor to
the CEO of Greatbatch Inc., providing guidance relative to the commercialization of medical device technologies in the cardiac, neurology,
vascular and orthopedic markets, from 2006 to 2009. He has also held executive positions at Hill-Rom Inc., a provider of medical technologies
for the health care industry, including the roles of President for the Asia Pacific region, Chief Technology Officer, and Vice President of several
business units, from 2008 to 2012. Mr. Ang also formerly headed the global Medical Technology and Biotechnology industry groups at the
Singapore Economic Development Board’s Biomedical Division, from 2004 to 2006. Mr. Ang is currently an Adjunct Associate Professor at the
Nanyang Business School in Singapore and Waseda University in Japan, where he teaches in their respective M.B.A. programs, positions he has
held since 2013. Mr. Ang holds a M.S. in Computational Biology from Rutgers University in New Jersey, and a Bachelor of Communication
Studies (First Class) from Nanyang Technological University Singapore.
Jun Wu, Ph.D. Dr. Wu has served as a member of our board of directors and representative for Alnair Investment since April 2016. Dr. Wu is
currently the Chairman and Managing Partner at Cenova Ventures, a principal investment firm for healthcare venture funds, a position he has
held since May 2009. Previously, Dr. Wu served as the Co-founder and Chief Executive Officer of Shanghai Genomics, a biotech company, from
September 2001 to May 2005, and as an Executive Managing Director of GNI Limited, a Tokyo Exchange Listed biotech company, from June
2005 to April 2009. Dr. Wu has previously served as a director of over 20 companies and investment funds in the pharmaceutical industry. Dr.
Wu holds a Ph.D. in Microbiology and Immunology from the University of California at San Francisco and a B.S. in Biology from San Jose
State University.
124
Lim Chin Hwee Damien has served as a member of our board of directors and representative for BV Healthcare II Pte Ltd. since April 2016. He
is the founder and currently serves as the General Partner of BioVeda Capital, a life science venture capital fund, a position he has held since
2000. He currently serves as a non-executive director of companies in a variety of industries. He has previously held senior positions in
PrimePartners and Vickers Ballas Asset Management, both private equity asset management companies, and Morgan Grenfell Asia, a merchant
bank now owned by Deutsche Bank. He received his B.B.A. from the University of Houston.
Andrew Howden. Mr. Howden has served as a member of our board of directors since April 2016. He currently serves as Chairman of the True
Origins Company P/L, an Australian company involved in the marketing of infant formula in China and Asia, a position he has held since June
2016, and Executive Chairman of First Pharma P/L, an Australian pharmaceutical company, a position he has held since September 2016. He
previously served as the Chief Executive Officer of iNova Pharmaceuticals, a global pharmaceutical company developing and commercializing
drugs across a range of therapeutic areas, from August 2008 to February 2015. Previously, he was the President of IMS Health, Asia Pacific, a
provider of information, services and technology for the healthcare industry, from 2007 to 2008, Regional Vice President of Asia Pacific for
AstraZeneca, a multinational pharmaceutical and biopharmaceutical company, from 2002 to 2006, and he has held senior executive roles at
Quintiles IMS Holdings, Inc., a public health information technologies and clinical research company, from 2000 to 2002. Mr. Howden has also
previously served on the board of directors of over 20 companies within the pharmaceutical and healthcare industries. He received a B.S. and an
M.Com. from the University of New South Wales, Australia.
Kelvin Sun. Mr. Sun has served as a member of our board of directors since April 2016. Mr. Sun has served as founder and president of Saga-
Unitek Ventures, a venture capital and private equity fund management company, specializing in investing in middle-market, growth-oriented
companies, as well as those funds under its management, since 1998. He currently serves as an independent director of TWi Pharmaceuticals
Inc., a public Taiwanese pharmaceutical company, a position he has held since June 2012, as an independent director of Wonderful Hi-Tech Co.
Ltd., a public Taiwanese electrical wire and cable manufacturing company, a position he has held since June 2010, and as an independent director
of Tah Tong Textile Co., Ltd., a Taiwanese textile manufacturing company, a position he has held since June 2015. Mr. Sun also currently serves
as a board member of Pixon Technologies, a Taiwanese optical light sources manufacturing company, a position he has held since June 2011,
Newmax Technology Co., Ltd., a Taiwanese optical lens manufacturing company, a position he has held since December 2017 and the Taiwan
Venture Capital Association, a position he has held since 2008. He previously served as the senior officer at Chengxin VC Group, a Taiwanese
venture capital firm, from 1997 to 1998, as the Director for the Asian Engineering Center of Emerson Electric, a U.S. publicly listed industrial
company, from 1995 to 1997, and as the R&D Section Leader at Prime Optical Fiber Corporation, a Taiwanese fiber optics manufacturing
company, from 1992 to 1993. He holds an M.B.A. from the University of Michigan at Ann Arbor and an M.S. in Materials Science from Wayne
State University.
Robert E. Hoffman. Mr. Hoffman has served a member of our board of directors since October 2018. Currently, Mr. Hoffman serves as Chief
Financial Officer and Senior Vice President, Finance of Heron Therapeutics, Inc., a Nasdaq-listed company. In addition, Mr. Hoffman serves as
a board member of the following Nasdaq-listed companies: Kura Oncology, Inc. (also serves as the chair of the audit committee), DelMar
Pharmaceuticals, Inc. (as the chairman of the board), Aravive, Inc. (also serves as the chair of the audit committee). Prior to joining Heron
Therapeutics, Mr. Hoffman served as Executive Vice President and Chief Financial Officer of Innovus Pharmaceuticals, Inc., a public
pharmaceutical company, from September 2016 to April 2017. From July 2015 to September 2016, Mr. Hoffman served as Chief Financial
Officer of AnaptysBio, Inc., a public biotechnology company. From June 2012 to July 2015, Mr. Hoffman served as the Senior Vice President,
Finance and Chief Financial Officer and part of the founding management team of Arena Pharmaceuticals, Inc., or Arena, a public
biopharmaceutical company. From August 2011 to June 2012 and previously from December 2005 to March 2011, he served
125
as Arena’s Vice President, Finance and Chief Financial Officer and in a number of various roles of increasing responsibility from 1997 to
December 2005. From March 2011 to August 2011, Mr. Hoffman served as Chief Financial Officer for Polaris Group, a biopharmaceutical drug
company. Mr. Hoffman formerly served as a member of the board of directors of CombiMatrix Corporation, a molecular diagnostics company,
and MabVax Therapeutics Holdings, Inc., a biopharmaceutical company. Mr. Hoffman serves as an advisory committee member of the Financial
Accounting Standards Board (FASB). Mr. Hoffman formerly served as a director and President of the San Diego Chapter of Financial Executives
International. Mr. Hoffman holds a B.B.A. from St. Bonaventure University, and is licensed as a C.P.A. (inactive) in the State of California.
Family Relationships
There are no family relationships among any of our executive officers or directors.
B.
Compensation.
Compensation of Executive Officers and Directors
Incentive Compensation
For the year ended December 31, 2018, the aggregate compensation accrued or paid to the members of our board of directors and our executive
officers for services in all capacities was $3,765,304.
We did not set aside or accrue any amounts for pension, retirement or similar benefits to members of our board of directors or executive officers
in the year ended December 31, 2018.
We do not maintain any cash incentive or bonus programs. During the year ended December 31, 2018, we had no performance based
compensation programs other than the 2018 SMT Long Term Incentive Plan, or the 2018 LTIP, and the 2017 SMT Long Term Incentive Plan, or
the 2017 LTIP. For more information on our Long Term Incentive Plans, see the discussion below under “—Compensation Plans—2017 and
2018 SMT Long Term Incentive Plans.”
Executive Officer Compensation
Equity Awards
We did not grant any share options to our executive officers during the fiscal year ended December 31, 2018.
Employment Agreements with Executive Officers
We have entered into employment agreements with our executive officers. Each of our executive officers is employed for a continuous term
unless either we or the executive officer gives prior notice to terminate such employment. We may terminate the employment for just cause, at
any time, without notice or remuneration, for certain acts of the executive officer. An executive officer may terminate his or her employment at
any time with six months’ prior written notice.
126
Each executive officer has agreed to maintain the confidentiality of any confidential information, both during and after the employment
agreement expires or is earlier terminated. In addition, all executive officers have agreed to be bound by a non-solicitation covenant that prohibits
each executive officer from contacting or communicating with our customers, members, partners, suppliers or any other persons or entities with
whom we do business or soliciting or hiring any of our employees during his or her employment and for one year after the termination of his or
her employment and by a non-compete covenant that prohibits each executive officer from competing with us, directly or indirectly, during his or
her employment and for six months after the termination of his or her employment.
Option Grants
We have made grants of options to our employees pursuant to our 2014 Employee Share Option Scheme Plan, or the 2014 Plan, and our 2017
Employee Share Option Plan 1, or the 2017 Plan. Options granted pursuant to the 2014 Plan are either vested in full as of the date of grant or are
25% vested as of the date of grant, with the remaining 75% vesting in equal annual installments over the three years following the date of grant.
Options granted pursuant to the 2017 Plan vest in full upon the two year anniversary of the date of grant. Vested options may be exercised during
their term and for varying periods following termination of service, depending on the reason for termination. Options will be adjusted to account
for any changes in capitalization or certain other corporate events and are not transferable (but may be exercised by the individual’s heirs in the
case of death, to the extent vested at the time of death).
LTIP
On August 23, 2017 and February 1, 2018, we granted 1,462,000 and 104,000 bonus entitlement units to our executive officers pursuant to the
2017 LTIP, respectively. 1,479,334 bonus entitlement units granted under the 2017 LTIP remained outstanding as of December 31, 2018. On July
30, 2018, we granted 241,142 bonus entitlement units to our executive officers pursuant to the 2018 LTIP, all of which remained outstanding as
of December 31, 2018.
Upon vesting and redemption, each unit award is converted into a cash payment equal to the number of units multiplied by the per-share fair
market value of our ordinary shares on the day following our receipt of a redemption notice. The 1,462,000 bonus entitlement units granted
under the 2017 LTIP will be one-third vested each year after the first, second, and third anniversary of the award. The 104,000 bonus entitlement
units granted under the 2017 LTIP will be one-half vested each year after the second and third anniversary of the award. The 241,142 bonus
entitlement units granted under the 2018 LTIP will be one-third vested each year after the first, second, and third anniversary of the award.
Regarding the Company’s 2017 and 2018 LTIPs, the respective quoted fair value of the awards on the grant date was NT$33.45 (or $1.10) and
$7.90, based on the Taiwan share price on August 23, 2017 and the closing price per ADS on July 30, 2018, respectively. The quoted fair value
on the reporting date is based on the closing price of Taiwan share price of NT$33.20 (or $1.12) as of December 31, 2017 and the closing price
per ADS of $3.60 as of December 31, 2018, respectively.
We recognized total expenses of $838,677 with respect to the LTIPs for the year ended December 31, 2018.
127
Other Programs
We have adopted defined contribution plans which are post-employment benefit plans under which we pay fixed contributions into the Singapore
Central Provident Fund on a mandatory basis. We have no further payment obligations once the contributions have been paid. The contributions
are recognized as employee compensation expense when they are due.
ASLAN Pharmaceuticals Taiwan Limited adopted a pension plan under the Labor Pension Act, or the LPA, which is a state-managed defined
contribution plan. Under the LPA, ASLAN Pharmaceuticals Taiwan Limited makes monthly contributions to its Taiwan-based employees’
individual pension accounts at 6% of monthly salaries and wages.
ASLAN Pharmaceuticals (Shanghai) Co. Ltd. makes monthly contributions at a certain percentage of its Shanghai-based employees’ payroll
expenses to pension accounts, which are operated by the Chinese government.
Director Compensation
We provide only cash compensation to each of our non-executive directors not serving as a representative of a shareholder for the time and effort
necessary to serve as a member of our board of directors. The compensation of the non-executive directors complies with our Articles and is
determined by our remuneration committee and board of directors as a whole, based on a review of individual contributions to our operations and
current practices in other companies.
2018 Director Compensation Table
The following table sets forth information regarding the compensation earned by our non-executive directors for service on our board of directors
during the year ended December 31, 2018.
Name
Abel Ang (representing Advanced MedTech Technologies
Pte Ltd.)
Jun Wu, Ph.D. (representing Alnair Investment)
Lim Chin Hwee Damien (representing BV Healthcare II
Pte Ltd.)
Jerome Shen, Ph.D.
Andrew Howden
Kelvin Sun
Mei-Shu Lai, Ph.D., M.D.
Robert E. Hoffman.
(1) Dr. Shen resigned from our board of directors on October 30, 2018.
(2) Dr. Lai resigned from our board of directors on October 30, 2018.
(3) Mr. Hoffman joined our board of directors on October 30, 2018.
128
Fees
Earned in
Cash
All Other
Compensation
Total
$
$
$
$
$
$
$
$
— $
— $
— $
25,000 $
30,000 $
30,000 $
25,000 $
12,500 $
— $
— $
— $
— $
— $
— $
— $
— $
—
—
—
25,000
30,000
30,000
25,000
12,500
We have not granted any options or issued any shares of restricted stock to our non-executive directors.
Grants of Share Options to Executive Officers
The following table summarizes, as of the date of this Annual Report, outstanding share options to purchase ordinary shares granted to our
executive officers. We have not granted any share options to our non-executive directors.
Carl Firth, Ph.D.
Name
Mark McHale, Ph.D
Ben Goodger
Kiran Asarpota
Number of
Shares
Underlying
Stock
Option
Exercise
Price per
Share
300,000 $
150,000 $
180,000 $
225,000 $
295,500 $
4,500 $
300,000 $
300,000 $
150,000 $
1,050,000 $
300,000 $
120,000 $
60,000 $
180,000 $
240,000 $
240,000 $
240,000 $
120,000 $
840,000 $
240,000 $
276,000 $
60,000 $
60,000 $
60,000 $
60,000 $
60,000 $
40,000 $
40,000 $
120,000 $
Stock Option
Expiration
Date
July 1, 2020
July 1, 2020
July 1, 2021
July 1, 2021
July 1, 2022
July 1, 2023
July 1, 2023
July 1, 2024
July 1, 2025
July 1, 2025
July 1, 2026
July 1, 2020
July 1, 2021
July 1, 2021
July 1, 2022
July 1, 2023
July 1, 2024
July 1, 2025
July 1, 2025
July 1, 2026
July 1, 2026
July 1, 2020
July 1, 2021
July 1, 2022
July 1, 2023
July 1, 2024
July 1, 2025
July 1, 2025
July 1, 2026
0.10
0.40
0.10
0.40
0.40
0.40
0.68
0.68
0.68
0.94
1.13
0.40
0.10
0.40
0.40
0.68
0.68
0.68
0.94
1.13
1.13
0.40
0.40
0.40
0.68
0.68
0.68
0.94
1.13
Grant Date
July 1, 2010
July 1, 2010
July 1, 2011
July 1, 2011
July 1, 2012
July 1, 2013
July 1, 2013
July 1, 2014
July 1, 2015
July 1, 2015
July 1, 2016
July 1, 2010
July 1, 2011
July 1, 2011
July 1, 2012
July 1, 2013
July 1, 2014
July 1, 2015
July 1, 2015
July 1, 2016
July 1, 2016
July 1, 2010
July 1, 2011
July 1, 2012
July 1, 2013
July 1, 2014
July 1, 2015
July 1, 2015
July 1, 2016
129
Compensation Plans
2014 Employee Share Option Scheme Plan
We maintain the 2014 Plan, pursuant to which we have granted share options to our employees, directors and consultants. The 2014 Plan became
effective on August 26, 2014, and has a term of ten years. After the effective date of the 2017 Plan, no additional awards were granted, and no
future awards are allowed to be granted, under the 2014 Plan.
The 2014 Plan may be administered by our board of directors or a committee thereof, which administrator has the authority to: determine the
individuals to whom awards may be granted and the terms of such awards; amend the terms of any outstanding award, provided that the consent
of the grantee is required where the grantee’s rights would be adversely affected; construe and interpret the terms of the 2014 Plan and awards
granted thereunder; and take such other action, not inconsistent with the terms of the 2014 Plan, as it deems appropriate.
The number of shares under the 2014 Plan and under outstanding awards, and the exercise price of outstanding awards, will be adjusted to reflect
certain changes in capitalization. In the event of a corporate transaction (as defined in the 2014 Plan), awards will terminate if not assumed. If
they are assumed, the awards will fully vest if the holder’s employment is terminated without cause or the holder resigns for good reason, in
either case within 12 months thereafter.
2017 Employee Share Option Plan 1
We maintain the 2017 Plan, pursuant to which we may grant share options. The 2017 Plan became effective on September 13, 2017, and has a
term of ten years. Awards under the 2017 Plan may be granted to our employees. The maximum aggregate number of shares that may be issued
under the plan is 1,000,000 shares.
The 2017 Plan is administered by our board of directors, which has the authority to determine the individuals to whom awards may be granted
and the terms of such awards; and to construe and interpret the terms of the 2017 Plan and awards granted thereunder.
The number of shares under the 2017 Plan and under outstanding awards, and the exercise price of outstanding awards, will be adjusted to reflect
certain changes in capitalization. In the event of a corporate transaction (as defined in the 2017 Plan), awards will terminate if not assumed. If
they are assumed, the awards will vest if the holder’s employment is terminated without cause or the holder resigns, in either case within 12
months thereafter. In the event of a change in control (as defined in the 2017 Plan) that is not a corporate transaction, awards will fully vest if the
holder’s employment is terminated without cause or the holder resigns, in either case within 12 months thereafter.
2017 and 2018 SMT Long Term Incentive Plans
We maintain the 2017 and 2018 LTIPs, pursuant to which we may grant bonus entitlement unit awards. The 2017 LTIP and 2018 LTIP became
effective on August 23, 2017 and July 30, 2018, respectively, and each has a term of ten years. Awards under each LTIP may be granted to our
employees. All of the awards granted in 2017 and 2018 were granted to our executive officers.
130
Each LTIP is administered by the members of the remuneration committee, which committee has the authority to: determine the individuals to
whom unit awards may be granted and the terms of such unit awards; amend the terms of any outstanding unit award, provided that the consent
of the grantee is required where the grantee’s rights would be adversely affected; construe and interpret the terms of each LTIP and unit awards
granted thereunder; and take such other action, not inconsistent with the terms of each LTIP, as it deems appropriate.
Upon vesting and redemption, each unit award is converted into a cash payment equal to the number of units multiplied by the per-share fair
market value of our ordinary shares on the day following our receipt of a redemption notice, up to a cap of five times the base value of the unit as
set forth in the grantee’s award agreement. Redemption occurs automatically upon termination of employment and upon the per-share fair market
value exceeding five times the base value of the unit award, to the extent not previously redeemed.
The terms of awards will be adjusted to reflect certain changes in capitalization. In the event of a corporate transaction (as defined in each LTIP),
awards will terminate if not assumed. If they are assumed, the awards will vest and be redeemed if the holder’s employment is terminated
without cause or the holder resigns for good reason, in either case within 12 months thereafter. In the event of a change in control (as defined in
each LTIP) that is not a corporate transaction, awards will fully vest if the holder’s employment is terminated without cause or the holder resigns
for good reason, in either case within 12 months thereafter.
Insurance and Indemnification
We are empowered by our Articles to indemnify our directors against any liability they incur by reason of their directorship. We maintain
directors’ and officers’ insurance to insure such persons against certain liabilities. In addition, our employment agreements with our executive
officers provide for indemnification. We have entered into an indemnification agreement with each of our directors and executive officers.
In addition to such indemnification, we provide our directors and executive officers with directors’ and officers’ liability insurance as permitted
by our Articles.
Insofar as indemnification of liabilities arising under the Securities Act may be permitted to our board, executive officers, or persons controlling
us pursuant to the foregoing provisions, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as
expressed in the Securities Act and is therefore unenforceable.
C.
Board practices.
Composition of our Board of Directors
Our board of directors is currently composed of seven members. Our board of directors has determined that, of our seven directors, three do not
have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of director and that each of
these directors is “independent” as that term is defined under the Taiwan Securities and Exchange Act, or the Taiwan Act. According to the
Taiwan Act, during the two years before being elected and during the term of office, none of our independent directors may have been or be any
of the following, which we refer to as a Restricted Person:
1. An employee of ours or any of our affiliates;
2. Our statutory auditor or of our affiliates;
3. A director of our affiliates, unless he or she was an independent director of our subsidiary;
131
4. A natural-person shareholder who holds in the aggregate, together with his or her spouse, minor children, and his or her nominees, one
percent or more of our ordinary shares outstanding or ranks among the top ten in our shareholdings;
5. A spouse, relative within the second degree of kinship, or lineal relative within the third degree of kinship, of any of the persons in the
preceding four items;
6. A director, statutory auditor, or employee of a corporate shareholder that directly holds five percent or more of our total number of
shares outstanding or of a corporate shareholder that ranks among the top five in our shareholdings;
7. A director, statutory auditor, officer, or shareholder holding five percent or more of the shares of a company or institution that meets
certain statutorily specified criteria and has a financial or business relationship with us; or
8. A professional individual who, or an owner, partner, director, statutory auditor, or officer of a sole proprietorship, partnership,
company, or institution that, provides commercial, legal, financial, accounting services or consultation to us or to any of our affiliates,
or a spouse thereof; provided that this restriction does not apply to a member of the remuneration committee, public tender offer
review committee, or special committee for merger/consolidation and acquisition, who exercises powers pursuant to the Taiwan Act or
to the Taiwan Business Mergers and Acquisitions Act or related laws or regulations.
The “during the two years before being elected” requirement does not apply when an independent director of ours has served as an independent
director of our or any of our affiliates, or of a specific company or institution that has a financial or business relationship with us, as stated in
items 3 or 7 above, but is currently no longer in that position.
In accordance with our Articles, our directors serve for a term of three years and, at the expiration of such term, are eligible for reelection by our
shareholders. If a new director is not elected after the expiration of the tenure of an existing director, the tenure of such out-going director shall
be extended until a new director has been elected.
Duties of Directors
Under Cayman Islands law, all of our directors owe us fiduciary duties, including a duty of loyalty, a duty to act honestly and a duty to act in
good faith and in a manner they believe to be in our best interests. Our directors also have a duty to exercise the skill they actually possess and
such care and diligence that a reasonably prudent person would exercise in comparable circumstances. In fulfilling their duty of care to us, our
directors must ensure compliance with our Articles, as amended and restated from time to time. We have the right to seek damages if we suffer
loss as a consequence of a duty owed by any of our directors being breached.
Committees of our Board of Directors
Our board of directors has three standing committees: an audit committee, a remuneration committee and a nomination committee.
132
Audit Committee
The audit committee, which consists of Mr. Howden, Mr. Hoffman and Mr. Sun, assists the board of directors in overseeing our accounting and
financial reporting processes and the audits of our financial statements. Mr. Sun serves as chairman of the audit committee. The audit committee
consists exclusively of independent members of our board. Our board of directors has determined that Kelvin Sun qualifies as an “audit
committee financial expert” as defined by applicable SEC rules and has the requisite financial sophistication as defined under the applicable
Nasdaq rules and regulations. Our board has determined that all of the members of the audit committee satisfy the “independence” requirements
set forth in Rule 10A-3 under the Exchange Act. The audit committee will be governed by a charter that complies with Nasdaq rules.
The audit committee’s responsibilities will include:
•
•
•
•
•
•
•
•
•
•
•
the adoption of or amendments to the internal control system;
assessment of the effectiveness of the internal control system;
the adoption or amendment, of the procedures for handling financial or business activities of a material nature such as acquisition or
disposal of assets, derivatives trading, lending of funds to others and endorsements or guarantees for others;
matters in which a director is an interested party;
asset transactions or derivatives trading of a material nature;
loans of funds, endorsements or provision of guarantees of a material nature;
the offering, issuance or private placement of equity-type securities;
the hiring or dismissal of a certified public accountant or their compensation;
the appointment or discharge of a financial, accounting or internal audit officer;
annual and semi-annual financial reports; and
other material matters as may be required by us or by the competent authority.
The audit committee will meet as often as one or more members of the audit committee deem necessary, but in any event will meet at least four
times per year according to the Taiwan Act.
Remuneration Committee
The remuneration committee, which consists of Mr. Howden, Mr. Hoffman and Mr. Sun, assists the board of directors in determining executive
officer compensation. Mr. Howden serves as chairman of the remuneration committee. Under the Taiwan Act, our remuneration committee shall
be comprised of at least three members, and at least one of them shall be an independent member of the board as defined under the Taiwan Act.
All members of our remuneration committee are independent members of the board as defined by the Taiwan Act. In addition, during the two
years before being appointed to his or her term of office, none of our remuneration committee members may have been or be a Restricted Person.
This “during the two years before being appointed” requirement does not apply where a remuneration committee member has served as an
independent director of ours or any of our affiliates, or of a specified company or institution that has a financial or business relationship with us,
as stated in items 3 or 7 of the definition of Restricted Person above, but is currently no longer in that position. Under SEC and Nasdaq rules,
there are heightened independence standards for members of the remuneration committee, including a prohibition against the receipt of any
compensation from us other than standard board member fees. Although foreign private issuers are not required to meet this heightened standard,
all of our remuneration committee members meet this heightened standard.
133
The remuneration committee’s responsibilities include:
•
•
•
•
professionally and objectively evaluate the policies and systems for compensation of the directors, supervisors, and managerial
officers of us, and submit recommendations to the board of directors for its reference in decision making;
establishing and periodically reviewing the annual and long-term performance goals for the directors and managerial officers of us and
the policies, systems, standards, and structure for their compensation;
periodically assessing the degree to which performance goals for the directors and managerial officers of us have been achieved, and
setting the types and amounts of their individual compensation; and
periodically review the charter and propose suggestion for amendments.
When performing these responsibilities, the remuneration committee shall follow the following principles:
•
•
•
•
•
ensuring that the compensation arrangements of us comply with applicable laws and regulations and are sufficient to recruit
outstanding talent;
performance assessments and compensation levels of the directors and managerial officers shall take into account the general pay
levels in the industry, the time spent by the individual and their responsibilities, the extent of goal achievement, their performance in
other positions, and the compensation paid to employees holding equivalent positions in recent years. Also to be evaluated are the
reasonableness of the correlation between the individual’s performance and our operational performance and future risk exposure,
with respect to the achievement of our short-term and long-term business goals and the financial position;
there shall be no incentive for the directors or managerial officers to pursue compensation by engaging in activities that exceed the our
tolerable risk level;
for directors and senior managerial officers, the percentage of bonuses to be distributed based on their short-term performance and the
time for payment of any variable compensation shall be decided with regard to the characteristics of the industry and the nature of our
business; and
no member of the committee may participate in discussion and voting when the committee is deciding on that member’s individual
compensation.
The remuneration committee shall submit its recommendations regarding the above for deliberation to the board. When deliberating the
recommendation of the remuneration committee, the board shall give comprehensive consideration to matters including the amounts of
remuneration, payment methods, and the potential future risk facing our company. If the board would like to decline to adopt, or would like to
modify, a recommendation of the remuneration committee, the consent of a majority of the directors in attendance at a meeting attended by two-
thirds or more of the entire board is required, and the board in its resolution shall provide its comprehensive consideration and shall specifically
explain whether the remuneration passed by it exceeds in any way the remuneration recommended by the remuneration committee.
Nomination Committee
The nomination committee, which consists of Mr. Howden, Mr. Sun, Mr. Ang and Dr. Firth, assists the board of directors in selecting and
approving director candidates to serve on the board. Under the Taiwan Act, all companies listed on the TPEx are required to adopt a director
candidate nomination mechanism for the election of directors, although there is no requirement that a listed company form a nomination
committee. Under SEC and Nasdaq rules, director nominees must either be selected, or recommended for
134
the board’s selection, either by independent directors constituting a majority of the board’s independent directors in a vote in which only
independent directors participate, or by a nomination committee comprised solely of independent directors. Foreign private issuers are not
required to have independent director oversight of director nominations, and out of those currently serving on our nomination committee, only
Mr. Howden and Mr. Sun are independent members of our board.
The nomination committee’s responsibilities include:
•
•
•
•
•
reviewing and assessing the composition of the board of directors;
identifying appropriate director candidates and independent director candidates;
reviewing the qualifications and suitability of each director candidate and independent director candidate identified by the committee;
submitting director and independent director recommendations to the board of directors for consideration; and
conducting all other necessary actions to facilitate the selection and approval of director candidates and independent director
candidates by the board.
The nomination committee shall submit its recommendations regarding the above for deliberation to the board. When deliberating with respect to
the recommendation of the nomination committee, the board shall give comprehensive consideration to matters including the current
composition of the board, the qualifications of director candidates, the overall diversity of the board and the need for refreshing. The nomination
committee will meet as often as one or more members of the nomination committee deem necessary.
Code of Business Conduct and Ethics
We have adopted a Code of Business Conduct and Ethics that covers a broad range of matters including the handling of conflicts of interest,
compliance issues and other corporate policies. Our Code of Business Conduct is applicable to both our directors and employees.
Other Corporate Governance Matters
The Sarbanes-Oxley Act of 2002, as well as related rules subsequently implemented by the SEC, requires foreign private issuers, including our
company, to comply with various corporate governance practices. In addition, Nasdaq rules provide that foreign private issuers may follow home
country practice in lieu of the Nasdaq corporate governance standards, subject to certain exceptions and except to the extent that such exemptions
would be contrary to U.S. federal securities laws.
Because we are a foreign private issuer, our members of our board of directors, executive board members and senior management are not subject
to short-swing profit and insider trading reporting obligations under section 16 of the Exchange Act. They will, however, be subject to the
obligations to report changes in share ownership under section 13 of the Exchange Act and related SEC rules.
D.
Employees.
As of December 31, 2018, we had 56 full-time employees. Of these, 28 were engaged in full-time research and development and 28 were
engaged in full-time general and administrative functions. By geography, 37 of our employees are located in Singapore, 15 are located in Taiwan,
and 4 are located in China.
135
We have also engaged and may continue to engage independent contractors to assist us with our operations. None of our employees are
represented by a labor union or covered by a collective bargaining agreement. We have never experienced any employment related work
stoppages, and we consider our relations with our employees to be good.
Function:
Research and development
General and administrative
Total
E.
Share ownership.
2016
As of December 31,
2017
2018
21
17
38
23
24
47
28
28
56
For information regarding the share ownership of our directors and executive officers, see “Item 6.B-Compensation” and “Item 7.A-Major
Shareholders.”
Item 7. Major Shareholders and Related Party Transactions
A.
Major Shareholders
The following table sets forth information with respect to the beneficial ownership of our ordinary shares as of March 31, 2019 for:
•
•
•
each beneficial owner of 5% or more of our outstanding ordinary shares determined as of March 31, 2019, which was the most recent
record date of our ordinary shares under applicable procedures in Taiwan (upon which basis we are able to ascertain whether or not a
holder otherwise not affiliated with us may be above the 5% threshold);
each of our executive officers and directors; and
all of our executive officers and directors as a group.
Beneficial ownership is determined in accordance with the rules of the SEC. These rules generally attribute beneficial ownership of securities to
persons who possess sole or shared voting power or investment power with respect to those securities and include ordinary shares issuable upon
the exercise of options that are immediately exercisable or exercisable within 60 days of March 31, 2019. Percentage ownership calculations are
based on 160,248,940 ordinary shares outstanding as of March 31, 2019.
As of October 1, 2018, to the best of our knowledge, approximately 32,058,513 ordinary shares (including ordinary shares in the form of ADSs),
or 20.0% of our outstanding ordinary shares as of such date, were held by nine shareholders of record in the United States. The actual number of
holders is greater than these numbers of record holders and includes beneficial owners whose ordinary shares or ADSs are held in street name by
brokers and other nominees. This number of holders of record also does not include holders whose shares may be held in trust by other entities.
136
Except as otherwise indicated, all of the shares reflected in the table are ordinary shares and all persons listed below have sole voting and
investment power with respect to the shares beneficially owned by them, subject to applicable community property laws. The information is not
necessarily indicative of beneficial ownership for any other purpose. None of our major shareholders have different voting rights with respect to
their ordinary shares. We have set forth below information known to us regarding any significant change in the percentage ownership of our
ordinary shares by any major shareholders during the past three years.
Except as otherwise indicated in the table below, addresses of the directors, executive officers and named beneficial owners are in care of
ASLAN Pharmaceutical Limited, 83 Clemenceau Avenue #12-03 UE Square, Singapore 239920 and our telephone number is +65 6222 4235.
Name of Beneficial Owner
5% or Greater Shareholders:
Alnair Investment(1)
Executive Officers and Directors:
Carl Firth, Ph.D.(2)
Mark McHale, Ph.D.(3)
Ben Goodger(4)
Kiran Asarpota(5)
Stephen Doyle(6)
Advanced Medtech Holdings Pte Ltd. (represented by
Abel Ang)(7)
Alnair Investment (represented by Jun Wu, Ph.D.)(8)
BV Healthcare II Pte Ltd. (represented by Lim Chin
Hwee Damien)(9)
Robert E. Hoffman(10)
Andrew Howden(11)
Kelvin Sun
All current executive officers and directors as a group
(11 persons)(12)
Number of
Shares
Beneficially
Owned
Percentage
of Shares
Beneficially
Owned
9,887,358
6,662,340
3,711,915
376,000
586,996
—
2,127,660
9,887,358
7,542,112
—
439,510
—
6.2%
4.1%
2.3%
*
*
—
1.3%
6.2%
4.7%
—
*
—
31,333,891
18.8%
Represents beneficial ownership of less than one percent.
*
(1) Consists of 8,823,528 ordinary shares held by Alnair Investment, or Alnair, and 1,063,830 ordinary shares held by Shanghai Cenova
Innovation Venture Fund L.P., or Shanghai Cenova. Alnair is wholly owned and controlled by Shanghai Cenova. Shanghai Cenova
Bioventure Equity Investment Fund Management Enterprise L.P., or Shanghai Cenova Bioventure, is the general partner of Shanghai
Cenova. Shanghai Cenova Bioventure is owned and controlled by Dr. Wu, a member of our board of directors. As such, Dr. Wu may be
deemed to have sole voting and dispositive power with respect to the shares held by Alnair and Shanghai Cenova. The addresses for Alnair
and Shanghai Cenova are P.O. Box 2075, George Town, Grand Cayman KY1-1105, Cayman Islands and No. 53 Gao You Road, Shanghai,
China 200031, respectively.
137
(2) Consists of (A) ADSs representing 63,000 ordinary shares held by Dr. Firth, (B) 3,344,340 ordinary shares held by Kimba Capital Limited,
or Kimba Capital, and (C) 3,255,000 ordinary shares issuable upon the exercise of share options granted to Dr. Firth that are exercisable
within 60 days of March 31, 2019. Dr. Firth is director of Kimba Capital and has sole voting and dispositive power with respect to the
shares held by Kimba Capital. As such, Dr. Firth may be deemed to be a beneficial owner of shares held by Kimba Capital.
(3) Consists of (A) 1,431,915 ordinary shares held by Match Point Developments Limited, or Match Point and (B) 2,280,000 ordinary shares
issuable upon the exercise of share options granted to Dr. McHale that are exercisable within 60 days of March 31, 2019. Dr. McHale is
director of Match Point and has sole voting and dispositive power with respect to the shares held by Match Point. As such, Dr. McHale may
be deemed to be a beneficial owner of shares held by Match Point.
(4) Consists of (A) 100,000 ordinary shares and (B) 276,000 ordinary shares issuable upon the exercise of share options granted to
Mr. Goodger that are exercisable within 60 days of March 31, 2019.
(5) Consists of (A) 86,996 ordinary shares held by Mr. Asarpota and (B) 500,000 ordinary shares issuable upon the exercise of share options
granted to Mr. Asarpota that are exercisable within 60 days of March 31, 2019.
(6) Mr. Doyle joined our senior management team as of February 1, 2018 and does not beneficially own any of our ordinary shares as of March
31, 2019.
(7) Consists of 2,127,660 ordinary shares held by Advanced Medtech Holdings Pte Ltd., or AMT. Mr. Ang is as a member of our board of
directors and serves in such capacity as a representative of AMT. Mr. Ang is also a director of AMT. As such, Mr. Ang may be deemed to
be a beneficial owner of shares held by AMT. While the directors of AMT have voting and dispositive power over the shares held by AMT,
none of them has a pecuniary interest therein. Accordingly, Mr. Ang disclaims beneficial ownership of such shares
(8) Consists of the shares described in footnote (1) above. Dr. Wu is a member of our board of directors and serves in such capacity as a
representative of Alnair. Dr. Wu is also a director of Alnair, general manager of Shanghai Cenova and owns and controls Shanghai Cenova
Bioventure, the general partner of Shanghai Cenova. As such, Dr. Wu may be deemed to be a beneficial owner of shares held by Alnair and
Shanghai Cenova.
(9) Consists of 7,542,112 ordinary shares held by BV Healthcare II Pte Ltd., or BV Healthcare. BioVeda Capital Singapore Pte Ltd, or
BioVeda, is the investment manager of BV Healthcare. An investment committee of BV Healthcare, which includes Mr. Lim, or the BV
Investment Committee, reviews and approves investment and divestment proposals submitted by BioVeda. As such, the BV Investment
Committee may be deemed to have voting and dispositive power with respect to the shares held by BV Healthcare. The address for BV
Healthcare is 50 Cuscaden Road #08-01 HPL House, Singapore 249724. Mr. Lim is a member of our board of directors and serves in such
capacity as a representative of BV Healthcare. Mr. Lim is also a director of BV Healthcare and on the BV Investment Committee. As such,
Mr. Lim may be deemed to be a beneficial owner of shares held by BV Healthcare.
(10) Mr. Hoffman joined our board of directors as of October 30, 2018 and does not beneficially own any of our ordinary shares as of March 31,
2019.
(11) Consists of 439,510 ordinary shares held by Mr. Howden.
(12) Consists of the shares referenced in footnotes (2) — (11) above.
B.
Related party transactions.
Since January 1, 2018, we have engaged in the following transactions with our directors, executive officers or holders of more than 5% of our
outstanding share capital and their affiliates, which we refer to as our related parties.
138
Agreements with Our Executive Officers and Directors
We have entered into employment agreements with our executive officers and director compensation agreements with our non-
executive directors. These agreements contain customary provisions and representations, including confidentiality, non-competition and non-
solicitation undertakings by the executive officers. However, the enforceability of the non-competition provisions may be limited under
applicable law.
Related Party Transaction Policy
We have adopted a related party transaction policy, which requires that certain related party transactions be approved by our board of directors
and audit committee. We intend to afford ourselves of the Nasdaq foreign private issuer exemption from the requirement that our audit
committee have review and oversight over all “related party transactions,” as defined in Item 7.B of Form 20-F. The definition of “related party
transactions” per our related party transaction policy and ROC law is not as broad as the definition in Item 7.B of Form 20-F.
Indemnification Agreements
We have entered into, and intend to continue to enter into, separate indemnification agreements with our directors and executive officers. These
indemnification agreements provide our directors and executive officers with contractual rights to indemnification and, in some cases, expense
advancement in any action or proceeding arising out of their services as one of our directors or executive officers or as a director or executive
officer of any other company or enterprise to which the person provides services at our request.
C.
Interests of experts and counsel.
Not applicable.
Item 8. Financial Information
The purpose of this standard is to specify which financial statements must be included in the document, as well as the periods to be covered, the
age of the financial statements and other information of a financial nature.
A.
Consolidated Statements and Other Financial Information.
Our consolidated financial statements are appended at the end of this Annual Report, starting at page F-1, and are incorporated herein by
reference.
Dividend Policy
The holders of our ordinary shares are entitled to receive such dividends as may be declared by an ordinary resolution and subject to our Articles
and the Companies Law. Under Cayman Islands law, dividends may be paid only out of profits, which include net earnings and retained earnings
undistributed in prior years, and out of share premium, a concept analogous to paid-in surplus in the United States. No dividend may be declared
and paid unless our directors determine that immediately after the payment, we will be able to satisfy our liabilities as they become due in the
ordinary course of business and we have funds lawfully available for such purpose. We are not permitted to pay any dividends or bonuses if (i)
we do not have earnings or (ii) we have not yet covered our losses. Our Articles set out further detailed provisions dealing with how we may
fund, create reserves for and pay dividends.
139
Any dividends will be paid to the custodian of the ADSs that were issued in our public offering and shall be subject to further distribution to you
as a beneficial owner of the underlying ordinary shares by the custodian.
Legal Proceedings
From time to time, we may be involved in legal proceedings or be subject to claims arising out of our operations. We are not currently a party to
any legal proceedings that in the opinion of our management, would have a material adverse effect on our business.
B.
Significant Changes.
Not applicable.
Item 9. The Offer and Listing.
A.
Offer and listing details.
Our ADSs began trading on The Nasdaq Global Market on May 4, 2018 under the trading symbol “ASLN”. Prior to that date, there was no
public trading market for our ADSs. Our ordinary shares have been trading on the TPEx under “6497” since June 1, 2017. Prior to that date,
there was no public trading market for our ordinary shares.
B.
Plan of distribution.
Not applicable.
C.
Markets.
Our ADSs began trading on The Nasdaq Global Market on May 4, 2018 under the trading symbol “ASLN”. Our ordinary shares have been
trading on the TPEx under “6497” since June 1, 2017.
D.
Selling shareholders
Not applicable.
E.
Dilution.
Not applicable.
F.
Expenses of the issue.
Not applicable.
140
Item 10. Additional Information.
A.
Share capital.
Not applicable.
B.
Memorandum and articles of association.
Sixth Amended and Restated Memorandum and Articles of Association
Subject to other provisions in our Articles, our shareholders may by ordinary resolution increase our authorized share capital or by special
resolution reduce the share capital and may also by special resolution amend our Articles.
Ordinary Shares
General
All of our outstanding ordinary shares are fully paid and non-assessable. No certificates representing the ordinary shares have been issued. The
ordinary shares are not entitled to any preemptive conversion or redemption rights at the sole option of the holder of ordinary shares. Our
shareholders may freely hold and vote their shares (subject to certain restrictions such as the number of proxies that may be held by a shareholder
at a general meeting).
Pre-emptive Rights
When we issue new shares for cash consideration, our board of directors may reserve 10% to 15% of the new shares for subscription by our
employees or of any of our subordinate companies, as determined by our board of directors in its reasonable discretion. Subject to several
statutory exceptions, our shareholders are entitled to subscribe for the remainder of the new shares in proportion to their existing shareholdings.
New shares not so subscribed by our employees and shareholders may be offered by us to the public or to specific persons designated by the
board.
Since our shares are publicly traded on the TPEx, in the event of offering new shares for cash, we are also mandatorily required to offer 10% of
the shares to the public at the market price, subject to a higher public offering percentage adopted by our shareholders at a shareholders’ meeting.
The new shares underlying the ADSs to be issued in this offering are not subject to the shareholders’ pre-emptive right as such pre-emptive
rights have been waived by our shareholders at the shareholders meeting held on October 30, 2018.
Repurchase Rights
For so long as the shares are registered in Taiwan, the repurchase of our own shares by us shall be approved by our board of directors in
compliance with Regulations Governing Share Repurchase by Exchange-Listed and OTC-Listed Companies and relevant laws of the Cayman
Islands. We may with the sanction of an ordinary resolution of the shareholders’ meeting purchase and cancel our own shares out of our share
capital. The number of shares to be repurchased and cancelled pursuant to our Articles shall be pro rata among our shareholders in proportion to
the number of shares held by each such shareholder. The number of shares purchased by us pursuant to our Articles shall not exceed 10% of the
total number of our issued shares. The total price of the shares so purchased shall not exceed the sum of retained earnings plus the premium paid
on the issuance of any share and income from endowments received by us.
141
The amount payable to the shareholders in connection with a repurchase of shares out of our share capital may be paid in cash or by way of
delivery of assets in specie. The assets to be delivered and the amount of such substitutive share capital in connection with a repurchase of shares
out of our share capital shall be approved by the shareholders at the general meeting and shall be subject to consent by the shareholder receiving
such assets. Prior to the aforementioned general meeting considering such repurchase, our board of directors shall have the value of assets to be
delivered and the amount of such substitutive share capital in respect of repurchase of the shares audited and certified by a Taiwan certified
public accountant.
Voting Rights
Each ordinary share is entitled to one vote. Voting at any meeting of shareholders is by a poll. Our Articles list a number of matters that must be
approved by the shareholders by Supermajority Resolution (as defined below). Other matters to be approved by shareholders will be decided
either by special resolution (where required by law) or by ordinary resolution. Written resolutions of shareholders in lieu of a meeting are not
permitted by our Articles.
A quorum required for a meeting of shareholders consists of at least a number of shareholders present in person or by proxy and entitled to vote
representing the holders of more than one-half of all of our issued voting share capital. Shareholders’ meetings are held annually and may
otherwise be convened by our board of directors on its own initiative. Shareholders’ meetings shall also be convened on the requisition in writing
of any shareholder or shareholders holding at least three percent of the issued voting share capital for one year or longer, subject to certain
procedural requirements. Advance notice of at least 30 calendar days is required for convening the annual general meeting and at least 15
calendar days’ notice is required for convening extraordinary general meetings.
Any ordinary resolution to be made by our shareholders requires the affirmative vote of a simple majority of the votes attaching to the ordinary
shares cast in person or by proxy at a meeting of our shareholders. A special resolution requires the affirmative vote of not less than two-thirds of
the votes cast in person or by proxy at a meeting of our shareholders. A special resolution is required for certain matters specified in the
Companies Law as requiring approval by special resolution, including appointing a voluntary liquidator, changing our name, reducing our
authorized share capital and amending our Articles and for other matters such as issuing preferred shares, transferring treasury shares at a
discount to employees or subordinate companies and approving the redemption terms of any preferred shares.
A “Supermajority Resolution” is defined in our Articles as a resolution adopted by a majority vote of the shareholders at a general meeting
attended by shareholders who represent two-thirds or more of our total outstanding shares or, if the total number of shares represented by the
shareholders present at the general meeting is less than two-thirds of our total outstanding shares, but more than one-half of our total outstanding
shares, means instead, a resolution adopted at such general meeting by the shareholders who represent two-thirds or more of the total number of
shares entitled to vote on such resolution at such general meeting. Among other things, approval by Supermajority Resolution is required for us
to: (i) enter into, amend, or terminate any contract for lease of its business in whole, or for entrusting business, or for regular joint operation with
others, (ii) transfer the whole or any material part of its business or assets, (iii) take over the transfer of another’s whole business or assets, which
will have a material effect on our business operation, (iv) effect any merger (subject to certain structural exceptions) or spin-off of the company
in accordance with applicable listing rules, (v) grant waiver to a director engaging in any business within the scope of our business, (vi) discharge
or remove a director, (vii) capitalize an amount standing to the credit of reserves or authorize the payment of dividends out of a reserve fund and
(viii) issue any employee share options at a discount. In addition, any merger, transfer of business and assets, share swap or other transaction that
results in our shares ceasing to be listed on the TWSE or TPEx must be approved by the shareholders representing at least two-thirds of our
issued shares.
142
Subject to certain exceptions specified in our Articles, when a person who acts as the proxy for two or more shareholders at a general meeting,
the number of votes represented by him shall not exceed three percent of the total number of votes of the company and the portion of excessive
votes represented by such proxy will not be counted.
Dividends
The holders of our ordinary shares are entitled to receive such dividends as may be declared by an ordinary resolution and subject to our Articles
and the Companies Law. Under Cayman Islands law, dividends may be paid only out of profits, which include net earnings and retained earnings
undistributed in prior years, and out of share premium, a concept analogous to paid-in surplus in the United States. No dividend may be declared
and paid unless our directors determine that immediately after the payment, we will be able to satisfy our liabilities as they become due in the
ordinary course of business and we have funds lawfully available for such purpose. We are not permitted to pay any dividends or bonuses if (i)
we do not have earnings or (ii) we have not yet covered our losses. Our Articles set out further detailed provisions dealing with how we may
fund, create reserves for and pay dividends.
Any dividends will be paid to the custodian of the ADSs being issued in this offering and shall be subject to further distribution to you as a
beneficial owner of the underlying ordinary shares by the custodian. See “Description of American Depositary Shares—Dividends and Other
Distributions.”
Liquidation
If we were to be liquidated and the assets available for distribution among our shareholders are insufficient to repay the whole of the share
capital, such assets shall be distributed so that, as nearly as may be, the losses shall be borne by our shareholders in proportion to the number of
the ordinary shares held by them. If in a winding up the assets available for distribution among our shareholders shall be more than sufficient to
repay the whole of the share capital at the commencement of the liquidation, the surplus shall be distributed among our shareholders in
proportion to the number of the ordinary shares held by them at the commencement of the liquidation, subject to a deduction from those ordinary
shares in respect of which there are monies due, of all monies payable to us, without prejudice to the rights of the holders of ordinary shares
issued upon special terms and conditions.
If we were to be liquidated, the liquidator may, with the approval by a special resolution of our shareholders (and any other approvals as may be
required by applicable listing rules), divide among our shareholders in species or in kind the whole or any part of our assets (whether they shall
consist of property of the same kind or not) and may, for such purpose set such value as he/she deems fair upon any property to be divided and
may determine how such division shall be carried out as between the shareholders or different classes of shareholders. The liquidator may, with
the approval by an ordinary resolution of our shareholders, vest the whole or any part of such assets in trustees upon such trusts for the benefit of
the contributories as the liquidator, with the approval by an ordinary resolution of our shareholders shall think fit, but so that no shareholder shall
be compelled to accept any shares or other securities whereon there is any liability.
143
Transfer of Shares
Subject to the restrictions of our Articles and applicable ROC laws, as applicable, any of our shareholders may transfer all or any of his or her
ordinary shares by an instrument of transfer in the usual or common form or any other form approved by our board, provided that certain transfer
restrictions apply to shares issued to our employees and subordinate companies. Subject to the requirements of applicable laws of the Cayman
Islands, transfers of uncertificated shares which are registered on the TPEx may be effected by any method of transferring or dealing in securities
introduced by the TPEx or operated in accordance with the applicable listing rules, as defined in our Articles, as appropriate.
Our board of directors may decline to register any transfer of shares unless (i) the instrument of transfer is lodged with us, accompanied by the
certificate (if any) for the ordinary shares to which it relates and such other evidence as our board of directors may reasonably require to show
the right of the transferor to make the transfer; (ii) the instrument of transfer is in respect of only one class of shares; (iii) the instrument of
transfer is duly and properly stamped (if required); or (iv) in the case of a transfer to joint holders, the number of joint holders to whom the share
is to be transferred does not exceed four.
The registration of transfers of shares may be suspended when our register of members is closed in accordance with our Articles for the purpose
of determining those shareholders that are entitled to receive notice of, attend or vote at any meeting of shareholders or any adjournment thereof,
or those shareholders that are entitled to receive payment of any dividend, or in order to make a determination as to who is a shareholder for any
other purpose.
Variation of Rights of Shares
Whenever our share capital is divided into different classes the rights attached to any class of our shares may (unless otherwise provided by the
terms of issue of the shares of that class) only be materially adversely varied or abrogated with the approval by special resolution passed at a
separate meeting of the holders of the shares of that class, but not otherwise. The necessary quorum shall be one or more persons at least holding
or representing by proxy one-half in nominal or par value amount of the issued shares of the relevant class.
Inspection of Books and Records
Holders of our ordinary shares will have no general right under Cayman Islands law to inspect or obtain copies of our list of shareholders or our
corporate records. Our board of directors is required to keep at the office of our service agent in Taiwan copies of our Articles, the minutes of
every meeting of the shareholders and the financial statements, the register of members and the counterfoil of corporate bonds issued by us. Any
shareholder may request, by submitting evidentiary documents to show his or her interests involved and indicating the scope of interested
matters, access to inspect and to make copies of our Articles and accounting books and records.
Without prejudice to the rights of shareholders set out in our Articles, no shareholder is entitled to require discovery of any information in respect
of any detail of our trading or any information which is or may be in the nature of a trade secret or secret process which may relate to the conduct
of our business and which in the opinion of our board of directors would not be in the interests of the shareholders to communicate to the public.
144
Borrowing Power
Subject to our Articles and the ROC Regulations Governing Loaning of Funds and Making Endorsement/Guarantee by Public Companies, our
board of directors may exercise its power to borrow money and to mortgage or charge our undertaking and property, to issue debentures,
debenture stock and other securities whenever money is borrowed or as security for any debt, liability or obligation of us or of any third party.
We, however, cannot borrow money or loan funds to any person except in accordance with the requirements stipulated in our internal policies
and the ROC Regulations Governing Loaning of Funds and Making Endorsement/Guarantee by Public Companies.
Listing Rules
As a listed company on the TPEx, we are required to comply with the relevant ROC laws, regulations, rules and code as amended, from time to
time, applicable as a result of the original and continued trading or listing of any shares on any Taiwan stock exchange or securities market,
including, without limitation the relevant provisions of the Taiwan Securities and Exchange Act, the Acts Governing Relations Between Peoples
of the Taiwan Area and the Mainland Area, or any similar statute and the rules and regulations of the Taiwan authorities thereunder, and the rules
and regulations promulgated by the ROC FSC, the TPEx or the TWSE. This body of rules is referred to in our Articles as “Applicable Listing
Rules” and a number of the provisions of our Articles are subject to the Applicable Listing Rules. In particular, provisions relating to the issue of
shares generally by us, the issue of shares to employees, the recording of shareholdings and the issue of share certificates, the issue of fractional
shares, the transfer of shares, carrying out mergers and spin-offs, independent directors, board powers and procedure, quorum requirements for
shareholder meetings and general meeting procedure, the redemption and purchase of our shares, dealing with treasury shares, borrowing
powers, the payment of dividends and other distributions, the preparation of reports and financial statements and the winding up of the company
are all matters expressed to be subject to, and should be read in conjunction with, the Applicable Listing Rules. In addition to the Applicable
Listing Rules, our Articles are required to be in compliance with the Shareholders’ Rights Protection Checklist, or the Checklist promulgated by
the TPEx or TWSE from time to time. On March 22, 2019, our board of directors approved the Seventh Amended and Restated Memorandum
and Articles of Association, which incorporated the requirements provided in the checklist promulgated by TPEx in December 2018, or the
Checklist. The Seventh Amended and Restated Memorandum and Articles of Association will be submitted to our annual general meeting to be
held on June 21, 2019 for approval by special resolution. We are required to incorporate such changes to our Articles in accordance with the
Checklist by the deadline requested by TPEx, so we expect that those shareholders’ rights will take effect by the end of June 2019. Except for the
requirement that non-resident or foreign investors are obligated to open certain accounts and appoint a tax guarantor in Taiwan and the
restrictions described herein, there are no other restrictions on holding or exercising voting rights on our ordinary shares.
Currently, a party who is a PRC person may not hold our ordinary shares unless it is a qualified domestic institutional investor, or QDII, in PRC.
In addition, we have committed to the TPEx that at no time will 30% or more of our shares be held by PRC persons. Therefore, at any time when
30% of our shares are held by PRC persons, you will not be entitled to withdraw and hold the underlying ordinary shares, even if you are a QDII
in PRC. Under current ROC law, a PRC person means an individual having residence in PRC (but not including a special administrative region
of China such as Hong Kong or Macau, if so excluded by applicable laws of the ROC), any legal person, group, or other institutions of China and
any corporation and other entity organized in countries outside of the ROC or PRC, but is directly or indirectly controlled by or directly or
indirectly has more than 30% of its capital beneficially owned by any PRC person described above.
145
We cannot exercise any voting rights attached to the treasury shares held by us.
No vote may be exercised with respect to any of the following shares and such shares shall not be counted in determining the number of issued
shares: (i) the shares held by any of our subsidiaries, where the total voting shares held by us in such a subsidiary represents more than one half
of the total number of voting shares of the total share equity of such a subsidiary; or (ii) the shares held by another company, where the total
number of the shares or total shares equity of that company held by us and our subsidiaries directly or indirectly represents more than one half of
the total number of voting shares or the total share equity of such a company. If a director gives security over more than 50% of the number of
shares the director held at the time such director was elected as a director of us, no vote may be exercised with respect to the shares representing
the difference between the pledged shares and 50% of the initial shares, and such shares representing the difference between the pledged shares
and 50% of the initial shares shall not be counted in the number of the votes cast by the shareholders present at the general meeting.
In the case of joint holders, the joint holders shall select among them a representative for the exercise of their shareholder’s rights and the vote of
their representative who tenders a vote, whether in person or by proxy, shall be accepted to the exclusion of the votes of the other joint holders.
A shareholder of unsound mind, or in respect of whom an order has been made by any court having jurisdiction in mental illness, may vote by
his committee, or other person in the nature of a committee appointed by that court, and any such committee or other person, may vote by proxy.
A shareholder cannot exercise his or her own vote or by vote by proxy on behalf of another shareholder in respect of any contract or proposed
contract or arrangement if he may be interested therein. Such shares shall not be counted in determining the number of votes of the shareholders
present at the meeting with regard to such resolution, but such shares may be counted in determining the number of shares represented at the
meeting for the purposes of determining the quorum.
If an ADS holder will receive more than 10% of the issued shares of the company after withdrawal of their deposited securities, then such holder
will be required to (i) make a filing with the ROC FSC of the required reporting in accordance with Article 43-1 of the Taiwan Act upon the
acquisition of more than 10% of shares of the company, (ii) make a filing with the ROC FSC in accordance with Article 25 of the Taiwan Act of
notification of any changes of the shareholding of a director, supervisor, manager or shareholder (together with his or her spouse, minor children
and nominee) holding more than 10% of the shares of the company, and (iii) apply for the prior approval of the Investment Commission,
Ministry of Economic Affairs, Executive Yuan of the ROC for acquiring 10% or more of shares of the company.
Preference Shares
Pursuant to our Articles, we may issue shares with rights which are preferential to those of ordinary shares issued by us with the approval of a
majority of our board of directors present at a meeting attended by two-thirds or more of the total number of directors and with the approval of a
special resolution. Our Articles must be amended by special resolution to provide for such preference shares.
146
Material Differences in Corporate Law
The Companies Law is modeled after the corporate legislation of the United Kingdom but does not follow recent United Kingdom statutory
enactments, and differs from laws applicable to United States corporations and their shareholders. Set forth below is a summary of the significant
differences between the provisions of the Companies Law applicable to us and the laws applicable to companies incorporated in Delaware and
their shareholders. In addition, because our Articles require us to comply with the Checklist, the below comparison also includes a brief summary
of the requirements we must follow to maintain such compliance with the TPEx or the TWSE.
Title of Organizational
Documents
Delaware
Cayman Islands
Certificate of Incorporation Bylaws
Memorandum of Association Articles of Association
147
Duties of Directors
Under Delaware law, the business and affairs of a
As a matter of Cayman Islands law, directors of
corporation are managed by or under the direction of
its board of directors. In exercising their powers,
directors are charged with a fiduciary duty of care to
protect the interests of the corporation and a fiduciary
duty of loyalty to act in the best interests of its
shareholders. The duty of care requires that directors
act in an informed and deliberative manner and
inform themselves, prior to making a business
decision, of all material information reasonably
available to them. The duty of care also requires that
directors exercise care in overseeing and investigating
the conduct of the corporation’s employees. The duty
of loyalty may be summarized as the duty to act in
good faith, not out of self-interest, and in a manner
which the director reasonably believes to be in the
best interests of the shareholders.
Limitations on Personal
Liability of Directors
Subject to the limitations described below, a
certificate of incorporation may provide for the
elimination or limitation of the personal liability of a
director to the corporation or its shareholders for
monetary damages for a breach of fiduciary duty as a
director.
Such provision cannot limit liability for breach of
loyalty, bad faith, intentional misconduct, unlawful
payment of dividends or unlawful share purchase or
redemption. In addition, the certificate of
incorporation cannot limit liability for any act or
omission occurring prior to the date when such
provision becomes effective.
Cayman Islands companies owe fiduciary duties to
their respective companies to, amongst other things,
act in good faith in their dealings with or on behalf of
the company and exercise their powers and fulfill the
duties of their office honestly. Five core duties are:
•
•
•
•
•
a duty to act in good faith in what the directors
bona fide consider to be the best interests of the
company (and in this regard, it should be noted
that the duty is owed to the company and not to
associate companies, subsidiaries or holding
companies);
a duty not to personally profit from
opportunities that arise from the office of
director;
a duty of trusteeship of the company’s assets;
a duty to avoid conflicts of interest; and
a duty to exercise powers for the purpose for
which such powers were conferred.
A director of a Cayman Islands company also owes
the company a duty to act with skill, care and
diligence. A director need not exhibit in the
performance of his or her duties a greater degree of
skill than may reasonably be expected from a person
of his or her knowledge and experience.
The Companies Law has no equivalent provision to
Delaware law regarding the limitation of director’s
liability. However, as a matter of public policy,
Cayman Islands law will not allow the limitation of a
director’s liability to the extent that the liability is a
consequence of the director committing a crime or of
the director’s own fraud, dishonesty or willful
default.
Indemnification of Directors,
A corporation has the power to indemnify any
Officers, Agents, and Others
director, officer, employee, or agent of the corporation
who was, is, or is threatened to be made a party who
acted in good faith and in a manner he believed to be
in the best interests of the corporation, and if with
respect to a criminal proceeding, had no reasonable
cause to believe his conduct would be unlawful,
against amounts actually and reasonably incurred.
148
Cayman Islands law does not limit the extent to
which a company’s articles of association may
provide for indemnification of directors and officers,
except to the extent any such provision may be held
by the Cayman Islands courts to be contrary to public
policy, such as to provide indemnification against the
consequences of committing a crime, or against the
indemnified person’s own fraud or dishonesty.
Interested Directors
Under Delaware law, a transaction in which a director
who has an interest is not void or voidable solely
because such interested director is present at or
participates in the meeting that authorizes the
transaction if: (i) the material facts as to such
interested director’s relationship or interests are
disclosed or are known to the board of directors and
the board in good faith authorizes the transaction by
the affirmative vote of a majority of the disinterested
directors, even though the disinterested directors are
less than a quorum, (ii) such material facts are
disclosed or are known to the shareholders entitled to
vote on such transaction and the transaction is
specifically approved in good faith by
vote of the shareholders, or (iii) the transaction is fair
as to the corporation as of the time it is authorized,
approved or ratified. Under Delaware law, a director
could be held liable for any transaction in which such
director derived an improper personal benefit.
Our Articles contain a provision that prohibits a
director from voting (or voting on behalf of another
director) in respect of any transaction in which he or
she is interested.
Our proposed Seventh Amended and Restated
Memorandum and Articles of Association if adopted
at the annual general meeting to be held on June 21,
2019 would provide that, where the spouse of a
director, a person with a kinship to a director within
the second degree, or a company controlled by or
controlling a director has a direct or indirect interest
in any matter, such director will be deemed to have
an interest in such matter.
Voting Requirements
The certificate of incorporation may include a
provision requiring supermajority approval by the
directors or shareholders for any corporate action.
In addition, under Delaware law, certain business
combinations involving interested shareholders
require approval by a supermajority of the non-
interested shareholders.
For the protection of shareholders, certain matters
must be approved by special resolution of the
shareholders as a matter of Cayman Islands law,
including alteration of the memorandum or articles
of association, appointment of inspectors to examine
company affairs, reduction of share capital (subject,
in relevant circumstances, to court approval), change
of name, authorization of a plan of merger or transfer
by way of continuation to another jurisdiction or
consolidation or voluntary winding up of the
company.
The Companies Law requires that a special
resolution be passed by a super majority of at least
two-thirds or such higher percentage as set forth in
the articles of association, of shareholders being
entitled to vote and do vote in person or by proxy at
a general meeting, or by unanimous written consent
of shareholders entitled to vote at a general meeting.
However, our Articles do not permit resolutions of
shareholders to be passed in writing in lieu of a
general meeting.
149
Voting for Directors
Under Delaware law, unless otherwise specified in the
certificate of incorporation or bylaws of the
corporation, directors shall be elected by a plurality of
the votes of the shares present in person or
represented by proxy at the meeting and entitled to
vote on the election of directors.
The Companies Law defines “special resolutions”
only. A company’s articles of association can
therefore tailor the definition of “ordinary
resolutions” as a whole, or with respect to specific
provisions. Our Articles provide that the election of
directors shall be subject to applicable listing rules.
At a general meeting of election of directors, the
number of votes exercisable in respect of one share
shall be the same as the number of directors to be
elected, and the total number of votes per share may
be consolidated for election of one
candidate or may be split for election of two or more
candidates. A candidate to whom the ballots cast
represent a prevailing number of votes shall be
deemed a director so elected.
Cumulative Voting
No cumulative voting for the election of directors
No cumulative voting for the election of directors
unless so provided in the certificate of incorporation.
Directors’ Powers Regarding
The certificate of incorporation may grant the
Bylaws
directors the power to adopt, amend or repeal bylaws.
Nomination and Removal of
Directors and Filling
Vacancies on Board
Mergers and Similar
Arrangements
Shareholders may generally nominate directors if they
comply with advance notice provisions and other
procedural requirements in company bylaws. Holders
of a majority of the shares may remove a director
with or without cause, except in certain cases
involving a classified board or if the company uses
cumulative voting. Unless otherwise provided for in
the certificate of incorporation, directorship vacancies
are filled by a majority of the directors elected or then
in office.
Under Delaware law, with certain exceptions, a
merger, consolidation, exchange or sale of all or
substantially all the assets of a corporation must be
approved by the board of directors and a majority of
the outstanding shares entitled to vote thereon. Under
Delaware law, a shareholder of a corporation
participating in certain major corporate transactions
may, under certain circumstances, be entitled to
appraisal rights pursuant to which such shareholder
may receive cash in the amount of the fair value of
the shares held by such shareholder (as
determined by a court) in lieu of the consideration
such shareholder would otherwise receive in the
transaction. Delaware law also provides that a parent
corporation, by resolution of its board of directors,
may merge with any subsidiary, of which it owns at
least
150
unless so provided in the articles of association. Our
Articles expressly provide for cumulative voting on
the election of directors as described above.
The memorandum and articles of association may
only be amended by a special resolution of the
shareholders.
Nomination and removal of directors and filling of
board vacancies are governed by the terms of the
articles of association. Our Articles provide that only
shareholders may elect directors by cumulative
voting and may remove directors by Supermajority
Resolution.
The Companies Law provides for the merger or
consolidation of two or more companies into a single
entity. The legislation makes a distinction between a
“consolidation” and a “merger.” In a consolidation, a
new entity is formed from the combination of each
participating company, and the separate
consolidating parties, as a consequence, cease to
exist and are each stricken by the Registrar of
Companies. In a merger, one company remains as the
surviving entity, having in effect absorbed the other
merging party that then ceases to exist
Two or more Cayman Islands companies may merge
or consolidate. Cayman Islands companies may also
merge or consolidate with foreign companies
provided that the laws of the foreign jurisdiction
permit such merger or consolidation.
90% of each class of capital stock without a vote by
shareholders of such subsidiary. Upon any such
merger, dissenting shareholders of the subsidiary
would have appraisal rights.
Under the Companies Law, a plan of merger or
consolidation shall be authorized by each constituent
company by way of (i) a special resolution of the
members of each such constituent company; and (ii)
such other authorization, if any, as may be specified
in such constituent company’s articles of association.
Shareholder approval is not required where a parent
company registered in the Cayman Islands seeks to
merge with one or more of its subsidiaries registered
in the Cayman Islands and a copy of the plan of
merger is given to every member of each subsidiary
company to be merged unless that member agrees
otherwise.
Secured creditors must consent to the merger
although application can be made to the Grand Court
of the Cayman Islands for such requirement to be
waived if such secured creditor does not grant its
consent to the merger. Where a foreign company
wishes to merge with a Cayman company, consent or
approval to the transfer of any security interest
granted by the foreign company to the resulting
Cayman entity in the transaction is required, unless
otherwise released or waived by the secured party. If
the merger plan is approved, it is then filed with the
Cayman Islands Registrar of Companies along with a
declaration by a director of each company. The
Registrar of Companies will then issue a certificate
of merger which shall be prima facie evidence of
compliance with all requirements of the Companies
Law in respect of the merger or consolidation.
151
The surviving or consolidated entity remains or
becomes active while the other company or
companies are automatically dissolved. Unless the
shares of such shareholder are publicly listed or
quoted, dissenting
shareholders in a merger or consolidation of this type
are entitled to payment of the fair value of their
shares if such shareholder provides a written
objection before the vote on such merger or
consolidation. With respect to shares that are listed or
quoted, a shareholder shall have similar rights only if
it is required by the terms of the merger or
consolidation to accept for such shares property other
than (i) shares (or depositary receipts in respect
thereof) in the surviving or consolidated company;
(ii) listed or quoted shares (or depositary receipts in
respect thereof) of another company; (iii) cash in lieu
of any fractions of shares or depositary receipts
described at (i) and (ii); or (iv) any combination of
shares, depositary receipts or cash described in (i) —
(iii).
152
Cayman companies may also be restructured or
amalgamated under supervision of the Grand Court
of the Cayman Islands by way of a court-sanctioned
“scheme of arrangement.” A scheme of arrangement
is one of several transactional mechanisms available
in the Cayman Islands for achieving a restructuring.
Others include share capital exchange, merger (as
described above), asset acquisition or control,
through contractual arrangements, of an operating
business. A scheme of arrangement must not be
beyond the powers of the company, as stated in the
constitutional documents of the company and also
requires the approval of a majority, in number, of
each class of shareholders and creditors with whom
the arrangement is to be made and who must in
addition represent three-fourths in value of each such
class of shareholders or creditors, as the case may be,
that are present and voting either in person or by
proxy at the meeting summoned for that purpose.
The convening of the meetings and subsequently the
terms of the arrangement must be sanctioned by the
Grand Court of the Cayman Islands. While a
dissenting shareholder would have the right to
express to the Court its view that the transaction
ought not be approved, the Court can be expected to
approve the scheme of arrangement if it is satisfied
that:
the classes which are required to approve the
•
scheme of arrangement have been properly
constituted, so that the members of such classes are
properly represented;
the meetings held by the company in relation to
•
the approval of the scheme of arrangement by such
classes have been convened and held in accordance
with any directions given by the Court;
the scheme of arrangement has been properly
•
explained to the shareholders or creditors so that they
have been able to exercise an informed vote in
respect of the scheme; the scheme of arrangement is
one which an intelligent and honest man, who is a
member of the relevant class and properly acting
might approve.
153
When a takeover offer is made and accepted by
holders of 90% of the shares within four months, the
offeror may, within a two-month period, require the
holders of the remaining shares to transfer such
shares on the terms of the offer. An objection may be
made to the Grand Court of the Cayman Islands but
is unlikely to succeed unless there is evidence of
fraud, bad faith or collusion. If the arrangement and
reconstruction are thus approved, any dissenting
shareholders would have no rights comparable to
appraisal rights, which would otherwise ordinarily be
available to dissenting shareholders of
United States corporations, providing rights to
receive payment in cash for the judicially determined
value of the shares.
Our Articles provide that in the event the resolutions
with respect to a merger are approved in accordance
with the laws of the Cayman Islands, any shareholder
who has notified us in writing of his objection to
such proposal prior to such meeting and
subsequently raised his objection at the meeting may
request us to purchase all of his shares at the then
prevailing fair price. In the event any part of the
company’s business is spun off or involved in any
merger, the shareholder, who has forfeited his right
to vote on such matter and expressed his dissent
therefor, in writing or verbally (with a record) before
or during the general meeting, may request us to buy
back all of his shares at the then prevailing fair price.
In the event that we fail to reach such agreement
with the shareholder within 60 days after the
resolution date, the shareholder may, within 30 days
after such 60-day period, file a petition to any
competent court of ROC for a ruling on the appraisal
price, and to the extent that the ruling is capable of
enforcement and recognition in the relevant
jurisdiction, such ruling by such ROC court shall be
binding and conclusive as between us and requested
shareholder solely with respect to the appraisal price.
154
Our Articles provide that, if we propose to effect any
merger, transfer and assumption of our business or
assets, share swap or spin-off, as a result of which we
would cease to be a TPEx-listed company and the
surviving company, transferee company, existing
company or newly set-up company (depending on
the circumstances) is not a company listed on TWSE
or TPEx, such transaction must be approved by the
shareholders
representing two thirds of the issued and outstanding
shares of us.
The mergers and acquisitions of the Company shall
also be subject to the procedural requirements under
the Applicable Listing Rules.
The rights of shareholders under Cayman Islands law
are not as extensive as those under Delaware law.
Class actions are generally not available to
shareholders under Cayman Islands laws;
historically, there have not been any reported
instances of such class actions having been
successfully brought before the Cayman Islands
courts. In principle, we will normally be the proper
plaintiff and a derivative action may be brought by a
minority shareholder in only limited circumstances.
In this regard, the Cayman Islands courts would
ordinarily be expected to follow English case law
precedent, which would permit a shareholder to
commence an action in the company’s name to
remedy a wrong done to the company where the act
complained of cannot be ratified by the shareholders
and where control of the company by the wrongdoer
results in the company not pursuing a remedy itself.
The case law shows that derivative actions have been
permitted in respect of acts that are beyond the
company’s corporate power, illegal, where the
individual rights of the plaintiff shareholder have
been infringed or are about to be infringed and acts
that are alleged to constitute a “fraud on the
minority.” The winning party in such an action
generally would be able to recover a portion of
attorney’s fees incurred in connection with such
action.
Shareholder Suits
Class actions and derivative actions generally are
available to shareholders under Delaware law for,
among other things, breach of fiduciary duty,
corporate waste and actions not taken in accordance
with applicable law. In such actions, the court
generally has discretion to permit the winning party to
recover attorneys’ fees incurred in connection with
such action.
155
Our Articles provide that, subject to the laws of the
Cayman Islands, any shareholder(s) holding three
percent or more of the total number of our issued
shares for a period of one year or a longer time shall
have the right to submit a petition for and on behalf
of
us against our director(s), and the Taipei District
Court, ROC, may be court of the first instance for
this matter.
Our proposed Seventh Amended and Restated
Memorandum and Articles of Association if adopted
at the annual general meeting to be held on June 21,
2019 would provide that, subject to the laws of the
Cayman Islands, any shareholder(s) holding one
percent or more of the total number of our issued
shares for a period of six months or a longer time
shall have the right to submit a petition for and on
behalf of us against our director(s), and Taipei
District Court, ROC, may have jurisdiction over such
petition.
Shareholders of a Cayman Islands exempted
company have no general right under Cayman
Islands law to inspect or obtain copies of a list of
shareholders or other corporate records (other than
the register of mortgages or charges) of the company.
However, these rights may be provided in the
company’s articles of association.
Our proposed Seventh Amended and Restated
Memorandum and Articles of Association if adopted
at the annual general meeting to be held on June 21,
2019 would provide that, in the event that a general
meeting is convened by the board of directors or any
other person having a right to convene the general
meeting, such convener(s) may request us or our
shareholders’ service agent provide the register of
members.
The Companies Law does not provide shareholders
any right to bring business before a meeting or
requisition a general meeting. However, these rights
may be provided in the company’s articles of
association. Our Articles do provide for these rights.
Inspection of Corporate
Records
Under Delaware law, shareholders of a Delaware
corporation have the right during normal business
hours to inspect for any proper purpose, and to obtain
copies of list(s) of shareholders and other books and
records of the corporation and its subsidiaries, if any,
to the extent the books and records of such
subsidiaries are available to the corporation.
Shareholder Proposals
Unless provided in the corporation’s certificate of
incorporation or bylaws, Delaware law does not
include a provision restricting the manner in which
shareholders may bring business before a meeting.
156
Approval of
Corporate Matters by
Written Consent
Calling of Special
Shareholders Meetings
Delaware law permits shareholders to take action by
written consent signed by the holders of outstanding
shares having not less than the minimum number of
votes that would be necessary to authorize or take
such action at a meeting of shareholders.
The Companies Law allows a special resolution to be
passed in writing if signed by all the voting
shareholders (if authorized by the articles of
association).
Our Articles do not authorize such written consents.
Delaware law permits the board of directors or any
person who is authorized under a corporation’s
certificate of incorporation or bylaws to call a special
meeting of shareholders.
The Companies Law does not have provisions
governing the proceedings of shareholders meetings
which are usually provided in the articles of
association.
Our Articles allow for shareholders’ meetings to be
convened on the requisition in writing of any
shareholder or shareholders holding at least three
percent of the issued voting share capital for one year
or longer, subject to certain procedural requirements.
Our proposed Seventh Amended and Restated
Memorandum and Articles of Association if adopted
at the annual general meeting to be held on June 21,
2019 would provide that, an extraordinary general
meeting may be convened on the requisition of one
or more shareholders(s) holding more than half of
the paid up capital of us having the right of voting at
a general meeting for a period of at least three
consecutive months at the date the book closure
period commences.
Our proposed Seventh Amended and Restated
Memorandum and Articles of Association if adopted
at the annual general meeting to be held on June 21,
2019 would provide that, in the event that our board
of directors does not or cannot convene a general
meeting, or an independent director member of audit
committee otherwise finds it necessary for the
interests of shareholders, the independent director
may convene a general meeting.
157
C.
Material contracts.
Except as otherwise disclosed in this Annual Report (including the exhibits thereto), we are not currently, and have not been in the last two years,
party to any material contract, other than contracts entered into in the ordinary course of our business.
Underwriting Agreement
We entered into an underwriting agreement among Leerink Partners LLC and Piper Jaffray & Co. as representatives of the underwriters, on May
4, 2018, with respect to the ADSs sold in our IPO. We have agreed to indemnify the underwriters against certain liabilities, including liabilities
under the U.S. Securities Act of 1933, as amended, and to contribute to payments the underwriters may be required to make in respect of such
liabilities.
D.
Exchange controls.
There are no governmental laws, decrees, regulations or other legislation in the Cayman Islands that may affect the import or export of capital,
including the availability of cash and cash equivalents for use by us, or that may affect the remittance of dividends, interest, or other payments by
us to non-resident holders of our ordinary shares or ADSs.
Approval by the Investment Commission, the Ministry of Economic Affairs, is required for all foreign investments into Taiwanese entities
regardless of the remittance amount, which does not relate to foreign exchange control but may be relevant to the import of capital. The Republic
of China, or the ROC, has foreign exchange controls over the import and export of capital relating to ASLAN Pharmaceuticals Taiwan Limited,
or ASLAN Taiwan. As long as ASLAN Taiwan receives the relevant governmental approval for the inward and outward remittances, or the
accumulated remittances in a year do not exceed the annual quota (which is currently $50 million for inward remittances and $50 million for
outward remittances), ASLAN Taiwan may import (subject to the foreign investment approval from the Investment Commission) or export
capital without foreign exchange controls, provided that it has submitted a foreign exchange report form, and in the case of a remittance in excess
of $1 million, has provided for review the necessary documents to prove the purpose of the remittances.
There are no governmental laws, decrees, regulations or other legislation in the ROC that may affect the remittance of dividends, interest, or
other payments by us to non-resident holders of our ordinary shares or ADSs.
E.
Taxation.
The following is a discussion of the material Cayman Islands, ROC and U.S. federal income tax considerations that may be relevant to an
investment decision by a potential investor with respect to our ADSs. This summary should not be considered a comprehensive description of all
the tax considerations that may be relevant to the decisions to acquire ADSs.
158
Material U.S. Federal Income Tax Considerations for U.S. Holders
The following discussion describes the material U.S. federal income tax consequences relating to the ownership and disposition of our ordinary
shares or ADSs by U.S. Holders (as defined below). This discussion applies to U.S. Holders that purchase our ADSs pursuant to our public
offering and hold such ADSs as capital assets. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended, or the Code,
U.S. Treasury regulations promulgated thereunder and administrative and judicial interpretations thereof, all as in effect on the date hereof and
all of which are subject to change, possibly with retroactive effect. This discussion does not address all of the U.S. federal income tax
consequences that may be relevant to specific U.S. Holders in light of their particular circumstances or to U.S. Holders subject to special
treatment under U.S. federal income tax law (such as certain financial institutions, insurance companies, dealers or traders in securities or other
persons that generally mark their securities to market for U.S. federal income tax purposes, tax-exempt entities or governmental organizations,
retirement plans, regulated investment companies, real estate investment trusts, grantor trusts, brokers, dealers or traders in securities,
commodities, currencies or notional principal contracts, certain former citizens or long-term residents of the United States, persons who hold our
ordinary shares or ADSs as part of a “straddle,” “hedge,” “conversion transaction,” “synthetic security” or integrated investment, persons that
have a “functional currency” other than the U.S. dollar, persons that own directly, indirectly or through attribution 10% or more of the voting
power or value of our ordinary shares, corporations that accumulate earnings to avoid U.S. federal income tax, partnerships and other pass-
through entities, and investors in such pass-through entities). This discussion does not address any U.S. state or local or non-U.S. tax
consequences or any U.S. federal estate, gift or alternative minimum tax consequences.
As used in this discussion, the term “U.S. Holder” means a beneficial owner of our ordinary shares or ADSs who is, for U.S. federal income tax
purposes, (1) an individual who is a citizen or resident of the United States, (2) a corporation (or entity treated as a corporation for U.S. federal
income tax purposes) created or organized in or under the laws of the United States, any state thereof, or the District of Columbia, (3) an estate
the income of which is subject to U.S. federal income tax regardless of its source or (4) a trust (x) with respect to which a court within the United
States is able to exercise primary supervision over its administration and one or more United States persons have the authority to control all of its
substantial decisions or (y) that has elected under applicable U.S. Treasury regulations to be treated as a domestic trust for U.S. federal income
tax purposes.
If an entity treated as a partnership for U.S. federal income tax purposes holds our ordinary shares or ADSs, the U.S. federal income tax
consequences relating to an investment in such ordinary shares or ADSs will depend in part upon the status and activities of such entity and the
particular partner. Any such entity should consult its own tax advisor regarding the U.S. federal income tax consequences applicable to it and its
partners of the purchase, ownership and disposition of our ordinary shares or ADSs.
Persons considering an investment in our ADSs should consult their own tax advisors as to the particular tax consequences applicable to them
relating to the purchase, ownership and disposition of our ADSs, including the applicability of U.S. federal, state and local tax laws and non-U.S.
tax laws.
The discussion below assumes that the representations contained in the deposit agreement are true and that the obligations in the deposit
agreement and any related agreement will be complied with in accordance with their terms. Generally, a holder of an ADS should be treated for
U.S. federal income tax purposes as holding the ordinary shares represented by the ADS. Accordingly, no gain or loss will be recognized upon an
exchange of ADSs for the underlying ordinary shares represented by such ADSs. The U.S. Treasury has expressed concerns that intermediaries
in the chain of ownership between the holder of an ADS and the issuer of the security underlying the ADS may be taking actions that are
inconsistent with the beneficial ownership of the underlying security. Accordingly, the creditability of foreign taxes, if any, as described below,
could be affected by actions taken by intermediaries in the chain of ownership between the holders of ADSs and our company if as a result of
such actions the holders of ADSs are not properly treated as beneficial owners of the underlying ordinary shares.
159
Passive Foreign Investment Company Consequences
In general, a corporation organized outside the United States will be treated as a passive foreign investment company, or PFIC, for any taxable
year in which either (1) at least 75% of its gross income is “passive income” (the “PFIC income test”), or (2) on average at least 50% of its
assets, determined on a quarterly basis, are assets that produce passive income or are held for the production of passive income (the “PFIC asset
test”). Passive income for this purpose generally includes, among other things, dividends, interest, royalties, rents, and gains from the sale or
exchange of property that gives rise to passive income. Assets that produce or are held for the production of passive income generally include
cash, even if held as working capital or raised in a public offering, marketable securities, and other assets that may produce passive income.
Generally, in determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which
it owns, directly or indirectly, at least a 25% interest (by value) is taken into account.
Although PFIC status is determined on an annual basis and generally cannot be determined until the end of the taxable year, based on the nature
of our current and expected income and the current and expected value and composition of our assets, we expect to be a PFIC for our current
taxable year. Because our income for the next several taxable years is expected to consist principally of interest from cash and cash equivalents
received from our public offering or prior offerings, we believe that we likely will be a PFIC under the PFIC income test in future taxable years
as well. In part, because we may hold a substantial amount of cash and cash equivalents, and because the calculation of the value of our assets
may be based in part on the value of our ordinary shares or ADSs, which may fluctuate considerably, we believe we may also be a PFIC in future
taxable years under the PFIC asset test. Even if we determine that we are not a PFIC for a taxable year, there can be no assurance that the Internal
Revenue Service, or IRS, will agree with our conclusion and that the IRS would not successfully challenge our position.
If we are a PFIC in any taxable year during which a U.S. Holder owns our ordinary shares or ADSs, the U.S. Holder could be liable for
additional taxes and interest charges under the “PFIC excess distribution regime” upon (1) a distribution paid during a taxable year that is greater
than 125% of the average annual distributions paid in the three preceding taxable years, or, if shorter, the U.S. Holder’s holding period for our
ordinary shares or ADSs, and (2) any gain recognized on a sale, exchange or other disposition, including a pledge, of our ordinary shares or
ADSs, whether or not we continue to be a PFIC. Under the PFIC excess distribution regime, the tax on such distribution or gain would be
determined by allocating the distribution or gain ratably over the U.S. Holder’s holding period for our ordinary shares or ADSs. The amount
allocated to the current taxable year (i.e., the year in which the distribution occurs or the gain is recognized) and any year prior to the first taxable
year in which we are a PFIC will be taxed as ordinary income earned in the current taxable year. The amount allocated to other taxable years will
be taxed at the highest marginal rates in effect for individuals or corporations, as applicable, to ordinary income for each such taxable year, and
an interest charge, generally applicable to underpayments of tax, will be added to the tax.
If we are a PFIC for any year during which a U.S. Holder holds our ordinary shares or ADSs, we must generally continue to be treated as a PFIC
by that holder for all succeeding years during which the U.S. Holder holds such ordinary shares or ADSs, unless we cease to meet the
requirements for PFIC status and the U.S. Holder makes a “deemed sale” election with respect to our ordinary shares or ADSs. If the election is
made, the U.S. Holder will be deemed to sell our ordinary shares or ADSs it holds at their fair market value on the last day of the last taxable
year in which we qualified as a PFIC, and any gain recognized from such deemed sale would be taxed under the PFIC excess distribution regime,
but any loss would not be recognized. After the deemed sale election, the U.S. Holder’s ordinary shares or ADSs would not be treated as shares
of a PFIC unless we subsequently become a PFIC.
160
If we are a PFIC for any taxable year during which a U.S. Holder holds our ordinary shares or ADSs and one of our non-United States
subsidiaries is also a PFIC (i.e., a lower-tier PFIC), such U.S. Holder would be treated as owning a proportionate amount (by value) of the shares
of the lower-tier PFIC and would be taxed under the PFIC excess distribution regime on distributions by the lower-tier PFIC and on gain from
the disposition of shares of the lower-tier PFIC even though such U.S. Holder would not receive the proceeds of those distributions or
dispositions. Any of our non-United States subsidiaries that have elected to be disregarded as entities separate from us or as partnerships for U.S.
federal income tax purposes would not be corporations under U.S. federal income tax law and accordingly, cannot be classified as lower-tier
PFICs. However, non-United States subsidiaries that have not made the election may be classified as a lower-tier PFIC if we are a PFIC during
your holding period and the subsidiary meets the PFIC income test or PFIC asset test. Each U.S. Holder is advised to consult its tax advisors
regarding the application of the PFIC rules to any of our non-United States subsidiaries.
If we are a PFIC, a U.S. Holder will not be subject to tax under the PFIC excess distribution regime on distributions or gain recognized on our
ordinary shares or ADSs if a valid “mark-to-market” election is made by the U.S. Holder for our ordinary shares or ADSs. An electing U.S.
Holder generally would take into account as ordinary income each year, the excess of the fair market value of our ordinary shares or ADSs held
at the end of such taxable year over the adjusted tax basis of such ordinary shares or ADSs. The U.S. Holder would also take into account, as an
ordinary loss each year, the excess of the adjusted tax basis of such ordinary shares or ADSs over their fair market value at the end of the taxable
year, but only to the extent of the excess of amounts previously included in income over ordinary losses deducted as a result of the mark-to-
market election. The U.S. Holder’s tax basis in our ordinary shares or ADSs would be adjusted to reflect any income or loss recognized as a
result of the mark-to-market election. Any gain from a sale, exchange or other disposition of our ordinary shares or ADSs in any taxable year in
which we are a PFIC would be treated as ordinary income and any loss from such sale, exchange or other disposition would be treated first as
ordinary loss (to the extent of any net mark-to-market gains previously included in income) and thereafter as capital loss. If, after having been a
PFIC for a taxable year, we cease to be classified as a PFIC because we no longer meet the PFIC income or PFIC asset test, the U.S. Holder
would not be required to take into account any latent gain or loss in the manner described above and any gain or loss recognized on the sale or
exchange of the ordinary shares or ADSs would be classified as a capital gain or loss.
A mark-to-market election is available to a U.S. Holder only for “marketable stock.” Generally, stock will be considered marketable stock if it is
“regularly traded” on a “qualified exchange” within the meaning of applicable U.S. Treasury regulations. A class of stock is regularly traded
during any calendar year during which such class of stock is traded, other than in de minimis quantities, on at least 15 days during each calendar
quarter.
Our ADSs will be marketable stock as long as they remain listed on The Nasdaq Global Market and are regularly traded. A mark-to-market
election will not apply to the ordinary shares or ADSs for any taxable year during which we are not a PFIC, but will remain in effect with respect
to any subsequent taxable year in which we become a PFIC. Such election will not apply to any of our non-U.S. subsidiaries. Accordingly, a U.S.
Holder may continue to be subject to tax under the PFIC excess distribution regime with respect to any lower-tier PFICs notwithstanding the
U.S. Holder’s mark-to-market election for the ordinary shares or ADSs.
The tax consequences that would apply if we are a PFIC would also be different from those described above if a U.S. Holder were able to make a
valid qualified electing fund, or QEF, election. As we do not expect to provide U.S. Holders with the information necessary for a U.S. Holder to
make a QEF election, prospective investors should assume that a QEF election will not be available.
161
The U.S. federal income tax rules relating to PFICs are very complex. Prospective U.S. investors are strongly urged to consult their own
tax advisors with respect to the impact of PFIC status on the purchase, ownership and disposition of our ADSs, the consequences to
them of an investment in a PFIC, any elections available with respect to the ADSs and the IRS information reporting obligations with
respect to the purchase, ownership and disposition of ADSs of a PFIC.
Distributions
Subject to the discussion above under “—Passive Foreign Investment Company Consequences,” a U.S. Holder that receives a distribution with
respect to our ordinary shares or ADSs generally will be required to include the gross amount of such distribution in gross income as a dividend
when actually or constructively received to the extent of the U.S. Holder’s pro rata share of our current and/or accumulated earnings and profits
(as determined under U.S. federal income tax principles). To the extent a distribution received by a U.S. Holder is not a dividend because it
exceeds the U.S. Holder’s pro rata share of our current and accumulated earnings and profits, it will be treated first as a tax-free return of capital
and reduce (but not below zero) the adjusted tax basis of the U.S. Holder’s ordinary shares or ADSs. To the extent the distribution exceeds the
adjusted tax basis of the U.S. Holder’s ordinary shares or ADSs, the remainder will be taxed as capital gain. Because we may not account for our
earnings and profits in accordance with U.S. federal income tax principles, U.S. Holders should expect all distributions to be reported to them as
dividends.
Distributions on our ordinary shares or ADSs that are treated as dividends generally will constitute income from sources outside the United
States for foreign tax credit purposes and generally will constitute passive category income. Such dividends will not be eligible for the
“dividends received’’ deduction generally allowed to corporate shareholders with respect to dividends received from U.S. corporations.
Dividends paid by a “qualified foreign corporation’’ to certain non-corporate U.S. Holders may be are eligible for taxation at a reduced capital
gains rate rather than the marginal tax rates generally applicable to ordinary income provided that a holding period requirement (more than 60
days of ownership, without protection from the risk of loss, during the 121-day period beginning 60 days before the ex-dividend date) and certain
other requirements are met. Each U.S. Holder is advised to consult its tax advisors regarding the availability of the reduced tax rate on dividends
to its particular circumstances. However, if we are a PFIC for the taxable year in which the dividend is paid or the preceding taxable year (see
discussion above under “—Passive Foreign Investment Company Consequences”), we will not be treated as a qualified foreign corporation, and
therefore the reduced capital gains tax rate described above will not apply.
Dividends will be included in a U.S. Holder’s income on the date of the Depositary’s receipt of the dividend. The amount of any dividend
income paid in NT dollars will be the U.S. dollar amount calculated by reference to the exchange rate in effect on the date of receipt, regardless
of whether the payment is in fact converted into U.S. dollars. If the dividend is converted into U.S. dollars on the date of receipt, a U.S. Holder
should not be required to recognize foreign currency gain or loss in respect to the dividend income. A U.S. Holder may have foreign currency
gain or loss if the dividend is converted into U.S. dollars after the date of receipt.
A non-U.S. corporation (other than a corporation that is classified as a PFIC for the taxable year in which the dividend is paid or the preceding
taxable year) generally will be considered to be a qualified foreign corporation with respect to any dividend it pays on ordinary shares or ADSs
that are readily tradable on an established securities market in the United States.
162
Sale, Exchange or Other Disposition of Our Ordinary Shares or ADSs
Subject to the discussion above under “—Passive Foreign Investment Company Consequences,’’ a U.S. Holder generally will recognize capital
gain or loss for U.S. federal income tax purposes upon the sale, exchange or other disposition of our ordinary shares or ADSs in an amount equal
to the difference, if any, between the amount realized (i.e., the amount of cash plus the fair market value of any property received) on the sale,
exchange or other disposition and such U.S. Holder’s adjusted tax basis in the ordinary shares or ADSs. Such capital gain or loss generally will
be long-term capital gain taxable at a reduced rate for non-corporate U.S. Holders or long-term capital loss if, on the date of sale, exchange or
other disposition, the ordinary shares or ADSs were held by the U.S. Holder for more than one year. Any capital gain of a non-corporate U.S.
Holder that is not long-term capital gain is taxed at ordinary income rates. The deductibility of capital losses is subject to limitations. Any gain or
loss recognized from the sale or other disposition of our ordinary shares or ADSs will generally be gain or loss from sources within the United
States for U.S. foreign tax credit purposes.
Medicare Tax
Certain U.S. Holders that are individuals, estates or trusts and whose income exceeds certain thresholds generally are subject to a 3.8% tax on all
or a portion of their net investment income, which may include their gross dividend income and net gains from the disposition of our ordinary
shares or ADSs. If you are a United States person that is an individual, estate or trust, you are encouraged to consult your tax advisors regarding
the applicability of this Medicare tax to your income and gains in respect of your investment in our ordinary shares or ADSs.
Information Reporting and Backup Withholding
U.S. Holders may be required to file certain U.S. information reporting returns with the IRS with respect to an investment in our ordinary shares
or ADSs, including, among others, IRS Form 8938 (Statement of Specified Foreign Financial Assets). As described above under “Passive
Foreign Investment Company Consequences,” each U.S. Holder who is a shareholder of a PFIC must file an annual report containing certain
information. U.S. Holders paying more than $100,000 for our ordinary shares or ADSs may be required to file IRS Form 926 (Return by a U.S.
Transferor of Property to a Foreign Corporation) reporting this payment. Substantial penalties may be imposed upon a U.S. Holder that fails to
comply with the required information reporting.
Dividends on and proceeds from the sale or other disposition of our ADSs may be reported to the IRS unless the U.S. Holder establishes a basis
for exemption. Backup withholding may apply to amounts subject to reporting if the holder (1) fails to provide an accurate U.S. taxpayer
identification number or otherwise establish a basis for exemption, or (2) is described in certain other categories of persons. However, U.S.
Holders that are corporations generally are excluded from these information reporting and backup withholding tax rules.
Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules generally will be allowed as a refund or
a credit against a U.S. Holder’s U.S. federal income tax liability if the required information is furnished by the U.S. Holder on a timely basis to
the IRS.
U.S. Holders should consult their own tax advisors regarding the backup withholding tax and information reporting rules.
163
EACH PROSPECTIVE INVESTOR IS URGED TO CONSULT ITS OWN TAX ADVISOR ABOUT THE TAX CONSEQUENCES TO
IT OF AN INVESTMENT IN OUR ADSs IN LIGHT OF THE INVESTOR’S OWN CIRCUMSTANCES.
Cayman Taxation
Prospective investors should consult their professional advisers on the possible tax consequences of buying, holding or selling any ADSs or
ordinary shares under the laws of their country of citizenship, residence or domicile.
The following is a discussion on certain Cayman Islands income tax consequences of an investment in the ADSs or ordinary shares. The
discussion is a general summary of present law, which is subject to prospective and retroactive change. It is not intended as tax advice, does not
consider any investor’s particular circumstances, and does not consider tax consequences other than those arising under Cayman Islands law.
No stamp duty, capital duty, registration or other issue or documentary taxes are payable in the Cayman Islands on the creation, issuance or
delivery of the ADSs or ordinary shares. The Cayman Islands currently have no form of income, corporate or capital gains tax and no estate duty,
inheritance tax or gift tax. There are currently no Cayman Islands’ taxes or duties of any nature on gains realized on a sale, exchange, conversion,
transfer or redemption of the ADSs or ordinary shares. Payments of dividends and capital in respect of the ADSs or ordinary shares will not be
subject to taxation in the Cayman Islands and no withholding will be required on the payment of interest and principal or a dividend or capital to
any holder of the ADSs or ordinary shares, nor will gains derived from the disposal of the ADSs or ordinary shares be subject to Cayman Islands
income or corporation tax as the Cayman Islands currently have no form of income or corporation taxes.
We are incorporated under the laws of the Cayman Islands as an exempted company with limited liability and, as such, have applied for and
expect to receive an undertaking from the Governor of the Cayman Islands that no law enacted in the Cayman Islands during the period of 20
years from the date of the undertaking imposing any tax to be levied on profits, income, gains or appreciation shall apply to us or our operations
and no such tax or any tax in the nature of estate duty or inheritance tax shall be payable (directly or by way of withholding) on the ADSs or
ordinary shares, debentures or other obligations of ours.
ROC Taxation
The following is a summary under present law of the principal ROC tax consequences of the ownership and disposition of ADSs and shares to a
Non-Resident Individual or a Non-Resident Entity that owns ADS or shares (each a Non-ROC Holder). As used in this section, a “Non-Resident
individual” is a foreign national individual who is not physically present in the ROC for 183 days or more during any calendar year; and a “Non-
Resident Entity” is a corporation or a non-corporate body that is organized under the laws of a jurisdiction other than the ROC and has no fixed
place of business or other permanent establishment or business agent in the ROC. Prospective purchasers of the ADSs should consult their tax
advisors concerning the ROC tax consequences of owning the ADSs or shares and the laws of any other relevant taxing jurisdiction to which
they are subject.
164
Sale
There is no ROC tax on (i) the purchase of the ADSs, (ii) the sale of the ADSs or (iii) conversion of the ADSs into their underlying shares.
However, securities transaction tax will be withheld at the rate of 0.3% of the transaction price upon a sale of the underlying shares in the ROC.
Under current ROC law, capital gains on transactions in securities issued by Cayman Islands companies and held by a Non-ROC Holder are
exempt from income tax. This exemption applies to capital gains derived from the sale of the said shares.
Tax Guarantor
If a holder of non-ROC nationality converts the ADSs held by the holder into the underlying shares, such holder is required under current ROC
law and regulations to appoint a tax agent in the ROC. Such agent must meet certain qualifications set by the Ministry of Finance of the ROC
and, upon appointment, become a guarantor of such holder’s ROC tax obligations. Evidence of the appointment of such agent and the approval
for such appointment by the ROC tax authorities would be required as conditions to such holder’s repatriation of the profit derived from the sale
of shares. There can be no assurance that a foreign holder will be able to appoint and obtain approval for the required agent in a timely manner.
Subject to certain exceptions, under current ROC law, upon the repatriation of profits of shares sold within the ROC, the tax agent so appointed
is required to submit evidence of the appointment of the tax agent to, and approval thereof by, the tax authority, or to submit tax clearance
certificates issued by the tax authority. Notwithstanding the above requirements for the appointment of a tax agent or submission of tax clearance
certificates as provided in the ROC regulations, the Central Bank of the ROC has not required submission of such evidence or tax clearance
certificates as condition to repatriation of sale proceeds of shares from sales that take place within the ROC. However, there can be no assurance
that the Central Bank of the ROC will not require submission of such evidence or tax clearance certificates in the future.
F.
Dividends and paying agents.
Not applicable.
G.
Statement by experts.
Not applicable.
H.
Documents on display.
We are subject to the informational requirements of the Exchange Act and are required to file reports and other information with the SEC. The
SEC maintains a website at www.sec.gov that contains reports, proxy and information statements, and other information regarding registrants
that make electronic filings with SEC using its EDGAR system.
165
We are a “foreign private issuer” as such term is defined in Rule 405 under the Securities Act, and are not subject to the same requirements that
are imposed upon U.S. domestic issuers by the SEC. Under the Exchange Act, we are subject to reporting obligations that, in certain respects, are
less detailed and less frequent than those of U.S. domestic reporting companies. As a result, we do not file the same reports that a U.S. domestic
issuer would file with the SEC. We also make available on our website’s investor relations page, free of charge, our annual report and the text of
our reports on Form 6-K, including any amendments to these reports, as well as certain other SEC filings, as soon as reasonably practicable after
they are electronically filed with or furnished to the SEC. The address for our investor relations page is www.aslanpharma.com. The information
contained on our website is not incorporated by reference in this annual report.
I.
Subsidiary Information.
Not applicable.
Item 11.
Quantitative and Qualitative Disclosures About Market Risk.
Our financial risk management objective is to monitor and manage the financial risks relating to our operations. These risks include risks in
financial markets (including currency risk, interest rate risk and other price risk), credit risk and liquidity risk. In order to minimize the effect of
financial risks, we devote time and resources to identifying and evaluating the uncertainty of the financial market to mitigate risk exposures.
Our activities expose us primarily to risks of changes in foreign currency exchange rates, interest rates and other price risks.
A.
Foreign Exchange Risk
We have foreign currency transactions, which expose us to foreign currency risks. The significant financial assets and liabilities denominated in
foreign currencies as of December 31, 2017 were as follows:
Financial assets
Cash and cash equivalents
SG$
1,778,293
0.7482 US$
1,330,600
Foreign
Currencies
December 31, 2017
Exchange
Rate
Carrying
Amount
Financial liabilities
Long-term borrowing
SG$
12,936,189
0.7482 US$
9,679,451
166
A hypothetical rate change of 5% is used when reporting foreign currency risk internally to key management personnel and represents
management’s assessment of the reasonably possible change in foreign exchange rates. Based on outstanding foreign currency-denominated
monetary items, a 5% weakening of the U.S. dollar against the Singapore dollar would result in a $0.4 million increase to net loss and decrease to
equity for the year ended December 31, 2017.
The significant financial assets and liabilities denominated in foreign currencies as of December 31, 2018 were as follows:
Financial assets
Monetary items
SG$
Financial liabilities
Monetary items
SG$
Foreign
Currencies
December 31, 2018
Exchange
Rate
Carrying
Amount
SG$
2,297,231
0.7335 US$
1,685,019
SG$
13,515,737
0.7335 US$
9,914,437
A hypothetical rate change of 5% is used when reporting foreign currency risk internally to key management personnel and represents
management’s assessment of the reasonably possible change in foreign exchange rates. Based on outstanding foreign currency-denominated
monetary items, a 5% weakening of the U.S. dollar against the Singapore dollar would result in a $0.4 million increase to net loss and decrease to
equity for the year ended December 31, 2018.
B.
Interest Rate Risk
We are exposed to interest rate risk because we have historically borrowed and from time to time may borrow funds at both fixed and floating
interest rates. Our interest rate risk was mainly concentrated in the fluctuation of the benchmark interest rates arising from long-term borrowings.
The sensitivity analysis below was determined based on our exposure to interest rates for both derivatives and non-derivative instruments at the
end of the reporting period. For floating rate liabilities, the analysis was prepared assuming the amount of the liability outstanding at the end of
the reporting period was outstanding for the whole year. A hypothetical 100 basis point increase or decrease is used when reporting interest rate
risk internally to key management personnel and represents management’s assessment of the reasonably possible change in interest rates. A 100
basis points increase in interest rates with all other variables held constant would result in a $0.1 million increase to our net loss and decrease to
equity for the years ended December 31, 2017 and for 2018.
167
Item 12. Description of Securities Other than Equity Securities.
A.
Debt Securities.
Not applicable.
B.
Warrants and Rights.
Not applicable.
C.
Other Securities
Not applicable.
D.
American Depositary Shares.
JPMorgan Chase Bank, N.A., or JPMorgan, as depositary bank, registers and delivers our American Depositary Shares, also referred to as ADSs.
Each ADS will represent an ownership interest in a designated number of our ordinary shares which we will deposit with the depositary or the
custodian, as agent of the depositary, under the deposit agreement among ourselves, the depositary and yourself as an ADR holder. In the future,
each ADS will also represent any securities, cash or other property deposited with the depositary but which have not distributed directly to you.
Unless certificated ADRs are specifically requested by you, all ADSs will be issued on the books of our depositary in book-entry form and
periodic statements will be mailed to you which reflect your ownership interest in such ADSs. In our description, references to American
depositary receipts or ADRs shall include the statements you will receive which reflect your ownership of ADSs. The depositary’s office is
located at 4 New York Plaza, Floor 12, New York, NY, 10004. A form of the deposit agreement is incorporated by reference as an exhibit to this
Annual Report.
Fees and Expenses
The depositary may charge each person to whom ADSs are issued, including, without limitation, issuances against deposits of ordinary shares,
issuances in respect of share distributions, rights and other distributions, issuances pursuant to a stock dividend or stock split declared by us or
issuances pursuant to a merger, exchange of securities or any other transaction or event affecting the ADSs or deposited securities, and each
person surrendering ADSs for withdrawal of deposited securities or whose ADRs are cancelled or reduced for any other reason, $5.00 for each
100 ADSs (or any portion thereof) issued, delivered, reduced, cancelled or surrendered, as the case may be. The depositary may sell (by public or
private sale) sufficient securities and property received in respect of a share distribution, rights and/or other distributions prior to such deposit to
pay such charge.
The following additional charges shall be incurred by the ADR holders, by any party depositing or withdrawing shares or by any party
surrendering ADSs and/or to whom ADSs are issued (including, without limitation, issuances pursuant to a stock dividend or stock split declared
by us or an exchange of stock regarding the ADSs or the deposited securities or a distribution of ADSs), whichever is applicable:
•
•
a fee of up to $0.05 per ADS for any cash distribution made pursuant to the deposit agreement;
an aggregate fee of $0.05 per ADS per calendar year (or portion thereof) for services performed by the depositary in administering the
ADRs (which fee may be charged on a periodic basis during
168
each calendar year and shall be assessed against holders of ADRs as of the record date or record dates set by the depositary during
each calendar year and shall be payable in the manner described in the next succeeding provision);
a fee for the reimbursement of such fees, charges and expenses as are incurred by the depositary and/or any of its agents (including,
without limitation, the custodian and expenses incurred on behalf of ADR holders in connection with compliance with foreign
exchange control regulations or any law or regulation relating to foreign investment) in connection with the servicing of the ordinary
shares or other deposited securities, the sale of securities (including, without limitation, deposited securities), the delivery of deposited
securities or otherwise in connection with the depositary’s or its custodian’s compliance with applicable law, rule or regulation (which
fees and charges shall be assessed on a proportionate basis against ADR holders as of the record date or dates set by the depositary and
shall be payable at the sole discretion of the depositary by billing such ADR holders or by deducting such charge from one or more
cash dividends or other cash distributions);
a fee for the distribution of securities (or the sale of securities in connection with a distribution), such fee being in an amount equal to
the $0.05 per ADS issuance fee for the execution and delivery of ADSs which would have been charged as a result of the deposit of
such securities (treating all such securities as if they were ordinary shares) but which securities or the net cash proceeds from the sale
thereof are instead distributed by the depositary to those ADR holders entitled thereto;
stock transfer or other taxes and other governmental charges;
SWIFT, cable, telex and facsimile transmission and delivery charges incurred at your request in connection with the deposit or
delivery of shares, ADRs or deposited securities;
transfer or registration fees for the registration or transfer of deposited securities on any applicable register in connection with the
deposit or withdrawal of deposited securities;
expenses of the depositary in connection with the sale of shares to pay ROC withholdings taxes on stock dividends pursuant to the
deposit agreement (which are paid out of such foreign currency);
in connection with the conversion of foreign currency into U.S. dollars, JPMorgan shall deduct out of such foreign currency the fees,
expenses and other charges charged by it and/or its agent (which may be a division, branch or affiliate) so appointed in connection
with such conversion; and
fees of any division, branch or affiliate of JPMorgan utilized to direct, manage and/or execute any public and/or private sale of
securities under the deposit agreement.
•
•
•
•
•
•
•
•
Certain of the depositary fees and charges described above may become payable immediately after the closing of the initial issuance of ADRs at
or following the date of the deposit agreement. In connection therewith, it is anticipated that the $0.05 per ADS administrative servicing fee per
calendar year described in the second bullet above will be charged to, and payable by, those ADS holders on a record date occurring during the
period immediately after the initial issuance of ADRs following the date of the deposit agreement and prior to the listing approval from the TPEx
with respect to such issuance.
169
As an ADR holder, you will also be responsible to pay any required charges to the Taiwan tax authority, which are subject to change. As of the
date hereof, the charges may include:
Service
Fee
Issuance of ADSs upon a deposit of ordinary shares
0.3% of the aggregate price of ADS issued
Withdrawal of ordinary shares upon cancellation of ADSs
0.3% of the aggregate price of ADS canceled
Sale of ordinary shares on the Taiwan Exchange
3% of the aggregate price of ordinary shares sold
JPMorgan and/or its agent may act as principal for any conversion of foreign currency. For further details see https://www.adr.com.
We will pay all other charges and expenses of the depositary and any agent of the depositary (except the custodian) pursuant to agreements from
time to time between us and the depositary. The charges described above may be amended from time to time by agreement between us and the
depositary. The right of the depositary to receive payment of fees, charges and expenses as provided above shall survive the termination of the
deposit agreement.
The depositary anticipates reimbursing us for certain expenses incurred by us that are related to the establishment and maintenance of the ADR
program upon such terms and conditions as we and the depositary may agree from time to time. The depositary may make available to us a set
amount or a portion of the depositary fees charged in respect of the ADR program or otherwise upon such terms and conditions as we and the
depositary may agree from time to time. The depositary collects its fees for issuance and cancellation of ADSs directly from investors depositing
shares or surrendering ADSs for the purpose of withdrawal or from intermediaries acting for them. The depositary collects fees for making
distributions to investors by deducting those fees from the amounts distributed or by selling a portion of distributable property to pay the fees.
The depositary may collect its annual fee for depositary services by deduction from cash distributions, or by directly billing investors, or by
charging the book-entry system accounts of participants acting for them. The depositary will generally set off the amounts owing from
distributions made to holders of ADSs. If, however, no distribution exists and payment owing is not timely received by the depositary, the
depositary may refuse to provide any further services to holders that have not paid those fees and expenses owing until such fees and expenses
have been paid. At the discretion of the depositary, all fees and charges owing under the deposit agreement are due in advance and/or when
declared owing by the depositary.
Payment of Taxes
If any taxes or other governmental charges (including any penalties and/or interest) shall become payable by or on behalf of the custodian or the
depositary with respect to any ADR, any deposited securities represented by the ADSs evidenced thereby or any distribution thereon, such tax or
other governmental charge shall be paid by the ADR holders to the depositary and by holding or having held an ADR the holder thereof and all
prior holders thereof, jointly and severally, agree to indemnify, defend and save harmless each of the depositary and its agents in respect thereof.
If an ADR holder owes any tax or other governmental charge, the depositary may (i) deduct the amount thereof from any distributions, or (ii) sell
deposited securities (by public or private sale) and deduct the amount owing from the net proceeds of such sale. In either case the ADR holder
remains liable for any shortfall. If any tax or governmental charge is unpaid, the depositary may also refuse to effect any registration, registration
of transfer, split-up
170
or combination of ADRs or withdrawal of deposited securities until such payment is made. If any tax or governmental charge is required to be
withheld on any cash distribution, the depositary may deduct the amount required to be withheld from any cash distribution or, in the case of a
non-cash distribution, sell the distributed property or securities (by public or private sale) in such amounts and in such manner as the depositary
deems necessary and practicable to pay such taxes and shall distribute any remaining net proceeds or the balance of any such property after
deduction of such taxes to the ADR holders entitled thereto.
Notwithstanding the above, we will pay all stamp duties and other similar duties or taxes payable in the Cayman Islands, the ROC, the United
States of America and any other jurisdiction, on or in connection with the constitution and issue of the ADSs and the execution or other event
concerning the deposit agreement. If any legal proceedings are taken to enforce our obligations under the deposit agreement or the ADSs and for
the purpose of such proceedings any of them are required to be taken into or enforced in any jurisdiction and stamp duties or other similar duties
or taxes become payable in connection with such proceedings in such jurisdiction, the ADR holders will pay (or reimburse the person making a
valid payment of) all such stamp duties and other similar duties and taxes, including any penalties and interest, unless otherwise ordered by a
court of competent jurisdiction in such proceedings. The depositary may sell any deposited securities and cancel ADSs with respect thereof in
order to pay any such stamp duties or other similar duties or taxes owed under the deposit agreement by ADR holders without the depositary
being required to request payment thereof from the ADR holders.
By holding an ADR or an interest therein, you will be agreeing to indemnify us, the depositary, its custodian and any of our or their respective
officers, directors, employees, agents and affiliates against, and hold each of them harmless from, any claims by any governmental authority with
respect to taxes, additions to tax, penalties or interest arising out of any refund of taxes, reduced rate of withholding at source or other tax benefit
obtained, and such obligations shall survive the transfer or surrender of ADSs or the termination of the deposit agreement.
Reclassifications, Recapitalizations and Mergers
If we take certain actions that affect the deposited securities, including (i) any change in par value, split-up, consolidation, cancellation or other
reclassification of deposited securities or (ii) any distributions of ordinary shares or other property not made to holders of ADRs or (iii) any
recapitalization, reorganization, merger, consolidation, liquidation, receivership, bankruptcy or sale of all or substantially all of our assets, then
the depositary may choose to, and shall if reasonably requested by us:
(1)
amend the form of ADR;
(2) distribute additional or amended ADRs;
(3) distribute cash, securities or other property it has received in connection with such actions;
(4)
sell by public or private sale any securities or property received; or
(5) none of the above.
If the depositary does not choose any of the above options, any of the cash, securities or other property it receives will constitute part of the
deposited securities and each ADS will then represent a proportionate interest in such property.
171
PART II
Item 13. Defaults, Dividend Arrearages and Delinquencies.
Not applicable.
Item 14. Material Modifications to the Rights of Security Holders and Use of Proceeds.
Not applicable.
Item 15. Controls and Procedures.
A. Disclosure Controls and Procedures.
Our management, with the participation of our Chief Executive Officer and Vice President of Finance, has evaluated the effectiveness of our
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of December 31, 2018. Based on such
evaluation, our Chief Executive Officer and Vice President of Finance have concluded that, as of December 31, 2018, our disclosure controls and
procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is
recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and is accumulated and
communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions
regarding required disclosure.
B. Management’s annual report on internal control over financial reporting.
This annual report does not include a report of management’s assessment regarding internal control over financial reporting due to a transition
period established by rules of the Securities and Exchange Commission for newly public companies.
C. Attestation report of the registered public accounting firm.
This annual report does not include an attestation report of the company’s registered public accounting firm due to a transition period established
by rules of the Securities and Exchange Commission for newly public companies.
D. Changes in internal control over financial reporting.
There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during
the period covered by this Annual Report that has materially affected, or is reasonably likely to materially affect, our internal control over
financial reporting.
Item 16A. Audit committee financial expert.
Our Audit Committee is comprised of three of our non-executive directors, Mr. Howden, Mr. Hoffman and Mr. Sun. The audit committee
consists exclusively of “independent directors” as such term is defined in Rule 10A-3 under the Exchange Act and under the listing standards of
the Nasdaq Stock Market. Mr. Sun serves as chair of this committee. Our Board has determined that Mr. Sun is an “audit committee financial
expert” as defined in Item 16A of Form 20-F.
172
Item 16B. Code of Ethics.
We have adopted a Code of Business Conduct that covers a broad range of matters including the handling of conflicts of interest, compliance
issues and other corporate policies. Our Code of Business Conduct is applicable to all of our employees, officers and directors, including our
principal executive officer, principal financial officer, principal accounting officer or controller, and persons performing similar functions. We
have posted a copy of our Code of Business Conduct on our website at http://ir.aslanpharma.com/corporate-governance/highlights . We expect
that any amendment to this code, or any waivers of its requirements, will be disclosed on our website and approve by board of directors.
Information contained on, or that can be accessed through, our website is not incorporated by reference into this annual report. See “Item 6.C.
Directors, Senior Management and Employees— Code of Business Conduct and Ethics” for more information.
Item 16C. Principal Accountant Fees and Services.
The table below summarizes the fees that we paid for services provided by Deloitte & Touche and its affiliated firms (the “Deloitte Entities”) for
the years ended December 31, 2017 and 2018. All audit and non-audit services provided by Deloitte & Touche were pre-approved by our audit
committee paragraph (c)(7)(i)(C) of Rule 2-01 of Regulation S-X, entitled “Audit Committee Administration of the Engagement”.
Fee Category
Audit fees
Audit-related fees
Tax fees
All other fees
Total
Year Ended December 31,
2018
2017
(in thousands)
$
$
124 $
—
—
—
124 $
404
—
—
—
404
Audit Fees. This category includes the audit of our annual financial statements, review of quarterly financial statements and services that are
normally provided by the independent auditors in connection with statutory and regulatory filings or engagements for those fiscal years. This
category also includes advice on audit and accounting matters that arose during, or as a result of, the audit or the review of quarterly financial
statements and statutory audits required by U.S. jurisdictions and non-U.S. jurisdictions and also IPO service fees occurred in the fiscal year if
applicable.
Audit Committee Pre-Approval Policies and Procedures
Our audit committee reviews and pre-approves the scope and the cost of audit services related to us and permissible non-audit services
performed by the independent auditors, other than those for de minimis services which are approved by the audit committee prior to the
completion of the audit. All of the services related to our company provided by Deloitte & Touche during the last fiscal year have been approved
by the audit committee.
Item 16D. Exemptions from the Listing Standards for Audit Committees.
Not applicable.
173
Item 16E Purchases of Equity Securities by the Issuer and Affiliated Purchasers.
Not applicable.
Item 16F. Change in Registrant’s Certifying Accountant.
Not applicable.
Item 16G. Corporate Governance
We are a “foreign private issuer,” as defined by the SEC. As a result, in accordance with the rules and regulations of The Nasdaq Stock Market
LLC, or Nasdaq, we comply with home country governance requirements and certain exemptions thereunder rather than complying with Nasdaq
corporate governance standards. While we voluntarily follow most Nasdaq corporate governance rules, we may choose to take advantage of the
following exemptions afforded to foreign private issuers:
•
•
•
•
•
•
•
•
•
Exemption from the requirement that a majority of our board of directors consists of independent directors.
Exemption from the requirement that our audit committee have a written charter addressing the audit committee’s responsibilities and
authority as set forth in Nasdaq Rule 5605(c)(1).
Exemption from the requirement that our remuneration committee have a written charter addressing the remuneration committee’s
responsibilities and authority as set forth in Nasdaq Rule 5605(d).
Exemption from the requirement to have independent director oversight of director nominations and a formal written charter or board
resolution addressing the nominations process as set forth in Nasdaq Rule 5605(e).
Exemption from the requirement that we have a code of conduct applicable to all directors, officers and employees and from any
requirement that we have a code of conduct in compliance with Section 406 of the Sarbanes-Oxley Act of 2002.
Exemption from the Nasdaq rules applicable to domestic issuers requiring disclosure within four business days of any determination
to grant a waiver of the code of business conduct and ethics to directors and officers. Although we will require board approval of any
such waiver, we may choose not to disclose the waiver in the manner set forth in the Nasdaq rules, as permitted by the foreign private
issuer exemption.
Exemption from the requirement to obtain shareholder approval for certain issuances of securities, including shareholder approval of
stock option plans.
Exemption from the requirements governing the review and oversight of all “related party transactions,” as defined in Item 7.B of
Form 20-F.
Exemption from the requirement that our board of directors shall have regularly scheduled meetings at which only independent
directors are present as set forth in Nasdaq Rule 5605(b)(2).
174
We intend to follow our home country practices in lieu of the foregoing requirements. Although we may rely on home country corporate
governance practices in lieu of certain of the rules in the Nasdaq Rule 5600 Series and Rule 5250(d), we must comply with Nasdaq’s Notification
of Noncompliance requirement (Rule 5625), the Voting Rights requirement (Rule 5640) and have an audit committee that satisfies Rule 5605(c)
(3), consisting of committee members that meet the independence requirements of Rule 5605(c)(2)(A)(ii). Although we currently intend to
comply with the Nasdaq corporate governance rules applicable other than as noted above, we may in the future decide to use the foreign private
issuer exemption with respect to some or all the other Nasdaq corporate governance rules.
In addition, as a foreign private issuer, we take advantage of the following exemptions from SEC reporting obligations:
•
•
Exemption from filing quarterly reports on Form 10-Q or provide current reports on Form 8-K, disclosing significant events within
four days of their occurrence.
Exemption from Section 16 rules regarding sales of common shares by insiders, which will provide less data in this regard than
shareholders of U.S. companies that are subject to the Exchange Act.
Accordingly, our shareholders will not have the same protections afforded to shareholders of companies that are subject to all of the corporate
governance requirements of Nasdaq and the domestic reporting requirements of the SEC. We may utilize these exemptions for as long as we
continue to qualify as a foreign private issuer.
Item 16H. Mine Safety Disclosure
Not applicable.
PART III
Item 17. Financial Statements.
See pages F-1 through F-44 of this Annual Report on Form 20-F.
Item 18. Financial Statements.
The financial statements are filed as part of this Annual Report beginning on page F-1.
Item 19. Exhibits.
List all exhibits filed as part of the registration statement or annual report, including exhibits incorporated by reference.
175
Exhibit
Description
Incorporated by Reference
Schedule/
Form
File
Number
Exhibit
File
Date
EXHIBIT INDEX
1.1*
2.1
2.2
4.1†
4.2†
4.3†
4.4#
4.5#
4.6#
4.7#
4.8
Sixth Amended and Restated Memorandum and Articles of
Association of the Registrant, as currently in effect.
Form of Deposit Agreement (incorporated by reference to
Exhibit A to the Registrant’s Form F-6 filed with the Securities
and Exchange Commission on April 13, 2018).
Form of American Depositary Receipt (included in Exhibit 2.1)
ASLAN Pharmaceuticals Limited 2014 Employee Share Option
Scheme Plan.
ASLAN Pharmaceuticals Limited 2017 Employee Share Option
Plan 1.
ASLAN Pharmaceuticals Pte. Ltd. 2017 SMT Long Term
Incentive Plan.
License Agreement, dated January 3, 2018, by and between
ASLAN Pharmaceuticals Pte. Ltd. and Array BioPharma Inc.
Amended Development and License Agreement, dated
December 21, 2015, by and between ASLAN Pharmaceuticals
Pte. Ltd. and Almirall, S.A., as amended.
License Agreement, dated May 12, 2014, by and between
ASLAN Pharmaceuticals Pte. Ltd. and CSL Limited, as
amended.
Agreement Amendment No. 1 to License Agreement, dated
September 18, 2018, by and between ASLAN Pharmaceuticals
PTE. Ltd. and CSL Limited.
Tenancy Agreement in Respect of Unit #12-03 83, Clemenceau
Avenue, UE Square, Singapore 239920, dated July 25, 2016, by
and between ASLAN Pharmaceuticals Pte. Ltd. and United
Engineers Limited.
F-6
F-6
F-1
F-1
F-1
F-1
F-1
333-224273
EX-99.A 04/13/2018
333-224273
EX-99.A 04/13/2018
333-223920
10.1
03/26/2018
333-223920
10.2
03/26/2018
333-223920
10.3
03/26/2018
333-223920
10.4
03/26/2018
333-223920
10.5
03/26/2018
F-1
333-223920
10.6
03/26/2018
6-K
001-38475
10.1
01/09/2019
F-1
333-223920
10.8
03/26/2018
4.9†
Form of Indemnity Agreement by and between ASLAN
Pharmaceuticals Limited and each director and executive officer.
F-1/A
333-223920
10.9
04/16/2018
176
4.10*+
4.11*+
8.1*
12.1*
12.2*
13.1**
13.2**
License Agreement, dated February 27, 2019, by and between
ASLAN Pharmaceuticals Pte. Ltd. and BioGenetics Co., Ltd.
License Agreement, dated March 11, 2019, by and between
ASLAN Pharmaceuticals Pte. Ltd. and BioGenetics Co., Ltd.
Subsidiaries of the registrant.
Certification by the Principal Executive Officer pursuant to
Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as
adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002
Certification by the Principal Financial Officer pursuant to
Securities Exchange Act Rules 13a-14(a) and 15d-14(a) as
adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
2002
Certification by the Principal Executive Officer pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002
Certification by the Principal Financial Officer pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002
101.INS* XBRL Instance Document
101.SCH* XBRL Taxonomy Extension Schema Document
101.CAL* XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF* XBRL Taxonomy Extension Definition Linkbase Document
101.LAB* XBRL Taxonomy Extension Label Linkbase Document
101.PRE* XBRL Taxonomy Extension Presentation Linkbase Document
*
**
†
#
+
Filed herewith.
Furnished herewith.
Indicates a management contract or any compensatory plan, contract or arrangement.
Confidential treatment has been granted from the Securities and Exchange Commission as to certain portions of this document.
Certain portions of this exhibit (indicated by “[***]”) have been omitted as the Company has determined (i) the omitted information is not
material and (ii) the omitted information would likely cause harm to the Company if publicly disclosed.
177
SIGNATURES
The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the
undersigned to sign this registration statement Annual Report on its behalf.
Date: April 29, 2019
By:
/s/ Carl Firth, Ph.D.
Carl Firth, Ph.D.
Chief Executive Officer and Chairman
ASLAN PHARMACEUTICALS LIMITED
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheets as of December 31, 2017 and 2018
Consolidated Statements of Comprehensive Loss for the Years Ended December 31, 2016, 2017, and 2018
Consolidated Statements of Changes in Equity for the Years Ended December 31, 2016, 2017, and 2018
Consolidated Statements of Cash Flows for the Years Ended December 31, 2016, 2017, and 2018
Notes to Consolidated Financial Statements for the Years Ended December 31, 2016, 2017, and 2018
F-1
F-2
F-3
F-4
F-5
F-6
F-7
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Shareholders and the Board of Directors of
ASLAN Pharmaceuticals Limited
Opinion on the Financial Statements
We have audited the accompanying consolidated balance sheets of ASLAN Pharmaceuticals Limited (the “Company”) and its subsidiaries
(collectively referred to as the “Group”) as of December 31, 2017 and 2018, and the related consolidated statements of comprehensive loss,
changes in equity and cash flows for each of the three years in the period ended December 31, 2018 and the related notes (collectively referred to
as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Group
as of December 31, 2017 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December
31, 2018, in conformity with International Financial Reporting Standards as issued by the International Accounting Standards Board.
Basis for Opinion
These financial statements are the responsibility of the Group’s management. Our responsibility is to express an opinion on the Group’s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States)
(PCAOB) and are required to be independent with respect to the Group in accordance with the U.S. federal securities laws and the applicable
rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Group is not
required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the
Group’s internal control over financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud,
and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and
disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by
management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for
our opinion.
/s/ Deloitte & Touche
Deloitte & Touche
Taipei, Taiwan
Republic of China
April 29, 2019
We have served as the Group’s auditor since 2014.
F-2
ASLAN PHARMACEUTICALS LIMITED AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
DECEMBER 31, 2017 AND 2018
(In U.S. Dollars)
ASSETS
CURRENT ASSETS
Cash and cash equivalents (Notes 4 and 6)
Prepayments
Total current assets
NON-CURRENT ASSETS
Financial assets at fair value through profit or loss (Notes 4, 7 and 15)
Financial assets at fair value through other comprehensive income (Notes 4, 8 and 15)
Property, plant and equipment (Notes 4 and 9)
Intangible assets (Notes 4, 5, 10 and 15)
Refundable deposits
Total non-current assets
TOTAL ASSETS
LIABILITIES AND EQUITY
CURRENT LIABILITIES
Trade payables
Other payables (Notes 11 and 19)
Total current liabilities
NON-CURRENT LIABILITIES
Long-term borrowings (Note 12)
Other non-current liabilities (Note 19)
Total non-current liabilities
Total liabilities
EQUITY (Note 14)
Ordinary shares
Capital surplus
Accumulated deficits
Total equity
TOTAL LIABILITIES AND EQUITY
The accompanying notes are an integral part of the consolidated financial statements.
F-3
2017
Amount
2018
Amount
50,573,211 $
71,946
50,645,157
—
—
443,566
84,052
160,947
688,565
51,333,722 $
3,898,291 $
2,080,544
5,978,835
9,679,451
162,000
9,841,451
15,820,286
28,908,901
183,599
29,092,500
60,004
187,244
288,418
23,080,592
172,080
23,788,338
52,880,838
5,315,737
2,682,661
7,998,398
13,974,794
289,613
14,264,407
22,262,805
41,514,016
84,282,681
(90,283,261)
35,513,436
51,333,722 $
51,627,219
111,459,672
(132,468,858)
30,618,033
52,880,838
$
$
$
$
ASLAN PHARMACEUTICALS LIMITED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
FOR THE YEARS ENDED DECEMBER 31, 2016, 2017 AND 2018
(In U.S. Dollars)
NET REVENUE (Notes 3, 4, 15 and 24)
COST OF REVENUE (Note 15)
OPERATING EXPENSES (Notes 13, 16 and 19)
General and administrative expenses
Research and development expenses
LOSS FROM OPERATIONS
NON-OPERATING INCOME AND EXPENSES
Interest income
Other income (Note 15)
Other gains and losses (Note 16)
Finance costs (Notes 4 and 16)
Total non-operating income and expenses
LOSS BEFORE INCOME TAX
INCOME TAX EXPENSE (Notes 4, 5 and 17)
NET LOSS FOR THE YEAR
TOTAL COMPREHENSIVE LOSS FOR THE YEAR
LOSS PER SHARE (Note 18)
Basic and diluted
2016
Amount
2017
Amount
2018
Amount
$
11,546,971
(125,000)
$
$
—
—
—
—
(6,956,345)
(13,165,286)
(8,699,660)
47,223
—
127,472
(524,138)
(349,443)
(9,049,103)
—
(9,049,103)
(9,049,103)
$
(8,758,710)
(30,381,016)
(39,139,726)
363,137
—
(698,691)
(416,698)
(752,252)
(39,891,978)
—
(39,891,978)
(39,891,978)
$
(10,513,707)
(31,834,364)
(42,348,071)
268,330
187,244
213,243
(491,904)
176,913
(42,171,158)
(14,439)
(42,185,597)
(42,185,597)
(0.09)
$
(0.32)
$
(0.28)
$
$
The accompanying notes are an integral part of the consolidated financial statements.
F-4
ASLAN PHARMACEUTICALS LIMITED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY
FOR THE YEARS ENDED DECEMBER 31, 2016, 2017 AND 2018
(In U.S. Dollars)
Ordinary Shares (Note 14)
Preference Shares (Note
14)
Capital Surplus (Note 14)
Share
Options
Accumulated
Shares
Amount
Shares
Amount
Ordinary
Shares
Reserve
Total
Deficits
Total Equity
to
BALANCE AT JANUARY 1,
2016
Issuance of preference shares
Conversion to ordinary shares
from preference shares
Adjustment of par value
NT$10 (US$0.6383)
Issuance of new share capital
(Notes 14 and 19)
Recognition of employee share
options by the Company (Note
19)
Net loss for the year ended
December 31, 2016
Total comprehensive loss for the
year ended December 31, 2016
BALANCE AT DECEMBER
31, 2016
Issuance of new share capital
(Notes 14 and 19)
Recognition of employee share
options by the Company (Note
19)
Net loss for the year ended
December 31, 2017
Total comprehensive loss for the
year ended December 31, 2017
BALANCE AT DECEMBER
31, 2017
Issuance of new share capital
(Note 14)
Transaction costs attributable to
the issuance of ordinary shares
Issuance of ordinary shares
under employee share option
plan (Note 19)
Recognition of employee share
options by the Company (Note
19)
Net loss for the year ended
December 31, 2018
Total comprehensive loss for the
year ended December 31, 2018
BALANCE AT DECEMBER
31, 2018
12,775,002 $
—
83,228,794
6,388 73,504,898
9,723,896
—
$
3,296
—
—
—
$ 3,716,905
—
$
3,716,905
—
$ (41,342,180) $ (37,615,591)
—
—
41,614 (83,228,794)
(3,296) 64,557,452
—
64,557,452
—
64,595,770
30,639,655
19,667,144 6,022,409
—
—
—
—
—
—
115,670,940 36,710,066
14,458,000 4,803,950
—
—
—
—
—
—
130,128,940 41,514,016
30,000,000 10,073,977
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
(30,639,655)
—
(30,639,655)
—
—
—
16,201,460
—
16,201,460
—
22,223,869
—
—
—
—
1,419,923
1,419,923
—
1,419,923
—
—
—
—
—
—
(9,049,103)
(9,049,103)
(9,049,103)
(9,049,103)
—
50,119,257
5,136,828
55,256,085
(50,391,283) 41,574,868
—
28,265,033
(8,032) 28,257,001
—
33,060,951
—
—
—
—
—
—
769,595
769,595
—
769,595
—
—
—
(39,891,978) (39,891,978)
—
(39,891,978) (39,891,978)
—
78,384,290
5,898,391
84,282,681
(90,283,261) 35,513,436
—
32,106,023
—
32,106,023
—
42,180,000
—
(5,388,866)
—
(5,388,866)
—
(5,388,866)
120,000
39,226
—
—
41,915
(33,141)
8,774
—
48,000
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
451,060
451,060
—
451,060
—
—
—
(42,185,597) (42,185,597)
—
(42,185,597) (42,185,597)
160,248,940 $ 51,627,219
—
$
—
$ 105,143,362
$ 6,316,310
$ 111,459,672
$ (132,468,858) $ 30,618,033
The accompanying notes are an integral part of the consolidated financial statements.
F-5
ASLAN PHARMACEUTICALS LIMITED AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE YEARS ENDED DECEMBER 31,2016, 2017 AND 2018
(In U.S. Dollars)
CASH FLOWS FROM OPERATING ACTIVITIES
Loss before income tax
Adjustments for:
Depreciation expenses
Amortization expenses
Finance costs
Interest income
Compensation costs of share-based payment transactions
Loss on disposal of property, plant and equipment
Unrealized (gain) loss on foreign exchange, net
Gain on disposal of licensed rights
Changes in operating assets and liabilities
Increase in financial assets mandatorily classified as at fair
value through profit or loss
(Increase) decrease in accounts receivable
(Increase) decrease in prepayments
Increase in trade payables
Increase (decrease) in other payables
Cash used in operations
Interest received
Interest paid
Income tax paid
Net cash used in operating activities
CASH FLOWS FROM INVESTING ACTIVITIES
Payments for property, plant and equipment
Proceeds from disposal of property, plant and equipment
Payments for intangible assets
Increase in refundable deposits
Net cash used in investing activities
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from long-term borrowings
Repayments of long-term borrowings
Issuance of preference shares
Proceeds from new share capital
Proceeds from exercise of employee share options
Payments for transaction costs attributable to the issuance of
ordinary shares
Net cash generated from financing activities
NET INCREASE (DECREASE) IN CASH AND CASH
EQUIVALENTS
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF
THE YEAR
CASH AND CASH EQUIVALENTS AT THE END OF
THE YEAR
2016
2017
2018
$
(9,049,103) $
(39,891,978) $
(42,171,158)
65,874
10,010
524,138
(47,223)
1,419,923
12,316
(206,334)
—
—
(1,294,034)
(52,034)
2,129,760
688,372
(5,798,335)
47,223
(38,036)
—
(5,789,148)
(374,425)
632
(81,209)
(68,474)
(523,476)
—
(376,968)
9,140,462
22,223,869
—
—
30,987,363
200,918
9,058
416,698
(363,137)
1,126,595
31,337
698,608
—
—
1,294,034
17,636
1,621,449
358,787
(34,479,995)
363,137
—
—
(34,116,858)
(291,432)
—
(8,844)
(36,168)
(336,444)
228,514
—
33,060,951
—
—
33,289,465
235,410
6,355
491,904
(268,330)
1,289,737
—
(256,918)
(187,244)
(60,004)
—
(111,653)
1,417,446
(108,947)
(39,723,402)
268,330
(14,439)
(39,469,511)
(80,262)
(23,002,895)
(11,133)
(23,094,290)
4,060,357
—
42,180,000
48,000
(5,388,866)
40,899,491
24,674,739
(1,163,837)
(21,664,310)
27,062,309
51,737,048
50,573,211
$
51,737,048 $
50,573,211 $
28,908,901
The accompanying notes are an integral part of the consolidated financial statements.
F-6
ASLAN PHARMACEUTICALS LIMITED AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
FOR THE YEARS ENDED DECEMBER 31, 2016, 2017 AND 2018
(In U.S. Dollars, Unless Stated Otherwise)
1.
GENERAL INFORMATION
ASLAN Pharmaceuticals Limited (the “Company”) was incorporated in the Cayman Islands in June 2014 as the listing vehicle for the
initial public offering and listing on the Taipei Exchange (“TPEx”) in Taiwan. The Company and its subsidiaries (collectively referred to
as the “Group”) are principally engaged in the development of novel drugs for Asia prevalent cancers.
The main businesses and intragroup relationships of the Group were as follows as of December 31, 2018:
Name
Place of Incorporation
Date of
Incorporation
ASLAN Pharmaceuticals Limited
ASLAN Pharmaceuticals Pte. Ltd.
Cayman Islands
Singapore
June 2014
April 2010
Main Business
Investment holding
New drug research and
development
ASLAN Pharmaceuticals Taiwan Limited
Taiwan
November 2013
New drug research and
ASLAN Pharmaceuticals Australia Pty Ltd.
Australia
ASLAN Pharmaceuticals Hong Kong Limited
Hong Kong
July 2014
July 2015
development
New drug research and
development
New drug research and
development
ASLAN Pharmaceuticals (Shanghai) Co. Ltd.
China
May 2016
New drug research and
ASLAN Pharmaceuticals (USA) Inc.
United States of
October 2018
New drug research and
America
development
development
F-7
Following the approval of the Company’s shareholders at a shareholders’ meeting on May 27, 2016, the Company completed a
restructuring of its share capital through the subdivision of the Company’s authorized share capital, the conversion of preference shares
into ordinary shares, and the repurchase of its USD shares in consideration for the issue of an equal number of NTD shares for the purpose
of the initial public offering and listing of the Company’s ordinary shares on the TPEx. On January 5, 2017, the General Stock Board
Applicant Committee of the General Stock Board (Market) of the TPEx approved the Company’s application for listing on the TPEx.
On January 20, 2017, the 8th session 22nd meeting of the board and supervisors of the TPEx passed a resolution, pursuant to which the
Company’s shares began trading on the TPEx on June 1, 2017. In addition, the Company’s American Depository Shares (“ADSs”)
representing ordinary shares have been listed on the Nasdaq Global Market since May 4, 2018.
The reporting currency of the Group is the U.S. dollar. The functional currency of the majority of the Group’s entities is the U.S. dollar.
2.
APPROVAL OF FINANCIAL STATEMENTS
The consolidated financial statements were approved by the board of directors on April 26, 2019.
3.
APPLICATION OF NEW, AMENDED AND REVISED STANDARDS AND INTERPRETATIONS
a.
Amendments to the International Financial Reporting Standards (“IFRS”) issued by the International Accounting Standards Board
(“IASB”) mandatorily effective for the current year
The Company has applied the amendments to IFRSs included in IFRS 9 “Financial Instruments”, IFRS 15 “Revenue from Contracts
with Customers”, Amendment to IFRS 2 “Classification and Measurement of Share-based Payment Transactions”, Amendments to
IAS 40 “Transfers of Investment Property”, Annual Improvement to IFRSs 2014-2016 Cycle, and IFRIC 22 “Foreign Currency
Transactions and Advance Consideration” for the annual period that began on or after January 1, 2018.
The adoption and impact of these standards from January 1, 2018 are described as below and the new accounting policies are
disclosed in Note 4. The other standards did not have material impact on the Group’s accounting policies.
IFRS 15 “Revenue from Contracts with Customers” and related amendments
IFRS 15 establishes principles for recognizing revenue that apply to all contracts with customers and supersedes IAS 18 “Revenue”,
IAS 11 “Construction Contracts” and a number of revenue-related interpretations.
Under IFRS 15, the Group recognizes revenue when (or as) a performance obligation is satisfied, i.e. when “control” of the goods or
services underlying the particular performance obligation is transferred to the customer. Prior to the application of IFRS 15, the
Group recognized revenue when the Group transferred the significant risks and rewards of ownership to the buyer.
IFRS 15 provides guidance to clarify the categorization of licenses of intellectual property and on whether revenue is to be
recognized over time or at a point in time. Under IFRS 15, when the nature of the Group’s promise in granting a license is to provide
a right to access the Group’s intellectual property, revenue is recognized over time if all of the following criteria are met. Otherwise,
the promise is to provide a right to use the Group’s intellectual property as it exists at the point in time at which the license is granted
and revenue is recognized when the license is transferred.
F-8
1)
2)
3)
The contract requires, or the customer reasonably expects, the Group to undertake activities that significantly affect the
intellectual property to which the customer has rights.
The rights granted by the license directly expose the customer to any positive or negative effects of the above activities.
Those activities do not result in the transfer of a good or a service to the customer as the activities occur.
Prior to the application of IFRS 15, license fees and royalties paid for the use of the Group’s assets are normally recognized in
accordance with the substance of the agreement. An assignment of rights for a fixed fee or non-refundable guarantee under a non-
cancellable contract which permits the licensee to exploit those rights freely and the Group has no remaining obligations to perform
is, in substance, a sale. In such cases, revenue is recognized at the time of sale. Otherwise, revenue is recognized on a straight-line
basis over the life of the agreement. In some cases, whether or not a license fee or royalty will be received is contingent on the
occurrence of a future event. In such cases, revenue is recognized only when it is probable that the license fee or royalty will be
received, which is normally when the event has occurred.
The Group elected only to retrospectively apply IFRS 15 to contracts that were not complete as of January 1, 2018. The Group had
no cumulative effect of retrospectively applying IFRS 15 in the retained earnings on January 1, 2018, and the Group does not have
any revenue from contracts with customers that are within scope of IFRS 15 in 2018.
b. New and revised IFRSs issued but not yet effective
Of the new, amended and revised standards and interpretations (collectively the “New IFRSs”) that have been issued but are not yet
effective, the Company has not applied the following.
New, Amended or Revised Standards and Interpretations
Effective Date
Announced by IASB (Note 1)
Annual Improvements to IFRSs 2015-2017 Cycle
Amendments to IFRS 9 “Prepayment Features with Negative Compensation”
IFRS 16 “Leases”
Amendments to IAS 19 “Plan Amendment, Curtailment or Settlement”
Amendments to IAS 28 “Long-term Interests in Associates and Joint Ventures”
IFRIC 23 “Uncertainty over Income Tax Treatments”
Amendments to IFRS 3 “Definition of a Business”
Amendments to IFRS 10 and IAS 28 “Sale or Contribution of Assets between An
Investor and Its Associate or Joint Venture”
IFRS 17 “Insurance Contracts”
Amendments to IAS 1 and IAS 8 “Definition of Material”
January 1, 2019
January 1, 2019
January 1, 2019
January 1, 2019 (Note 2)
January 1, 2019
January 1, 2019
January 1, 2020 (Note 3)
To be determined by IASB
January 1, 2021
January 1, 2020 (Note 4)
Note 1:Unless stated otherwise, the above New IFRSs are effective for annual periods beginning on or after their respective effective
dates.
Note 2:The Group shall apply these amendments to plan amendments, curtailments or settlements occurring on or after January 1,
2019.
F-9
Note 3:The Group shall apply these amendments to business combinations for which the acquisition date is on or after the beginning
of the first annual reporting period beginning on or after January 1, 2020 and to asset acquisitions that occur on or after the
beginning of that period.
Note 4:The Group shall apply these amendments prospectively for annual reporting periods beginning on or after January 1, 2020.
The initial application of the above New IFRSs, whenever applied, would not have any material impact on the Group’s accounting
policies, except for the following:
IFRS 16 “Leases”
IFRS 16 sets out the accounting standards for leases that will supersede IAS 17, IFRIC 4 and a number of related interpretations.
Definition of a lease
Upon initial application of IFRS 16, the Group will elect to apply the guidance of IFRS 16 in determining whether contracts are, or
contain, a lease only to contracts entered into (or changed) on or after January 1, 2019. Contracts identified as containing a lease
under IAS 17 and IFRIC 4 will not be reassessed and will be accounted for in accordance with the transitional provisions under IFRS
16.
The Group as lessee
Upon initial application of IFRS 16, the Group will recognize right-of-use assets and lease liabilities for all leases on the consolidated
balance sheets except for those whose payments under low-value and short-term leases will be recognized as expenses on a straight-
line basis. On the consolidated statements of comprehensive income, the Group will present the depreciation expense charged on
right-of-use assets separately from the interest expense accrued on lease liabilities; interest is computed using the effective interest
method. On the consolidated statements of cash flows, cash payments for the principal portion of lease liabilities will be classified
within financing activities; cash payments for the interest portion will be classified within operating activities. Currently, payments
under operating lease contracts are recognized as expenses on a straight-line basis. Cash flows for operating leases are classified
within operating activities on the consolidated statements of cash flows.
The Group anticipates applying IFRS 16 retrospectively with the cumulative effect of the initial application of this standard
recognized on January 1, 2019. Comparative information will not be restated.
Lease liabilities will be recognized on January 1, 2019 for leases currently classified as operating leases with the application of IAS
17. Lease liabilities will be measured at the present value of the remaining lease payments, discounted using the lessee’s incremental
borrowing rate on January 1, 2019. Right-of-use assets will be measured at an amount equal to the lease liabilities. The Group will
apply IAS 36 to all right-of-use assets.
The Group expects to apply the following practical expedients:
a)
b)
The Group will apply a single discount rate to the leases with reasonably similar characteristics to measure lease liabilities.
The Group will account for those leases for which the lease term ends on or before December 31, 2019 as short-term leases.
F-10
c)
d)
The Group will exclude initial direct costs from the measurement of right-of-use assets on January 1, 2019.
The Group will use hindsight, such as in determining lease terms, to measure lease liabilities.
Anticipated impact on assets and liabilities
Total effect on assets (right-of-use assets)
Lease liabilities - current
Lease liabilities - non-current
Total effect on liabilities
Carrying
Amount as
of December
31, 2018
Adjustments
Arising from
Initial
Application
$
$
$
— $
— $
— $
$
323,850 $
219,039 $
104,811 $
323,850
Adjusted
Carrying
Amount as
of January
1, 2019
323,850
219,039
104,811
Except for the above impact, as of the date the consolidated financial statements were authorized for issue, the Group is continuously
assessing the possible impact that the application of other standards and interpretations will have on the Group’s financial position
and financial performance and will disclose the relevant impact when the assessment is completed.
4.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
a.
Statement of compliance
The accompanying consolidated financial statements have been prepared in conformity with IFRSs issued by the IASB.
b.
Basis of preparation
The consolidated financial statements have been prepared on the historical cost basis except for financial instruments and other
payable arising from cash-settled share-based payment arrangements which are measured at fair value.
The preparation of these consolidated financial statements in conformity with IFRSs requires management to exercise its judgment in
the process of applying the Group’s accounting policies. It also requires the use of certain critical accounting estimates and
assumptions. The areas involving a higher degree of judgment or complexity, or areas where estimates and assumptions are
significant to the consolidated financial statements, are disclosed in Note 5.
c.
Classification of current and non-current assets and liabilities
Current assets include:
1) Assets held primarily for the purpose of trading;
2) Assets expected to be realized within 12 months after the reporting period; and
3)
Cash and cash equivalents unless the asset is restricted from being exchanged or used to settle a liability for at least 12
months after the reporting period.
Current liabilities include:
1)
Liabilities held primarily for the purpose of trading;
F-11
2)
3)
Liabilities due to be settled within 12 months after the reporting period; and
Liabilities for which the Group does not have an unconditional right to defer settlement for at least 12 months after the
reporting period.
Assets and liabilities that are not classified as current are classified as non-current.
d.
Basis of consolidation
The consolidated financial statements include the financial statements of the Company and its subsidiaries. All intragroup
transactions, balances, income and expenses are eliminated in full upon consolidation.
e.
Foreign currencies
The reporting currency of the Group is the U.S. dollar. The functional currency of the majority of the Group’s entities is the U.S.
dollar.
Monetary assets and liabilities denominated in currencies other than the applicable functional currencies are translated into the
functional currencies at the prevailing rates of exchange at the balance sheet date. Nonmonetary assets and liabilities are remeasured
into the applicable functional currencies at historical exchange rates. Transactions in currencies other than the applicable functional
currencies during the year are converted into the functional currencies at the applicable rates of exchange prevailing at the dates of
the transactions. Exchange differences are recognized in “other gains and losses, net” in the consolidated statement of comprehensive
loss.
f.
Property, plant and equipment
Property, plant and equipment are stated at cost, less recognized accumulated depreciation and accumulated impairment loss.
Depreciation is recognized using the straight-line method. Each significant part is depreciated separately. The estimated useful lives,
residual values and depreciation methods are reviewed at the end of each reporting period, with the effect of any changes in estimates
accounted for on a prospective basis.
Any gain or loss arising on the disposal or retirement of an item of property, plant and equipment is determined as the difference
between the sales proceeds and the carrying amount of the respective asset and is recognized in the consolidated statement of
comprehensive loss.
g.
Intangible assets
1)
Intangible assets acquired separately
Intangible assets with finite useful lives that are acquired separately are initially measured at cost and subsequently measured at
cost, less accumulated amortization and accumulated impairment loss. Amortization is recognized on a straight-line basis. The
estimated useful lives, residual values, and amortization methods are reviewed at the end of each reporting period, with the
effect of any changes in estimates accounted for on a prospective basis. Intangible assets with indefinite useful lives that are
acquired separately are measured at cost, less accumulated impairment loss.
2)
Internally-generated intangible assets - research and development expenditures
F-12
Expenditure on research activities is recognized as an expense in the period in which it is incurred.
An internally-generated intangible asset arising from the development phase of an internal project is recognized only if all of
the following have been demonstrated:
a)
b)
c)
d)
e)
The technical feasibility of completing the intangible asset so that it will be available for use or sale;
The intention to complete the intangible asset and use or sell it;
The ability to use or sell the intangible asset;
The manner in which intangible asset will generate probable future economic benefits;
The availability of adequate technical, financial and other resources to complete the development and to use or sell the
intangible asset; and
f)
The ability to measure reliably the expenditure attributable to the intangible asset during its development.
The amount initially recognized for internally-generated intangible assets is the sum of the expenditure incurred from the date
when an intangible asset first meets the recognition criteria listed above. Subsequent to initial recognition, they are measured on
the same basis as intangible assets that are acquired separately.
3) Derecognition of intangible assets
On derecognition of an intangible asset, the difference between the net disposal proceeds and the carrying amount of the asset is
recognized in profit or loss.
h.
Impairment of tangible and intangible assets
At the end of each reporting period, the Group reviews the carrying amounts of its tangible and intangible assets in order to
determine whether there is any indication that those assets have suffered any impairment loss. If any such indication exists, the
recoverable amount of an asset is estimated in order to determine the extent of the impairment loss. When it is not possible to
estimate the recoverable amount of an individual asset, the Group estimates the recoverable amount of the cash-generating unit to
which the asset belongs.
Intangible assets with indefinite useful lives and intangible assets not yet available for use are not subject to amortization, but are
tested annually for impairment or more frequently if there are indicators of impairment. In respect of the impairment indicators, the
Group considers both internal and external sources of information to determine whether an asset may be impaired, which may
include the significant underperformance of the business in relation to expectations, significant negative industry or economic trends,
and significant changes or planned changes with adverse effects in the use of the assets, as well as the internal reporting which
indicates the economic performance of an asset is worse than expected. If any such indicators exist, the Group will estimate the
recoverable amount of such indefinite-lived intangible asset and compare it with its carrying amount. The recoverable amount is the
higher of fair value, less costs to sell and value in use. If the recoverable amount of an asset or cash-generating unit is estimated to be
less than its carrying amount, the carrying amount of the asset or cash-generating unit is reduced to its recoverable amount, with the
resulting impairment loss recognized in profit or loss.
An impairment loss recognized in prior periods shall be reversed if, and only if, there has been a change in the estimates used to
determine the recoverable amount since the last impairment loss was recognized. When an impairment loss is subsequently reversed,
the carrying amount of the corresponding asset or cash-generating unit is increased to the revised
F-13
estimate of its recoverable amount, but only to the extent of the carrying amount that would have been determined had no impairment
loss been recognized on the asset or cash-generating unit in prior years. A reversal of an impairment loss is recognized in the
consolidated statement of comprehensive loss.
i.
Financial instruments
Financial assets and financial liabilities are recognized when a group entity becomes a party to the contractual provisions of the
instruments.
Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the
acquisition or issuance of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value
through profit or loss (i.e., FVTPL)) are added to or deducted from the fair value of the financial assets or financial liabilities, as
appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at
FVTPL are recognized immediately in profit or loss.
1)
Financial assets
All regular way purchases or sales of financial assets are recognized and derecognized on a trade date basis.
a) Measurement categories
2017 (prior to adoption of IFRS 9)
Financial assets are classified into the following categories: Financial assets at FVTPL, held-to-maturity investments,
available-for-sale financial assets and loans and receivables. Financial assets held by the Group in 2017 are classified as
loans and receivables.
Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an
active market. Loans and receivables (including cash and cash equivalents and refundable deposits) are measured using the
effective interest method at amortized cost less any impairment.
Cash equivalents include highly liquid investments which are readily convertible to a known amount of cash and subject to
an insignificant risk of change in value.
2018 (after adoption of IFRS 9)
Financial assets are classified into the following categories: Financial assets at FVTPL, financial assets at amortized cost
and equity instruments at fair value through other comprehensive income (i.e., FVTOCI).
i.
Financial assets at FVTPL
Derivative financial assets are classified as at FVTPL when such a financial asset is mandatorily classified as at
FVTPL.
F-14
Financial assets at FVTPL are subsequently measured at fair value, with any gains or losses arising on
remeasurement recognized in profit or loss. The net gain or loss recognized in profit or loss incorporates any
dividends or interest earned on such a financial asset. Fair value is determined in the manner described in Note 22.
ii.
Financial assets at amortized cost
A financial asset shall be measured at amortized cost if both of the following conditions are met:
i)
ii)
The financial asset is held within a business model whose objective is to hold financial assets in order to collect
contractual cash flows; and
The contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of
principal and interest on the principal amount outstanding.
For the financial assets measured at amortized cost (including cash and cash equivalents and refundable deposits),
the Group applies the effective interest method to the gross carrying amount at amortized cost less any impairment
from initial recognition. Any foreign exchange gains and losses are recognized in profit or loss.
Interest income is calculated by applying the effective interest rate to the gross carrying amount of such a financial
asset.
Cash equivalents include time deposits, which are highly liquid, readily convertible to a known amount of cash and
are subject to an insignificant risk of changes in value. These cash equivalents are held for the purpose of meeting
short-term cash commitments.
iii.
Investments in equity instruments at FVTOCI
On initial recognition, the Group may make an irrevocable election to designate investments in equity instruments as
at FVTOCI. Designation as at FVTOCI is not permitted if the equity investment is held for trading or if it is
contingent consideration recognized by an acquirer in a business combination.
Investments in equity instruments at FVTOCI are subsequently measured at fair value with gains and losses arising
from changes in fair value recognized in other comprehensive income and accumulated in other equity. The
cumulative gain or loss will not be reclassified to profit or loss on disposal of the equity investments; instead, it will
be transferred to retained earnings.
Dividends on these investments in equity instruments are recognized in profit or loss when the Group’s right to
receive the dividends is established, unless the dividends clearly represent a recovery of part of the cost of the
investment.
b)
Impairment of financial assets
2017
Financial assets, other than those at fair value through profit or loss, are assessed for indicators of impairment at the end of
each reporting period. Financial assets are considered to be impaired when there is objective evidence that, as a result of
one or more events that occurred after the initial recognition of the financial assets, the estimated future cash flows of the
investment have been affected.
F-15
For financial assets measured at amortized cost, such as accounts receivable, assets are assessed for impairment on a
collective basis even if they were assessed not to be impaired individually.
For a financial asset measured at amortized cost, the amount of the impairment loss recognized is the difference between
the asset’s carrying amount and the present value of estimated future cash flows, discounted at the financial asset’s original
effective interest rate.
For financial assets measured at amortized cost, if, in a subsequent period, the amount of the impairment loss decreases
and the decrease can be related objectively to an event occurring after the impairment was recognized, the previously
recognized impairment loss is reversed through profit or loss to the extent that the carrying amount of the investment (at
the date the impairment is reversed) does not exceed what the amortized cost would have been had the impairment not
been recognized.
For all other financial assets, objective evidence of impairment could include significant financial difficulty of the issuer
or counterparty, breach of contract, such as a default or delinquency in interest or principal payments, and if it becomes
probable that the borrower will enter bankruptcy or financial re-organization.
The carrying amount of a financial asset is reduced by the impairment loss directly for all financial assets, with the
exception of accounts receivable and other receivables where the carrying amount is reduced through the use of an
allowance account. When accounts receivable and other receivables are considered uncollectible, they are written off
against the allowance account. Subsequent recoveries of amounts previously written off are credited against the allowance
account. Except for uncollectible trade receivables and other receivables that are written off against the allowance account,
changes in the carrying amount of the allowance account are recognized in profit or loss.
2018
The Group recognizes a loss allowance for expected credit losses on financial assets at amortized cost.
For financial instruments, the Group recognizes lifetime expected credit losses (i.e., ECLs) when there has been a
significant increase in credit risk since initial recognition. If, on the other hand, the credit risk on a financial instrument has
not increased significantly since initial recognition, the Group measures the loss allowance for that financial instrument at
an amount equal to 12-month ECLs.
Expected credit losses reflect the weighted average of credit losses with the respective risks of default occurring as the
weights. Lifetime ECLs represent the expected credit losses that will result from all possible default events over the
expected life of a financial instrument. In contrast, 12-month ECLs represent the portion of lifetime ECLs that is expected
to result from default events on a financial instrument that are possible within 12 months after the reporting date.
The Group recognizes an impairment gain or loss in profit or loss for all financial instruments with a corresponding
adjustment to their carrying amount through a loss allowance account.
F-16
c) Derecognition of financial assets
The Group derecognizes a financial asset only when the contractual rights to the cash flows from the asset expire or when
it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another party.
Before 2018, on derecognition of a financial asset in its entirety, the difference between the asset’s carrying amount and
the sum of the consideration received and receivable and the cumulative gain or loss which had been recognized in other
comprehensive income is recognized in profit or loss. Starting from 2018, on derecognition of a financial asset at
amortized cost in its entirety, the difference between the asset’s carrying amount and the sum of the consideration received
and receivable is recognized in profit or loss. On derecognition of an investment in an equity instrument at FVTOCI, the
difference between the asset’s carrying amount and the sum of the consideration received and receivable is recognized in
profit or loss, and the cumulative gain or loss which had been recognized in other comprehensive income is transferred
directly to retained earnings, without recycling through profit or loss.
2)
Equity instruments
Equity instruments issued by a group entity are classified as equity in accordance with the substance of the contractual
arrangements and the definitions of an equity instrument.
Equity instruments issued by a group entity are recognized at the proceeds received, net of direct issue costs.
No gain or loss is recognized in profit or loss on the issuance of the Company’s own equity instruments.
3)
Financial liabilities
a)
Subsequent measurement
All financial liabilities are measured at amortized cost using the effective interest method.
b) Derecognition of financial liabilities
The difference between the carrying amount of a financial liability derecognized and the consideration paid, including any
non-cash assets transferred or liabilities assumed, is recognized in profit or loss.
j.
Revenue recognition
2017
Revenue comprises the fair value of the consideration received or receivable for the out-licensing of experimental drugs that have
reached ‘proof of concept’ to customers for ongoing global development and launch, in the ordinary course of the Group’s activities.
Revenue is presented, net of goods and services tax, rebates and discounts. See Note 15 for details of the Group’s licensing
agreements.
The Group recognizes revenue when the Group has completed the out-licensing of the experimental drug to the customers, the
customers have accepted the products and the collectability of the related receivables is reasonably assured.
F-17
Typically income from out-licensing may take the form of upfront fees, milestones and/or sales royalties. Revenue is recognized
upon the receipt of the non-refundable upfront payment if the license of intellectual property has stand-alone value and the Group has
no remaining, subsequent performance obligation in accordance with the licensing agreements. Otherwise, revenue recognition is
deferred and spread over the period of performance on a straight-line basis. Milestone payments which are contingent on achieving
certain clinical milestones are recognized as revenues either on achievement of such milestones, or over the period of the
performance obligation if the Group has continuing performance obligations. Royalties on marketed drugs, which are recognized as
revenue on an accrual basis and in accordance with the substance of the contracts, are recognized when it is probable that the
economic benefits of a transaction will flow to the Group and the revenue can be measured reliably.
Revenue from the sale of research material is recognized when all the following conditions are satisfied:
1)
2)
3)
4)
5)
The Group has transferred the significant risks and rewards of the research material to the buyer;
The Group retains neither continuing managerial involvement to the degree usually associated with ownership nor effective
control over the research material sold;
The amount of revenue can be measured reliably;
It is probable that the economic benefits will flow to the Group; and
The costs incurred or to be incurred can be measured reliably.
Interest income is primarily a result of deposits in banks and is recognized as non-operating income when it is probable that the
economic benefits will flow to the Group and the amount of income can be measured reliably. Interest income is accrued on a time
basis, by reference to the principal outstanding and at the applicable effective interest rate.
2018
Revenue comprises the fair value of the consideration received or receivable for the out-licensing of experimental drugs that have
reached ‘proof of concept’ to business partners for ongoing global development and launch, in the ordinary course of our activities.
Revenue is presented, net of goods and services tax, rebates and discounts. See Note 15 for details of the Group’s licensing
agreements.
The group recognizes revenue when it has completed the out-licensing of the experimental drug to business partners, and such
partners have accepted the products, and the collectability of the related receivables is reasonably assured.
Typically the consideration received from out-licensing may take the form of upfront payments, option payments, milestone
payments, and royalty payments on licensed products. To determine revenue recognition for contracts with customers, the Group
performs the following five steps:
1)
2)
Identify the contract with a customer;
Identify the performance obligations in the contract;
3) Determine the transaction price;
4) Allocate the transaction price to the performance obligations in the contract; and
5)
Recognize revenue when (or as) the group satisfies the performance obligations.
F-18
At the inception of a contract, the Group assesses the goods or services promised within each contract to determine whether each
promised good or service is distinct and identify those that are performance obligations. The Group recognizes as revenue the amount
of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.
Upfront License Fees
If a license to the Group’s intellectual property is determined to be distinct from the other performance obligations identified in the
arrangement, the Group will recognize revenues from non-refundable, upfront fees allocated to the license when the license is
transferred to the licensee and the licensee is able to use and benefit from the license. Licenses that are not distinct shall be bundled
with other performance obligations until it identifies a bundle of performance obligations that is distinct. The Group uses judgment to
assess the nature of the combined performance obligation to determine whether it is satisfied over time or at a point in time and, if
over time, the appropriate method of measuring progress for purposes of recognizing revenue. The Group evaluates the measure of
progress at the end of each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
Milestone Payments
At the inception of each contract with customers that includes development or regulatory milestone payments (i.e., the variable
consideration), the Group includes some or all amount of variable consideration in the transaction price estimated only to the extent
that it is highly probable that a significant reversal in the amount of cumulative revenue recognized would not occur when the
uncertainty related to the variable consideration is subsequently resolved. Milestone payments that are contingent upon the
achievement of events that are uncertain or not controllable, such as regulatory approvals, are generally not considered highly
probable of being achieved until those approvals are received. Therefore, they are not included in the transaction price. At the end of
each reporting period, the Group evaluates the probability of achievement of such milestone payments and any related constraints,
and if necessary, adjusts our estimate of the overall transaction price.
Royalties
For arrangements that include sales-based royalties, including commercial milestone payments based on the level of sales, and for
which the license is deemed to be the predominant item to which the royalties relate, the Group recognizes revenue at the later of the
following:
1) when the subsequent sales occur, or
2) when the performance obligation, to which some or all of the royalty has been allocated, has been satisfied (or partially
satisfied).
To date, the group has not recognized any royalty revenue resulting from any of out-licensing arrangements.
k.
Research and development expenses
Elements of research and development expenses primarily include:
1)
payroll and other related costs of personnel engaged in research and development activities;
F-19
2)
3)
4)
costs related to preclinical testing of the Group’s technologies under development and clinical trials, such as payments to
contract research organizations (“CROs”), investigators and clinical trial sites that conduct the Group’s clinical studies;
costs to develop the product candidates, including raw materials, supplies and product testing related expenses; and
other research and development expenses.
Research and development expenses are expensed as incurred when these expenditures relate to the Group’s research and
development services and have no alternative future uses. The conditions enabling the capitalization of development costs as an asset
have not yet been met and, therefore, all development expenditures are recognized in profit or loss when incurred.
l.
Leasing
Leases are classified as finance leases whenever the terms of a lease transfer substantially all the risks and rewards of ownership to
the lessee. All other leases are classified as operating leases.
The Group as lessee
Operating lease payments are recognized as expenses on a straight-line basis over the lease term.
m. Retirement benefits
Payments to defined contribution retirement benefit plans are recognized as expenses when employees have rendered services
entitling them to the contributions.
n.
Share-based payment arrangements
Equity-settled share-based payments to employees are measured at the fair value of the equity instruments at the grant date.
The fair value determined at the grant date of the employee share options is expensed on a straight-line basis over the vesting period,
based on the Group’s estimate of the number of employee share options that will eventually vest, with a corresponding increase in
“capital surplus - employee share options”. The fair value determined at the grant date of the employee share options is recognized as
an expense in full at the grant date when the share options granted vest immediately.
At the end of each reporting period, the Group revises its estimate of the number of employee share options expected to vest. The
impact of the revision of the original estimates is recognized in profit or loss such that the cumulative expense reflects the revised
estimate, with a corresponding adjustment to the capital surplus.
The fair value of the amount payable to beneficiaries in respect of bonus entitlement unit grants, which are settled in cash, is
recognized as an expense with a corresponding increase in liabilities, over the period during which the beneficiaries become
unconditionally entitled to payment. The amount is remeasured at each reporting date and at settlement based on the fair value of the
bonus entitlement units. Any changes in the liability are recognized in profit or loss.
F-20
o.
Taxation
The provision for income tax recognized in profit or loss comprises current and deferred tax. Current tax is income tax paid and
payable for the current year based on the taxable profit of the year and any adjustments to tax payable (or receivable) in respect of
prior years. Deferred tax is accounted for using the balance sheet liability method in respect of temporary differences arising from
differences between the carrying amount of assets and liabilities in the financial statements and the corresponding tax basis used in
the computation of taxable profit or loss. Deferred tax assets are recognized to the extent that it is probable that future taxable profits
will be available against which the temporary differences can be utilized. The carrying amount is reviewed at the end of each
reporting period on the same basis. Deferred tax is measured at the tax rates that are expected to apply in the period in which the
asset or liability is settled, based on tax rates that have been enacted or substantively enacted by the end of the reporting period.
5.
CRITICAL ACCOUNTING JUDGMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY
In the application of the Group’s accounting policies, management is required to make judgments, estimates and assumptions about the
carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are
based on historical experience and other factors that are considered relevant. Actual results may differ from these estimates.
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the
period in which the estimates are revised if the revisions affect only that period or in the period of the revisions and future periods if the
revisions affect both current and future periods.
a.
Income tax
No deferred tax assets have been recognized on tax losses due to the unpredictability of future profit streams. The realizability of
deferred tax assets mainly depends on whether sufficient future profit or taxable temporary differences will be available. In cases
where the actual future profit generated is different from expected, a material adjustment of deferred tax assets may arise, which
would be recognized in profit or loss for the period in which such adjustment takes place.
b.
Impairment of intangible assets
Intangible assets with indefinite useful lives are tested for impairment annually and whenever an indicator of impairment exists. The
Group assesses whether there is an indication of impairment based on internal and external information, including the progress of
research and development project and the prospect of such technology. Determining whether an intangible asset is impaired requires
an estimation of the recoverable amount and a comparison with the carrying amount. The calculation of the recoverable amount
requires management to estimate the future cash flows that are expected to arise from the intangible asset and a suitable discount rate
in order to calculate the present value. Any change of estimation arising from economic environment changes or the Group’s
strategies may lead to significant impairment loss in the future.
F-21
6.
CASH AND CASH EQUIVALENTS
Cash on hand
Deposits in banks
December 31
2017
2,396 $
50,570,815
50,573,211 $
2018
2,318
28,906,583
28,908,901
$
$
Deposits in banks consisted of highly liquid time deposits that are readily convertible to known amounts of cash and were subject to an
insignificant risk or change in value.
7.
FINANCIAL ASSETS AT FAIR VALUE THROUGH PROFIT OR LOSS
Non-current
Financial assets mandatorily classified as at FVTPL
Derivative financial assets – warrants
December 31,
2018
$
60,004
In July 2018, the Group acquired warrants to subscribe for ordinary shares of DotBio Pte. Ltd., as detailed in Note 15 (under the heading
of “Nanyang Technological University”).
8.
FINANCIAL ASSETS AT FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME
Non-current
Investments in equity instruments at FVTOCI
Foreign unlisted ordinary shares
December 31,
2018
$
187,244
In July 2018, the Group acquired ordinary shares of DotBio Pte. Ltd., as detailed in Note 15 (under the heading of “Nanyang
Technological University”), which were not held for trading. The management believes that to recognize short-term fluctuations in the
investments’ fair value in profit or loss would not be consistent with the Group’s purpose of holding the investments. As a result, the
Group elected to designate the investments in equity instruments as at FVTOCI.
9.
PROPERTY, PLANT AND EQUIPMENT
The carrying amounts of each class of property, plant and equipment were as follows:
Office Equipment
Other Equipment
Leasehold Improvements
December 31
2017
2018
$
$
95,866 $
20,809
326,891
443,566 $
98,820
11,052
178,546
288,418
F-22
For the year ended December 31, 2017
Cost
Balance at January 1, 2017
Additions
Disposals
Balance at December 31, 2017
Accumulated depreciation
Balance at January 1, 2017
Depreciation expenses
Disposals
Balance at December 31, 2017
For the year ended December 31, 2018
Cost
Balance at January 1, 2018
Additions
Balance at December 31, 2018
Accumulated depreciation
Balance at January 1, 2018
Depreciation expenses
Balance at December 31, 2018
Office
Equipment
Other
Equipment
Leasehold
Improvements
Total
148,703 $
62,599
—
211,302 $
63,515 $
51,921
—
115,436 $
26,053 $
9,100
—
35,153 $
4,949 $
9,395
—
14,344 $
328,479 $
219,733
(73,708)
474,504 $
50,382 $
139,602
(42,371)
147,613 $
503,235
291,432
(73,708)
720,959
118,846
200,918
(42,371)
277,393
Office
Equipment
Other
Equipment
Leasehold
Improvements
Total
211,302 $
65,633
276,935 $
115,436 $
62,679
178,115 $
35,153 $
1,027
36,180 $
14,344 $
10,784
25,128 $
474,504 $
13,602
488,106 $
147,613 $
161,947
309,560 $
720,959
80,262
801,221
277,393
235,410
512,803
$
$
$
$
$
$
$
$
The above items of property, plant and equipment are depreciated on a straight-line basis over their estimated useful lives as follow:
Office equipment
Other equipment
Leasehold improvements
10.
INTANGIBLE ASSETS
The carrying amounts of each class of intangible assets were as follows:
Licenses
Computer software
F-23
3 years
3 years
3-5 years
December 31
2017
73,400 $
10,652
2018
23,073,400
7,192
84,052 $
23,080,592
$
$
For the year ended December 31, 2017
Cost
Balance at January 1, 2017
Additions
Licenses
Computer
Software
Total
$
73,400 $
—
31,331 $
8,844
104,731
8,844
Balance at December 31, 2017
$
73,400 $
40,175 $
113,575
Accumulated amortization
Balance at January 1, 2017
Amortization expenses
Balance at December 31, 2017
For the year ended December 31, 2018
Cost
Balance at January 1, 2018
Additions
$
$
— $
—
20,465 $
9,058
20,465
9,058
— $
29,523 $
29,523
Licenses
Computer
Software
Total
$
73,400 $
23,000,000
40,175 $
2,895
113,575
23,002,895
Balance at December 31, 2018
$
23,073,400 $
43,070 $
23,116,470
Accumulated amortization
Balance at January 1, 2018
Amortization expenses
Balance at December 31, 2018
$
$
— $
—
29,523 $
6,355
29,523
6,355
— $
35,878 $
35,878
The intangible assets, namely licenses, include the acquisitions in August 2016 of ASLAN005 from Exploit Technologies Pte. Ltd. and in
January 2018 of exclusive and worldwide rights to develop, manufacture and commercialize varlitinib from Array Biopharma Inc.,
respectively. The information related to these license agreements is further disclosed in Note 15.
As of December 31, 2017 and 2018, the aforementioned intangible assets were not amortized since they were not yet available for use.
Instead they would be tested for impairment, by comparing the recoverable amounts with the carrying amounts, annually and whenever
there is an indication that they may be impaired. For the years ended December 31, 2017 and 2018, there was no impairment loss
recognized.
Computer software is amortized on a straight-line basis over the estimated useful life of 3 years.
F-24
11. OTHER PAYABLES
Payables for salaries and bonuses
Payables for professional fees
Payables for cash-settled share-based payment transactions
(Note 19)
Interest payables
Others
12. LONG-TERM BORROWINGS
Unsecured borrowings
Loans from government
Other long-term borrowings
Interest payables
a.
Loans from government
December 31
2017
2018
1,376,197 $
412,676
195,000
—
96,671
2,080,544 $
1,153,048
680,708
669,042
50,430
129,433
2,682,661
December 31
2017
2018
7,411,912 $
—
2,267,539
9,679,451 $
7,266,315
4,060,357
2,648,122
13,974,794
$
$
$
$
On April 27, 2011, the Singapore Economic Development Board (the “EDB”) awarded the Company a repayable grant (the “Grant”)
not exceeding SGD 10 million (approximately $7,482,459) to support the Company’s drug development activities over a five-year
qualifying period commencing February 24, 2011 (the “Project”). The Project was successfully implemented, resulting in
substantially the full amount of the Grant being disbursed to the Company.
In the event any of the Company’s clinical product candidates achieve commercial approval after Phase 3 clinical trials, the Company
will be required to repay the funds disbursed to the Company under the Grant plus interest of 6%. Until the Company has fulfilled its
repayment obligations under the Grant, the Company has ongoing update and reporting obligations to the EDB. In the event the
Company breaches any of its ongoing obligations under the Grant, EDB can revoke the Grant and demand that the Company repay
the funds disbursed to the Company under the Grant.
As of December 31, 2017 and 2018, the amounts of the funds disbursed to the Company plus accrued interest were $9,679,451 and
$9,914,437, respectively.
b. Other long-term borrowings
On May 12, 2014, ASLAN Pharmaceuticals Pte. Ltd. obtained a loan facility of $4.5 million from CSL Finance Pty Ltd. The amount
was based on 75% of research and development costs approved by CSL Finance Pty Ltd. at each drawdown period. The loan is
repayable within 10 years from the date of the facility agreement. Interest on the loan is computed at 6% plus LIBOR and is payable
on a quarterly basis.
Mandatory prepayment of the loan is required upon a successful product launch occurring before maturity of the loan.
F-25
As of December 31, 2017 and 2018, the amount of funds disbursed to the Company plus accrued interest, was nil and $4,110,787,
respectively.
13. RETIREMENT BENEFIT PLANS
Defined Contribution Plans
ASLAN Pharmaceuticals Pte. Ltd. adopted a defined contribution plan, which is a post-employment benefit plan, under which ASLAN
Pharmaceuticals Pte. Ltd. pays fixed contributions into the Singapore Central Provident Fund on a mandatory basis. ASLAN
Pharmaceuticals Pte. Ltd. has no further payment obligations once the contributions have been paid. The contributions are recognized as
“employee compensation expenses” when they are due.
ASLAN Pharmaceuticals Taiwan Limited adopted a pension plan under the Labor Pension Act (the “LPA”) of the ROC, which is a state-
managed defined contribution plan. Under the LPA, ASLAN Pharmaceuticals Taiwan Limited makes monthly contributions to its Taiwan-
based employees’ individual pension accounts at 6% of monthly salaries and wages.
ASLAN Pharmaceuticals (Shanghai) Co. Ltd. makes monthly contributions at a certain percentage of its Shanghai-based employees’
payroll expenses to pension accounts, which are operated by the Chinese government. Beside the aforementioned monthly contributions,
the Group has no further obligation.
For the years ended December 31, 2016, 2017 and 2018, the total expense for such employee benefits in the amount of $251,187,
$329,455 and $424,157 were recognized, respectively.
14. EQUITY
a.
Ordinary shares
Number of shares authorized
Amount of shares authorized (NT$ thousand)
Number of shares issued and fully paid
Amount of shares issued and fully paid
2016
200,000,000
December 31
2017
200,000,000
$
2,000,000 $
2,000,000 $
115,670,940
130,128,940
$
36,710,066 $
41,514,016 $
2018
500,000,000
5,000,000
160,248,940
51,627,219
The issued ordinary shares with a par value of NT$10 entitle holders with the rights to vote and receive dividends.
On May 27, 2016, the holders of the Preference Shares approved the conversion of all the Preference Shares into an equal number,
41,614,397 of Ordinary Shares, which increased the share capital by $41,614 (NT$ 1,304 thousand) and the capital surplus by
$64,557,452 (NT$ 2,053,693 thousand).
On May 27, 2016, in the shareholders’ meeting, the shareholders resolved to adjust the par value of the Company’s ordinary shares
from US$0.001 to NT$10 and approved a share split, at a ratio of 1-to-2 after the conversion of Preference Shares into Ordinary
Shares for the purpose of the proposed initial public offering and listing on TPEx. The accompanying consolidated financial
statements have been retroactively adjusted to take the share split into account for the year presented.
F-26
On May 27, 2016, the Company’s board of directors resolved to issue 19,667,144 ordinary shares, with a par value of NT$10, for
consideration of $1.13 per share, which increased the share capital to $36,710,066 (NT$ 1,156,709 thousand).
On February 28, 2017, the Company’s board of directors resolved to issue 14,458,000 ordinary shares for initial public offering on
the TPEx, with a par value of NT$10, amounting to $4,803,950 (NT$ 144,580 thousands), which increased the balance of the share
capital to $41,514,016 (NT$ 1,301,289 thousands). The above issuance was declared effective by the TPEx on April 7, 2017, and the
subscription base date was determined as at May 25, 2017. The abovementioned shares were issued at a weighted-average bid price
of NT$68.92 per share. The Company collected the above proceeds amounting to $33,060,951 (NT$ 996,495 thousands) for new
shares issued on May 25, 2017.
The Company completed its initial public offering of 6,000,000 ADSs representing 30,000,000 ordinary shares on May 8, 2018 in the
United States. The Company’s ADSs have been listed on the Nasdaq Global Market since May 4, 2018. Each ADS represents five of
the Company’s ordinary shares. The offering price per ADS was $7.03. The payment for the initial public offering was fully collected
as of May 8, 2018, and the record date for this capital increase was May 8, 2018.
On September 10, 2018, the Company’s board of directors resolved to increase the amount of shares authorized to NT$5,000,000
thousand.
For long-term development purposes, on November 7, 2018, the board of directors resolved to issue ordinary shares ranging from
15,000,000 to 40,000,000 shares for the purpose of issuing the ADR, American Depository Receipts. On December 5, 2018, the
Company received the approval letter No.1070344286 from the Financial Supervisory Commission (FSC) in accordance with the
regulatory requirement.
b.
Capital surplus
Arising from issuance of new share capital
Arising from employee share options
$
2016
50,119,257 $
5,136,828
December 31
2017
78,384,290 $ 105,143,362
6,316,310
5,898,391
2018
$
55,256,085 $
84,282,681 $ 111,459,672
c.
Retained earnings and dividends policy
Under the Company’s Articles of Incorporation, the Company may declare dividends by ordinary resolution of the Company’s board
of directors, but no dividends shall exceed the amount recommended by the directors of the Company.
The Company may set aside out of the funds legally available for distribution, for equalizing dividends or for any other purpose to
which those funds may be properly applied, either employed in the business of the Company or invested in such investments as the
directors of the Company may from time to time think fit.
F-27
The accumulated deficits for 2016 and 2017 approved in the shareholders’ meetings on June 28, 2017 and June 15, 2018,
respectively, were as follows:
Accumulated deficits at the beginning of the year
Net loss for the year
For the Year Ended
December 31
$
2016
(41,342,180) $
(9,049,103)
2017
(50,391,283)
(39,891,978)
Accumulated deficits at the end of the year
$
(50,391,283) $
(90,283,261)
The accumulated deficits for 2018 which had been proposed by the Company’s board of directors on March 22, 2019 were as
follows:
Accumulated deficits at the beginning of the year
Net loss for the year
Accumulated deficits at the end of the year
For the Year
Ended
December 31
2018
(90,283,261)
(42,185,597)
$
$
(132,468,858)
The accumulated deficits for 2018 are subject to the resolution of the shareholders’ meeting to be held on June 21, 2019.
15. LICENSE AGREEMENTS
Array Biopharma
The Company entered into a license agreement in 2011 with Array Biopharma Inc. (“Array”) to develop Array’s pan-HER inhibitor,
ARRY-543 (which the Company refers to as ASLAN001 or varlitinib), for the treatment or prevention of any disease or condition in
humans, without upfront payments. Under the license agreement, the Company agreed to fund and globally develop ASLAN001 through
proof of concept, initially targeting patients with gastric cancer through a development program conducted in Asia.
Upon achievement of proof of concept, the Company agreed to collaborate or out-license to third parties for the further phase 3
development and commercialization. Under the license agreement, the Company agreed to pay Array 50% of the proceeds from out-
licensing as royalties.
On January 3, 2018, the Company entered into a new license agreement with Array pursuant to which the Company obtained an exclusive,
worldwide license to develop, manufacture and commercialize varlitinib for all human and animal therapeutic, diagnostic and prophylactic
uses. This new license agreement replaces and supersedes the previous collaboration and license agreement with Array dated July 12,
2011.
Under the new license agreement, the Company agreed to use commercially reasonable efforts to obtain approval by the U.S. FDA or the
applicable health regulatory authority and commercialize varlitinib.
F-28
In consideration of the rights granted under the agreement, the Company made an initial upfront payment to Array of $12,000,000 in
January 2018 and an additional payment $11,000,000 in June 2018, respectively, that were capitalized as a separately acquired intangible
asset. In addition, the Company will be required to pay up to $30,000,000 if certain development milestones are achieved, $20,000,000 if
certain regulatory milestones are achieved, and up to $55,000,000 if certain commercial milestones are achieved. The Company is also
required to pay Array tiered royalties in the low tens on net sales of varlitinib. The royalty obligations will continue on a country-by-
country basis through the later of the expiration of the last valid patent claim for varlitinib or ten years after the first commercial sale of
varlitinib in a given country. As of December 31, 2018, the Company did not accrue for the above contingent payments since the
milestones are not achieved.
If within two years of the date of the new license agreement the Company sublicenses varlitinib and is paid an upfront payment, Array will
be further entitled to receive one-half of the portion of any such upfront payment that exceeds a specified amount. In the event that the
base royalty under a sublicense agreement is 20% or less, the Company will only be required to share with Array one-half of the amount
actually received by the Company under such sublicense agreement in lieu of the tiered royalties described above, provided that the
royalty paid in such case shall in no event be less than a royalty in the high single digit range.
If the Company undergoes a change in control during a defined period following execution of the new license agreement, Array will also
be entitled to receive a low to mid single-digit percentage of the proceeds resulting from the change in control. Unless earlier terminated,
the agreement will continue on a country-by-country basis until the expiration of the respective royalty obligations in such country. Upon
such expiration in such country, Array will grant to the Company a perpetual, royalty-free, non-terminable, non-revocable, non-exclusive
license to exploit certain know-how in connection with the development, manufacturing and/or commercialization of varlitinib for all
human and animal therapeutic, diagnostic and prophylactic uses in such country. Either party may terminate the agreement (i) in the event
of the other party’s material breach of the agreement that remains uncured for a specified period of time or (ii) the insolvency of the other
party. In addition, if there is a change in control, the Company may also terminate the agreement without cause at any time upon 180 days
advance notice to Array.
Bristol-Myers Squibb
The Company entered into a license agreement with Bristol-Myers Squibb in 2011, to receive exclusive rights to develop and
commercialize BMS-777607 (which the Company refers to as ASLAN002) in China, Australia, Korea, Taiwan and other selected Asian
countries, without upfront payments. Bristol-Myers Squibb retains the exclusive rights in the rest of the world. Under the license
agreement, the Company would fund and develop ASLAN002 through proof of concept under a development plan that would initially
target gastric cancer and lung cancer.
After the Company completed the phase 1 clinical trial, Bristol-Myers Squibb licensed the exclusive rights from the Company to further
the development and commercialization of ASLAN002 worldwide. Under the terms of the license agreement, the Company has received
an upfront payment of $10,000,000 in 2016. The Company is eligible to receive additional payments upon Bristol-Myers Squibb’s
achievement of development and regulatory milestones in the future. Furthermore, the Company is eligible to receive royalty payments on
future worldwide sales generated by Bristol-Myers Squibb. Bristol-Myers Squibb also purchased the related research materials, supplies,
research documentation and clinical trial results that are used for further developing ASLAN002 from the Company in the amount of
$1,294,034 which was delivered in 2016. Such amount was recorded in the accounts receivable as of December 31, 2016 and was
collected during the first quarter of 2017. As Bristol-Myers Squibb assumes the responsibility for all development and commercialization
activities and expenses, and the Company currently has no further obligations under the license agreement. Accordingly, the Company
recognized the upfront payment from out-licensing and other payment from the sale of research materials, supplies, research
documentation and clinical trial results, totaling $11,294,034, in revenue for the year ended December 31, 2016.
F-29
Almirall
In 2012, the Company originally entered into a global licensing agreement with Almirall to develop DHODH inhibitor, LAS186323,
which the Company refers to as ASLAN003, for rheumatoid arthritis (excluding any topical formulation), without upfront payments.
Under the license agreement, the Company agreed to fund and develop ASLAN003 to the end of Phase 2 through a development program
conducted in the Asia-Pacific region.
The original license agreement was replaced by a new agreement, executed in December 2015 and amended in March 2018, granting an
exclusive, worldwide license to develop, manufacture and commercialize ASLAN003 products for all human diseases with primary focus
on oncology diseases, excluding topically-administered products embodying the compound for keratinocyte hyperproliferative disorders,
and the non-melanoma skin cancers basal cell carcinoma, squamous cell carcinomas and Gorlin Syndrome. Under the license agreement,
Almirall is eligible to receive milestone payments and royalties based on the sales generated by the Company and/or sublicensees.
CSL
The Company entered into a global license agreement with CSL Limited (“CSL”), in May 2014, to develop the anti-IL13 receptor
monoclonal antibody, CSL334 (which the Company refers to as ASLAN004) and antigen binding fragments thereof, for the treatment,
diagnosis or prevention of diseases or conditions in humans, without upfront payments. This license agreement was amended in September
2018. Under the license agreement (as amended), the Company will be responsible to develop ASLAN004 through to clinical proof of
concept in a development program, targeting patients suffering moderate to severe atopic dermatitis. Upon achievement of clinical proof of
concept (or earlier, if agreed), the Company will collaborate or out-license to third parties for further Phase 3 development and
commercialization. Under the global license agreement, the Company will pay to CSL a share in the range of 40 to 50 percent of all
licensing revenue it receives from future out-licensing agreements.
Hyundai Pharm Co., Ltd.
In October 2015, the Company entered into a license agreement with Hyundai Pharm Co., Ltd. (“Hyundai”). Under the terms of the license
agreement, the Company granted Hyundai options to acquire the rights to use its intellectual property to develop and commercialize
varlitinib for the treatment of cholangiocarcinoma (i.e., CCA) in South Korea, and the Company has received an option payment of
$250,000 from Hyundai in 2016. As there was no performance obligation required for the Company, the payment was recognized as
revenue, and the related cost of revenue in the amount of $125,000 paid to one of the third parties with whom the Company has a licensing
agreement as part of the payment for the proceeds from out-licensing was recognized as cost of revenue, for the year ended December 31,
2016. The Company was eligible for additional regulatory and commercial milestones payments as well as royalties on product sales.
In February 2019, the Company made a payment of $325,000 to Hyundai in order to buy back the rights to commercialize varlitinib in
CCA.
Exploit Technologies Pte Ltd. (“ETPL”)/P53 Laboratory
The Company entered into a licensing agreement with ETPL, in August 2016, to license Intellectual Property (IP) arising from a research
collaboration with ETPL’s P53 Laboratory. The IP focuses on generation of novel immuno-oncology antibodies targeting recepteur
d’origine nantais (“RON”) and such antibodies are referred to by the Company collectively as ASLAN005. The license fee of SG$100,000
(or $73,400) is capitalized as a separately acquired intangible
F-30
asset. Under the license agreement, the Company has the exclusive rights to develop and commercialize ASLAN005 worldwide. ETPL is
eligible to receive up to an aggregate of SG$12,000,000 (or $8,978,951) in milestone payments if certain development and commercial
milestones are achieved, as well as royalties calculated based on any sales generated by the Company.
In August 2016, the Company and ETPL’s P53 Laboratory entered into a three-year research collaboration agreement. Under the terms of
the agreement, the Company will be responsible for the design of innovative clinical development programs, in collaboration with P53
Laboratory, which will continue to be responsible for the preclinical development of the antibody assets.
Nanyang Technological University
The Company entered into a licensing and research collaboration agreement with Nanyang Technological University (NTU) in October
2016, for the development of modybodies against three targets of the Company’s choice. The agreement expired in April 2018, but the
Company retained continuing rights: a half share ownership in the resulting IP, together with an exclusive option to obtain global rights to
develop and commercialize the modybodies, with such option exercisable until October 2018. In July 2018, the technology for
modybodies was separated from NTU and licensed to a new company, DotBio Pte. Ltd. In exchange for the Company’s giving up its
residual rights and options in respect to the technology, the Company received 599,445 shares of DotBio Pte. Ltd. equivalent to
SG$255,000 ($187,244) (see Note 8), together with 599,445 units of warrant to subscribe for the same number of shares at a subscription
price of $0.32 which was the same value per share as applied to other new investors in this round (see Note 7); in addition, the Company
also retained a right of first refusal to take an exclusive license for any modybodies produced by DotBio Pte. Ltd. that are based on the
work generated from the collaborative agreement between NTU and the Company. However, as the right of first refusal did not limit
DotBio Pte. Ltd.’s ability to direct the use of the asset, or to obtain substantially all the remaining benefits from the asset, this would not
prevent DotBio Pte. Ltd. from obtaining control of the asset. Accordingly, the Company recognized the non-cash gain arising from the
derecognition and recorded it as other income of $187,244 for the year ended December 31, 2018, because it was not a good or service that
was an output of the Company’s ordinary activities.
BioGenetics Co. Ltd.
In February 2019, the Company entered into a licensing agreement with BioGenetics to grant exclusive rights to commercialise varlitinib
in South Korea in exchange for an upfront payment of $2,000,000 and up to $11,000,000 in sales and development milestone payments.
The Company is also eligible to receive tiered double digit royalties on net sales up to the mid-twenties. The Company has no other
performance obligation in addition to the license, and BioGenetics will be responsible for obtaining initial and all subsequent regulatory
approvals of varlitinib in South Korea.
In March 2019, the Company entered into another licensing agreement with BioGenetics to grant exclusive rights to commercialise
ASLAN003 in South Korea in exchange for an upfront payment of $1,000,000 and up to $8,000,000 in sales and development milestone
payments. The Company is also eligible to receive tiered double digit royalties on net sales from the high-teens to the mid-twenties range.
The Company has no other performance obligation in addition to the license, and BioGenetics will be responsible for obtaining initial and
all subsequent regulatory approvals of ASLAN003 in South Korea.
F-31
16. LOSS BEFORE INCOME TAX
a.
Other gains and losses
Net foreign exchange gains (losses)
Fair value changes of financial assets mandatorily
classified as at FVTPL
Loss on disposal of property, plant and equipment
Others
b.
Finance costs
Interest on government loans
Preference share dividends
Interest on CSL loan
Other interest expenses
c.
Depreciation and amortization
Property, plant and equipment
Computer software
For the Year Ended December 31
2017
2018
2016
$
165,807 $
(667,130) $
95,894
—
(12,316)
(26,019)
127,472 $
—
(31,298)
(263)
(698,691) $
60,004
—
57,345
213,243
For the Year Ended December 31
2017
2018
2016
417,812 $
87,889
18,437
—
524,138 $
416,698 $
—
—
—
416,698 $
441,474
—
—
50,430
491,904
For the Year Ended December 31
2017
2018
2016
65,874 $
10,010
75,884 $
200,918 $
9,058
209,976 $
235,410
6,355
241,765
$
$
$
$
$
All depreciation and amortization expenses were recognized as general and administrative expenses for the years ended December 31,
2016, 2017 and 2018.
d.
Employee benefits expense
Short-term benefits
Post-employment benefits
Share-based payments (Note 19)
Equity-settled
Cash-settled
Total employee benefits expense
An analysis of employee benefits expense
by function
General and administrative expenses
Research and development expenses
For the Year Ended December 31
2017
7,062,311 $
329,455
2016
5,212,357 $
251,187
2018
8,002,069
424,157
$
1,419,923
—
$
6,883,467 $
769,595
357,000
8,518,361 $
451,060
838,677
9,715,963
$
$
4,224,919 $
2,658,548
6,883,467 $
4,664,285 $
3,854,076
8,518,361 $
6,294,470
3,421,493
9,715,963
F-32
e.
Employees’ compensation and remuneration of directors
Under the Company’s Articles of Incorporation, the Company shall accrue employees’ compensation and remuneration of directors
at the rates of no less than 0.1% and no higher than 1%, respectively, of profit before income tax, net of employees’ compensation
and remuneration of directors.
The Company had accumulated deficits for the years ended December 31, 2016, 2017 and 2018; therefore, no compensation for
employees and remuneration of directors was accrued.
17.
INCOME TAXES
Income tax recognized in profit or loss
Current tax
Adjustments for prior periods
For the Year Ended
December 31
2017
2018
2016
$
— $
— $
14,439
A reconciliation of accounting profit and income tax expense was as follows:
Loss before income tax
$
For the Year Ended
December 31
2017
2018
(39,891,978) $
(42,171,158)
2016
(9,049,103) $
Income tax benefit calculated at the statutory rate
Nondeductible expenses in determining taxable
income
Tax credits for research and development expenditures
Unrecognized loss carryforward
Effect of different tax rates of group entities operating
in other jurisdictions
Adjustments for prior years’ tax
$
(1,538,347) $
(6,781,636) $
(7,169,097)
473,085
(990,065)
2,011,373
4,288,090
(2,224,348)
4,519,942
112,263
(2,312,251)
9,261,996
43,954
—
197,952
—
107,089
14,439
Income tax expense recognized in profit or loss
$
— $
— $
14,439
a.
Cayman Islands
The Company is incorporated in the Cayman Islands. Under the current laws of the Cayman Islands, the Company is not subject to
tax on income or capital gains. Additionally, the Cayman Islands does not impose a withholding tax on payments of dividends to
shareholders.
b.
Singapore
ASLAN Pharmaceuticals Pte. Ltd. is subject to the statutory corporate income tax rate of 17%. As of December 31, 2018, the
Company has unrecognized loss carryforward of $146,316,690. Deferred tax assets are not recognized for loss carryforward since the
future taxable profits available to offset against those loss carryforward are uncertain.
F-33
c.
Taiwan
ASLAN Pharmaceuticals Taiwan Limited, incorporated in Taiwan, is subject to the statutory corporate income tax rate of 17% for the
year ended December 31, 2016 and 2017. The Income Tax Act in the ROC was amended in 2018, and the corporate income tax rate
was adjusted from 17% to 20%, effective in 2018. In addition, the rate of the corporate surtax applicable to the 2018 unappropriated
earnings is reduced from 10% to 5%.
The income tax returns have been assessed by the tax authorities through 2017.
d. Australia
ASLAN Pharmaceuticals Australia Pty Ltd., incorporated in Australia, is subject to the statutory corporate income tax of 30%.
ASLAN Pharmaceuticals Australia Pty Ltd. has no taxable income for the years ended December 31, 2017 and 2018, and therefore,
no provision for income tax is required.
e.
Hong Kong
ASLAN Pharmaceuticals Hong Kong Limited, incorporated in Hong Kong, is subject to the statutory corporate income tax of 16.5%.
Under the Hong Kong tax law, ASLAN Pharmaceuticals Hong Kong Limited is exempted from income tax on its foreign derived
income and there are no withholding taxes in Hong Kong on the remittance of dividends. ASLAN Pharmaceuticals Hong Kong
Limited has no taxable income for the years ended December 31, 2016, 2017 and 2018, and therefore, no provision for income tax is
required.
f.
China
ASLAN Pharmaceuticals (Shanghai) Co. Ltd., incorporated in China, is subject to the statutory corporate income tax rate of 25%.
ASLAN Pharmaceuticals (Shanghai) Co. Ltd. has no taxable income for the years ended December 31, 2016, 2017 and 2018, and
therefore, no provision for income tax is required.
g. United States of America
ASLAN Pharmaceuticals (USA) Inc., incorporated in Delaware, U.S.A. in October 2018, is subject to the statutory federal income
tax rate of 21% and state income tax rate of 8.7%. ASLAN Pharmaceuticals (USA) Inc. has no taxable income for the year ended
December 31, 2018, and therefore, no provision for income tax is required.
18. LOSS PER SHARE
Basic and diluted loss per share
$
(0.09) $
(0.32) $
(0.28)
F-34
For the Year Ended December 31
2017
2016
2018
The loss and weighted-average number of ordinary shares outstanding used in the computation of loss per share are as follows:
Loss used in the computation of basic and diluted loss per share
Weighted-average number of ordinary shares in the
computation of basic loss per share
$
For the Year Ended December 31
2017
2018
2016
(9,049,103) $
(39,891,978) $
(42,185,597)
105,027,040
124,424,960
149,739,242
If the outstanding employee share options issued by the Company are converted to ordinary shares, they are anti-dilutive and excluded
from the computation of diluted earnings per share. For the year ended December 31, 2016, 34,678,664 weighted-average number of outstanding
convertible preference shares and 12,884,672 weighted-average number of employee share options were excluded from the computation of diluted
earnings/loss per share because their impact was anti-dilutive. Potential ordinary shares arising from the aforementioned anti-dilutive
outstanding employee share options are 7,224,123 and 6,664,244 shares for the years end 2017 and 2018, respectively.
19.
SHARE-BASED PAYMENT ARRANGEMENTS
New Shares Reserved for Subscription by Employees under Cash Injection
On February 28, 2017, the Company’s board of directors approved the issuance of 14,458,000 ordinary shares for initial public offering on
the TPEx and simultaneously reserved 1,446,000 ordinary shares for subscription by employees according to the Company Act of the
ROC, and employees were granted the share options to subscribe for all of the reserved ordinary shares on May 16, 2017.
The Group used the binomial option price model to determine the fair value of the share options granted to employees on May 16, 2017,
and the related assumptions and the fair value of the options are as follows:
Grant-date share price (NT$)
Exercise price (NT$)
Expected volatility
Expected life
Dividends yield
Risk-free interest rate
Weighted-average fair value of options (NT$)
Share Options
Granted on
May 16, 2017
$
$
$
68.92
68.92
37.33%
0.02 year
—
0.08%
1.44
Expected volatility was based on the average annualized historical share price volatility of the Company’s comparable companies before
the grant date.
The aforementioned options granted to employees are accounted for and measured at fair value in accordance with IFRS 2. The recognized
compensation costs were $8,032 for the year ended December 31, 2017 and were classified as “captial surplus – ordinary shares” after
collecting the proceeds for employee share subscriptions.
F-35
Employee Share Option Plan
Under the Company’s employee share option plan, qualified employees of the Company and its subsidiaries were granted 661,000 options
in July 2010, 910,000 options in July 2011, 669,750 options in July 2012, 619,250 options in July 2013, 680,625 options in July 2014,
2,477,336 options in July 2015, 1,032,250 options in July 2016 and 825,833 options in September 2017. Each option entitles the holder to
subscribe for one ordinary share of the Company. The options granted are valid for 10 years and exercisable at certain percentages once
they have vested. No performance conditions were attached to the plan. The Company has no legal constructive obligation to repurchase or
settle the options in cash.
The board of directors of the Company, as of July 26, 2016, resolved to double the number of shares underlying each outstanding award
granted previously to reflect the subdivision ratio of the share split made in connection with the corporate restructuring of May 27, 2016.
The exercise price for each award previously granted was correspondingly adjusted by a decrease of 50%. The modification did not cause
any incremental adjustments to the fair value of the granted awards.
As of December 31, 2018, there are 14,343,213 ordinary shares issuable on the exercise of share options outstanding under the Company’s
equity incentive plans.
Information on employee share options granted from July 2010 to July 2016 is as follows:
2016
For the Year Ended December 31
2017
2018
Balance at January 1
Options granted
Options forfeited
Options exercised
Balance at December 31
Options exercisable, end
of period
Weighted-average fair
value of options
granted
Weighted-
average
Exercise
Price
Weighted-
average
Exercise
Price
Number of
Options
Weighted-
average
Exercise
Price
Number of
Options
1.27 6,958,461 $
2.26
—
(70,938)
1.36
—
—
1.42 6,887,523
—
1.95
—
1.42 6,887,523 $
—
(5,000)
(60,000)
1.41 6,822,523
1.41
—
2.13
0.80
1.41
Number of
Options
5,946,461 $
1,032,250
(20,250)
—
6,958,461
4,830,503
1.20 5,825,816
1.30 6,595,294
1.38
$
0.89
$
0.89
$
0.89
F-36
Information on employee share options granted in September 2017 is as follows:
Balance at January 1
Options granted
Options forfeited
Balance at December 31
Options exercisable, end of period
Weighted-average fair value of options granted
For the Year Ended December 31
2017
2018
Number of
Options
— $
825,833
(70,000)
755,833
—
0.62
Weighted-
average
Exercise
Price
Number of
Options
Weighted-
average
Exercise
Price
—
1.28
1.28
1.28
—
$
755,833 $
—
(57,666)
698,167
—
0.62
1.28
—
1.28
1.28
—
$
F-37
Information on outstanding options as of December 31, 2018 is as follows:
July 2010
July 2011
July 2012
July 2013
July 2014
July 2015
July 2016
September
2017
Weighted-
average
Remaining
Contractual
Life
(Years)
Weighted-
average
Remaining
Contractual
Life
(Years)
Range of
Exercise
Price
Weighted-
average
Remaining
Contractual
Life
(Years)
Range of
Exercise
Price
Weighted-
average
Remaining
Contractual
Life
(Years)
Range of
Exercise
Price
Weighted-
average
Remaining
Contractual
Life
(Years)
Range of
Exercise
Price
Weighted-
average
Remaining
Contractual
Life
(Years)
Weighted-
average
Remaining
Contractual
Life
(Years)
Weighted-
average
Remaining
Contractual
Life
(Years)
Range of
Exercise
Price
Range of
Exercise
Price
Range of
Exercise
Price
1.5 $0.20-$0.80
2.5
$0.80
3.5 $0.80-$1.36
4.5
$1.36
5.5 $1.36-$1.88
6.5
$2.26
7.5
$1.28
8.7
Range of
Exercise
Price
$0.20-$0.80
F-38
Options granted in July of 2010, 2011, 2012, 2013, 2014, 2015, 2016 and September 2017 were priced using the binomial option pricing
model, and the inputs to the model were as follows:
July
2010
July
2011
July
2012
Grant-date share price
Exercise price
Expected volatility
Expected life (years)
Expected dividend yield
Risk-free interest rate
$
0.80
$0.20-$0.80
$
59.16%
10
—
2.954%
$
$
0.80
$0.20-$0.80
54.26%-54.44%
10
—
2.96%-3.22%
$
1.25
0.80
52.25%
10
—
1.61%
July
2013
1.36
$0.80-$1.36
$
$
50.58%
10
—
2.5%
July
2014
$
1.36
1.36
50.86%
10
—
2.58%
July
2015
1.88
$1.36-$1.88
$
$
36.37%
10
—
2.43%
July
2016
September
2017
$
$
2.26
2.26
39.34%
10
—
1.46%
1.28
1.28
38.33%
10
—
1.1027%
Expected volatility was based on the average annualized historical share price volatility of comparable companies before the grant date.
Compensation costs recognized for the years ended December 31, 2016, 2017 and 2018 were $1,419,923, $769,595 and $451,060,
respectively.
Long Term Incentive Plan
On August 23, 2017 and July 30, 2018, the Company’s board of directors approved the 2017 and 2018 Senior Management Team (SMT)
Long Term Incentive Plans (the “2017 LTIP” and “2018 LTIP”), respectively, which outlines awards that may be granted to qualified
employees of the Company. These plans are applicable to the SMT of the Company and are used for long-term retention of key
management. The LTIPs are each valid for ten years, and grantees of the bonus entitlement units can exercise their rights once they have
vested. The Company shall pay the intrinsic value of the units awarded to the employees at the date of exercise of their awards, if
redeemed by an employee.
As of December 31, 2018, there are 1,566,000 bonus entitlement units which have been granted under the 2017 LTIP by the Company. For
the 1,462,000 units under the 2017 LTIP which were granted in 2017, they will vest in thirds each year after the first, second, and third
anniversary of the award, and for the 104,000 units under the 2017 LTIP which were granted in 2018, they will vest in halves each year
after the second and third anniversary of the award.
The value of the 2017 LTIP is measured based on the quoted share price. On July 30, 2018 the board of directors approved the
modification of the 2017 LTIP which retrospectively changes the share price Taiwan share price to ADS price at a 5:1 conversion ratio.
The LTIP are consider cash-settled awards and are measured at fair value. The change in fair value from the modification was insignificant
and was recognized immediately in profit or loss.
The Company’s 2017 LTIP is described as follows:
Balance at January 1
Awards granted
Awards exercised
Balance at December 31
Balance exercisable, end of period
F-39
For the Year Ended December 31
2018
2017
—
1,462,000
—
1,462,000
—
1,462,000
104,000
(86,666)
1,479,334
400,667
As of December 31, 2018, there are 241,142 bonus entitlement units which have been granted under the 2018 LTIP by the Company. For
the 241,142 units under the 2018 LTIP, they will vest in thirds each year after the first, second, and third anniversary of the award. The
value of the 2018 LTIP will be linked to the ADS price. All of the 2018 LTIP granted bonus entitlement units remained outstanding as of
December 31, 2018.
The Company’s 2018 LTIP is described as follows:
Balance at January 1
Awards granted
Balance at December 31
Balance exercisable, end of period
For the Year
Ended December 31,
2018
—
241,142
241,142
—
Each bonus entitlement unit grants the holders of the 2017 LTIP and the 2018 LTIP a conditional right to receive an amount of cash equal
to the per-unit fair market value of the Company’s ordinary shares and ADSs, respectively, on the settlement date. The LTIPs qualify as
cash-settled share-based payment transactions. The Company recognizes the liabilities in respect of its obligations under the LTIPs, which
are measured based on the Company’s quoted market price of its ADSs at the reporting date, and takes into account the extent to which the
services have been rendered to date.
Regarding the Company’s 2017 and 2018 LTIPs, the respective quoted fair value of the awards on the grant date was NT$33.45 (or $1.10)
and $7.90, based on the Taiwan share price on August 23, 2017 and the closing price per ADS on July 30, 2018, respectively. The quoted
fair value on the reporting date is based on the closing price of Taiwan share price of NT$33.20 (or $1.12) as of December 31, 2017 and
the closing price per ADS of $3.60 as of December 31, 2018, respectively.
The Company recognized total expenses of $357,000 and $838,677 in respect of the LTIPs for the years ended December 31, 2017 and
2018, respectively. As of December 31, 2017 and 2018, the Company recognized compensation liabilities of $195,000 and $669,042 as
current (classified as other payables) , respectively, and $162,000 and $289,613 as non-current, respectively.
20. OPERATING LEASE ARRANGEMENTS
The Group as lessee
Operating leases relate to leases of office, parking space and copiers with lease terms between 1 and 5 years. The Group does not have a
bargain purchase option to acquire the leased office, parking space and copiers at the expiration of the lease periods.
F-40
The future minimum lease payments of non-cancellable operating lease commitments were as follows:
No later than 1 year
Between 1 and 5 years
21. CAPITAL MANAGEMENT
2016
December 31
2017
$
309,220 $
485,053
555,133 $
632,340
2018
493,534
105,859
$
794,273 $
1,187,473 $
599,393
The Group manages its capital to ensure that entities in the Group will be able to safeguard cash as well as maintain financial liquidity and
flexibility to support the development of its product candidates and programs as a going concern through the optimization of the debt and
equity balance.
The Group’s financial strategy is designed to maintain a flexible capital structure consistent with the objectives stated above and to
respond to business growth opportunities and changes in economic conditions. The capital structure of the Group mainly consists of
borrowings and equity of the Group. Key management personnel of the Group review the capital structure periodically. In order to
maintain or balance the overall capital structure, the Group may adjust the amounts of long-term borrowings, or the issuance of new shares
capital or other equity instruments.
As of December 31, 2018, there were no changes in the Group’s capital management policy, and the Group is not subject to any externally
imposed capital requirements.
22.
FINANCIAL INSTRUMENTS
a.
Fair value of financial instruments not measured at fair value
The Group believes that the carrying amounts of financial assets and financial liabilities not measured at fair value approximate their
fair values.
b.
Fair value of financial instruments measured at fair value on a recurring basis
1)
Fair value hierarchy
December 31, 2018
Financial assets at FVTPL
Derivative financial assets
Financial assets at FVTOCI
Investments in equity instruments at
FVTOCI of unlisted companies.
Level 1
Level 2
Level 3
Total
$
— $
— $
60,004 $
60,004
$
— $
187,244 $
— $
187,244
There were no transfers between Levels 1 and 2 in the current and prior periods.
2) Valuation techniques and inputs applied for Level 2 fair value measurement
F-41
The fair values of unlisted equity investments are measured on the basis of the prices of recent investment by third parties with
the consideration of other factors that market participants would take into account.
3) Valuation techniques and inputs applied for Level 3 fair value measurement
The fair values of warrants are determined using option pricing models where the significant unobservable input is historical
volatility. An increase in the historical volatility used in isolation would result in an increase in the fair value. As of December
31, 2018, the historical volatility used was 42.33(cid:0).
c.
Categories of financial instruments
Financial assets
Financial assets at FVTPL
Mandatorily classified as at FVTPL
Loans and receivables (1)
Financial assets at amortized cost (2)
Financial assets at FVTOCI
Equity instruments
Financial liabilities
2016
December 31
2017
2018
$
— $
— $
53,155,861 50,734,158
—
—
60,004
—
29,080,981
—
—
187,244
Financial liabilities at amortized cost (3)
12,139,230 15,463,286
21,304,150
1)
2)
3)
The balances include loans and receivables measured at amortized cost, which comprise cash and cash equivalents and
refundable deposits.
The balances included financial assets at amortized cost, which comprise cash and cash equivalents and refundable deposits.
The balances include financial liabilities at amortized cost, which comprise trade payables, partial other payables and long-term
borrowings.
c.
Financial risk management objectives and policies
The Group’s financial risk management objective is to monitor and manage the financial risks relating to the operations of the Group.
These risks include market risk (including foreign currency risk and interest rate risk), credit risk and liquidity risk. In order to
minimize the effect of financial risks, the Group devoted time and resources to identify and evaluate the uncertainty of the market to
mitigate risk exposures.
1) Market risk
The Group’s activities exposed it primarily to the financial risks of changes in foreign currency exchange rates (see (a) below)
and interest rates (see (b) below).
a)
Foreign currency risk
The Group had foreign currency transactions, which exposed the Group to foreign currency risk.
F-42
The Group’s significant financial assets and liabilities denominated in foreign currencies were as follows:
Financial assets
Monetary items
SGD
Financial liabilities
Monetary items
SGD
Financial assets
Monetary items
SGD
Financial liabilities
Monetary items
SGD
Financial assets
Monetary items
SGD
Financial liabilities
Monetary items
SGD
Sensitivity analysis
Foreign
Currencies
December 31, 2016
Exchange
Rate
Carrying
Amount
$
1,627,096
0.6916 $
1,125,364
12,051,989
0.6916
8,335,631
Foreign
Currencies
December 31, 2017
Exchange
Rate
Carrying
Amount
$
1,778,293
0.7482 $
1,330,600
12,936,189
0.7482
9,679,451
Foreign
Currencies
December 31, 2018
Exchange
Rate
Carrying
Amount
$
2,297,231
0.7335 $
1,685,019
13,515,737
0.7335
9,914,437
The Group is mainly exposed to the Singapore dollar.
The following table details the Group’s sensitivity to a 5% increase and decrease in the US dollar against the relevant
foreign currency. The rate of 5% is the sensitivity rate used when reporting foreign currency risk internally to key
management personnel and represents management’s assessment of the reasonably possible change in foreign exchange
rates. The sensitivity analysis includes only outstanding foreign currency denominated monetary items. A positive number
below indicates a decrease in pre-tax loss where the US dollar strengthens 5% against the relevant currency. For a 5%
weakening of the US dollar against the relevant currency, there would be an equal and opposite impact on pre-tax loss,
and the balances below would be negative.
Profit or loss
SGD*
$
(360,513) $
(417,443) $
(411,471)
F-43
For the Year Ended December 31
2017
2016
2018
*
This is mainly attributable to the exposure to outstanding deposits in banks and loans in foreign currency at the end
of the reporting period.
b)
Interest rate risk
The Group is exposed to interest rate risk because entities in the Group borrowed funds at both fixed and floating interest
rates. The risk is managed by the Group by maintaining an appropriate mix of fixed and floating rate borrowings.
The sensitivity analysis below is determined based on the Group’s exposure to interest rates for fixed rate borrowings at
the end of the reporting period, and is prepared assuming that the amounts of liabilities outstanding at the end of the
reporting period are outstanding for the whole year. A 100-basis point increase or decrease is used when reporting interest
rate risk internally to key management personnel and represents management’s assessment of the reasonably possible
change in interest rates.
If interest rates had been 100 basis points higher/lower and all other variables were held constant, the Group’s pre-tax loss
for the years ended December 31, 2016, 2017 and 2018 would have decreased/increased by $83,356, $96,795 and
$99,144, respectively.
2)
Credit risk
Credit risk refers to the risk that a counterparty will default on its contractual obligations resulting in a financial loss to the
Group. The Group adopted a policy of only dealing with creditworthy counterparties and financial institutions, where
appropriate, as a means of mitigating the risk of financial loss from defaults.
3)
Liquidity risk
The Group manages liquidity risk by monitoring and maintaining a level of cash and cash equivalents that are deemed adequate
to finance the Group’s operations and mitigate the effects of fluctuations in cash flows. In addition, management monitors the
utilization of long-term borrowings and ensures compliance with loan covenants. The Group evaluates that, based upon the
current operating plan, the existing capital resources will be sufficient to fund the anticipated operations for at least the next 12
months.
23. TRANSACTIONS WITH RELATED PARTIES
Balances and transactions between the Company and its subsidiaries, which are related parties of the Company, have been eliminated on
consolidation and are not disclosed in this note. Details of transactions between the Group and other related parties are disclosed below.
F-44
Compensation of Key Management Personnel
Short-term employee benefits
Post-employment benefits
Share-based payments
2016
2,276,467
75,989
1,078,054
3,430,510
$
$
For the Year Ended
December 31
2017
3,203,745
125,237
801,701
4,130,683
$
$
2018
2,833,520
140,474
791,310
3,765,304
$
$
The remuneration of directors and key executives was determined by the remuneration committee based on the performance of individuals
and market trends.
24.
SEGMENT INFORMATION
The Group’s chief operating decision maker, the Chief Executive Officer, reviews the Group’s consolidated results when making decisions
about the allocation of resources and when assessing performance of the Group as a whole, and hence, the Group has only one reportable
segment. The Group does not distinguish between markets or segments for the purpose of internal reporting. The basis of information
reported to the chief operating decision maker is the same as the Group’s consolidated financial statements. As the Group’s long-lived
assets are substantially located in and derived from Asia, no geographical segments are presented.
The following is an analysis of the Group’s revenue from its major products and services.
Out-licensing
Others
$
For the Year Ended
December 31
2017
— $
2016
10,250,000 $
1,296,971
$
11,546,971 $
— $
2018
—
—
Out-licensing is the revenue generated from out-licensing to Hyundai in the amount of $250,000 and to Bristol-Myers Squibb in the
amount of $10,000,000. Others refers to the revenue generated from the sale of research materials, supplies, research documentation and
clinical trial results to Bristol-Myers Squibb. See Note 15 for details.
F-45
Exhibit 1.1
THE COMPANIES LAW (AS AMENDED)
COMPANY LIMITED BY SHARES
SIXTH AMENDED AND RESTATED
MEMORANDUM AND ARTICLES OF ASSOCIATION
OF
ASLAN PHARMACEUTICALS LIMITED
(Adopted by Special Resolution passed on 30 October 2018)
THE COMPANIES LAW (AS AMENDED)
COMPANY LIMITED BY SHARES
SIXTH AMENDED AND RESTATED
MEMORANDUM OF ASSOCIATION
OF
ASLAN PHARMACEUTICALS LIMITED
(Adopted by Special Resolution passed on 30 October 2018)
1.
2.
3.
4.
5.
6.
The name of the Company is ASLAN PHARMACEUTICALS LIMITED (the “Company”).
The registered office of the Company is situated at the offices of Intertrust Corporate Services (Cayman) Limited, 190
Elgin Avenue, George Town, Grand Cayman KY1-9005, Cayman Islands or at such other location as the Directors may
from time to time determine.
The objects for which the Company is established are unrestricted and the Company shall have full power and authority to
carry out any object not prohibited by any law as provided by Section 7(4) of the Companies Law of the Cayman Islands (as
amended) (the “Law”).
The Company shall have and be capable of exercising all the functions of a natural person of full capacity irrespective of
any question of corporate benefit as provided by Section 27(2) of the Law.
The Company will not trade in the Cayman Islands with any person, firm or corporation except in furtherance of the
business of the Company carried on outside the Cayman Islands; provided that nothing in this section shall be construed as
to prevent the Company effecting and concluding contracts in the Cayman Islands, and exercising in the Cayman Islands
all of its powers necessary for the carrying on of its business outside the Cayman Islands.
The liability of the shareholders of the Company is limited to the amount, if any, unpaid on the shares respectively held by
them.
7.
8.
The capital of the Company is NT$5,000,000,000 divided into 500,000,000 ordinary shares of a nominal or par value of
NT$10.00 each provided always that subject to the Law and the Articles of Association the Company shall have power to
redeem or purchase any of its shares and to sub-divide or consolidate the said shares or any of them and to issue all or any
part of its capital whether original, redeemed, increased or reduced with or without any preference, priority, special privilege
or other rights or subject to any postponement of rights or to any conditions or restrictions whatsoever and so that unless
the conditions of issue shall otherwise expressly provide every issue of shares whether stated to be ordinary, preference or
otherwise shall be subject to the powers on the part of the Company hereinbefore provided.
The Company will not exercise the power contained in Section 226 of the Law to deregister in the Cayman Islands and be
registered by way of continuation in some other jurisdiction.
TABLE OF CONTENTS
PAGE
CLAUSE
TABLE A
INTERPRETATION
PRELIMINARY
SHARES
MODIFICATION OF RIGHTS
CERTIFICATES
FRACTIONAL SHARES
TRANSFER OF SHARES
TRANSMISSION OF SHARES
ALTERATION OF SHARE CAPITAL
REDEMPTION AND PURCHASE OF SHARES
TREASURY SHARES
CLOSING REGISTER OR FIXING RECORD DATE
GENERAL MEETINGS
NOTICE OF GENERAL MEETINGS
PROCEEDINGS AT GENERAL MEETINGS
VOTES OF SHAREHOLDERS
CORPORATIONS ACTING BY REPRESENTATIVES AT MEETINGS
DIRECTORS
DIRECTORS’ FEES AND EXPENSES
ALTERNATE DIRECTOR
POWERS AND DUTIES OF DIRECTORS
BORROWING POWERS OF DIRECTORS
THE SEAL
DISQUALIFICATION OF DIRECTORS
PROCEEDINGS OF DIRECTORS
DIVIDENDS AND DISTRIBUTIONS
ACCOUNTS, AUDIT AND ANNUAL RETURN AND DECLARATION
AUDIT
CAPITALISATION OF RESERVES OR PROFITS
TENDER OFFER
SHARE PREMIUM ACCOUNT
NOTICES
INFORMATION
INDEMNITY
NON-RECOGNITION OF TRUSTS
FINANCIAL YEAR
WINDING- UP
i
1
1
5
5
8
8
9
9
10
10
12
13
13
14
14
15
17
19
20
21
21
22
23
23
24
25
27
28
29
29
30
30
30
31
32
32
32
32
THE COMPANIES LAW (AS AMENDED)
COMPANY LIMITED BY SHARES
SIXTH AMENDED AND RESTATED
ARTICLES OF ASSOCIATION
OF
ASLAN PHARMACEUTICALS LIMITED
(Adopted by Special Resolution passed on 30 October 2018)
TABLE A
The Regulations contained or incorporated in Table ‘A’ in the First Schedule of the Law shall not apply to ASLAN
PHARMACEUTICAL LIMITED (the “Company”) and the following Articles shall comprise the Articles of Association of the
Company.
1.
In these Articles the following defined terms will have the meanings ascribed to them, if not inconsistent with the subject or
context:
INTERPRETATION
“10% Reserve” has the meaning given thereto in Article 136;
“Applicable Listing Rules” means the relevant ROC laws, regulations, rules and code as amended, from time to time,
applicable as a result of the original and continued trading or listing of any shares on any Taiwan stock exchange or
securities market, including, without limitation the relevant provisions of Securities and Exchange Act, the Acts Governing
Relations Between Peoples of the Taiwan Area and the Mainland Area, or any similar statute and the rules and regulations
of the Taiwan authorities thereunder, and the rules and regulations promulgated by the Financial Supervisory Commission,
the Taipei Exchange (formally known as GreTai Securities Market) or the Taiwan Stock Exchange;
“Articles” means these articles of association of the Company, as amended or substituted from time to time;
“Audit Committee” means the audit committee under the Board of Directors, which shall comprise solely of Independent
Directors of the Company;
“Branch Register” means any branch register of such category or categories of Members as the Company may determine;
“Chairman” has the meaning given thereto in Article 96;
“Class” or “Classes” means any class or classes of Shares as may from time to time be issued by the Company;
“Commission” means Financial Supervisory Commission of Taiwan or any other authority for the time being administering
the Securities and Exchange Act of Taiwan;
“Constituent Company” means an existing company that is participating in a Merger with one or more other existing
companies within the meaning of the Law;
1
“Directors” and “Board of Directors” and “Board” means the directors of the Company for the time being, or as the case
may be, the directors assembled as a board or as a committee thereof;
“Directors’ Remunerations” has the meaning given thereto in Article 136;
“electronic” shall have the meaning given to it in the Electronic Transactions Law (as amended) of the Cayman Islands and
any amendment thereto or re-enactments thereof for the time being in force and includes every other law incorporated
therewith or substituted therefore;
“electronic communication” means transmission to any number, address or internet website or other electronic delivery
methods as otherwise decided and approved by not less than two-thirds of the vote of the Board;
“Emerging Market” means the emerging market board of the TPEx;
“Employees’ Remunerations” has the meaning given thereto in Article 136;
“Indemnified Person” has the meaning given thereto in Article 163;
“Independent Director” means a director who is an independent director as defined in the Applicable Listing Rules;
“Law” means the Companies Law of the Cayman Islands (as amended);
“Memorandum of Association” means the memorandum of association of the Company, as amended or substituted from
time to time;
“Merger” means the merging of two or more Constituent Companies and the vesting of their undertaking, property and
liabilities in one of such company as the Surviving Company within the meaning of the Law;
“Office” means the registered office of the Company as required by the Law;
“Ordinary Resolution” means a resolution passed by a simple majority of such Shareholders as, being entitled to do so,
vote in person or, where proxies are allowed, by proxy at a general meeting of the Company;
“paid up” means paid up as to the par value and any premium payable in respect of the issue of any Shares and includes
credited as paid up;
“Person” means any natural person, firm, company, joint venture, partnership, corporation, association or other entity
(whether or not having a separate legal personality) or any of them as the context so requires;
“preferred Shares” has the meaning given thereto in Article 12;
“Principal Register”, where the Company has established one or more Branch Registers pursuant to the Law and there
Articles, means the Register maintained by the Company pursuant to the Law and these Articles that is not designated by
the Directors as a Branch Register;
“Private Placement” means issuance of securities of the Company (including Shares, options, warrants, rights attached to
debt or equity securities to subscribe further for securities and other securities) to specific persons pursuant to the
Applicable Listing
2
Rules, but excluding any employee incentive programme or issuance of Shares in connection with meeting the Company’s
obligations under warrants, options, convertible bonds or preferred Shares;
“Register” means the register of Members of the Company required to be kept pursuant to the Law and includes any
Branch Registers established by the Company in accordance with the Law;
“Remuneration Committee” means the remuneration committee established and appointed by the Board of Directors;
“Republic of China”, “ROC” or “Taiwan” means the Republic of China, its territories, its possessions and all areas subject
to its jurisdiction;
“Seal” means the common seal of the Company (if adopted) including any facsimile thereof;
“Secretary” means any Person appointed by the Directors to perform any of the duties of the secretary of the Company;
“Securities and Futures Institute” means the Securities and Futures Institute in the Republic of China;
“Share” means a share in the capital of the Company. All references to “Shares” herein shall be deemed to be Shares of
any or all Classes as the context may require. For the avoidance of doubt in these Articles the expression “Share” shall
include a fraction of a Share;
“Share Exchange” means the transfer of all the issued shares of the Company by the Shareholders to another company in
exchange for the shares issued by such company to the Shareholders;
“Shareholder” or “Member” means a Person who is registered as the holder of Shares in the Register and includes each
subscriber to the Memorandum of Association pending the issue to such subscriber of the subscriber Share or Shares;
“Share Premium Account” means the share premium account established in accordance with these Articles and the Law;
“Shareholders’ Service Agent” means the agent licensed by Taiwan authorities to provide certain shareholders services in
accordance with the Applicable Listing Rules to the Company;
“signed” means bearing a signature or representation of a signature affixed by mechanical means or an electronic symbol
or process attached to or logically associated with an electronic communication and executed or adopted by a person with
the intent to sign the electronic communication;
“Special Resolution” means a special resolution of the Company passed in accordance with the Law, being a resolution
passed by a majority of not less than two-thirds of such Shareholders as, being entitled to do so, vote in person or, where
proxies are allowed, by proxy at a general meeting of the Company of which notice specifying the intention to propose the
resolution as a special resolution has been duly given;
3
“Spin-off” refers to an act wherein a transferor company transfers all of its independently operated business or any single
independently operated business to an existing or a newly incorporated company as consideration for that existing
transferee company or newly incorporated transferee company to issue new shares to the transferor company or to
shareholders of the transferor company;
“Subordinate Company” means a company:
(a)
(b)
of which the Company holds a majority of the total number of issued voting shares or to which the Company
contributes a majority of the total capital amount; or
over which the Company has direct or indirect managerial control of the personnel, financial or business
operations.
“Supermajority Resolution” means a resolution adopted by a majority vote of the Members at a general meeting attended
by Members who represent two-thirds or more of the total outstanding shares of the Company or, if the total number of
shares represented by the Members present at the general meeting is less than two-thirds of the total outstanding shares of
the Company, but more than one-half of the total outstanding shares of the Company, means instead, a resolution adopted
at such general meeting by the Members who represent two-thirds or more of the total number of shares entitled to vote on
such resolution at such general meeting;
“Surviving Company” means the sole remaining Constituent Company into which one or more other Constituent
Companies are merged within the meaning of Law;
“TPEx” means the Taipei Exchange in Taiwan which was formerly known as GreTai Securities Market;
“TDCC” means the Taiwan Depository & Clearing Corporation;
“Treasury Shares” means Shares that were previously issued but were purchased, redeemed, surrendered or otherwise
acquired by the Company and not cancelled in accordance with the Law, these Articles and the Applicable Listing Rules;
and
“TSE” means the Taiwan Stock Exchange.
2.
In these Articles, save where the context requires otherwise:
(a)
(b)
(c)
(d)
(e)
words importing the singular number shall include the plural number and vice versa;
words importing the masculine gender only shall include the feminine gender and any Person as the context may
require;
the word “may” shall be construed as permissive and the word “shall” shall be construed as imperative;
reference to a statutory enactment shall include reference to any amendment or re-enactment thereof for the time
being in force;
reference to any determination by the Directors shall be construed as a determination by the Directors in their
absolute discretion and shall be applicable either generally or in any particular case; and
4
3.
4.
5.
6.
7.
8.
9.
(f)
reference to “in writing” shall be construed as written or represented by any means reproducible in writing, including
any form of print, lithograph, email, facsimile, photograph or telex or represented by any other substitute or format
for storage or transmission for writing or partly one and partly another.
Subject to the last two preceding Articles, any words defined in the Law shall, if not inconsistent with the subject or context,
bear the same meaning in these Articles.
The business of the Company may be commenced at any time after incorporation.
PRELIMINARY
The Office shall be at such address in the Cayman Islands as the Directors may from time to time determine. The Company
may in addition establish and maintain such other offices and places of business and agencies in such places as the
Directors may from time to time determine.
The preliminary expenses incurred in the formation of the Company and in connection with the issue of Shares shall be
paid by the Company. Such expenses may be amortised over such period as the Directors may determine and the amount
so paid shall be charged against income and/or capital in the accounts of the Company as the Directors shall determine.
The Directors shall keep, or cause to be kept, the Register at such place as the Directors may from time to time determine
and, in the absence of any such determination, the Register shall be kept at the Office.
If the Directors consider it necessary or appropriate, the Company may establish and maintain one or more Branch
Registers as well as the Principal Register at such location or locations within or outside the Cayman Islands as the
Directors think fit, provided always that a duplicate of such Branch Register(s) shall be maintained with the Principal
Register in accordance with the Law. The Principal Register and the Branch Register(s) shall together be treated as the
Register for the purposes of the Articles.
For so long as any Shares are traded on the Emerging Market, the TPEx or the TSE, the record of the shareholders of the
Company maintained by TDCC shall be a listed shares register.
SHARES
10.
Subject to these Articles, all Shares for the time being unissued shall be under the control of the Directors who may :
(a)
issue, allot and dispose of the same to such Persons, in such manner, on such terms and having such rights and
being subject to such restrictions as they may from time to time determine; and
(b)
grant options with respect to such Shares and issue warrants or similar instruments with respect thereto;
and, for such purposes, the Directors may reserve an appropriate number of Shares for the time being unissued.
5
11.
12.
13.
14.
15.
16.
The Directors may authorise the division of Shares into any number of Classes and the different Classes shall be
authorised, established and designated (or re-designated as the case may be) and the variations in the relative rights
(including, without limitation, voting, dividend and redemption rights), restrictions, preferences, privileges and payment
obligations as between the different Classes (if any) shall be fixed and determined by the Directors.
The Company may issue Shares with rights which are preferential to those of ordinary Shares issued by the Company
(“preferred Shares”) with the approval of a majority of the Directors present at a meeting attended by two-thirds or more of
the total number of the Directors and with the approval of a Special Resolution. Prior to the issuance of any preferred
Shares approved pursuant to this Article 12, these Articles shall be amended to set forth the rights and obligations of the
preferred Shares, including but not limited to the following terms, and the same shall apply to any variation of rights of
preferred Shares:
(a)
(b)
(c)
(d)
(e)
order, fixed amount or fixed ratio of allocation of Dividends and bonus on preferred Shares;
order, fixed amount or fixed ratio of allocation of surplus assets of the Company;
order of or restriction on the voting right(s) (including declaring no voting rights whatsoever) of preferred
Shareholders;
other matters concerning rights and obligations incidental to preferred Shares; and
the method by which the Company is authorized or compelled to redeem the preferred Shares, or a statement that
redemption rights shall not apply.
The issue of new Shares of the Company shall be approved by a majority of the Directors present at a meeting attended by
two-thirds or more of the total number of the Directors. The issue of new Shares shall at all times be subject to the
sufficiency of the authorised capital of the Company.
The Company shall not issue any unpaid Shares or partly paid-up Shares. The Company shall not issue shares in bearer
form.
Where the Company increases its issued share capital by issuing new Shares for cash consideration, the Directors may
reserve ten to fifteen percent of the new shares for subscription by the employees of the Company or of any of its
Subordinate Companies who are determined by the Board in its reasonable discretion.
For so long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, unless otherwise resolved
by the Members in general meeting by Ordinary Resolution, if at anytime the Board resolves to issue any new Share, the
Company shall subject to Applicable Listing Rules, after reserving the portion of Shares for subscription by its employees
and for public offering in Taiwan pursuant to Article 15 and Article 18 respectively, first offer such remaining new Shares by
a written notice and a public announcement to each then Shareholder for their subscriptions in proportion to the number of
Shares held by them respectively, and shall state in the notice that if any Shareholder fails to subscribe for new Shares, his
right shall be forfeited. Where a fractional percentage of the original Shares being held by a Shareholder is insufficient to
subscribe for one new Share, the fractional percentages of the original Shares being held by several Shareholders may be
combined for joint subscription of one or more integral new Shares or for subscription of new Shares in the name of a single
Shareholder. New Shares left unsubscribed by original Shareholders may be open for public issuance or for subscription by
specific person or persons through negotiation.
6
17.
The Shareholders’ pre-emptive right prescribed under Article 16 shall not apply in the event that new Shares are issued due
to the following reasons or for the following purpose:
(a)
(b)
(c)
(d)
in connection with a merger with another company, or the Spin-off of the Company, or pursuant to any
reorganization of the Company;
in connection with meeting the Company’s obligation under Share subscription warrants and/or options;
in connection with meeting the Company’s obligation under corporate bonds which are convertible bonds or vested
with rights to acquire Shares;
in connection with meeting the Company’s obligation under preferred Shares vested with rights to acquire Shares;
or
(e)
in connection with a Private Placement.
18.
19.
20.
Where the Company increases its capital by issuing new Shares for cash consideration in Taiwan, the Company shall
allocate 10% of the total amount of the new Shares to be issued, for offering in Taiwan to the public unless it is not
necessary or appropriate, according to the Applicable Listing Rules, for the Company to conduct the aforementioned public
offering. Provided however, if a percentage higher than the aforementioned 10% is resolved by a general meeting to be
offered, the percentage determined by such resolution shall prevail.
The Company may, upon resolution by a majority votes at a meeting of the Board of Directors attended by two-thirds or
more of the Directors, adopt one or more employee incentive programmes pursuant to which shares, options, warrants, or
other similar instruments to acquire Shares may be granted to employees of the Company or any Subordinate Company
who meet the requirements and qualifications to subscribe for Shares; provided that, in no event shall the aggregate
number of shares to be issued pursuant to such employee incentive programs exceed fifteen percent (15%) of the then
total issued and outstanding shares of the Company. The options, warrants, or other similar instruments to acquire Shares
granted to any employee under any employee stock option plan shall be non-transferable, except to the heirs of the
employees.
Subject to Article 49, the Company may, by Special Resolution at the most recent general meeting, transfer Treasury
Shares to employees of the Company or of any of its Subordinate Company at less than the average actual repurchase
price. The Company shall have listed the following matters with respect to such transfer in the notice of that general
meeting and may not raise those matters by ad hoc motions:
(a)
(b)
(c)
the exercise price, the discount percentage, the bases of calculations, and the reasonableness thereof;
the number of Treasury Shares to be transferred, the purpose, and the reasonableness thereof;
qualification requirements for employees of the Company or of any of its Subordinate Company subscribing to the
Treasury Shares, and the number of Treasury Shares they are allowed to subscribe for;
(d)
factors affecting shareholders’ equity, including:
7
(1)
(2)
the expensable amount, and dilution of the Company’s earnings per Share;
explanation on the financial burden imposed on the Company by transferring Treasury Shares to
employees at less than the average actual repurchase price.
In previous instances where the transfer of Treasury Share to the employees have been approved at general meetings and
the Treasury Shares have been transferred, the aggregate number of Treasury Shares so transferred may not exceed 5
percent of the total issued Shares of the Company, and the aggregate number of Shares subscribed by any single
employee may not exceed 0.5 percent of total issued Shares.
The Company may issue shares being subject to the restrictions as the Directors may from time to time agree with the
employees for subscription by the employees of the Company or any subordinate company by a Supermajority Resolution,
in which event Articles 15 and 16 shall not apply. For so long as the Shares are registered in the Emerging Market or listed
on the TPEx or TSE, the issuance of such shares for employees, including but not limited to the issuance amount, issuance
price, and issuance conditions, shall be set in compliance with the Applicable Listing Rules.
MODIFICATION OF RIGHTS
Whenever the capital of the Company is divided into different Classes the rights attached to any such Class may (unless
otherwise provided by the terms of issue of the Shares of that Class) only be materially adversely varied or abrogated with
the sanction of a Special Resolution passes at a separate meeting of the holders of the Shares of that Class, but not
otherwise. To every such separate meeting all the provisions of these Articles relating to general meetings of the Company
or to the proceedings thereat shall, mutatis mutandis, apply, except that the necessary quorum shall be one or more
Persons at least holding or representing by proxy one-half in nominal or par value amount of the issued Shares of the
relevant Class (but so that if at any adjourned meeting of such holders a quorum as above defined is not present, those
Shareholders who are present shall form a quorum) and that, subject to the terms of issue of the Shares of that Class,
every Shareholder of the Class shall on a poll have one vote for each Share of the Class held by him.
The rights conferred upon the holders of the Shares of any Class issued with preferred or other rights shall not, unless
otherwise expressly provided by the terms of issue of the Shares of that Class, be deemed to be materially adversely varied
or abrogated by, inter alia, the creation, allotment or issue of further Shares ranking pari passu with or subsequent to them,
the redemption or purchase of Shares of any Class by the Company.
CERTIFICATES
Subject to the provisions of the Law, the Company may issue Shares without printing share certificates for the Shares
issued, and the details regarding such issue of Shares shall be recorded by TDCC in accordance with the Applicable Listing
Rules. Every person whose name is entered as a member in the Register may be entitled to a certificate in the form
determined by the Board of Directors if the Board of Directors resolves that a share certificate shall be issued.
In the event the Board of Directors resolves that share certificates shall be issued pursuant to Article 24 hereof, the
Company shall deliver the share certificates to the subscribers within thirty days from the date such share certificates may
be issued
8
21.
22.
23.
24.
25.
pursuant to the Law, the Memorandum of Association, the Articles, and the Applicable Listing Rules, and shall make a
public announcement prior to the delivery of such share certificates pursuant to the Applicable Listing Rules.
FRACTIONAL SHARES
26.
27.
28.
Subject to the Applicable Listing Rules and these Articles, the Directors may issue fractions of a Share and, if so issued, a
fraction of a Share shall be subject to and carry the corresponding fraction of liabilities (whether with respect to nominal or
par value, premium, contributions, calls or otherwise), limitations, preferences, privileges, qualifications, restrictions, rights
(including, without prejudice to the generality of the foregoing, voting and participation rights) and other attributes of a whole
Share. If more than one fraction of a Share of the same Class is issued to or acquired by the same Shareholder such
fractions shall be accumulated.
TRANSFER OF SHARES
Subject to the Law, Shares issued by the Company shall be freely transferable, provided that any Shares issued or
transferred to the employees of the Company or of any of its Subordinate Companies pursuant to Articles 15 or 21 or 41
may be subject to transfer restrictions for a specific period of time as may be agreed with the Company and such employee
and such period for the Shares issued or transferred to the employees pursuant to Article 15 or 41 shall be no longer than
two years.
The instrument of transfer of any Share shall be in any usual or common form or such other form as the Directors may, in
their absolute discretion, approve and be executed by or on behalf of the transferor and if so required by the Directors, shall
also be executed on behalf of the transferee and shall be accompanied by the certificate (if any) of the Shares to which it
relates and such other evidence as the Directors may reasonably require to show the right of the transferor to make the
transfer. The transferor shall be deemed to remain a Shareholder until the name of the transferee is entered in the Register
in respect of the relevant Shares. Subject to the requirements of applicable laws of the Cayman Islands, transfers of
uncertificated Shares which are registered in the Emerging Market or listed in the TPEx or the TSE may be effected by any
method of transferring or dealing in securities introduced by the TPEx or TSE or operated in accordance with the Applicable
Listing Rules as appropriate.
29.
The Board may decline to register any transfer of any Share unless:
(a)
(b)
(c)
(d)
the instrument of transfer is lodged with the Company, accompanied by the certificate (if any) for the Shares to
which it relates and such other evidence as the Board may reasonably require to show the right of the transferor to
make the transfer;
the instrument of transfer is in respect of only one class of Shares;
the instrument of transfer is properly stamped, if required; or
in the case of a transfer to joint holders, the number of joint holders to whom the Share is to be transferred does not
exceed four.
30.
The registration of transfers may be suspended when the Register is closed in accordance with Article 53.
9
31.
All instruments of transfer that are registered shall be retained by the Company, but any instrument of transfer that the
Directors decline to register shall (except in any case of fraud) be returned to the Person depositing the same.
32.
33.
34.
35.
36.
TRANSMISSION OF SHARES
The legal personal representative of a deceased sole holder of a Share shall be the only Person recognised by the
Company as having any title to the Share. In the case of a Share registered in the name of two or more holders, the
survivors or survivor, or the legal personal representatives of the deceased holder of the Share, shall be the only Person
recognised by the Company as having any title to the Share.
Any Person becoming entitled to a Share in consequence of the death or bankruptcy of a Shareholder shall upon such
evidence being produced as may from time to time be required by the Directors, have the right either to be registered as a
Shareholder in respect of the Share or, instead of being registered himself, to make such transfer of the Share as the
deceased or bankrupt Person could have made. If the person so becoming entitled shall elect to be registered himself as
holder he shall deliver or send to the Company a notice in writing signed by him stating that he so elects, but the Directors
shall, in either case, have the same right to decline or suspend registration as they would have had in the case of a transfer
of the Share by the deceased or bankrupt Person before the death or bankruptcy.
A Person becoming entitled to a Share by reason of the death or bankruptcy of a Shareholder shall be entitled to the same
dividends and other advantages to which he would be entitled if he were the registered Shareholder, except that he shall
not, before being registered as a Shareholder in respect of the Share, be entitled in respect of it to exercise any right
conferred by membership in relation to meetings of the Company; provided however, that the Directors may at any time
give notice requiring any such person to elect either to be registered himself or to transfer the Share, and if the notice is not
complied with within ninety days, the Directors may thereafter withhold payment of all dividends, bonuses or other monies
payable in respect of the Share until the requirements of the notice have been complied with.
The Company may from time to time by Ordinary Resolution increase its authorized share capital by such amount as it
thinks expedient.
ALTERATION OF SHARE CAPITAL
(a)
(b)
(c)
The Company may also by Special Resolution:
change its name;
alter or add to these Articles;
alter or add to the Memorandum of Association with respect to any objects, powers or other matters specified
therein; and
(d)
reduce its share capital and any capital redemption reserve in any manner authorised by law.
37.
The Company may also by Supermajority Resolution:
(a)
enter into, amend, or terminate any contract for lease of its business in whole, or for entrusting business, or for
regular joint operation with others;
10
(b)
(c)
(d)
(e)
(f)
(g)
(h)
transfer the whole or any material part of its business or assets;
take over the transfer of another’s whole business or assets, which will have a material effect on the business
operation of the Company;
effect any merger (other than a Merger) or Spin-off of the Company in accordance with the Applicable Listing
Rules;
grant waiver to the Director’s engaging in any business within the scope of the Company’s business;
discharge or remove any Director;
resolve to capitalize an amount standing to the credit of reserves (including a share premium account and/or profit
account), whether or not available for distribution, or subject to Cayman Islands law, distribute cash out of legal
reserve, the premium paid on the issuance of any share and income from endowments received by the Company
to the Shareholders
issue employee stock options where the exercise price for such options is lower than the closing price of the
Shares of the Company as of the issuance date (provided such exercise price shall not be less than the par value
per Share).
37A.
Notwithstanding anything to the contrary in these Articles, if the Company proposes to effect any merger,
transfer and assumption of its business or assets, share swap or spin-off, as a result of which the Company would cease to
be a TPEx-listed company and the surviving company, transferee company, existing company or newly set-up company
(depending on the circumstances) is not a company listed on TSE or TPEx, such transaction must be approved by the
Shareholders representing two thirds of the issued and outstanding shares of the Company.
38.
Subject to the Law, these Articles and the quorum requirement under the Applicable Listing Rules, with regard to the
dissolution procedures of the Company, the Company shall pass:
(a)
(b)
an Ordinary Resolution, if the Company resolves that it be wound up voluntarily because it is unable to pay its
debts as they fall due; or
a Special Resolution, if the Company resolves that it be wound up voluntarily for reasons other than the reason
stated in Article 38 (a) above.
39.
In the event any of the resolutions with respect to the paragraph (a), (b), or (c) of the preceding Article 37 is adopted by the
Shareholders at a general meeting or a Merger is approved in accordance with the provisions of the Law, any Shareholder
who has notified the Company in writing of his objection to such proposal prior to such meeting and subsequently raised his
objection at the meeting may request the Company to purchase all of his Shares at the then prevailing fair price; provided,
however, that no Shareholder shall have the abovementioned appraisal right if the Shareholders at a general meeting
resolve on the dissolution of the Company after the completion of transfer of business or assets under the paragraph (b) of
Article 37. In the event any part of the Company’s business is Spun Off or involved in any merger or Share Exchange with
any other company, the Shareholder, who has forfeited his right to vote on such matter and expressed his dissent therefor,
in writing or verbally (with a record) before or during the general meeting, may request the Company to buy back all of his
Shares at the then prevailing fair price. In the event the Company fails to reach such agreement
11
with the Shareholder within sixty days after the resolution date, the Shareholder may, within thirty days after such sixty-day
period, file a petition to any competent court of Taiwan for a ruling on the appraisal price, and to the extent that the ruling is
capable of enforcement and recognition in the relevant jurisdiction, such ruling by such Taiwan court shall be binding and
conclusive as between the Company and requested Shareholder solely with respect to the appraisal price.
REDEMPTION AND PURCHASE OF SHARES
40.
41.
42.
43.
44.
45.
Subject to the Law, the Applicable Listing Rules and these Articles, the Company may issue preferred Shares on terms that
they are to be redeemed or are liable to be redeemed at the option of the Company or the Shareholder on such terms and
in such manner as the Company may by Special Resolution, before the issue of such Shares, determine. Subject to the
Law, the preferred shares shall be redeemable pursuant to the terms; provided that the privileges accorded to preferred
shareholders by these Articles shall not be impaired.
For so long as the Shares are registered in the Emerging Market or the TPEx or TSE, matters with respect to the purchase
of its own Shares by the Company shall be approved by the Board of Directors in compliance with the Applicable Listing
Rules and the Law.
Notwithstanding Articles 40 and 41 and subject to the Law, the Company may with the sanction of an Ordinary Resolution
purchase and cancel its own Shares out of the share capital of the Company. The number of Shares to be repurchased and
cancelled pursuant to this Article shall be pro rata among the Shareholders in proportion to the number of Shares held by
each such Shareholder.
The amount payable to the Shareholders in connection with a repurchase of Shares out of the share capital of the
Company may be paid in cash or by way of delivery of assets in specie (i.e., non-cash). The assets to be delivered and the
amount of such substitutive share capital in connection with a repurchase of Shares out of the share capital of the
Company shall be approved by the Shareholders at the general meeting and shall be subject to consent by the
Shareholder receiving such assets. Prior to the general meeting considering such repurchase, the Board of Directors shall
have the value of assets to be delivered and the amount of such substitutive share capital in respect of repurchase of the
Shares audited and certified by an ROC certified public accountant.
The number of Shares purchased by the Company pursuant to the preceding Article 41 shall not exceed ten percent (10%)
of the total number of issued Shares of the Company. The total price of the Shares so purchased shall not exceed the sum
of retained earnings plus the premium paid on the issuance of any share and income from endowments received by the
Company.
The Directors or managerial officers of the Company, or their spouse, minor children (under age of 20), or any other
persons who hold the Shares for the benefits of the Directors, officers, their spouses or minor children, shall not sell or
otherwise transfer their Shares during the period when the Company is purchasing its own Shares pursuant to the Article
41.
The resolution for the purchase of the Shares by the Company pursuant to the Article 41 and the implementation thereof
shall be reported in the most recent general meeting regardless of whether the Company does purchase the Shares in
accordance with such resolution or not.
12
46.
47.
48.
49.
50.
Any Share in respect of which notice of redemption has been given shall not be entitled to participate in the profits of the
Company in respect of the period after the date specified as the date of redemption in the notice of redemption.
The redemption, purchase of any Share shall not be deemed to give rise to the redemption, purchase of any other Share.
Subject to the Law, the Applicable Listing Rules and Article 42, the Directors may when making payments in respect of
redemption or purchase of Shares, if authorised by the terms of issue of the Shares being redeemed or purchased or with
the agreement of the holder of such Shares, make such payment either in cash or in specie.
TREASURY SHARES
Subject to Article 41, Shares that the Company purchases, redeems or acquires (by way of surrender or otherwise) may, at
the option of the Company, be cancelled immediately or held as Treasury Shares in accordance with the Law. In the event
that the Directors do not specify that the relevant Shares are to be held as Treasury Shares, such Shares shall be
cancelled.
No dividend may be declared or paid, and no other distribution (whether in cash or otherwise) of the Company’s assets
(including any distribution of assets to members on a winding up) and the allotment of bonus shares may be declared or
paid in respect of a Treasury Share.
51.
The Company shall be entered in the Register as the holder of the Treasury Shares provided that:
(a)
(b)
the Company shall not be treated as a member for any purpose and shall not exercise any right in respect of the
Treasury Shares, and any purported exercise of such a right shall be void;
a Treasury Share shall not be voted, directly or indirectly, at any meeting of the Company and shall not be counted
in determining the total number of issued shares at any given time, whether for the purposes of these Articles or the
Law.
52.
Subject to Articles 20 and 41 and the Applicable Listing Rules, Treasury Shares may be disposed of by the Company on
such terms and conditions as determined by the Directors.
CLOSING REGISTER OR FIXING RECORD DATE
53.
For the purpose of determining those Members that are entitled to receive notice of, attend or vote at any meeting of
Members or any adjournment thereof, or those Members that are entitled to receive payment of any dividend, or in order to
make a determination as to who is a Member for any other purpose, the Directors may provide that the Register shall be
closed for transfers for a stated period. For so long as the Shares are registered in the Emerging Market or listed in the
TPEx or TSE, the Register shall be closed not less than the minimum period, as prescribed by the Applicable Listing Rules.
54.
The Directors shall make a public announcement of the closing of the Register on the website designated by the
Commission and the TPEx or TSE pursuant to the Applicable Listing Rules, if required.
13
55.
56.
57.
58.
59.
60.
GENERAL MEETINGS
All general meetings other than annual general meetings shall be called extraordinary general meetings.
The Board may, whenever they think fit, convene a general meeting of the Company; provided that the Company shall in
each year hold a general meeting as its annual general meeting within six months after close of each fiscal year and shall
specify the meeting as such in the notices calling it.
At these meetings the report of the Directors (if any) shall be presented. For so long as the Shares are registered in the
Emerging Market or listed in the TPEx or TSE, all general meetings shall be held in Taiwan. If the Directors resolve to hold
a general meeting outside Taiwan or the shareholder(s) obtain the approval of the Commission to hold a general meeting
outside Taiwan, the Company or such shareholders shall apply for the approval of the TPEx (or the TSE, if applicable)
thereof within two days after the board resolution or the Commission’s approval (as applicable). Where a general meeting
is to be held outside Taiwan, the Company shall engage a designated institute approved by the Commission and the TPEx
(or the TSE, if applicable) to handle the administration of such general meeting and shall allow the votes of the
Shareholders to be exercised in writing or by way of electronic transmission.
Extraordinary general meetings shall also be convened on the requisition in writing of any Shareholder or Shareholders
entitled to attend and vote at general meetings of the Company holding at least three percent (3%) of the paid up voting
share capital of the Company for a period of one year or a longer time deposited at the Office or the Shareholders’ Service
Agent specifying the subjects for discussion and the reasons, and if the Board fails to give a notice for convening such
meeting within 15 days after the date of such deposit, for so long as the Shares are registered in the Emerging Market or
listed on the TPEx or TSE, the requisitionists themselves may convene the general meeting in the same manner, as nearly
as possible, as that in which general meetings may be convened by the Directors, and all reasonable expenses incurred by
the requisitionists as a result of the failure of the Directors to convene the general meeting shall be reimbursed to them by
the Company. However, any meeting convened pursuant to this Article shall be held within three months after the expiration
of the said 15-day period.
If at any time there are no Directors, any Shareholder or Shareholders holding at least three percent (3%) of the paid up
voting share capital of the Company for a period of one year or a longer time may, subject to the approval of the
Commission for so long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, convene a
general meeting in the same manner as nearly as possible as that in which general meetings may be convened by the
Directors.
NOTICE OF GENERAL MEETINGS
At least thirty and fifteen days’ notices in writing shall be given for any annual and extraordinary general meetings,
respectively. Every notice shall be exclusive of the day on which it is given or deemed to be given and of the day for which
it is given and shall specify the place, the day and the hour of the meeting and the general nature of the business. The
notice for a general meeting may be given by means of electronic communication if the Company obtains prior consent by
the individual recipients. The Company shall make a public announcement on the website designated by the Commission
and the TPEx or TSE 30 days before an annual general meeting or 15 days before an extraordinary general meeting,
regarding the meeting notice, proxy form, explanatory materials relating to proposals for ratification, matters for resolution,
election or dismissal of directors and other matters on the meeting agenda. Where votes of shareholders are to be
exercised by way of a written ballot, a copy of the materials referred to in the preceding provision and the written ballot shall
also be sent to the Shareholders.
14
61.
The following matters shall be specified in the notice of a general meeting, and shall not be proposed as ad hoc motions:
(a)
(b)
(c)
(d)
(e)
(f)
(g)
(h)
(i)
(j)
(k)
(l)
(m)
(n)
election or discharge of directors;
amendments to these Articles;
dissolution, merger, Share Exchange or Spin-off of the Company;
repurchasing and cancelling Shares out of the share capital of the Company pursuant to Article 42;
applying for the cessation of its status as a public company;
entering into, amendment to, or termination of any contract for lease of its business in whole, or for entrusting
business, or for regular joint operation with others;
the transfer of the whole or any material part of its business or assets;
taking over another’s whole business or assets, which will have a material effect on the business operation of the
Company;
carrying out private placement of its securities;
granting waiver to the Director’s engaging in any business within the scope of business of the Company;
distributing part or all of its dividends or bonus by way of issuance of new Shares;
capitalization of the statutory reserve or any other amount prescribed under Article 151 hereof;
issuance of employee stock options where the exercise price for such options is lower than the closing price of the
Shares of the Company as of the issuance date; and
matters with respect to the issuance of restricted Shares for the employees as required by the Applicable Listing
Rules.
62.
63.
64.
For so long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, the Company shall prepare
a manual for each general meeting and the relevant materials, which will be made available to all Shareholders and shall
be published on the website designated by the Commission and the TPEx or TSE pursuant to the Applicable Listing Rules.
PROCEEDINGS AT GENERAL MEETINGS
No business shall be transacted at any general meeting unless a quorum of Shareholders is present at the time when the
meeting proceeds to business. Save as otherwise provided by these Articles, the holders of Shares being more than an
aggregate of one-half of all Shares in issue present in person or by proxy and entitled to vote shall be a quorum for all
purposes.
Shareholder(s) holding one percent or more of the total number of issued Shares immediately prior to the relevant book
close period may propose in writing to the Company a proposal for discussion at an annual general meeting. Where the
number of
15
Shares held by the Shareholder(s) making the said proposal is less than one percent (1%) of the total number of issued
Shares, or where the subject (the matter) of the said proposal cannot be settled or resolved by a resolution at a general
meeting, or that a proposal contains more than one matter, or that a proposal is submitted on a day beyond the deadline
fixed and announced by the Company for accepting shareholders’ proposals, such proposal shall not be included in the
agenda.
The Chairman, if any, of the Board of the Directors shall preside as chairman at every general meeting of the Company
convened by the Board of the Directors. For a general meeting convened by any other person having the convening right,
such person shall act as the chairman of that meeting; provided that if there are two or more persons jointly having the
convening right, the chairman of the meeting shall be elected from those persons.
If there is no such chairman, or if at any general meeting he is not present within fifteen minutes after the time appointed for
holding the meeting or is unwilling to act as chairman, any Director nominated by the Directors shall preside as chairman,
failing which the Shareholders present shall choose any Person present to be chairman of that meeting.
Unless otherwise expressly provided herein, if a quorum is not present at the time appointed for the general meeting or if
during such a general meeting a quorum ceases to be present, the chairman may postpone the general meeting to a later
time, provided, however, that the maximum number of times a general meeting may be postponed shall be two and the total
time postponed shall not exceed one hour. If the general meeting has been postponed for two times, but at the postponed
general meeting a quorum is still not present, the chairman shall declare the general meeting is dissolved, and if it is still
necessary to convene a general meeting, it shall be reconvened as a new general meeting in accordance with these
Articles. The chairman may by Ordinary Resolution (and shall if so directed by the meeting) adjourn a meeting from time to
time and from place to place, but no business shall be transacted at any adjourned meeting other than the business left
unfinished at the meeting from which the adjournment took place. When a meeting, or adjourned meeting, is adjourned for
more than five (5) days, notice of the adjourned meeting shall be given as in the case of an original meeting. Save as
aforesaid it shall not be necessary to give any notice of an adjournment or of the business to be transacted at an adjourned
meeting.
At any general meeting a resolution put to the vote of the meeting shall be decided on a poll. The number or proportion of
the votes in favour of, or against, that resolution shall be recorded in the minutes of the meeting.
Unless otherwise expressly required by the Law or these Articles, any matter which has been presented for resolution,
approval, confirmation or adoption by the Shareholders at any general meeting may be passed by an Ordinary Resolution.
The minutes of the general meeting shall be distributed to each Shareholder after the meeting and/or made public pursuant
to the Applicable Listing Rules.
65.
66.
67.
68.
69.
70.
71.
In the case of an equality of votes, the chairman of the meeting shall not be entitled to a second or casting vote.
16
VOTES OF SHAREHOLDERS
72.
Subject to any rights and restrictions for the time being attached to any Share, every Shareholder and every Person
representing a Shareholder by proxy shall have one vote for each Share of which he or the Person represented by proxy is
the holder. For so long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, subject to the
laws of the Cayman Islands and in accordance with the Applicable Listing Rules, a Shareholder shall not exercise the votes
with respect to the Shares he/it holds separately unless he/it holds certain Shares for the benefit of others; the
qualifications, scope, methods of exercise, operating procedures and other matters with respect to the exercise of votes
separately by the Shareholders shall be in compliance with the Applicable Listing Rules.
73.
No vote may be exercised with respect to any of the following Shares and such Shares shall not be counted in determining
the number of issued Shares:
(a)
(b)
the Shares held by any subsidiary of the Company, where the total number of voting shares or total shares equity
held by the Company in such a subsidiary represents more than one half of the total number of voting shares or the
total shares equity of such a subsidiary; or
the Shares held by another company, where the total number of the shares or total shares equity of that company
held by the Company and its subsidiaries directly or indirectly represents more than one half of the total number of
voting shares or the total share equity of such a company.
For so long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, if a Director gives security
over more than 50% of the number of Shares (the “Pledged Shares”) he/it held at the time he/it was elected as a Director
(the “Initial Shares”), no vote may be exercised with respect to the Shares representing the difference between the Pledged
Shares and 50% of the Initial Shares, and such Shares representing the difference between the Pledged Shares and 50%
of the Initial Shares shall not be counted in the number of the votes casted by the Shareholders present at the general
meeting. The voting restriction referred to in the preceding provision shall also apply to such Shares held by a Person who
ceases to be a Director during the period when the Register is closed for transfer for the purpose of the same general
meeting.
74.
75.
76.
In the case of joint holders, the joint holders shall select among them a representative for the exercise of their shareholder’s
rights and the vote of their representative who tenders a vote whether in person or by proxy shall be accepted to the
exclusion of the votes of the other joint holders.
A Shareholder of unsound mind, or in respect of whom an order has been made by any court having jurisdiction in mental
illness, may vote by his committee, or other Person in the nature of a committee appointed by that court, and any such
committee or other Person, may vote by proxy.
A Shareholder may appoint a proxy to attend a general meeting on his behalf by executing a proxy prepared by the
Company stating therein the scope of power authorized to the proxy. A Shareholder may only execute one proxy and
appoint one proxy for each general meeting, and shall serve such written proxy to the Company no later than five (5) days
prior to the meeting date. In case the Company receives two or more written proxies from one Shareholder, the first one
arriving at the Company shall prevail unless an explicit statement to revoke the previous written proxy is made in the
17
77.
78.
79.
80.
81.
82.
83.
proxy which comes later. In case a Shareholder who has submitted a proxy appointing a person as his or her proxy to
attend the general meeting on his or her behalf intends to attend the general meeting in person or to submit his votes by
way of a written ballot or by way of electronic transmission, he shall, at least two days prior to the date of the meeting
revoke such proxy. If a Shareholder who has submitted a proxy does not submit such a revocation before the prescribed
time, the appointment of that person as his or her proxy and the vote casted by that person as his or her proxy shall prevail.
The instrument appointing a proxy shall be in the form approved by the Board and be expressed to be for a particular
meeting only.
The instrument appointing a proxy shall be in writing under the hand of the appointor or of his attorney duly authorised in
writing or, if the appointor is a corporation, either under Seal or under the hand of an officer or attorney duly authorised. A
proxy need not be a Shareholder.
Except for trust enterprises organized under the laws of the ROC or Shareholders’ Service Agents approved by Taiwan
competent authorities, when a person who acts as the proxy for two or more Shareholders, the number of votes
represented by him shall not exceed three percent (3%) of the total number of votes of the Company and the portion of
excessive votes represented by such proxy shall not be counted.
For so long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, the use and solicitation of
proxies shall be in compliance with the Applicable Listing Rules, including but not limited to “Regulations Governing the Use
of Proxies for Attendance at Shareholder Meetings of Public Companies”.
A Shareholder cannot exercise his own vote or by proxy on behalf of another Shareholder in respect of any contract or
proposed contract or arrangement if he may be interested therein. Such Shares shall not be counted in determining the
number of votes of the Shareholders present at the said meeting with regard to such resolution, but such Shares may be
counted in determining the number of Shares represented at the meeting for the purposes of determining the quorum.
The votes may be exercised by way of a written ballot or by way of electronic transmission if the method for exercising the
votes has been described in the notice of the general meeting. The Company shall adopt the electronic transmission as one
of the methods for exercising the votes if so required pursuant to the Applicable Listing Rules. Where the Company allows
the votes of the Shareholders to be exercised by way of a written ballot or by way of electronic transmission, it shall have
listed all proposals and matters in the notice that general meeting and may not raise any matter by ad hoc motions; the
Company shall adopt the candidate nomination mechanism in accordance with the Applicable Listing Rules if the
Shareholders will elect directors at such general meeting.
A Shareholder who exercises his votes by way of a written ballot or by way of electronic transmission as set forth in the
preceding Article 82 shall be deemed to have, to the extent permitted by the Cayman Islands law and the Applicable Listing
Rules, appointed the chairman of the meeting as such Shareholder’s proxy and such appointment shall not be treated as
an appointment of any proxy as defined under the Applicable Listing Rules but any Shareholder voting in such manner shall
be deemed to waive notice of, and the right to vote in regard to, any ad hoc motion or amendment to the original agenda
items to be resolved at the said general meeting, and shall therefore not be entitled to such notice or right to vote. The
chairman of the meeting shall vote on behalf of such Shareholders according to their voting instructions. In the event that
the chairman of the
18
84.
85.
86.
87.
88.
meeting does not vote on behalf of such Shareholders according to their voting instructions, such votes shall not be
counted in determining the number of votes of the Shareholders present at the said meeting provided that such shares may
be counted in determining the number of shares of the Shareholders present at such general meeting for the purpose of
determining the quorum.
A Shareholder shall submit his vote by way of a written ballot or by way of electronic transmission to the Company no later
than the second (2nd) day prior to the scheduled meeting date of the general meeting; whereas if two or more such written
ballot or electronic transmission are submitted to the Company, the proxy deemed to be given to the chairman of the
general meeting pursuant to Article 82 by the first written ballot or transmission shall prevail unless it is expressly included
in the subsequent vote by written ballot or electronic transmission that the original vote submitted by written ballot or
electronic transmission be revoked.
In case a Shareholder who has exercised his votes by way of a written ballot or by way of electronic transmission intends to
attend the general meeting in person, he shall, at least two days prior to the date of the meeting revoke such vote by written
ballot or electronic transmission and such revocation shall constitute a revocation of the proxy deemed to be given to the
chairman of the general meeting pursuant to Article 84. If a Shareholder who has submitted his or her vote in writing or by
way of electronic transmission pursuant to Article 83 does not submit such a revocation before the prescribed time, his or
her vote by written ballot or electronic transmission and the proxy deemed to be given to the chairman of the general
meeting pursuant to Article 83 shall prevail.
If a Shareholder has submitted his or her vote in writing or by way of electronic transmission pursuant to Article 83, and has
subsequently submitted a proxy appointing a person as his or her proxy to attend the general meeting on his or her behalf,
the subsequent appointment of that person as his or her proxy shall be deemed to be a revocation of such Shareholder’s
deemed appointment of the chairman of the general meeting as his or her proxy pursuant to Article 83 and the vote casted
by that person subsequently appointed as his or her proxy shall prevail.
In case the procedure for convening a general meeting of Members or the method of adopting resolutions is in violation of
the Law, Applicable Listing Rules or these Articles, a Shareholder may, within thirty (30) days from the date of the
resolution, submit a petition for an appropriate remedy to the court of the Cayman Islands or Taiwan, and if Taiwan, the
Taipei District Court as the court of first instance to the extent available under the relevant laws.
CORPORATIONS ACTING BY REPRESENTATIVES AT MEETINGS
Any government or corporation which is a Shareholder or a Director may by resolution of its directors or other governing
body authorise such Person as it thinks fit to act as its representative at any meeting of the Company or of any meeting of
holders of a Class or of the Board of Directors or of a committee of Directors, and the Person so authorised shall be entitled
to exercise the same powers on behalf of the government/corporation which he represents as that government/corporation
could exercise if it were an individual Shareholder or Director.
19
DIRECTORS
89.
90.
91.
92.
93.
94.
95.
96.
Unless otherwise determined by the Company in general meeting, the number of Directors shall be no less than five
Directors and no more than nine Directors, the exact number of Directors to be determined from time to time solely by an
Ordinary Resolution of the general meeting. For so long as the Shares are listed on the TPEx or TSE, the Directors shall
include such number of Independent Directors as applicable law, rules or regulations or the Applicable Listing Rules require
for a foreign issuer.
For so long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, the qualifications,
composition, election, removal, duties and powers and other relevant matters of Directors, Independent Directors, Audit
Committee and Remuneration Committee shall be in compliance with the Applicable Listing Rules.
The Shareholders may in a general meeting appoint natural person or corporation to be a Director. At a general meeting of
election of Directors, the number of votes exercisable in respect of one Share shall be the same as the number of directors
to be elected, and the total number of votes per share may be consolidated for election of one candidate or may be split for
election of two or more candidates. A candidate to whom the ballots cast represent a prevailing number of votes shall be
deemed a director so elected.
So long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, the Company shall adopt a
candidate nomination mechanism for the election of the Directors and Independent Directors which is in compliance with
Applicable Listing Rules. The rules and procedures for such candidate nomination shall be in accordance with policies
established by the Directors and by an Ordinary Resolution from time to time, which policies shall be in accordance with the
Law, these Articles and the Applicable Listing Rules.
Subject to these Articles, the term for which a Director will hold office shall be three years; thereafter he/she may be eligible
for re-election. In case no election of new Directors is effected after expiration of the term of office of the existing Directors,
the term of office of such Directors shall be extended until the time new Directors are elected and assume their office.
A Director may be discharged at any time by a Supermajority Resolution adopted at a general meeting. If a Director is
discharged during the term of his/her office as a director without good cause, such Director may make a claim against the
Company for any and all damages sustained by him/her as a result of such discharge.
If prior to the expiration of the term of the existing Directors, the shareholders elect new Directors to replace all existing
Directors, unless otherwise resolved at such general meeting, the existing Directors’ office shall be deemed discharged
immediately upon the appointment of such new Directors.
The Board of Directors shall have a Chairman (the “Chairman”) elected and appointed by a majority of the Directors
present at the Board meeting the quorum of which shall be two-thirds of all of the Directors then in office. The period for
which the Chairman will hold office will also be determined by a majority of the Directors present at the Board meeting with
a quorum of at least two-thirds of all of the Directors then in office. The Chairman shall preside as chairman at every
meeting of the Board. To the extent the Chairman is not present at a meeting of the Board of Directors within fifteen
minutes after the time appointed for holding the same, the attending Directors may choose one of their number to be the
chairman of the meeting.
20
97.
The Board may, from time to time, and except as required by the applicable laws and Applicable Listing Rules, adopt,
institute, amend, modify or revoke the corporate governance policies or initiatives, which shall be intended to set forth the
policies of the Company and the Board on various corporate governance related matters as the Board shall determine by
resolution from time to time.
98.
A Director shall not be required to hold any Shares in the Company by way of qualification.
DIRECTORS’ FEES AND EXPENSES
99.
100.
101.
102.
The remuneration of the Directors may only be paid in cash. The amount of such remuneration is authorized to be decided
by the Board of Directors, taking into account suggestions made by the Remuneration Committee, the extent and value of
the services provided for the management of the Company and the standard of the same industry worldwide. Each Director
shall be entitled to be repaid or prepaid all travelling, hotel and incidental expenses reasonably incurred or expected to be
incurred by him in attending meetings of the Board or committees of the Board or general meetings or separate meetings of
any class of Shares or of debentures of the Company or otherwise in connection with the discharge of his duties as a
Director.
Any Director who, by request, goes or resides abroad for any purpose of the Company or who performs services which in
the opinion of the Board go beyond the ordinary duties of a Director may be paid such extra remuneration (whether by way
of salary, commission, participation in profits or otherwise) as the Board may determine and such extra remuneration shall
be in addition to or in substitution for any ordinary remuneration provided for by or pursuant to any other Article.
ALTERNATE DIRECTOR
Any Director may in writing appoint another Director to be his alternate and, save to the extent provided otherwise in the
form of appointment, such alternate shall have authority to act in such Director’s place at any meeting of the Directors at
which he is unable to be present. Every such alternate shall be entitled to attend and vote at meetings of the Directors as a
Director when the Director appointing him is not personally present and to have a separate vote on behalf of the Director he
is representing in addition to his own vote. A Director may at any time in writing revoke the appointment of an alternate
appointed by him. Such alternate shall not be an officer of the Company. The remuneration of such alternate shall be
payable out of the remuneration of the Director appointing him and the proportion thereof shall be agreed between them.
Any Director may appoint another Director to be the proxy of that Director to attend and vote on his behalf, in accordance
with instructions given by that Director at a meeting or meetings of the Directors which that Director is unable to attend
personally. A proxy of a Director shall accept an appointment to act as the proxy of one other Director only. The instrument
appointing the proxy shall be in writing under the hand of the appointing Director and shall be in any usual or common form
or such other form as the Directors may approve, and must be lodged with the chairman of the meeting of the Directors at
which such proxy is to be used, or first used, prior to the commencement of the meeting.
21
POWERS AND DUTIES OF DIRECTORS
103.
104.
105.
106.
107.
108.
Subject to the Law, these Articles, Applicable Listing Rules and to any resolutions passed in a general meeting, the
business of the Company shall be managed by the Directors, who may pay all expenses incurred in setting up and
registering the Company and may exercise all powers of the Company. No resolution passed by the Company in general
meeting shall invalidate any prior act of the Directors that would have been valid if that resolution had not been passed.
A Director shall have loyalty and shall exercise due care of a good administrator in conducting the business operations of
the Company; and if he/she has acted contrary thereto, he/she may be liable for the damages sustained by the Company
therefrom. If the Director does anything for himself/herself or on behalf of another person in violation of the preceding
provision subject to Cayman Islands law the Shareholders may, by Ordinary Resolution, consider the benefits to such
Director as a result of such act as benefits of the Company and request the relevant Director to return the benefits. If a
Director has, in the course of conducting the business operations of the Company, violated any provision of the applicable
laws and/or regulations and thus caused damages to any other person, subject to Cayman Islands law, he/she shall be
liable, jointly and severally, for the damages to such other person.
A managerial officer of the Company shall have the same liabilities as those of a Director in carrying out his/her duties.
The Directors may from time to time appoint any Person, whether or not a Director to hold such office in the Company as
the Directors may think necessary for the administration of the Company, including but not limited to, the office of the chief
executive officer, president, one or more vice-presidents, chief financial officer or controller, treasurer, assistant treasurer, or
manager, and for such term and at such remuneration (whether by way of salary or commission or participation in profits or
partly in one way and partly in another), and with such powers and duties as the Directors may think fit. Any Person so
appointed by the Directors may be removed by the Directors. The Directors may also appoint one or more of their number
to the office of managing director upon like terms, but any such appointment shall ipso facto determine if any managing
director ceases from any cause to be a Director, or if the Company by Supermajority Resolution resolves that his tenure of
office be terminated.
The Directors may appoint a Secretary (and if need be an assistant Secretary or assistant Secretaries) who shall hold office
for such term, at such remuneration and upon such conditions and with such powers as they think fit. Any Secretary or
assistant Secretary so appointed by the Directors may be removed by the Directors.
The Directors may delegate any of their powers to committees consisting of such member or members of their body as they
think fit; any committee so formed shall in the exercise of the powers so delegated conform to any regulations that may be
imposed on it by the Directors.
Notwithstanding anything contained in these Articles and to the extent as required by the Applicable Listing Rules, the
Company shall establish a Remuneration Committee to review the salary, stock options, and any other substantive
incentive measures for Directors and managerial officers of the Company. The composition, power and relevant matters of
the Remuneration Committee shall be subject to the Applicable Listing Rules.
22
109.
110.
111.
112.
113.
114.
The Directors may from time to time and at any time by power of attorney (whether under Seal or under hand) or otherwise
appoint any company, firm or Person or body of Persons, whether nominated directly or indirectly by the Directors, to be the
attorney or attorneys of the Company for such purposes and with such powers, authorities and discretion (not exceeding
those vested in or exercisable by the Directors under these Articles) and for such period and subject to such conditions as
they may think fit, and any such power of attorney or other appointment may contain such provisions for the protection and
convenience of Persons dealing with any such attorney as the Directors may think fit, and may also authorise any such
attorney to delegate all or any of the powers, authorities and discretion vested in him. For so long as the Shares are
registered in the Emerging Market or listed in the TPEx or TSE, the Company shall appoint in Taiwan a litigious and non-
litigious agent who shall also be the responsible person under the Applicable Listing Rules in Taiwan. Such representative
shall have a domicile or residence within the territory of Taiwan.
The Directors may from time to time provide for the management of the affairs of the Company in such manner as they
shall think fit and the provisions contained in Articles 111, 112 and 113 shall not limit the general powers conferred by this
Article.
The Directors from time to time and at any time may establish any committees, local boards or agencies for managing any
of the affairs of the Company and may appoint any Persons to be members of such committees or local boards and may
appoint any managers or agents of the Company and may fix the remuneration of any such Persons.
The Directors from time to time and at any time may delegate to any such committee, local board, manager or agent any of
the powers, authorities and discretions for the time being vested in the Directors and may authorise the members for the
time being of any such local board, or any of them to fill any vacancies therein and to act notwithstanding vacancies and
any such appointment or delegation may be made on such terms and subject to such conditions as the Directors may think
fit and the Directors may at any time remove any Person so appointed and may annul or vary any such delegation, but no
Person dealing in good faith and without notice of any such annulment or variation shall be affected thereby.
Any such delegates as aforesaid may be authorised by the Directors to sub-delegate all or any of the powers, authorities,
and discretion for the time being vested in them.
The Company shall establish an Audit Committee pursuant to the Applicable Listing Rules. The composition and
qualification of the members of the Audit Committee shall be subject to Applicable Listing Rules.
115.
The power and authority of the Audit Committee shall be subject to the Applicable Listing Rules.
BORROWING POWERS OF DIRECTORS
116.
Subject to these Articles and the Applicable Listing Rules, the Directors may exercise all the powers of the Company to
borrow money and to mortgage or charge its undertaking and property, to issue debentures, debenture stock and other
securities whenever money is borrowed or as security for any debt, liability or obligation of the Company or of any third
party.
23
THE SEAL
117.
118.
The Seal shall not be affixed to any instrument except by the authority of a resolution of the Directors provided always that
such authority may be given prior to or after the affixing of the Seal and if given after may be in general form confirming a
number of affixings of the Seal. The Seal shall be affixed in the presence of a Director or a Secretary (or an assistant
Secretary) or in the presence of any one or more Persons as the Directors may appoint for the purpose and every Person
as aforesaid shall sign every instrument to which the Seal is so affixed in their presence.
The Company may maintain a facsimile of the Seal in such countries or places as the Directors may appoint and such
facsimile Seal shall not be affixed to any instrument except by the authority of a resolution of the Directors provided always
that such authority may be given prior to or after the affixing of such facsimile Seal and if given after may be in general form
confirming a number of affixings of such facsimile Seal. The facsimile Seal shall be affixed in the presence of such Person
or Persons as the Directors shall for this purpose appoint and such Person or Persons as aforesaid shall sign every
instrument to which the facsimile Seal is so affixed in their presence and such affixing of the facsimile Seal and signing as
aforesaid shall have the same meaning and effect as if the Seal had been affixed in the presence of and the instrument
signed by a Director or a Secretary (or an assistant Secretary) or in the presence of any one or more Persons as the
Directors may appoint for the purpose.
Notwithstanding the foregoing, a Secretary or any assistant Secretary shall have the authority to affix the Seal, or the
facsimile Seal, to any instrument for the purposes of attesting authenticity of the matter contained therein but which does
not create any obligation binding on the Company.
119.
The office of Director shall be vacated, if the Director:
DISQUALIFICATION OF DIRECTORS
(a)
(b)
(c)
(d)
(e)
(f)
(g)
(h)
committed a felony and has been adjudicated guilty by a final judgment, and the time elapsed after he has served
the full term of the sentence is less than five years;
has been sentenced to imprisonment for a term of more than one year for commitment of fraud, breach of trust or
misappropriation, and the time elapsed after he has served the full term of such sentence is less than two years;
has been adjudicated guilty by a final judgment for misappropriating company or public funds during the time of his
public service, and the time elapsed after he has served the full term of such sentence is less than two years;
becomes bankrupt or makes any arrangement or composition with his creditors;
has been dishonored for unlawful use of credit instruments, and the term of such sanction has not expired yet;
losses all or part of legal capacity;
dies or is found to be or becomes of unsound mind;
resigns his office by notice in writing to the Company;
24
(i)
for so long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, has transferred more
than one half of the Shares being held by him/it on the date of the general meeting at which his/its appointment was
approved (the “Approval Date”); or
(j)
is removed from office pursuant to these Articles.
For so long as the Shares are registered in the Emerging Market or listed on the TPEx or TSE, if the Director, after the
Approval Date and before his/its commencement of the office of Director, has transferred more than one half of the Shares
being held by him/it as at the Approval Date he/it was elected or had transferred more than one half of the Shares being
held by him/it within relevant book close period prior to such general meeting, the election of his/its directorship shall be
deemed invalid.
Subject to the Law and Cayman Islands law, any Shareholder(s) holding 3% or more of the total number of issued Shares
for a period of one year or a longer time shall have the right to submit a petition for and on behalf of the Company against
its director(s), and the Taipei District Court, ROC, may be court of the first instance for this matter. If a director has, in the
course of performing his duties, committed any act resulting in material damage to the Company or in serious violation of
applicable laws and/or regulations or these Articles, but has not been removed by the Company pursuant to a
Supermajority Resolution vote, then, subject to the Law and Cayman Islands law, any Shareholder(s) holding 3% or more
of the total number of issued Shares shall have the right, within 30 days after that general meeting, to petition any
competent court for the removal of such Director, at the Company’s expense. The Taipei District Court, ROC, may be court
of the first instance for this matter.
PROCEEDINGS OF DIRECTORS
The Directors may meet together (either within or outside the Cayman Islands) for the dispatch of business, adjourn, and
otherwise regulate their meetings and proceedings as they think fit. The notice for a Board meeting may be given by
means of electronic communication. Questions arising at any meeting shall be decided by a majority of votes present at
such meeting. In case of an equality of votes the chairman shall not have a second or casting vote. A Director may, and on
the requisition of a Director shall, at any time summon a meeting of the Directors.
A Director may participate in any meeting of the Board of Directors, or of any committee appointed by the Board of
Directors of which such Director is a member, via video conference by way of which all Persons participating in such
meeting can communicate with each other and such participation shall be deemed to constitute presence in person at the
meeting.
Subject to these Articles, the quorum necessary for the transaction of the business of the Directors shall be more than one-
half of the Directors. A Director represented by an alternate Director at any meeting shall be deemed to be present for the
purposes of determining whether or not a quorum is present. When the number of vacancies in the Board of Directors of
the Company equals to one third of the total number of Directors, the Board of Directors shall hold, within 60 days, a
general meeting of Shareholders to elect succeeding Directors to fill the vacancies.
120.
121.
122.
123.
124.
A Director who is in any way, whether directly or indirectly, interested in a contract or proposed contract with the Company
or in any other matters discussed at the meeting of the Directors shall declare the nature and relevant material contents of
his interest at such meeting of the Directors. A Director cannot vote his own vote or on behalf of
25
125.
126.
another Director in respect of any contract or proposed contract or arrangement when he may be interested therein. The
voting right of such Director who cannot vote or exercise any voting right as prescribed above shall not be counted in the
number of votes of Directors present at the board meeting (but shall still be counted in the quorum for such meeting).
A Director who does anything for himself or on behalf of another person that is within the scope of the Company’s business
shall declare the essential contents of such behaviour to the general meeting of the Shareholders and be approved by a
Supermajority Resolution. Failure in obtaining such approval shall cause the Director being so interested be liable to
account to the Company for any profit realised by any such behaviour if the general meeting so resolves by an Ordinary
Resolution within one year from such behaviour.
Notwithstanding the preceding Articles, a Director may hold any other office or place of profit under the Company (other
than the office of auditor) in conjunction with his office of Director for such period and on such terms (as to remuneration
and otherwise) as the Directors may determine and no Director or intending Director shall be disqualified by his office from
contracting with the Company either with regard to his tenure of any such other office or place of profit nor shall any
Director so contracting or being so interested be liable to account to the Company for any profit realised by any such
contract or arrangement by reason of such Director holding that office or of the fiduciary relation thereby established.
127.
Subject to these Articles, any Director may act by himself or his firm in a professional capacity for the Company, and he or
his firm shall be entitled to remuneration for professional services as if he were not a Director; provided that nothing herein
contained shall authorise a Director or his firm to act as auditor to the Company.
128.
The Directors shall cause all minutes to be made in books or loose-leaf folders provided for the purpose of recording:
(a)
(b)
(c)
all appointments of officers made by the Directors;
the names of the Directors present at each meeting of the Directors and of any committee of the Directors; and
all resolutions and proceedings at all meetings of the Company, and of the Directors and of committees of
Directors.
129. When the chairman of a meeting of the Directors signs the minutes of such meeting the same shall be deemed to have
been duly held notwithstanding that all the Directors have not actually come together or that there may have been a
technical defect in the proceedings.
130.
131.
The continuing Directors may act notwithstanding any vacancy in their body but if and for so long as their number is
reduced below the number fixed by or pursuant to these Articles as the necessary quorum of Directors, the continuing
Directors may act for summoning a general meeting of the Company, but for no other purpose.
Subject to any regulations imposed on it by the Directors, a committee appointed by the Directors may elect a chairman of
its meetings. If no such chairman is elected, or if at any meeting the chairman is not present within fifteen minutes after the
time appointed for holding the meeting, the committee members present may choose one of their number to be chairman of
the meeting.
26
132.
133.
A committee appointed by the Directors may meet and adjourn as it thinks proper. Subject to any regulations imposed on it
by the Directors, questions arising at any meeting shall be determined by a majority of votes of the committee members
present.
All acts done by any meeting of the Directors or of a committee of Directors, or by any Person acting as a Director, shall
notwithstanding that it be afterwards discovered that there was some defect in the appointment of any such Director or
Person acting as aforesaid, or that they or any of them were disqualified, be as valid as if every such Person had been duly
appointed and was qualified to be a Director.
134.
The following actions require the approval of a majority of the votes of the Directors present at a Board meeting attended by
at least two-thirds of all Directors:
(a)
(b)
(c)
(d)
(e)
(f)
entering into, amendment to, or termination of any contract for lease of its business in whole, or for entrusted
business, or for regular joint operation with others;
the sale or transfer of the whole or any material part of its business or assets;
taking over the transfer of another’s whole business or assets, which will have a material effect on the business
operation of the Company;
the election of Chairman of the Board pursuant to these Articles;
issuance of corporate bonds;
the allocation of Employees’ Remunerations and Directors’ Remunerations pursuant to Article 136.
DIVIDENDS AND DISTRIBUTIONS
135.
136.
Subject to any rights and restrictions for the time being attached to any Shares, the Company by Ordinary Resolution may
declare dividends and other distributions on Shares in issue and authorise payment of the same out of the funds of the
Company lawfully available therefor. For so long as the Shares are registered in the Emerging Market or listed on the TPEx
or TSE, the Company shall not pay any dividends or bonuses if (a) it does not have earnings, or (b) it has not yet covered
its losses.
Subject to the Law, when allocating the earnings for each fiscal year, the Company shall, after paying all or reserving such
amounts for applicable taxes and offsetting losses from previous years, set aside 10% of the balance as a reserve (the
“10% Reserve”) and other special reserve or reverse special reserve pursuant to the Applicable Listing Rules, the Board of
Directors may distribute the remaining earnings together with any undistributed retained earnings accrued from prior years
of the Company as cash dividends and/or stock dividends to the Shareholders; provided that the dividends distributed to
the Shareholders pursuant to this Article 136 shall comprise no less than 1% of the net profit after tax of the relevant fiscal
year. The cash dividends shall comprise no less than [ ]% of the total dividends declared in such year.
Subject to the Law, where the Company incurs no loss it may by a Supermajority Resolution declare dividends and/or
bonuses to the Shareholders out of from the 10% Reserve, the premium paid on the issuance of any share and income
from endowments received by the Company; provided that, where the cash dividends and/or stock dividends are out of
from the 10% Reserve, only the portion of the 10% Reserve which exceeds 25 percent of the paid-in capital of the
Company may be distributed. Subject to Article 37, the Board of Directors shall prepare the plan of distributions and submit
such plan for the approval of the Shareholders at the general meeting.
27
Unless otherwise provided in the Applicable Listing Rules, where the Company makes profits before tax for the annual
financial year, the Company shall allocate (a) no less than 0.1% of such annual profits before tax for the purpose of
employees' remunerations (including employees of the Company and/or any subsidiaries of the Company) (the
"Employees' Remunerations"); and (b) a maximum of 1% of such annual profits before tax for the purpose of Directors’
remunerations (the “Directors’ Remunerations”). Notwithstanding the foregoing paragraph, if the Company has
accumulated losses of the previous years for the annual financial year, the Company shall set aside the amount of such
accumulated losses prior to the allocation of Employees' Remunerations and Directors’ Remunerations. Subject to the Law,
the Applicable Listing Rules and notwithstanding Article 151, the Employees' Remunerations and the Directors’
Remunerations may be distributed in the form of cash and/or bonus shares, upon resolution by a majority votes at a
meeting of the Board of Directors attended by two-thirds or more of the Directors. The resolutions of Board of Directors
regarding the distribution of the Employees' Remunerations and the Directors’ Remunerations in the preceding paragraph
shall be reported to the Shareholders at the general meeting after such Board resolutions are passed.
While the Company is still at the growth stage, any balance earnings together with any undistributed retained earnings
accrued from prior years of the Company may be distributed as cash dividends and/or bonus shares in accordance with the
Law and Applicable Listing Rules, after taking into consideration the investment environment, capital requirement, domestic
and overseas competition environment and capital budget of the Company current or future, as well as shareholders
interest, balance of dividend and long term financial plan of the Company.
The Company shall not be required to set aside the 10% Reserve pursuant to this Article if and when the aggregate
reserves from the 10% Reserve reach 100% of the paid-in capital of the Company.
137.
138.
139.
Any dividend may be paid by cheque sent through the post to the registered address or by remittance or otherwise to the
designated account of the Shareholder or Person entitled thereto, or in the case of joint holders, to the representative of
such joint holders at his registered address or to his designated account or to such Person and such address/account as
the Shareholder or Person entitled, or such joint holders as the case may be, may direct. Every such cheque shall be
made payable to the order of the Person to whom it is sent or to the order of such other Person as the Shareholder or
Person entitled, or such joint holders as the case may be, may direct.
Subject to any rights and restrictions for the time being attached to any Shares, all dividends shall be declared and paid
according to the number of the Shares held by the Shareholders.
If several Persons are registered as joint holders of any Share, any of them may give effectual receipts for any dividend or
other moneys payable on or in respect of the Share.
140.
No dividend shall bear interest against the Company.
ACCOUNTS, AUDIT AND ANNUAL RETURN AND DECLARATION
141.
142.
The books of account relating to the Company’s affairs shall be kept in such manner as may be determined from time to
time by the Directors.
The books of account shall be kept at the Office or at such other place or places as the Directors think fit, and shall always
be open to the inspection of the Directors.
28
143.
144.
145.
146.
147.
148.
149.
150.
The Board of Directors shall prepare and submit the business report, financial statements, and surplus earning distribution
or loss off-setting proposals to the annual general meeting of Shareholders for its ratification and after the meeting shall
distribute to each Shareholder the copies of ratified financial statements and the resolutions on the earning distribution
and/or loss offsetting and/or make them public pursuant to the Applicable Listing Rules.
The Board shall keep copies of the yearly business report and financial statements at the office of its Shareholders’ Service
Agent before ten (10) days of the annual general meeting and any of its Shareholders is entitled to inspect such documents
during normal business hours of such service agent.
Save for the Article 144 and Article 161, the Directors shall from time to time determine whether and to what extent and at
what times and places and under what conditions or regulations the accounts and books of the Company or any of them
shall be open to the inspection of Shareholders not being Directors, and no Shareholder (not being a Director) shall have
any right of inspecting any account or book or document of the Company except as conferred by law or authorised by the
Directors or by Ordinary Resolution.
The accounts relating to the Company’s affairs shall only be audited in such manner and with such financial year end as
may be determined from time to time by the Directors, or required by the Applicable Listing Rules.
The Directors in each year shall prepare, or cause to be prepared, an annual return and declaration setting forth the
particulars required by the Law and deliver a copy thereof to the Registrar of Companies in the Cayman Islands.
AUDIT
The Directors may appoint an Auditor of the Company who shall hold office until removed from office by a resolution of the
Directors and may fix his remuneration.
Every Auditor of the Company shall have a right of access at all times to the books and accounts and vouchers of the
Company and shall be entitled to require from the Directors and Officers of the Company such information and explanation
as may be necessary for the performance of the duties of the auditors.
Auditors shall, if so required by the Directors, make a report on the accounts of the Company during their tenure of office at
the next annual general meeting following their appointment, and at any time during their term of office, upon request of the
Directors or any general meeting of the Members.
151.
Subject to the Law, the Company may, with the authority of a Supermajority Resolution:
CAPITALISATION OF RESERVES OR PROFITS
(a)
(b)
resolve to capitalise an amount standing to the credit of reserves (including a share premium account, capital
redemption reserve, special capital reserve and profit and loss account), whether or not available for distribution;
appropriate the sum resolved to be capitalised to the Shareholders in proportion to the number of Shares held by
them respectively for the purpose of the payment of bonuses in the form of Shares and apply that sum on their
behalf in or towards paying up in full unissued Shares or debentures of a nominal amount equal to that sum, and
allot the Shares or debentures, credited as fully paid, to the Shareholders, or partly in one way and partly in the
other;
29
(c)
(d)
make any arrangements it thinks fit to resolve a difficulty arising in the distribution of a capitalised reserve or other
funds and in particular, without limitation, where Shares or debentures become distributable in fractions the
Directors may deal with the fractions as they think fit;
authorise a Person to enter (on behalf of all the Shareholders or other persons concerned) into an agreement with
the Company providing for the allotment to the Shareholders or other persons respectively, credited as fully paid, of
Shares or debentures to which they may be entitled on the capitalisation, and any such agreement made under this
authority being effective and binding on all those Shareholders or other persons; and
(e)
generally do all acts and things required to give effect to the resolution.
152.
For the avoidance of doubts, the allotment of bonus shares in connection with the Employees' Remunerations and
Directors’ Remunerations pursuant to Article 136 shall not require the approval of a Supermajority Resolution.
TENDER OFFER
153.
Upon the receipt of the copy of a tender offer application form and relevant documents by the Company or its litigation or
non-litigation agent appointed pursuant to the Applicable Listing Rules, the Board of Directors shall, subject to the
Applicable Listing Rules, proceed to, including but not limited to make resolution and public announcement.
154.
155.
156.
SHARE PREMIUM ACCOUNT
The Directors shall in accordance with the Law establish a share premium account and shall carry to the credit of such
account from time to time a sum equal to the amount or value of the premium paid on the issue of any Share.
There shall be debited to any share premium account on the redemption or purchase of a Share the difference between the
nominal value of such Share and the redemption or purchase price provided always that at the discretion of the Directors
such sum may be paid out of the profits of the Company or, if permitted by the Law, out of capital.
NOTICES
Except as otherwise provided in these Articles, any notice or document may be served by the Company or by the Person
entitled to give notice to any Shareholder either personally, or by facsimile, or by sending it through the post in a prepaid
letter or via a recognised courier service, fees prepaid, addressed to such Shareholder at his address as appearing in the
Register, or to the extent permitted by all applicable laws and regulations, by electronic means by transmitting it to any
electronic mail number or address such Shareholder may have positively confirmed in writing for the purpose of such
service of notices. In the case of joint holders of a Share, all notices shall be given to that one of the joint holders whose
name stands as their representative in the Register in respect of the joint holding, and notice so given shall be sufficient
notice to all the joint holders.
157.
Any Shareholder present, either personally or by proxy, at any meeting of the Company shall for all purposes be deemed to
have received due notice of such meeting and, where requisite, of the purposes for which such meeting was convened.
30
158.
Any notice or other document, if served by:
(a)
(b)
(c)
(d)
post or courier, shall be deemed to have been served five days after the time when the letter containing the same is
posted or delivered to the courier;
facsimile, shall be deemed to have been served upon production by the transmitting facsimile machine of a report
confirming transmission of the facsimile in full to the facsimile number of the recipient;
recognised courier service, shall be deemed to have been served 48 hours after the time when the letter containing
the same is delivered to the courier service; or
electronic mail, shall be deemed to have been served immediately upon the time of the transmission by electronic
mail.
In proving service by post or courier service it shall be sufficient to prove that the letter containing the notice or documents
was properly addressed and duly posted or delivered to the courier service.
159.
Any notice or document delivered or sent by post to or left at the registered address of any Shareholder in accordance with
the terms of these Articles shall notwithstanding that such Shareholder be then dead or bankrupt, and whether or not the
Company has notice of his death or bankruptcy, be deemed to have been duly served in respect of any Share registered in
the name of such Shareholder as sole or joint holder, unless his name shall at the time of the service of the notice or
document, have been removed from the Register as the holder of the Share, and such service shall for all purposes be
deemed a sufficient service of such notice or document on all Persons interested (whether jointly with or as claiming
through or under him) in the Share.
160.
Notice of every general meeting of the Company shall be given to:
(a)
(b)
all Shareholders holding Shares with the right to receive notice and who have supplied to the Company an address
for the giving of notices to them; and
every Person entitled to a Share in consequence of the death or bankruptcy of a Shareholder, who but for his death
or bankruptcy would be entitled to receive notice of the meeting.
No other Person shall be entitled to receive notices of general meetings.
INFORMATION
161.
The Board of Directors shall keep at the office of its Shareholders’ Service Agent in Taiwan copies of these Articles, the
minutes of every meeting of the Shareholders and the financial statements, the Register of Members and the counterfoil of
corporate bonds issued by the Company. Any Shareholder of the Company may request, by submitting evidentiary
document(s) to show his/her interests involved and indicating the scope of interested matters, an access to inspect and to
make copies of the Memorandum and Articles and accounting books and records.
Without prejudice to the rights set forth in these Articles, no Shareholder shall be entitled to require discovery of any
information in respect of any detail of the Company’s trading or any information which is or may be in the nature of a trade
secret or secret process which may relate to the conduct of the business of the Company and which in the opinion of the
Board would not be in the interests of the members of the Company to communicate to the public.
31
162.
The Board shall be entitled to release or disclose to any regulatory or judicial authority any information in its possession,
custody or control regarding the Company or its affairs to any of its Shareholder including, without limitation, information
contained in the Register of Members and transfer books of the Company.
INDEMNITY
163.
Every Director (including for the purposes of this Article any alternate Director appointed pursuant to the provisions of these
Articles)and other officer for the time being and from time to time of the Company (each an “Indemnified Person”) shall be
indemnified and secured harmless out of the assets and funds of the Company against all actions, proceedings, costs,
charges, expenses, losses, damages or liabilities incurred or sustained by such Indemnified Person, other than by reason
of such Indemnified Person’s own dishonesty, wilful default or fraud, in or about the conduct of the Company’s business or
affairs (including as a result of any mistake of judgment) or in the execution or discharge of his duties, powers, authorities
or discretions, including without prejudice to the generality of the foregoing, any costs, expenses, losses or liabilities
incurred by such Indemnified Person in defending (whether successfully or otherwise) any civil proceedings concerning the
Company or its affairs in any court whether in the Cayman Islands or elsewhere.
164.
The Company may purchase and maintain insurance for the benefit of the Director or the officers of the Company against
any liability incurred by him/her in his/her capacity as a Director or officer, as applicable, in order to minimize the relevant
indemnity liabilities incurred or sustained by the Company and the Shareholders.
165.
No Indemnified Person shall be liable to the Company unless such liability arises through such Indemnified Person’s own
dishonesty, wilful default or fraud.
NON-RECOGNITION OF TRUSTS
166.
Subject to the proviso hereto, no Person shall be recognised by the Company as holding any Share upon any trust and the
Company shall not, unless required by law, be bound by or be compelled in any way to recognise (even when having notice
thereof) any equitable, contingent, future or partial interest in any Share or (except only as otherwise provided by these
Articles or as the Law requires) any other right in respect of any Share except an absolute right to the entirety thereof in
each Shareholder registered in the Register, provided that, notwithstanding the foregoing, the Company shall be entitled to
recognise any such interests as shall be determined by the Directors in their absolute discretion.
167.
Unless the Directors otherwise prescribe, the financial year of the Company shall end on December 31st in each year and
shall begin on January 1st in each year.
FINANCIAL YEAR
WINDING- UP
168.
If the Company shall be wound up, and the assets available for distribution amongst the Shareholders shall be insufficient
to repay the whole of the share capital, such assets shall be distributed so that, as nearly as may be, the losses shall be
borne by the Shareholders in proportion to the number of the Shares held by them. If in a winding up the assets available
for distribution amongst the Shareholders shall be more than sufficient to repay the whole of the share capital at the
commencement of the winding up, the surplus shall be distributed amongst the Shareholders in proportion to the number of
the Shares held by them at the commencement of the winding up. This Article is without prejudice to the rights of the
holders of Shares issued upon special terms and conditions.
32
If the Company shall be wound up, the liquidator may, with the sanction of an Special Resolution and any other sanction
required by the Law and in compliance with the Applicable Listing Rules, divide amongst the Shareholders in specie or kind
the whole or any part of the assets of the Company (whether they shall consist of property of the same kind or not) and
may, for such purpose set such value as he deems fair upon any property to be divided as aforesaid and may determine
how such division shall be carried out as between the Shareholders or different Classes. The liquidator may, with the like
sanction, vest the whole or any part of such assets in trustees upon such trusts for the benefit of the Shareholders as the
liquidator, with the like sanction shall think fit, but so that no Shareholder shall be compelled to accept any asset whereon
there is any liability.
169.
The Company shall keep all statements, records of account and documents for a period of ten years from the date of the
completion of liquidation, and the custodian thereof shall be appointed by the liquidator or the Company by Ordinary
Resolution.
33
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE
ASLAN PHARMACEUTICALS PTE LTD. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY
CAUSE COMPETITIVE HARM TO ASLAN PHARMACEUTICALS PTE LTD. IF PUBLICLY DISCLOSED.
Exhibit 4.10
LICENCE AGREEMENT
FOR VARLITINIB (ASLAN001)
BETWEEN
ASLAN Pharmaceuticals Pte Ltd
AND
BioGenetics Co., Ltd.
Dated: 27th February 2019
THIS AGREEMENT is made on 27th February 2019
BETWEEN:-
(1)
(2)
ASLAN PHARMACEUTICALS PTE. LTD. (“ASLAN”), incorporated and registered in Singapore with company number
201007695N, having its principal offices at 83 Clemenceau Avenue, #12-03 UE Square, Singapore 239920; and
BIOGENETICS CO., LTD. (“BIOGENETICS”), a Republic of Korea corporation having its principal offices at 11th Liveplex
Tower, 702 Eonju-ro, Gangnam-gu, Seoul, Republic of Korea.
WHEREAS:-
A.
ASLAN owns, and has a master licence from Array BioPharma Inc. for, certain intellectual property rights and know-how
with respect to that certain chemical compound designated by ASLAN as ASLAN001, and believes that ASLAN001 has the potential to become a
therapeutic drug with significant commercial potential.
B.
ASLAN desires to find a partner capable of realizing promptly the therapeutic and commercial potential of Products in the
Territory and within the Field (terms as defined below).
C.
BIOGENETICS possesses pharmaceutical development capabilities, and desires to collaborate with ASLAN to develop the
therapeutic and commercial potential of Products in the Territory.
D.
Now, therefore, in consideration of the premises and mutual covenants herein contained, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows:
1. DEFINITIONS AND INTERPRETATION
1.1.
The definitions and rules of interpretation in this Section apply in this Agreement:
"Affiliate" shall mean, with respect to a legal entity, any corporation or other entity which directly or indirectly Controls, is Controlled
by or is under common Control with, such entity.
“Array Head Licence Agreement” shall mean a licence agreement between ASLAN and Array BioPharma Inc. originally dated 13th
July 2011 and re-entered into in amended form on 3rd January 2018 which grants exclusive worldwide rights over ASLAN001 to
ASLAN.
“ASLAN001” shall mean the synthetic chemical entity described in Schedule 1 hereto, with the generic name of varlitinib and
Improvements thereto made during the Term of this Agreement.
“ASLAN In-Licensed Know-How” means all results, data, know-how, compounds, processes, discoveries, formulations,
materials, inventions, techniques or proprietary confidential information which:
(a)
are necessary for manufacturing, applying for and obtaining marketing authorisations or licences in respect of,
marketing or selling Products; and
(b)
are licensed to ASLAN pursuant to the Array Head Licence Agreement in respect of which, and to the extent that,
ASLAN is entitled to grant a sub-licence of such know-how.
“ASLAN In-Licensed Patents” means patents and patent applications listed in Schedule 2 part (i) licensed to ASLAN at the date of
the Agreement pursuant to the Array Head Licence Agreement, to the extent that ASLAN is entitled to grant sub-licences of the same,
and to the extent that they relate to the Commercialization of Products, to the extent that ASLAN is entitled to grant sub-licences of
the same.
"ASLAN Know-How" shall mean all results, data, know-how, compounds, processes, discoveries, formulations, materials,
inventions, techniques or proprietary confidential information which:
(a)
licences in respect of, marketing or selling Products; and
(b)
are necessary for researching, developing, manufacturing, applying for and obtaining marketing authorisations or
are owned or Controlled by ASLAN as at the date of this Agreement.
"ASLAN Patents" shall mean the patents and patent applications owned or Controlled by ASLAN relating to ASLAN001 and listed
in Schedule 2 parts (i) and (ii), and any other patents and patent applications relating to Products Controlled by ASLAN from time to
time during the Licence Period covering the Territory.
“Business Day” means a day that is not a Saturday, Sunday or public holiday in Singapore or the Republic of Korea.
“Claim” means, in relation to a person, a demand, claim, action or proceeding made or brought by or against the person,
however arising.
“Commercialize” means use, apply for or obtain marketing authorizations or licences, import, sell, have sold, promote, market or
distribute, and, if agreed in accordance with Section 4.2, manufacture, have manufactured, make and have made; and
"Commercialization" shall be construed accordingly;
"Commercially Reasonable Efforts" shall mean the carrying out of obligations or tasks in a reasonable, good faith, and diligent
manner consistent with efforts and resources as commonly used by a company with experience and expertise in the
development and commercialization of pharmaceutical products, in such a company’s ordinary course of business, for a
pharmaceutical product at a similar stage of research and development, and having similar market potential to the Product, taking
into account, without limitation, issues of safety, efficacy, product profile, status of the Product, the development costs, the
regulatory environment, and other scientific factors, market conditions then prevailing, including competitive environment,
profitability, the competitiveness of alternative products that are or are expected to be in the relevant marketplace, and other
similar factors.
“Competing Product” means any product which is intended to be used for the treatment of the same disease indications as Products
(now or in the future) by means of an agent that directly binds to and inhibits the activity of (i) tyrosine kinase receptor or (ii) EGFR,
Her-2 (ErbB-2) receptor, Her-3 (ErbB-3) receptor, Her-4 (ErbB-4) receptor and/or any heterodimer combination of the Her receptor
family.
“Confidential Information” has the meaning given to it in Section 10.1.
"Control," "Controls," "Controlled" or "Controlling" shall mean:
(a)
in relation to a legal entity, the possession, directly or indirectly, of more than 50% of the issued shares in that entity or
the power to direct, or cause the direction of, the management or policies of that entity, whether through the ownership
of voting securities, by contract or otherwise; and;
(b)
in relation to Intellectual Property, possession of the ability to grant the licences or sub-licences as provided herein
without violating the terms of any agreement or other arrangements with any Third Party.
"Effective Date" shall mean 27th February 2019.
"Field" shall mean all human and animal therapeutic, diagnostic and prophylactic uses.
“First Commercial Sale” means the first commercial sale of a Product in the relevant indication in the Field in the Territory by
BIOGENETICS, or its Affiliates. Sales for clinical study purposes, “early access programs” or similar uses shall not constitute a
First Commercial Sale. In addition, sales of a Product between BIOGENETICS and its Affiliates shall not constitute a First
Commercial Sale.
“Improvement” means any improvement, development, modification or enhancement of the ASLAN Patents, the ASLAN Know-
How or the Licensed Technology, whether patentable or not.
"Intellectual Property" (or "IP") shall mean any patents, rights to inventions, registered designs, copyright and related rights,
database rights, design rights, topography rights, trade marks, service marks, trade names and domain names, trade secrets,
confidential information, rights in unpatented know-how, and any other intellectual or industrial property rights of any nature
including all applications (or rights to apply) for, and renewals or extensions of such rights and all similar or equivalent rights or
forms of protection which subsist or will subsist now or in the future in any part of the world.
“Generic Product” means with respect to the Product, a pharmaceutical product (a) containing ASLAN001 (b) that has obtained
MFDS approval in the Territory solely by means of a procedure for establishing equivalence to the Product; and (c) that is legally
marketed in such country by or under authority of an entity other than BIOGENETICS or its Affiliates.
“Liabilities” means Claims, losses, liabilities, costs, expenses or damage of any kind and however arising, including
investigative costs, court costs, legal fees, penalties, fines and interest and amounts paid in settlement.
“Licence Period” shall mean the period commencing on the Effective Date and, unless terminated earlier pursuant to the terms of
this Agreement, expiring on the tenth (10th) anniversary of the date of First Commercial Sale, subject to Section 11.2.
“Licensed Know-How” means the ASLAN Know-How, the ASLAN In-Licensed Know How and ASLAN’s interest in any
Improvements which are not patented.
“Licensed Patents” means the ASLAN Patents, and the ASLAN In-Licensed Patents.
"Licensed Technology" shall mean the Licensed Patents and the Licensed Know-How, including any right, title and interest in any
Improvements assigned to ASLAN pursuant to Section 7.11.
“Licensing Revenue” shall mean all gross revenue that BIOGENETICS receives from a Third Party in connection with the
Commercialization of the Licensed Technology.
“Material Safety Risk” means, in a Party’s reasonable belief, there is an unacceptable risk a Product will cause harm in humans
(according to the regulatory or ethical practices in the Territory) based upon: (i) pre-clinical safety data, including data from animal
toxicology studies; or (ii) the observation of serious adverse effects in humans after that Product has been administered to or taken by
humans, such as during a clinical trial or after the launch of such Product.
"MFDS" shall mean the Korean Ministry of Food and Drug Safety (formerly known as the Korea Food & Drug Administration).
"Net Sales Proceeds" shall mean in respect of direct sales to Third Parties by BIOGENETICS and its Affiliates in the Territory, the
gross invoice price charged from time to time by BIOGENETICS or by its Affiliates, together with all upfront payments, milestones
payments, or advances, as the case may be (referred to herein as the "Selling Party"), for all Products sold or supplied by the Selling
Party, in arm's length sales or supplies to Third Parties less deductions allowed to the Third Party customer by the Selling Party, to
the extent actually taken by the Third Party customer, on such sales for:
•
•
•
•
trade, quantity, and cash discounts (including to wholesalers) consistent with usual industry practice in the Territory
credits, rebates and chargebacks (including those to managed-care entities and government agencies), and allowances or
credits to customers on account of rejection or returns (including, but not limited to, wholesaler and retailer returns);
freight, postage and duties, and transportation charges specifically relating to Product, including handling and insurance
thereto; and
sales (such as VAT or its equivalent) and excise taxes, other consumption taxes, customs duties and compulsory payments
to governmental authorities and any other governmental charges imposed upon the sale of such Product to Third Parties;
In the event of supplies to Third Parties for non-cash or nil consideration, the gross invoice price charged from time to time by the
Selling Party shall be deemed to have been charged for such supply, and prices shall be calculated and payable on the basis set out in
Section 5.
Sales among the Selling Party and its Affiliates shall be excluded from the computation of Net Sales Proceeds.
"NHIP" shall mean the National Health Insurance Price in the Territory for the Product as determined and approved from time to time
by the relative government authorities.
“Party” shall mean a party to this Agreement.
"Product" shall mean, unless otherwise defined, any pharmaceutical or medicinal item, substance, formulation or dosage for human
use containing ASLAN001 as an active ingredient.
“Regulatory Filings” means, with respect to Products, any submission to MFDS or any other regulatory body in the Territory with
authority to grant marketing approvals for Products, of any regulatory application together with any material related correspondence
and documentation and shall include, without limitation, any submission to a regulatory advisory board, marketing authorization
application and any supplement or amendment thereto. For the avoidance of doubt, Regulatory Filings shall include any IND, MAA
or the equivalent in the Territory.
"Territory" shall mean the Republic of Korea.
"Third Party" shall mean any entity other than ASLAN, BIOGENETICS or any Affiliate of ASLAN or BIOGENETICS.
1.2.
1.3.
1.4.
1.5.
1.6.
1.7.
1.8.
Section, Schedule and paragraph headings shall not affect the interpretation of this Agreement.
The Schedules form part of this Agreement and shall have effect as if set out in full in the body of this
agreement and any reference to this Agreement includes the Schedules.
Unless the context otherwise requires, words in the singular include the plural and in the plural include the singular.
Unless the context otherwise requires, a reference to one gender shall include a reference to the other genders.
Writing or written includes faxes.
Any words following the terms ‘including’, ‘include’, ‘in particular’ or any similar expression shall be
construed as illustrative and shall not limit the sense of the words preceding those terms.
A ”person” includes a natural person, corporate or unincorporated body (whether or not having separate legal
personality), partnership, joint venture and a government or statutory body or authority.
1.9.
If a word is defined or phrase is defined, its other grammatical forms have the corresponding meaning.
1.10.
No rule of construction will apply to a provision to the disadvantage of a Party merely because that Party
proposed the provision or would otherwise benefit from it.
2.
LICENCE GRANT
2.1.
Subject to the terms of this Agreement, ASLAN hereby grants to BIOGENETICS an exclusive, even as to ASLAN,
license under ASLAN’s rights in the Licensed Technology to Commercialize and, if agreed in accordance with
Section 4.2, manufacture Products in the Territory in the Field. To make it clear, ASLAN shall not distribute the
Products nor grant to Third Party any license to Commercialize the Products in the Territory during the Licence
Period of this Agreement.
2.2.
All rights granted in this Agreement by ASLAN to BIOGENETICS shall be exercised in the Territory, during the
Licence Period and in accordance with the terms and conditions set out in this Agreement.
2.3.
2.4.
2.5.
For the avoidance of doubt, ASLAN shall retain all rights to the Licensed Technology other than the commercial
and (subject to Section 4.2) manufacturing rights granted to BIOGENETICS under Section 2.1.
During the Licence Period and for one (1) year thereafter, neither BIOGENETICS, nor any of its Affiliates, will
conduct, participate in, or fund, directly or indirectly, either alone or with a Third Party, the development,
manufacture or commercialization of a Competing Product, or conduct a drug discovery or other research program
the goal of which is to identify Competing Products (“Competing Products Development”); provided however,
BIOGENETICS may participate in the Competing Products Development during the Licence Period with the prior
written approval of ASLAN.
None of the rights under this Agreement may be sub-licensed or sub- contracted by BIOGENETICS unless
ASLAN’s prior written consent has been obtained; provided however, either Party may assign, transfer, sub-license
or sub-contract to any of its Affiliates.
3.
DILIGENCE
3.1.
3.2.
3.3.
BIOGENETICS and/or its Affiliates shall use Commercially Reasonable Efforts to (i) obtain marketing approvals
for Products in the Territory, and (ii) Commercialize Products in the Territory after receipt of such marketing
approvals.
BIOGENETICS’s activities under Section 3.1 shall be performed by BIOGENETICS at its sole risk and
responsibility, cost and expense, and in compliance with all applicable laws and regulatory requirements, including
without limitation GCP, GLP and GMP. Therefore, BIOGENETICS assumes full responsibility for any loss or
damage derived from the conduct and performance of this Agreement and shall be responsible for any such Claims
resulting from such activities except to the extent that such loss or damage arises out of or results from, directly or
indirectly, breach of any term of this Agreement, negligence, or wilful misconduct of ASLAN.
Information and Reports. BIOGENETICS shall keep ASLAN informed regarding the ongoing
Commercialization of Products through reasonably detailed reports to be provided to ASLAN on a semi-annual
basis, together with, if requested by ASLAN, face to face meetings or telephone conferences to discuss the same
during ordinary business hours of BIOGENETICS. Such semi-annual reports shall include summaries of all
material activities (including regulatory activities) and results with respect to the Products in the Territory. ASLAN
shall keep BIOGENETICS informed regarding the ongoing development status of Products including but not
limited to any clinical trial studies, registration status and price information in other countries except for the
Territory through reasonably detailed reports to be provided to BIOGENETICS on a semi-annual basis, together
with, if requested by BIOGENETICS, face to face meetings or telephone conferences to discuss the same during
ordinary business hours of ASLAN. Notwithstanding the foregoing, and for the purposes of Section 5.2:
3.4.
(a) ASLAN shall promptly (and in any event within 30 days) inform BIOGENETICS of the occurrence of FDA
approval for the first indication for a Product; and
(b) BIOGENETICS shall promptly (and in any event within 30 days) inform ASLAN of the occurrence of the other
events relating to Products triggering milestone payments set out in Section 5.2.
Responsibility for regulatory interactions. BIOGENETICS shall be responsible for the preparation and filing of
any and all Regulatory Filings. ASLAN shall use Commercially Reasonable Efforts to provide BIOGENETICS
with appropriate documents and data required, and general cooperation, to enable the dossiers and other
documentation required for MFDS submissions and other Regulatory Filings to be completed. All such Regulatory
Filings will be filed in BIOGENETICS’ name and/or on its behalf. BIOGENETICS shall promptly notify ASLAN
of all Regulatory Filings submitted or received by BIOGENETICS or its Affiliates with respect to Products, and
upon ASLAN’s request, shall provide to ASLAN one paper copy or electronic file of all such regulatory
Filings. Additionally, BIOGENETICS will upon ASLAN’s request, to the extent reasonably required to confirm
BIOGENETICS’ compliance with its obligations hereunder, provide ASLAN with reasonable additional
information and data generated by or on behalf of BIOGENETICS in such semi-annual period, it being understood
that ASLAN shall keep such information and data in strict confidence. Notwithstanding the foregoing, prior to any
application for determination of NHIP for Products, BIOGENETICS and ASLAN shall discuss the range of target
pricing to seek in such application, including a lowest acceptable price, and ASLAN’s prior approval (not to be
unreasonably withheld or delayed) shall be obtained before such application is made. Any formal acceptance by
BIOGENETICS of a NHIP price proposed by the relative government authorities which is lower than the lowest
acceptable price agreed with ASLAN beforehand, shall require prior discussion with ASLAN and ASLAN’s prior
approval, which shall not be unreasonably withheld or delayed.
3.5.
The Parties shall establish procedures for the exchange and reporting of all adverse events related to the Product,
which shall be governed by a Pharmacovigilance & Safety Exchange Agreement, to be entered into in due course.
4.
MANUFACTURE & SUPPLY
4.1
4.2
ASLAN agrees to provide clinical drug supplies to BIOGENETICS required for Regulatory Filings by or on behalf
of BIOGENETICS and for Commercialisation of Products, pursuant to a separate manufacturing and supply
agreement to be negotiated in good faith by the Parties and which the Parties shall use Commercially Reasonable
Efforts to enter into no later than 30th June 2020.
Notwithstanding the foregoing, that if BIOGENETICS wishes to manufacture by itself or have manufactured by a
third party the Products during the Licence Period under this Agreement, ASLAN agrees to engage in good faith
discussions, using Commercially Reasonable Efforts, to negotiate and execute a manufacturing licence conferring
such rights on BIOGENETICS.
5.
PAYMENTS TO ASLAN
5.1
Initial Payment. In consideration of the licenses and rights granted to BIOGENETICS hereunder, BIOGENETICS
shall pay to ASLAN an initial payment of two million USD (US $2,000,000) (“the Initial Payment”), to be paid no
later than fifteen (15) days of ASLAN’s invoice for the same, which may be issued to BIOGENETICS any time from
mutual signature of this Agreement. The Initial Payment shall consist of (i) an upfront licence fee component, and
(b) a reimbursement component, to cover ASLAN’s costs associated with the development of the Product in the
Territory up to the Effective Date. The Parties shall work in good faith to agree the relative allocation of the
different components of the Initial Payment in writing as soon as possible after the Effective Date [and in any event
no later than 31st March 2019]. The Parties acknowledge that BIOGENETICS may be required to pay Korean
withholding tax (“WHT”) at a rate of […***…] percent ([…***…] %) on all or part of the Initial Payment,
depending on the agreed allocation and the WHT treatment in Korea of the different components, but that as of the
Effective Date this issue has not been finally determined between the Parties. Accordingly BIOGENETICS shall be
entitled to retain fifty per cent (50%) of the estimated maximum potential WHT charge on the Initial Payment, that
is, the sum of […***…] USD ($[…***…]) (“the WHT Retention”) to cover potential WHT liability. If a suitably
qualified tax expert agreeable to both Parties determines that a sum exceeding the WHT Retention is required to be
paid by BIOGENETICS to the Korean National Tax Service (the “WHT Balance”), then ASLAN undertakes, upon
BIOGENETICS’s request, to remit the whole of the WHT Balance to BIOGENETICS no later than 5th April 2019.
On the other hand, if a suitably qualified tax expert agreeable to both Parties determines that a sum less than the
WHT Retention is required to be paid by BIOGENETICS to the Korean National Tax Service, then BIOGENETICS
undertakes, upon ASLAN’s request, to remit to ASLAN, no later than 5th April 2019, the whole or whatever portion
of the WHT Retention is not required to be paid to the Korean National Tax Service.
5.2
Development Milestones. Upon achieving certain development milestones as set out below, BIOGENETICS will
make one-time milestone payments to ASLAN:
Event
First indication - FDA approval:
First indication - MFDS approval:
First indication - NHIP price listing in the Territory:
Second indication - First Commercial Sale
Third indication - First Commercial Sale
The provisions of Section 6 shall apply in respect of ASLAN’s obligation to keep records and accounts in respect of ASLAN001
development costs and BIOGENETICS’s right of audit, mutatis mutandis.
Payment
USD$[…***…] ([…***…] dollars)
USD$[…***…] ([…***…] dollars)
USD$[…***…] ([…***…] dollars)
USD$[…***…] ([…***…] dollars)
USD$[…***…] ([…***…] dollars)
5.3
Sales Milestones. Upon achieving certain sales milestones as set out below, BIOGENETICS will make one-time
milestone payments to ASLAN:
Event
Annual Net Sales in Territory exceed $[…***…] ([…***…]
US dollars):
Payment
USD$[…***…] ([…***…] dollars)
Annual Net Sales in Territory exceed $[…***…] ([…***…]
US dollars):
USD$[…***…] ([…***…] dollars)
Annual Net Sales in Territory exceed $[…***…] ([…***…]
US dollars):
USD$[…***…] ([…***…] dollars)
Annual Net Sales in Territory exceed $[…***…] ([…***…]
US dollars):
USD$[…***…] ([…***…] dollars)
Annual Net Sales in Territory exceed $[…***…] ([…***…]
US dollars):
USD$[…***…] ([…***…] dollars)
Annual Net Sales in Territory exceed $[…***…] ([…***…]
US dollars):
USD$[…***…] ([…***…] dollars)
Where the Product is approved in different indications, Net Sales for the different indications for that drug shall be
aggregated for the purposes of calculating whether Net Sales during any calendar year have reached milestones as set out
above.
5.3A
Royalties. Royalties shall be paid by BIOGENETICS to ASLAN in accordance with this Section 5.3 on Net Sales of
the Products in the Territory in the Field, as follows:
For Net Sales up to the equivalent of US$[…***…] ([…***…]
US dollars) during any particular calendar year:
For Net Sales above the equivalent of US$[…***…] ([…***…]
US dollars) and up to US$[…***…] ([…***…] US dollars)
during any particular calendar year
For Net Sales above the equivalent of US$[…***…] ([…***…]
US dollars) during any particular calendar year
[…***…]% ([…***…] percent) on Net Sales
[…***…]% ([…***…] percent) on Net Sales
[…***…]% ([…***…] percent) on Net Sales
5.4
5.5
Payments to ASLAN shall be on a quarterly basis and in US dollars and shall be made within thirty (30) days
following the applicable calendar quarter.
Taxes. BIOGENETICS agrees to pay to ASLAN the full amount of all payments stated in this Agreement without
deductions, subject to compliance with applicable laws. For the avoidance of doubt, ASLAN shall bear ultimate
liability for any tax or duties arising as a result of such payments (whether in Singapore, the Territory or otherwise).
In the event that BIOGENETICS is required to withhold any taxes on amounts payable to ASLAN in accordance
with applicable
laws, each Party agrees to provide the other with reasonable assistance including provision of any tax forms,
evidence of taxes withheld and such other information as may be reasonably necessary in order for the paying Party
not to withhold tax, to withhold tax at a reduced rate under an applicable bilateral income tax treaty or for ASLAN to
reclaim withheld tax.
5.6
Statement. At the time of each quarterly payment in accordance with Section 5.4, BIOGENETICS shall provide
ASLAN with a statement specifying:
5.6.1
5.6.2
5.6.3
5.6.4
5.6.5
5.6.6
5.6.7
the nature of and amount of the payment received that contributes to Licensing Revenue (including
copies of any notifications, reports or statements from any Third Party relating to the contribution);
the calculation of Licensing Revenue based on such payment including details and amount of any
deductions made in calculating such revenue;
details of any exchange rates used to convert any currencies;
details of the Net Sales for the period of the statement; and
a statement of the amount of payment due to ASLAN in respect of such Licensing Revenue;
upon receipt of such statement, ASLAN may issue an invoice to BIOGENETICS for such amount.
Within 30 days of receipt of such invoice, BIOGENETICS must remit payment to ASLAN to a bank
account nominated by ASLAN
in respect of the fourth quarter of each calendar year, where there has been over- or under-payment to
ASLAN over the previous calendar year based on the rates applicable for Net Sales in each calendar year,
an explanation of any relevant adjustments (up or down) in the payment for that fourth quarter.
5.7
5.8
5.9
Royalty Term. Royalties payable under this Section 5 shall be paid on a Product-by-Product basis with respect to
Net Sales made during the Licence Period.
Generics. From the time that the Licensed Patents have expired and one or more Third Parties is selling a Generic
Product in the Territory, then as from the next quarter year the royalty applicable under Section 5.3 shall be
discounted by […***…] per cent ([…***…]) %.
Interest. Where ASLAN does not receive payment of any sum required on or before the day on which such
payment is due, BIOGENETICS shall pay ASLAN interest on the past due amount as follows: interest shall accrue
thereafter on the sum due and owing to ASLAN at the lesser of seven percent (7%) over the LIBOR rate for a three
month deposit in US dollars on the last Business Day of the previous calendar month, or the maximum amount
allowed by law, with interest to accrue on a day to day basis without prejudice to ASLAN’s right to receive payment
on the due date.
5.10
Economic Viability. If any of the following apply:
(a)
(b)
(c)
sales of Generic Products in the Territory result in an erosion of 60% or more of the price of Products in the
Territory from the price at First Commercial Sale;
fluctuations in the exchange rate between the South Korean won and US dollar for a continuous period of more
than two (2) months, resulting in a differential of higher than twenty per cent (20%) in comparison to the
exchange rate in force on the date of signature of this Agreement; or
the official Korean reimbursement price for a Product as determined from time to time by the respective
governmental authority shows dramatic change (that is to say, at the end of any two month period there has
been a more than 10% aggregate increase or decrease),
the Parties shall meet together either face to face or by telephone conference to discuss how to proceed, including without
limitation adjusting NHIP with the consent of both Parties..
5.11
Array Head Licence Agreement. BIOGENETICS will take all reasonable steps to assist ASLAN in ensuring that it
complies with its obligations under the Array Head Licence Agreement.
6.
RECORDS AND ACCOUNTS
6.1.
6.2.
6.3.
6.4.
BIOGENETICS must keep complete and accurate records of all matters connected with the Commercialization of
Products and must also keep proper accounts in relation to Licensing Revenue and other payments payable to
ASLAN under this Agreement containing all data necessary for the calculation of the amounts payable to ASLAN
pursuant to this Agreement. BIOGENETICS must keep those records and books of account for five (5) years
following the end of the year to which they relate.
Not more than once in any twelve (12) month period, BIOGENETICS must permit during business hours an
independent accountant nominated by ASLAN to inspect the records and accounts maintained under Section 6.1 for
the purpose of verifying their accuracy with a prior notice of ten (10) Business Days, and confirming whether all
payments payable to ASLAN under this Agreement have been properly calculated and paid by BIOGENETICS.
BIOGENETICS must provide to the accountant such assistance as is reasonably required by that person in order to
verify the accuracy of those records and accounts and confirm whether all payments payable to ASLAN under this
Agreement have been properly calculated and paid by BIOGENETICS.
If ASLAN’s inspection reveals that any monies are outstanding then BIOGENETICS must, within 30 days after
receiving notice of the amount due, pay ASLAN the outstanding amount. If the inspection reveals there was an
overpayment then the amount of the overpayment may be credited against future payments due to ASLAN under
this Agreement.
6.5.
ASLAN shall bear the cost of the independent accountant appointed under this Section 6 except if the inspection
reveals that any monies are outstanding by more than 5%, in which case BIOGENETICS must pay ASLAN’s
reasonable inspection costs.
7.
INTELLECTUAL PROPERTY
Patent Prosecution
7.1.
7.2.
7.3.
ASLAN shall have the right to control the preparation, filing, prosecution and maintenance of all the ASLAN
Patents. ASLAN shall give BIOGENETICS an opportunity to review and comment on the text of each patent
application for the Territory within the ASLAN Patents, as well as any other material submissions related to the
ASLAN Patents in the Territory before filing, and shall supply BIOGENETICS with a copy of such patent
application as filed, together with notice of its filing date and serial number. BIOGENETICS has a right to make
reasonable recommendations in relation to the filing, prosecution, maintenance, enforcement and defence of the
ASLAN Patents in the Territory and ASLAN shall accept BIOGENETICS’ recommendations, in good faith, unless
such recommendations would adversely affect the ASLAN Patents in the Territory.
BIOGENETICS shall reimburse ASLAN for the amounts paid to Third Parties by ASLAN in connection with the
filing, prosecution and maintenance of the ASLAN Patents in the Territory as from the Effective Date, including
without limitation, amounts paid by ASLAN as filing and maintenance fees, translation fees and amounts paid to
outside patent counsel and foreign associates (“Patent Costs”). ASLAN shall provide BIOGENETICS with an
invoice for Patent Costs on a monthly basis, and payment shall be due within thirty (30) days thereafter.
If ASLAN, in its sole discretion, which discretion shall not be exercised unreasonably, decides to abandon the
preparation, filing, prosecution or maintenance of any patent or patent application in the ASLAN Patents in the
Territory, then ASLAN shall notify BIOGENETICS in writing thereof at least ninety(90) days prior to any due date
that requires action to avoid loss of rights in connection with the applicable patent and/or patent application, and
following the date of such notice BIOGENETICS shall have the right, at its cost, to prosecute and maintain such
patents and patent applications in ASLAN’s name, provided that BIOGENETICS shall give ASLAN an
opportunity to review and comment on the text of each patent application or other material submissions related to
the ASLAN Patents before filing, and shall supply ASLAN with a copy of such patent application as filed, together
with notice of its filing date and serial number.
Enforcement
7.4.
In the event that either Party becomes aware of actual or threatened infringement of any ASLAN Patents in the
Territory by the manufacture or sale or use of a Product or competing product in the Field (“Infringing Product”),
it shall provide the other Party with the available evidence, if any, of such infringement.
7.5.
7.6.
7.7.
ASLAN, at its sole expense, shall have the initial right to initiate and control any enforcement of the ASLAN
Patents in the Territory with respect to an Infringing Product or to defend any declaratory judgments seeking to
invalidate or hold the ASLAN Patents unenforceable (each, an “Enforcement Action”), in each case in ASLAN’s
own name and, if necessary for standing purposes, in the name of BIOGENETICS or its nominee and shall protect,
in good faith, the interests of BIOGENETICS in taking such enforcement action. If ASLAN does not, within one
hundred twenty (120) days of receipt of notice from BIOGENETICS, take significant steps to abate the
infringement or file suit to enforce the ASLAN Patents against at least one infringing party in the Territory,
BIOGENETICS shall have the right to take whatever action it deems appropriate, acting in good faith and
reasonably, to enforce the ASLAN Patents. To make it clear of the responsibilities on the costs and expenses for
the afore-mentioned enforcement action taken by BIOGENETICS, ASLAN shall fully reimburse the reasonable
costs and expenses incurred to BIOGENETICS unless BIOGENETICS has breached the terms and conditions of
this Agreement. The Party controlling any such enforcement action shall not settle the action or otherwise consent
to an adverse judgment in such action that diminishes the rights or interests of the non-controlling Party (including
in the case of BIOGENETICS, entering into any settlement admitting the invalidity of, or otherwise impairing, the
ASLAN Patents) without the prior written consent of the other Party. All monies recovered upon the final
judgment or settlement of any such suit to enforce the ASLAN Patents shall be shared, after reimbursement of
expenses, as follows: (i) in the event that ASLAN brought the claim, suit or action, any remaining amount shall be
shared eighty percent (80%) to ASLAN, 20% to BIOGENETICS , and (ii) in the event that BIOGENETICS
brought the claim, suit or action, any remaining amount shall be retained by BIOGENETICS.
In any suit to enforce and/or defend the ASLAN Patents pursuant to this Section 7, the Party not in control of such
suit (a) shall, at the request and expense of the controlling Party, (b) reasonably cooperate and, to the extent
possible, have its employees testify when requested and make available relevant records, papers, information,
samples, specimens, and the like, and (c) further agrees to be named in and consents to join in any suit, action, or
proceeding as a party to the suit, action, or proceeding to the extent necessary to establish standing in the suit,
action, or proceeding.
If a Third Party asserts that a patent or other right owned by it is infringed by the manufacture, use, marketing, sale
or importation of any Product, the Party becoming aware of such a matter shall immediately notify the other of it.
ASLAN shall have the right to initiate, prosecute, defend and control legal action (whether by suit, proceedings,
counter-claim, oppositions, customs procedure or otherwise) in respect of any such assertion. BIOGENETICS shall
have the right actively to co-operate and join with ASLAN in any legal action if (acting in good faith and
reasonably) it considers it necessary or desirable, and ASLAN shall have the right to have BIOGENETICS and/or
its nominee joined as a passive party to any legal action if necessary, and in either circumstance each party shall
reasonably co-operate with the other in regard to the same. All costs and expenses (including attorneys' fees) of any
legal action brought in accordance with this Section 7.7 shall be borne by ASLAN, provided that where ASLAN is
bearing BIOGENETICS’s costs and expenses (including attorneys' fees) if BIOGENETICS actively elects to be
joined as a party to such action (as above), these shall be reasonable. Any monetary recovery in connection with
legal action shall be applied first to reimburse ASLAN for its out-of-pocket costs and
7.8.
7.9.
7.10.
7.11.
expenses (including management time and reasonable attorneys' fees) incurred in connection with any legal action.
The remainder shall be split between the Parties in proportion to the relative degree of their active involvement in
connection with the action, but if the Parties, acting in good faith, cannot agree such relative proportions, then on
the basis of 50% to BIOGENETICS and 50% to ASLAN.
Patent Marking. BIOGENETICS agrees to mark and have its Affiliates mark all patented Products they sell or
distribute pursuant to this Agreement in accordance with the applicable patent statutes or regulations in the
Territory.
Patent Term Extensions. The Parties will reasonably discuss patent term adjustment, patent term extension,
supplemental patent protection or related extension of rights with respect to ASLAN Patents in the Territory. To
the extent permitted by applicable law, ASLAN shall apply for and pursue any such adjustment, extension or
protection as directed by BIOGENETICS, at BIOGENETICS’ cost.
Improvements by ASLAN. If any Improvements are made by ASLAN or its Third Party collaborators during
the Licence Period, the Parties acknowledge that ASLAN will own such Improvements and the Intellectual
Property therein. ASLAN will promptly disclose such Improvements to BIOGENETICS and they will form part of
the Licensed Technology licensed hereunder.
Improvements by BIOGENETICS. All rights, title and interest in any Improvements made by or on behalf of
BIOGENETICS or its Affiliates during the Licence Period shall be owned by ASLAN; and BIOGENETICS hereby
assigns all of its rights, title and interest in and to such Improvements to ASLAN and agrees to do all such other
acts as appropriate to allow ASLAN to perfect such rights, title and interest. BIOGENETICS will promptly disclose
such BIOGENETICS Improvements to ASLAN if they are necessary or useful to the development or
Commercialization of Products.
8.
WARRANTIES
8.1.
Each of the Parties warrants that:
8.1.1
8.1.2
8.1.3
it has full power and authority to enter into and observe the obligations under this Agreement and,
for the avoidance of doubt ASLAN warrants that the Licensed Patents and the Licensed Know-how are
either owned or Controlled by it;
to the best of its actual knowledge as at the Effective Date, its entry into and performance under the terms
of this Agreement will not infringe the rights of any Third Party or cause it to be in breach of any
obligations to a Third Party;
all information, data and materials provided by it to the other pursuant to this Agreement will be, to the
best of its knowledge and belief, accurate and complete in all material respects.
8.2.
ASLAN warrants that, to the best of its actual knowledge as at the Effective Date:
8.2.1
8.2.2
the exercise by BIOGENETICS of the licence rights granted to BIOGENETICS under Section 2 does not
infringe the rights of any Third Party and any terms and conditions of Array Head Licence Agreement;
no Third Party has threatened or, so far as it is aware, is currently threatening proceedings in respect of
infringement of any the Licensed Patents and the Licensed Know-how, and none of the same is the subject
of any actual or, so far as it is aware, threatened challenge, opposition or revocation proceedings.
8.3.
8.4.
8.5.
Any condition, warranty or other term which is not expressly set out in this Agreement which might
otherwise be implied or incorporated into this Agreement, whether by statute, common law or otherwise, is,
insofar as it is lawful to do so, hereby excluded.
Compliance with Law. Each Party covenants to the other that it will comply with all applicable laws as
amended, in carrying out its obligations pursuant to this Agreement. Each Party covenants to the other that it and
any sub-contractor legitimately appointed by it currently holds or at the relevant time will hold any and all consents,
approvals, orders or authorizations necessary to comply with its obligations under this Agreement.
Disclaimers. Without prejudice to ASLAN's warranties set out in Sections 8.1 and 8.2, BIOGENETICS
acknowledges that ASLAN licences the Licensed Technology “as is”, that is, without any warranty of any
kind, express or implied, including, without limitation, warranty of its accuracy or completeness, of
merchantability, fitness for a particular purpose (including but not limited to manufacture the Product or conduct
the development), commercial value, and without any warranty of any kind, express or implied, of the
inexistence of adverse effects, of the safety or other quality, efficiency, stability, characteristics or usefulness
of, or merchantability, or fitness for a particular purpose of any Product.
9.
LIABILITY
9.1.
BIOGENETICS Indemnities. BIOGENETICS shall indemnify, keep indemnified and hold harmless ASLAN,
its Affiliates and their directors, officers and employees (“ASLAN Indemnitees”) from and against all
Liabilities incurred in connection with any Third Party claim arising out of or resulting from:
9.1.1
9.1.2
9.1.3
breach of any term of this Agreement by BIOGENETICS, or its Affiliates, contractors or sub-licensees;
the negligence, recklessness or wilful misconduct of BIOGENETICS, its Affiliates or its contractors or
sub-licensees;
the Commercialization of Products by BIOGENETICS or its Affiliates, sub-licensees or contractors
or any end-use of such Products in a manner and for a purpose authorised by any of them,
except to the extent that the Liabilities arise out of or result from, directly or indirectly, breach of any term of
this Agreement, negligence, or wilful misconduct of any ASLAN Indemnitees.
9.2.
ASLAN Indemnities. ASLAN shall indemnify, keep indemnified and hold harmless BIOGENETICS and its
Affiliates, directors, officers and employees (“BIOGENETICS Indemnitees”) from and against all Liabilities
incurred in connection with any Third Party claim arising out of or resulting from:
9.2.1
9.2.2
breach of any term of this Agreement by ASLAN, or its Affiliates, contractors or sub-licensees;
the negligence, recklessness or wilful misconduct of ASLAN or its Affiliates or contractors in the
performance of its obligations under this Agreement,
except to the extent that the Liabilities arise out of or result from, directly or indirectly, breach of any term of
this Agreement, negligence, or wilful misconduct of any BIOGENETICS Indemnitees.
9.3.
It is a condition of indemnification under this Agreement that:
9.3.1
9.3.2
9.3.3
the indemnified Party gives written notice to the indemnifying Party of the Claim in respect of which
indemnification is sought promptly on becoming aware of it and does not at any time admit liability or
otherwise attempt to settle or compromise such Claim without the indemnifying Party’s prior written
consent;
the indemnifying Party shall, at its cost, have sole conduct of the defence or compromise of any such
Claim and as between the indemnifying Party and the indemnified Party shall have the sole right to
any costs and damages awarded as a result of any such Claim; and
the indemnified Party provides the indemnifying Party such assistance and co-operation as it shall
reasonably require, at the indemnifying Party’s reasonable cost, in respect of the conduct of such defence
or compromise.
9.4.
9.5.
Insurance. During the Licence Period, each Party, at its own expense, shall maintain product liability and other
appropriate insurance or self-insure in an amount consistent with industry standards to a reasonably adequate
level, and upon request each Party shall provide proof of such coverage to the other Party.
Excluded Liabilities. Subject to this Section 9.5, the Parties agree that with respect to any claim by one Party
against the other arising out of the performance or failure of performance of the other Party under this Agreement,
a Party shall be liable to the other Party for direct damages only and shall not be liable for any indirect or
consequential loss or damage whatsoever arising under or in relation to the Agreement whether arising from
breach of contract (including under any indemnity), misrepresentation (whether tortuous or statutory), tort
(including negligence), breach of statutory duty, strict liability including but not limited to loss of profits, loss of
business, loss of goodwill or similar loss, regardless of whether arising from warranty, strict liability or otherwise
or any other legal theory howsoever
arising, even if that Party was aware of the possibility that such loss or damage might be incurred by the other,
except as a result of a Party’s wilful misconduct. Nothing in this Section 9.5 is intended to limit or restrict the
rights or obligations of either Party under Section 8 [Warranties] or to limit a Party’s liability in respect of
wilful misconduct.
10.
CONFIDENTIALITY
10.1.
Confidentiality; Exceptions. In this Agreement, “Confidential Information” means any information and
materials disclosed or made available to one Party by or on behalf of the other Party in connection with this
Agreement, whether disclosed in writing, orally or by any other means and regardless of the date it was
disclosed, except to the extent that it can be established by the receiving Party that such Confidential
Information:
10.1.1
10.1.2
10.1.3
10.1.4
10.1.5
is in the lawful knowledge or possession of the receiving Party prior to the time it was disclosed to,
or learned by, the receiving Party;
is developed independently by the receiving Party by an employee with no knowledge of the
disclosure;
was generally available to the public or otherwise part of the public domain at the time of its
disclosure to the receiving Party;
became generally available to the public or otherwise part of the public domain after its disclosure and
other than through any act or omission of the receiving Party in breach of this Agreement; or
is disclosed to the receiving Party, other than under an obligation of confidentiality, by a Third Party
who has the lawful power to disclose such information to the receiving Party.
Confidential Information shall be deemed to include the terms of this Agreement.
10.2.
Authorized Use and Disclosure. Except as expressly provided otherwise in this Agreement or on receiving the
prior written consent of the other Party, each Party:
10.2.1
10.2.2
10.2.3
must keep the Confidential Information of the other Party confidential;
must not use any Confidential Information of the other Party except as reasonably necessary in
carrying out its obligations, or exercising its rights, under this Agreement (“Permitted Purpose”);
may only disclose any Confidential Information of the other Party as follows:
(i)
to its Affiliates, directors, employees, permitted sub- licensees, consultants and advisors
(and the directors, employees, consultants and advisors of its Affiliates)
(“Representatives”) to the extent necessary for the Permitted Purpose provided that the Party
must ensure that any such Representative complies with the obligations of confidence and non-
use set out in this Agreement;
the terms of this Agreement may be disclosed to its legal and financial advisors, who must
be bound by similar obligations of confidentiality as contained in this Agreement;
(ii)
(iii)
(iv)
(v)
if required to be disclosed to a competent authority in accordance with applicable laws,
regulations or stock exchange rules (as applicable), in which case the disclosing Party shall
promptly notify the other Party of such disclosure requirement to enable the other Party to seek a
protective order or other form of confidential treatment for the Confidential Information, and shall
thereafter disclose only that portion of the Confidential Information which is required to be
disclosed in order to comply;
with ASLAN’s prior written consent (not to be unreasonably withheld), BIOGENETICS may
disclose ASLAN’s Confidential Information to potential investors, or acquirers, on a need to
know basis, and who must be bound by similar obligations of confidentiality as contained in
this Agreement;
BIOGENETICS may disclose IP of ASLAN to the extent such disclosure is reasonably
necessary in prosecuting or defending litigation,, or conducting preclinical or clinical trials.
10.3.
Term of confidentiality. The obligations of confidentiality set out in this Section 10 apply from the Effective
Date until five (5) years after the expiration or termination of this Agreement.
10.4.
Specific enforcement. Each Party acknowledges that:
10.4.1
10.4.2
10.4.3
the value of the other Party’s Confidential Information, which includes any jointly owned
Confidential Information, is unique and difficult to assess in monetary terms;
a breach by it of any of its obligations of confidentiality under this Agreement may irreparably harm the
Party disclosing such Confidential Information, and damages may not be an adequate remedy for any such
breach; and
therefore, if it actually breaches or threatens to breach the confidentiality obligations set forth in this
Agreement, the Party whose Confidential Information is the subject of such breach, or who is affected by
such breach, may seek to enforce this Agreement by way of injunctive relief or specific performance as
a remedy (in addition to any other available relief) without proof of actual or special damage.
10.5.
Publications. ASLAN and BIOGENETICS agree not to issue any press releases or public announcements
concerning the terms of this Agreement if the other Party (or its Affiliates or products) is named therein (directly or
by referencing items such as logotypes, corporate image, commercial brands, or trademarks) or such release or
announcement discloses Confidential Information of the other Party or discloses information which will or may
(assessed reasonably) cause harm to the commercial value or reputation of the other’s products containing the
Compound (and to ensure that their respective Affiliates do not do so) without the prior written consent of the other
Party, subject to Section 10.2.3 (iii). The Party interested in issuing the publication shall submit the proposal to the
other Party, who shall have at least seven (7) Business Days for
review, except as required by a governmental authority and applicable Law, including disclosure required by any
securities exchange; provided that following agreement upon the content of such disclosure, subsequent releases
which do not materially depart from such agreed content may be made without prior written consent from the other
Party.
11.
TERM AND TERMINATION
11.1.
11.2.
11.3.
11.4.
11.5.
Term. This Agreement shall become effective as of the Effective Date and, unless earlier terminated under this
Agreement, shall continue in full force and effect until the expiry of the Licence Period, subject to Section 11.2.
Automatic Renewal For One Further Year. If either Party wishes this Agreement to expire without automatic
renewal for a further year, then it must serve notice on the other to that effect at least ninety (90) days before expiry
of the Licence Period. In the absence of such notice, then this Agreement shall automatically renew for one (1)
further year at which point it shall definitively expire unless the Parties mutually agree in writing otherwise.
Termination For Breach. Either Party may terminate this Agreement in the event the other Party shall have
breached or defaulted in the performance of any of its material obligations hereunder, and such default shall
have continued for ninety (90) days after written notice thereof was provided to the breaching Party by the non-
breaching Party. Any termination shall become effective at the end of such ninety (90) day period unless the
breaching Party (or any other Party on its behalf) has cured any such breach or default prior to the expiration of
the ninety (90) day period.
Termination For Material Safety Risk. Either Party may terminate the Agreement at any time in the event of a
Material Safety Risk associated with the Product.
Termination on Insolvency. Either Party may terminate this Agreement by notice, if, at any time, the other Party
(i) suspends payment of its debts or is unable to pay its debts as they fall due or admits inability to pay its debts or
is deemed unable to pay its debts or (ii) a resolution is passed, or an order is made, for or in connection with the
winding up of that Party (other than for the sole purpose of a scheme for a solvent amalgamation of that Party
with one or more other companies or the solvent reorganisation of that Party); or (iii) an order is made for the
appointment of an administrator, or if an administrator is appointed over that Party; or (iv) a receiver is
appointed over all or any of the assets of that Party; or (v) a creditor or encumbrancer of that Party attaches or takes
possession of, or a distress, execution, sequestration or other such process is levied or enforced on or sued against,
the whole or any part of the assets of that Party and such attachment or process is not discharged within thirty
(30) days; or (vi) any similar insolvency event to any of the foregoing occurs in any jurisdiction; or (vii) that
Party suspends or ceases, or threatens to suspend or cease, to carry on all or a substantial part of its business.
11.6.
Notwithstanding the foregoing, in the event of any termination under Section 11.5, ASLAN shall use Commercially
Reasonable Efforts to assist BIOGENETICS to put in place suitable practical arrangements to enable
BIOGENETICS to continue to exercise its rights under this Agreement, including (without limitation) assisting
BIOGENETICS to negotiate in good faith with ASLAN’s head licensor Array BioPharma Inc. (“Array”) a direct
licence of the rights for the Licensed Technology in the Territory to BIOGENETICS, on substantially the same
terms as are set out in this Agreement, subject to BIOGENETICS covenanting to assure to Array the same
obligations (including financial obligations) as it covenants to ASLAN under this Agreement.
12.
EFFECT OF TERMINATION.
12.1.
12.2.
Accrued Rights, Surviving Obligations. Termination or expiration of the Agreement for any reason shall be
without prejudice to any obligations which shall have accrued prior to such termination or expiration,
including, without limitation, any and all damages arising from any breach hereunder.
Upon any termination of the Agreement, the licence granted to BIOGENETICS in Section 2.1 shall terminate,
except and only for long as needed by BIOGENETICS to meet its obligations under this Section 12.
12.3.
Upon any termination of the Agreement for any reason:
a)
BIOGENETICS shall promptly assign and transfer to ASLAN all Regulatory Filings with respect to Products
in the Territory that are held or Controlled by or under authority of BIOGENETICS or its Affiliates (including
Regulatory Filings obtained by permitted sub-licensees to the extent such sub-licensees’ sublicense(s) do not
survive the termination of this Agreement), and shall take such actions and execute such other instruments,
assignments and documents as may be necessary to effect the transfer of rights under such Regulatory Filings
to ASLAN. BIOGENETICS shall cause each of its Affiliates and all such sub-licensees whose sublicense(s)
do not survive the termination of this Agreement to transfer any such Regulatory Filings to ASLAN if this
Agreement terminates. If applicable laws, rules or regulations prevent or delay the transfer of ownership of a
Regulatory Filing to ASLAN, BIOGENETICS shall grant, and does hereby grant, to ASLAN an exclusive and
irrevocable right of access and reference to such Regulatory Filing for the Product(s), and shall cooperate fully
to make the benefits of such Regulatory Filings available to ASLAN and/or its designee(s). Within ninety (90)
days after notice of such termination, BIOGENETICS shall provide to ASLAN copies of all such Regulatory
Filings, and of all preclinical and clinical data (including raw data, original records, investigator reports, both
preliminary and final, statistical analyses, expert opinions and reports, safety and other electronic databases)
and other Know-How information pertaining to the Product, or the manufacture thereof. ASLAN shall be free
to use and disclose such Regulatory Filings and other items in connection with the exercise of its rights and
licences under this Section 12.3.
b)
c)
d)
BIOGENETICS shall grant, and hereby does grant, effective upon the effective date of such termination: (i) an
exclusive, worldwide, irrevocable, fully paid-up licence to ASLAN to make, use, sell, offer for sale or import
Product(s), under any patent rights owned or Controlled by BIOGENETICS or its Affiliates that: (A) were
generated by BIOGENETICS or its Affiliates in connection with the Development or Commercialization of the
Product(s) prior to the effective date of such termination, or (B) were otherwise utilized by BIOGENETICS, its
Affiliates or permitted sub-licensees in the Development or Commercialization of the Product(s); and (ii) a
non-exclusive, worldwide, fully-paid licence to ASLAN under any know-How that: (A) were generated by
BIOGENETICS or, its Affiliates in connection with the development or Commercialization of the Product(s)
prior to the effective date of such termination, or (B) were otherwise utilized by BIOGENETICS, its Affiliates
or such sub-licensees in the development or Commercialization of the Product(s), in case under the preceding
sub-clauses (i) and (ii) solely to the extent reasonably necessary for ASLAN to make, use, sell, offer for sale or
import Product(s) in the Field; provided, however, if any such patent rights or other Intellectual Property
licensed to ASLAN hereunder is subject to payment obligations to a Third Party, BIOGENETICS shall
promptly disclose such obligations to ASLAN in writing and such patent rights or other Intellectual Property
shall be deemed to be Controlled by BIOGENETICS only if ASLAN agrees in writing to reimburse all
amounts owed to such Third Party as a result of ASLAN’s exercise of such licence.
BIOGENETICS shall cause to be assigned, and hereby does assign, to ASLAN all rights in and to any and all
trademarks used in connection with the Commercialization of the Product by BIOGENETICS or its
Affiliates. It is understood that such assignment shall not include the name or trademark for BIOGENETICS’
company itself.
If there are any ongoing clinical trials with respect to the Product being conducted by or on behalf of
BIOGENETICS, its Affiliates at the time of notice of termination, BIOGENETICS agrees to (i) promptly
transition to ASLAN or its designee all of such clinical trials and the activities related to or (ii) terminate such
clinical trials; in each case as requested by ASLAN and subject to compliance with applicable laws, rules and
regulations.
12.4.
12.5.
For a) through d) in Section 12.3 above, ASLAN shall be responsible for the reasonable costs of such transition
except in the case of a termination of this Agreement by ASLAN pursuant to Section 11.3 or 11.5, in which case
BIOGENETICS shall be responsible for such costs.
(a) If requested by ASLAN, BIOGENETICS or its Affiliates shall continue to distribute and sell the Products in the
Territory, in accordance with the terms and conditions of this Agreement, for a period requested by ASLAN not to
exceed six (6) months following the effective date of termination (“Commercialization Wind-Down Period”)
provided that ASLAN may
12.6.
terminate this Commercialization Wind-Down Period upon thirty (30) days’ notice to
BIOGENETICS. Notwithstanding any other provision of this Agreement, during this Commercialization Wind-
Down Period, BIOGENETICS’ and its Affiliates’ rights with respect to the Products (including the licences granted
under Section 2.1) shall be non-exclusive, and ASLAN shall have the right to engage one or more other partner(s)
or distributor(s) of the Products in all or part of the Territory. The Products sold or disposed by BIOGENETICS or
its Affiliates during this Commercialization Wind-Down Period shall be subject to royalties under Section 5.3
above. After the Commercialization Wind-Down Period, BIOGENETICS, and its Affiliates shall not sell the
Products or make any representation that, or implying that, they are a continuing licensee of or distributor for
ASLAN for the Products.
(b) If ASLAN wishes BIOGENETICS or its Affiliates to terminate to distribute and sell the Products in the
Territory without the Wind-Down Period mentioned above, ASLAN or its designee(s) shall purchase all quantities
of the Product in BIOGENETICS’ or its Affiliates’ inventory at the price BIOGENETICS actually incurred to
purchase the quantities so provided to ASLAN within thirty (30) days after the effective date of termination.
BIOGENETICS agrees to fully cooperate with ASLAN and its designee(s) to facilitate a smooth, orderly and
prompt transition of the development and Commercialization of Products to ASLAN and/or its designee(s) during
the Commercialization Wind-Down Period. Without limiting the foregoing BIOGENETICS shall, subject to
applicable date privacy laws and its relevant contractual confidentiality obligations to Third Parties, promptly
provide ASLAN (i) copies of customer lists, customer data and other customer information relating to the Products
and (ii) (if applicable) manufacturing information (including protocols for the production, packaging, testing and
other manufacturing activities) relating to the Product in BIOGENETICS’ Control, which in each case ASLAN
shall have the right to use and disclose for any purpose during this Commercialization Wind-Down Period and
thereafter. Upon request by ASLAN, BIOGENETICS shall transfer to ASLAN all quantities of the Product in its
or its Affiliates’ Control (as requested by ASLAN), within thirty (30) days after the end of this Commercialization
Wind-Down Period; provided, however, that ASLAN shall reimburse BIOGENETICS for the costs that
BIOGENETICS actually incurred to manufacture or purchase the quantities so provided to ASLAN, which in the
case BIOGENETICS has manufactured such quantities of Product itself, shall be BIOGENETICS’ fully-burdened
manufacturing cost. If any Product was manufactured by any Third Party for BIOGENETICS, or BIOGENETICS
had contracts with vendors which contracts are necessary or reasonably useful for ASLAN to take over
responsibility for the Product in the Territory, then BIOGENETICS shall cooperate to the extent reasonably
possible and requested in writing by ASLAN, to assign all of the relevant Third-Party contracts to ASLAN, and in
any case, BIOGENETICS agrees to cooperate with ASLAN to ensure uninterrupted supply of the
Products. ASLAN shall be responsible for the reasonable costs of such assignment except in the case of a
termination of this Agreement by ASLAN pursuant to Section 11.3 or 11.5, in which case BIOGENETICS shall be
responsible for such costs. If BIOGENETICS or its Affiliate manufactured any Product at the time of termination,
then BIOGENETICS (or its Affiliate) shall continue to provide for manufacturing of such Product for ASLAN,
at its fully-burdened manufacturing costs therefor, from the date of notice of such termination until such time as
ASLAN is able, using diligent efforts to do so but no longer than the expiration
of the Commercialization Wind-Down Period, to secure an acceptable alternative commercial manufacturing
source from which sufficient quantities of the Product may be procured and legally sold in the Territory.
12.7.
Survival. Sections 5, 6, 7.11, 9, 10, 12 and 13.11 of this Agreement shall survive expiration or termination of this
Agreement for any reason. With respect to any termination or expiration of this Agreement, all rights and
obligations of the Parties under this Agreement shall terminate upon such expiration or termination, except to the
extent otherwise provided in this Article 12.
12.8.
Termination is not the sole remedy under this Agreement and, whether or not termination is effected, all other
remedies will remain available except as agreed to otherwise herein.
13.
GENERAL
13.1.
13.2.
13.3.
13.4.
Assignment. This Agreement shall not be assignable by either Party to any Third Party hereto without the
written consent of the other Party hereto, not to be unreasonably withheld or delayed except to the extent
provided in Section 2.5 under this Agreement. If any permitted assignment would result in withholding or other
similar taxes becoming due on payments from the assigning Party to the other Party under this Agreement, the
assigning Party shall be responsible for all such taxes resulting from such assignment, and the amount of such
taxes shall not be withheld or otherwise deducted from any amounts payable to other Party. No assignment and
transfer shall be valid and effective unless and until the assignee/transferee agrees in writing to be bound by the
provisions of this Agreement. The terms and conditions shall be binding on and inure to the benefit of the
permitted successors and assigns of the Parties.
Independent status of the Parties. The Parties to this Agreement are independent contractors and agree that the
relationship between the Parties shall not constitute a partnership, joint venture or agency. No Party shall have the
authority to make any statement, representation or commitment of any kind, or to take any action, which shall be
binding on the other Party, without the prior written consent of the other Party.
Waiver. No delay or omission by a Party in exercising or availing itself of any right, power or privilege hereunder
shall preclude the later exercise of any such right, power or privilege by such Party. No waiver shall be effective
unless made in writing with specific reference to the relevant provision(s) of this Agreement and signed by a duly
authorized representative of the Party granting the waiver. Waiver by a Party of a breach hereunder by the other
Party shall not be construed as a waiver of any succeeding breach of the same or any other provision.
Force majeure. Neither Party shall be deemed to be in breach of this Agreement or otherwise liable to the other by
reasons of any delay in performance or non-performance of any of its obligations under this Agreement, to the extent
that such delay or non-performance is due to any event of force majeure, including without limitation any wars,
insurrections, strikes, acts of God, Governmental actions or controls or any other contingency beyond its control.
The Party whose performance of obligations has been delayed by force majeure shall use its best efforts to overcome
the effect of the
13.5.
13.6.
13.7.
force majeure event as soon as possible. The Party affected by the force majeure shall notify immediately to the
other Party the existence of the force majeure. The other Party shall have no right to demand indemnity or damages
as a result of the force majeure event. If the event of force majeure preventing performance continues for more than
six (6) months from the date of notice given pursuant thereto and such suspension of performance would otherwise
constitute a material breach under this Agreement, the non-force majeure Party may terminate this Agreement, by
giving written notice of termination to the other without liability to any of the Parties, except the obligation to make
any payments due up to such date under this Agreement. Termination under this Section 13.4 shall be considered as
termination under Section 11.3 provided that no Party shall be entitled to damages or any other legal remedy in
connection therewith.
Entire Agreement. This Agreement embodies all of the understandings and obligations between the Parties with
respect to the subject matter hereof, and supersedes, replaces and cancels all prior agreements or understandings
between the Parties with respect to the same.
Amendments. No amendments to this Agreement shall be valid unless executed in writing duly authorized
signatories of both Parties.
Notices. All notices, instructions and other communications hereunder or in connection herewith shall be in writing,
shall be sent to the address of the relevant Party set forth below and shall be (a) delivered personally, (b) sent via a
reputable international overnight courier service, or (c) sent by facsimile transmission with confirmation by
overnight courier. Any such notice, instruction or communication shall be deemed to be delivered by the sending
Party in the case of (a) actual receipt, (b) signature of the receipt by the receiving Party and (c) issuance of electronic
confirmation of receipt, if transmitted by facsimile (if such transmission is on a Business Day, or otherwise, on the
next Business Day following such transmission). Either Party may change its address by giving notice to the other
Party in the manner provided above. All notices shall be in English language. Additionally, all information,
documents and reports which ASLAN is required to provide or send to BIOGENETICS under this Agreement, and
which are not originally in English, shall be sent together with their applicable translation into English.
(a)
If to ASLAN:
ASLAN Pharmaceuticals Pte Limited
83 Clemenceau Avenue
#12-03 UE Square
Singapore 239920
Attention: General Counsel
Fax No.: +65 6225 2419
(b)
BIOGENETICS CO., LTD
If to BIOGENETICS:
11th Liveplex Tower,
702 Eonju-ro,
Seoul,
Republic of Korea
Attention: Joohoon Ahn / CEO
Fax No.: + 82 2 2622 7799
13.8.
13.9.
13.10.
Severability. In the event any portion of this Agreement shall be held illegal, void or ineffective, the remaining
portion hereof shall remain in full force and effect and shall not be affected. If any of the terms or provisions of this
Agreement are in conflict with any applicable statute or rule of law, then such terms or provisions shall be deemed
inoperative to the extent they may conflict therewith and shall be deemed to be modified to conform to such statute
or rule of law. However, in case such invalidation or unenforceability injures the rights and interests of either Party,
the Parties hereto shall renegotiate the corresponding provisions of this Agreement in good faith.
Third-Party beneficiaries. None of the provisions of this Agreement shall be for the benefit of or enforceable by
any Third Party including, without limitation, any creditor of any Party hereto. No such Third Party shall obtain any
right under any provision of this Agreement or shall by reason of any such provision make any claim in respect of
any debt, liability or obligation (or otherwise) against any Party hereto.
Governing Law. This Agreement and any dispute arising from the performance or breach hereof shall be governed,
construed and enforced in accordance with the laws of Singapore, without regard or giving effect to the conflicts of
law principles thereof. The Parties expressly exclude application of the United Nations Convention for the
International Sale of Goods.
13.11.
Dispute Resolution.
(a)
Internal Resolution. Except as otherwise expressly provided herein, in the event of any controversy, claim or
other dispute arising out of or relating to any provision of this Agreement or the interpretation, enforceability,
performance, breach, termination or validity hereof (a “Dispute”), such Dispute shall be first referred to the Chief
Executive Officer (CEO) of each Party or the Person that each of them may delegate (such delegate being a senior
director or above), for resolution, prior to proceeding under the following provisions of this Section. For the
avoidance of doubt, this internal resolution proceeding shall not and cannot be used by any of the Parties as a way
to modify the rights and obligations under the Agreement or as a way to modify the agreements already reached by
the Parties as they have been reflected in the Agreement. Any Parties’ resolution under this proceeding shall be
resolved in accordance with the terms and conditions of the Agreement and the rights and obligations of the
Parties as they are currently reflected in the Agreement. This internal resolution proceeding will be used as the last
resort for the Parties to avoid to enter into a dispute to be resolved by
the arbitration proceeding below. A Dispute shall be referred to such executives upon any Party providing the
other Party with written notice that such Dispute exists, and such executives, or their designees, shall attempt to
resolve such Dispute through good faith discussions, each Party acting reasonably, within sixty (60) Business
Days of being referred to such executives.
(b) Arbitration. Except as otherwise agreed in writing, the Parties agree that any Dispute over any matter which has
not been resolved following the procedures set out in Section 13.11(a) must be finally resolved through a binding
arbitration which the Parties agree to accept in lieu of litigation or other legally available remedies (except for
injunctive relief where such relief is necessary to protect a Party from irreparable harm pending the outcome of the
arbitration). Any such arbitration shall be settled in Hong Kong International Arbitration Centre (“HKIAC”) in
accordance with its Rules of Arbitration by one (1) arbitrator chosen in accordance with said Rules. The
arbitration shall be conducted in English and will be held in Hong Kong. The award rendered by HKIAC shall be
binding and final upon the Parties.
13.12.
13.13.
13.14.
Use of Name. None of the Parties is entitled to use the corporate or commercial name of the other Party, for any
advertisement or promotional purposes without the prior written consent of the other Party.
Awareness. In this Agreement when a Party's liability for a statement is limited by the extent of its 'awareness', this
shall be construed to mean a level of awareness assuming reasonable enquiries have been made.
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument.
14.
NEW COMMERCIAL ENTITY
14.1.
14.2.
The Parties acknowledge that ASLAN and BIOGENETICS may wish in the future to establish a new commercial
entity (the “Commercial JV Co”) intended to promote the introduction and Commercialization of oncology drugs
in the Territory.
If the Commercial JV Co is established, the financial and other terms and conditions set out in this Agreement shall
be reviewed and discussed by both parties and revised as mutually agreed. However the Parties agree to negotiate
in principle that:
(a) BIOGENETICS shall own a majority stake in the Commercial JV Co;
(b) ASLAN shall own a minority stake in the Commercial JV Co but shall have board representation; and
(c) ASLAN shall have a right (but not the obligation) to co-invest at each funding round for the Commercial JV Co at
a valuation per share (to be negotiated among ASLAN, BIOGENETICS and where relevant, other investors)
applying to other new investors in the Commercial JV in each funding round.
14.3.
Prior to establishing the Commercial JV, ASLAN and BIOGENETICS shall enter into a separate definitive
agreement setting forth among others, the ownership structure described in Section 14.2 above, the rights and
obligations of ASLAN and BIOGENETICS and other terms.
IN WITNESS WHEREOF, the Parties have executed this Agreement in duplicate originals by their duly authorized representatives as of the date
and year first above written.
Each person executing this Agreement on behalf of a Party represents and warrants his / her capacity and authority to do so.
ASLAN PHARMACEUTICALS PTE LTD
By:
Name:
Title:
/s/ Carl Firth
Carl Firth
CEO
Date: 27th February 2019
[…***…]
BIOGENETICS CO., LTD
By:
Name:
Title:
/s/ Joohoon Ahn
Joohoon Ahn
CEO
Date: 27th February 2019
Schedule 1
[…***…]
Schedule 2
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY […***…], HAS BEEN OMITTED BECAUSE
ASLAN PHARMACEUTICALS PTE LTD. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY
CAUSE COMPETITIVE HARM TO ASLAN PHARMACEUTICALS PTE LTD. IF PUBLICLY DISCLOSED.
Exhibit 4.11
LICENCE AGREEMENT
FOR ASLAN003
BETWEEN
ASLAN Pharmaceuticals Pte Ltd
AND
BioGenetics Co., Ltd.
Dated: 11th March 2019
THIS AGREEMENT is made on 2019
BETWEEN:-
(1)
(2)
ASLAN PHARMACEUTICALS PTE. LTD. (“ASLAN”), incorporated and registered in Singapore with company number
201007695N, having its principal offices at 83 Clemenceau Avenue, #12-03 UE Square, Singapore 239920; and
BIOGENETICS CO., LTD. (“BIOGENETICS”), a Republic of Korea corporation having its principal offices at 11th Liveplex
Tower, 702 Eonju-ro, Gangnam-gu, Seoul, Republic of Korea.
WHEREAS:-
A.
ASLAN owns, and has a master licence from Almirall S.A. for, certain intellectual property rights and know-how with
respect to that certain chemical compound designated by ASLAN as ASLAN003, and believes that ASLAN003 has the potential to become a
therapeutic drug with significant commercial potential.
B.
ASLAN desires to find a partner capable of realizing promptly the therapeutic and commercial potential of Products in the
Territory and within the Field (terms as defined below).
C.
BIOGENETICS possesses pharmaceutical development capabilities, and desires to collaborate with ASLAN to develop the
therapeutic and commercial potential of Products in the Territory.
D.
Now, therefore, in consideration of the premises and mutual covenants herein contained, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows:
1. DEFINITIONS AND INTERPRETATION
1.1.
The definitions and rules of interpretation in this Section apply in this Agreement:
"Affiliate" shall mean, with respect to a legal entity, any corporation or other entity which directly or indirectly Controls, is Controlled
by or is under common Control with, such entity.
“Almirall Head Licence Agreement” shall mean a licence agreement between ASLAN and Almirall S.A. originally dated 16th May
2012 and most recently re-stated in amended form on 16th March 2018 which grants exclusive worldwide rights over ASLAN003 to
ASLAN.
“ASLAN003” shall mean the synthetic chemical entity identified as […***…] by its ultimate owner Almirall SA and identified by
ASLAN as ASLAN003, which is an inhibitor of human dihydroorotate dehydrogenase and Improvements thereto made during the
Term of this Agreement.
“ASLAN In-Licensed Know-How” means all results, data, know-how, compounds, processes, discoveries, formulations,
materials, inventions, techniques or proprietary confidential information which:
(a)
(b)
are necessary for manufacturing, applying for and obtaining marketing authorisations or licences in respect of,
marketing or selling Products; and
are licensed to ASLAN pursuant to the Almirall Head Licence Agreement in respect of which, and to the extent that,
ASLAN is entitled to grant a sub-licence of such know-how.
2
“ASLAN In-Licensed Patents” means patents and patent applications listed in Schedule 1 part (i) licensed to ASLAN at the date of
the Agreement pursuant to the Almirall Head Licence Agreement, to the extent that ASLAN is entitled to grant sub-licences of the
same, and to the extent that they relate to the Commercialization of Products, to the extent that ASLAN is entitled to grant sub-
licences of the same.
"ASLAN Know-How" shall mean all results, data, know-how, compounds, processes, discoveries, formulations, materials,
inventions, techniques or proprietary confidential information which:
(a)
(b)
are necessary for researching, developing, manufacturing, applying for and obtaining marketing authorisations or
licences in respect of, marketing or selling Products; and
are owned or Controlled by ASLAN as at the date of this Agreement.
"ASLAN Patents" shall mean the patents and patent applications owned or Controlled by ASLAN relating to ASLAN003 and
listed in Schedule 1 parts (i) and (ii), and any other patents and patent applications relating to Products Controlled by ASLAN from
time to time during the Licence Period covering the Territory.
“Business Day” means a day that is not a Saturday, Sunday or public holiday in Singapore or the Republic of Korea.
“Claim” means, in relation to a person, a demand, claim, action or proceeding made or brought by or against the person,
however arising.
“Commercialize” means use, apply for or obtain marketing authorizations or licences, import, sell, have sold, promote, market or
distribute, and, if agreed in accordance with Section 4.2, manufacture, have manufactured, make and have made; and
"Commercialization" shall be construed accordingly;
"Commercially Reasonable Efforts" shall mean the carrying out of obligations or tasks in a reasonable, good faith, and diligent
manner consistent with efforts and resources as commonly used by a company with experience and expertise in the
development and commercialization of pharmaceutical products, in such a company’s ordinary course of business, for a
pharmaceutical product at a similar stage of research and development, and having similar market potential to the Product, taking
into account, without limitation, issues of safety, efficacy, product profile, status of the Product, the development costs, the
regulatory environment, and other scientific factors, market conditions then prevailing, including competitive environment,
profitability the competitiveness of alternative products that are or are expected to be in the relevant marketplace, and other
similar factors.
“Competing Product” means any product which is intended to be used for the treatment of same disease indications as Products
(now or in the future) by means of an agent that has the same mechanism of action (DHODH inhibitor) as ASLAN003.
“Confidential Information” has the meaning given to it in Section 10.1.
"Control," "Controls," "Controlled" or "Controlling" shall mean:
3
(a)
(b)
in relation to a legal entity, the possession, directly or indirectly, of more than 50% of the issued shares in that entity
or the power to direct, or cause the direction of, the management or policies of that entity, whether through the
ownership of voting securities, by contract or otherwise; and;
in relation to Intellectual Property, possession of the ability to grant the licences or sub-licences as provided herein
without violating the terms of any agreement or other arrangements with any Third Party.
“Clinical Trial Costs” means the costs incurred by ASLAN, as from the Effective Date up till the date of ASLAN’s Buy-Back
Notice (as defined in Section 15.2), of carrying out clinical trials and clinical studies for the Product, such trials or studies being
additional or supplementary to the Ongoing Clinical Trials as listed and defined and in Schedule 2; including, without limitation,
costs of clinical research organisations, payments to clinical trial centres, and costs of Regulatory Filings.
“Clinical Trial Costs Contribution” shall be as defined in Section 5.2.
"Effective Date" shall mean 11th March 2019.
"Field" shall mean all human and animal therapeutic, diagnostic and prophylactic uses, excluding topically administered products
for the treatment of keratinocyte hyperproliferative disorders and the following non-melanoma skin cancers: basal cell carcinoma,
squamous cell carcinomas and Gorlin Syndrome.
“First Commercial Sale” means the first commercial sale of a Product in the relevant indication in the Field in the Territory by
BIOGENETICS, or its Affiliates. Sales for clinical study purposes, “early access programs” or similar uses shall not constitute a
First Commercial Sale. In addition, sales of a Product between BIOGENETICS and its Affiliates shall not constitute a First
Commercial Sale.
“Improvement” means any improvement, development, modification or enhancement of the ASLAN Patents, the ASLAN Know-
How or the Licensed Technology, whether patentable or not.
"Intellectual Property" (or "IP") shall mean any patents, rights to inventions, registered designs, copyright and related rights,
database rights, design rights, topography rights, trade marks, service marks, trade names and domain names, trade secrets,
confidential information, rights in unpatented know-how, and any other intellectual or industrial property rights of any nature
including all applications (or rights to apply) for, and renewals or extensions of such rights and all similar or equivalent rights or
forms of protection which subsist or will subsist now or in the future in any part of the world.
“Generic Product” means with respect to the Product, a pharmaceutical product (a) containing ASLAN003 (b) that has obtained
MFDS approval in the Territory solely by means of a procedure for establishing equivalence to the Product; and (c) that is legally
marketed in such country by or under authority of an entity other than BIOGENETICS or its Affiliates.
“Liabilities” means Claims, losses, liabilities, costs, expenses or damage of any kind and however arising, including
investigative costs, court costs, legal fees, penalties, fines and interest and amounts paid in settlement.
4
“Licence Period” shall mean the period commencing on the Effective Date and, unless terminated earlier pursuant to the terms of
this Agreement, expiring on the tenth (10th) anniversary of the date of First Commercial Sale, subject to Section 11.2.
“Licensed Know-How” means the ASLAN Know-How, the ASLAN In-Licensed Know How and ASLAN’s interest in any
Improvements which are not patented.
“Licensed Patents” means the ASLAN Patents, and the ASLAN In-Licensed Patents.
"Licensed Technology" shall mean the Licensed Patents and the Licensed Know-How, including any right, title and interest in any
Improvements assigned to ASLAN pursuant to Section 7.11.
“Licensing Revenue” means all gross revenue that BIOGENETICS receives from a Third Party in connection with
Commercialization of the Licensed Technology.
“Material Safety Risk” means, in a Party’s reasonable belief, there is an unacceptable risk a Product will cause harm in humans
(according to the regulatory or ethical practices in the Territory) based upon: (i) pre-clinical safety data, including data from animal
toxicology studies; or (ii) the observation of serious adverse effects in humans after that Product has been administered to or taken by
humans, such as during a clinical trial or after the launch of such Product.
"MFDS" shall mean the Korean Ministry of Food and Drug Safety (formerly known as the Korea Food & Drug Administration).
"Net Sales" shall mean in respect of direct sales to Third Parties by BIOGENETICS and its Affiliates in the Territory, the gross
invoice price charged from time to time by BIOGENETICS or by its Affiliates, together with all upfront payments, milestones
payments, or advances, as the case may be (referred to herein as the "Selling Party"), for all Products sold or supplied by the Selling
Party, in arm's length sales or supplies to Third Parties less deductions allowed to the Third Party customer by the Selling Party, to
the extent actually taken by the Third Party customer, on such sales for:
•
•
•
•
trade, quantity, and cash discounts (including to wholesalers) consistent with usual industry practice in the Territory;
credits, rebates and chargebacks (including those to managed-care entities and government agencies), and allowances or
credits to customers on account of rejection or returns (including, but not limited to, wholesaler and retailer returns);
freight, postage and duties, and transportation charges specifically relating to Product, including handling and insurance
thereto; and
sales (such as VAT or its equivalent) and excise taxes, other consumption taxes, customs duties and compulsory
payments to governmental authorities and any other governmental charges imposed upon the sale of such Product to
Third Parties;
In the event of supplies to Third Parties for non-cash or nil consideration, the gross invoice price charged from time to time by the
Selling Party shall be deemed to have been charged for such supply, and prices shall be calculated and payable on the basis set out in
Section 5.
Sales among the Selling Party and its Affiliates shall be excluded from the computation of Net Sales.
"NHIP" shall mean the National Health Insurance Price in the Territory for the Product as determined and approved from time to time
by the relative government authorities.
“Ongoing Clinical Trials” means those clinical trials and clinical studies run by ASLAN which were completed or ongoing as at the
Effective Date for the Product, as detailed in Schedule 2.
5
“Party” shall mean a party to this Agreement.
"Product" shall mean, unless otherwise defined, any pharmaceutical or medicinal item, substance, formulation or dosage for human
use containing ASLAN003 as an active ingredient.
“Regulatory Filings” means, with respect to Products, any preparation and/or submission to MFDS or any other regulatory body in
the Territory with authority to grant marketing approvals for Products, of any regulatory application together with any material
related correspondence and documentation and shall include, without limitation, any submission to a regulatory advisory board,
marketing authorization application, and any supplement or amendment thereto. For the avoidance of doubt, Regulatory Filings
shall include any IND, MAA or the equivalent in the Territory.
"Territory" shall mean the Republic of Korea.
"Third Party" shall mean any entity other than ASLAN, BIOGENETICS or any Affiliate of ASLAN or BIOGENETICS.
“Varlitinib Agreement” means an agreement between the Parties dated 27th February 2019 relating to the exclusive licensing in
the Territory of rights in the drug known as ASLAN001 and with the generic name varlitinib.
“Varlitinib Products” means any pharmaceutical or medicinal item, substance, formulation or dosage for human use containing
ASLAN001 as an active ingredient, as governed by the Varlitinib Agreement
1.2.
1.3.
1.4.
1.5.
1.6.
1.7.
1.8.
Section, Schedule and paragraph headings shall not affect the interpretation of this Agreement.
The Schedules form part of this Agreement and shall have effect as if set out in full in the body of this
agreement and any reference to this Agreement includes the Schedules.
Unless the context otherwise requires, words in the singular include the plural and in the plural include the
singular.
Unless the context otherwise requires, a reference to one gender shall include a reference to the other genders.
Writing or written includes faxes.
Any words following the terms ‘including’, ‘include’, ‘in particular’ or any similar expression shall be
construed as illustrative and shall not limit the sense of the words preceding those terms.
A “person” includes a natural person, corporate or unincorporated body (whether or not having separate legal
personality), partnership, joint venture and a government or statutory body or authority.
6
1.9.
If a word is defined or phrase is defined, its other grammatical forms have the corresponding meaning.
1.10.
No rule of construction will apply to a provision to the disadvantage of a Party merely because that Party
proposed the provision or would otherwise benefit from it.
2.
LICENCE GRANT
2.1.
2.2.
2.3.
2.4.
2.5.
Subject to the terms of this Agreement, ASLAN hereby grants to BIOGENETICS an exclusive, even as to
ASLAN, license under ASLAN’s rights in the Licensed Technology to Commercialize and, if agreed in accordance
with Section 4.2, manufacture Products in the Territory in the Field. To make it clear, ASLAN shall not distribute
the Products nor grant to Third Party any license to Commercialize the Products in the Territory during the Licence
Period of this Agreement.
All rights granted in this Agreement by ASLAN to BIOGENETICS shall be exercised in the Territory, during the
Licence Period and in accordance with the terms and conditions set out in this Agreement.
For the avoidance of doubt, ASLAN shall retain all rights to the Licensed Technology other than the commercial
and (subject to Section 4.2) manufacturing rights granted to BIOGENETICS under Section 2.1.
During the Licence Period and for one (1) year thereafter, neither BIOGENETICS, nor any of its Affiliates, will
conduct, participate in, or fund, directly or indirectly, either alone or with a Third Party, the development,
manufacture or commercialization of a Competing Product, or conduct a drug discovery or other research program
the goal of which is to identify Competing Products (“Competing Products Development”); provided however,
BIOGENETICS may participate in the Competing Products Development during the Licence Period with the prior
written approval of ASLAN.
None of the rights under this Agreement may be sub-licensed or sub- contracted by BIOGENETICS unless
ASLAN’s prior written consent has been obtained; provided however, BIOGENETICS may assign, transfer, sub-
license or sub-contract to an its Affiliates.
3.
DILIGENCE
3.1.
3.2.
BIOGENETICS and/or its Affiliates shall use Commercially Reasonable Efforts to (i) obtain marketing approvals
for Products in the Territory, and (ii) Commercialize Products in the Territory after receipt of such marketing
approvals.
BIOGENETICS’s activities under Section 3.1 shall be performed by BIOGENETICS at its sole risk and
responsibility, cost and expense, and in compliance with all applicable laws and regulatory requirements, including
without limitation GCP, GLP and GMP. Therefore, BIOGENETICS assumes full responsibility for any loss or
damage derived from the conduct and performance of this Agreement and shall be responsible for any such Claims
resulting from such activities except to the extent that such loss or damage arises out of or results from, directly or
indirectly, breach of any term of this Agreement, negligence, or wilful misconduct of ASLAN.
7
3.3.
3.4.
Information and Reports. BIOGENETICS shall keep ASLAN informed regarding the ongoing
Commercialization of Products through reasonably detailed reports to be provided to ASLAN on a semi-annual
basis, together with, if requested by ASLAN, face to face meetings or telephone conferences to discuss the same
during ordinary business hours of BIOGENETICS. Such semi-annual reports shall include summaries of all
material activities (including regulatory activities) and results with respect to the Products in the
Territory. ASLAN shall keep BIOGENETICS informed regarding the ongoing development status of Products
including but not limited to any clinical trial studies, registration status and price information in other countries
except for the Territory through reasonably detailed reports to be provided to BIOGENETICS on a semi-annual
basis, together with, if requested by BIOGENETICS, face to face meetings or telephone conferences to discuss the
same during ordinary business hours of ASLAN. ASLAN shall keep BIOGENETICS informed regarding the
ongoing Clinical Trial Costs through a reasonably detailed report to be provided to BIOGENETICS on an annual
basis. BIOGENETICS shall have fifteen (15) days from the date of such report to review and raise any bona fide
queries on the same. If ASLAN does not receive a notice of inquiries within such fifteen (15)-day period,
BIOGENETICS shall be deemed to accept such report and ASLAN may thereafter submit its
invoice. BIOGENETICS shall pay the invoice within thirty (30) days in accordance with Section 5.2. The
provisions of Section 6 shall apply to ASLAN’s record keeping in respect of the Clinical Trial Costs and
BIOGENETICS’s rights of inspection thereof, mutatis mutandis. Notwithstanding the foregoing, and for the
purposes of Section 5.3:
(a) ASLAN shall promptly (and in any event within 30 days) inform BIOGENETICS of the occurrence of FDA
approval for the first indication for a Product; and
(b) BIOGENETICS shall promptly (and in any event within 30 days) inform ASLAN of the occurrence of the
other events relating to Products triggering milestone payments set out in Section 5.3.
Responsibility for regulatory interactions. BIOGENETICS shall be responsible for the preparation and filing of
any and all Regulatory Filings. ASLAN shall use Commercially Reasonable Efforts to provide BIOGENETICS
with appropriate documents and data required, and general cooperation, to enable the dossiers and other
documentation required for MFDS submissions and other Regulatory Filings to be completed. All such Regulatory
Filings will be filed in BIOGENETICS’ name and/or on its behalf. BIOGENETICS shall promptly notify ASLAN
of all Regulatory Filings submitted or received by BIOGENETICS or its Affiliates with respect to Products, and
upon ASLAN’s request, shall provide to ASLAN one paper copy or electronic file of all such regulatory
Filings. Additionally, BIOGENETICS will upon ASLAN’s request, to the extent reasonably required to confirm
BIOGENETICS’ compliance with its obligations hereunder, provide ASLAN with reasonable additional
information and data generated by or on behalf of BIOGENETICS in such semi-annual period, it being understood
that ASLAN shall keep such information and data in strict confidence. Notwithstanding the foregoing, prior to any
application for determination of NHIP for Products, BIOGENETICS and ASLAN shall discuss the range of target
pricing to seek in such application, including a lowest acceptable price, and ASLAN’s prior approval (not to be
unreasonably withheld or delayed) shall be obtained before such application is made. Any formal acceptance by
8
BIOGENETICS of a NHIP price proposed by the relative government authorities which is lower than the lowest
acceptable price agreed with ASLAN beforehand, shall require prior discussion with ASLAN and ASLAN’s prior
approval, which shall not be unreasonably withheld or delayed.
3.5.
The Parties shall establish procedures for the exchange and reporting of all adverse events related to the Product,
which shall be governed by a Pharmacovigilance & Safety Exchange Agreement, to be entered into in due course.
4.
MANUFACTURE & SUPPLY
4.1
4.2
ASLAN agrees to provide clinical drug supplies to BIOGENETICS required for Regulatory Filings by or on
behalf of BIOGENETICS and for Commercialisation of Products, pursuant to a separate manufacturing and supply
agreement to be negotiated in good faith by the Parties and which the Parties shall use Commercially Reasonable
Efforts to enter into no later than 30th June 2020.
Notwithstanding the foregoing, that if BIOGENETICS wishes to manufacture by itself or have manufactured by a
third party the Products during the Licence Period under this Agreement, ASLAN agrees to engage in good faith
discussions, using Commercially Reasonable Efforts, to negotiate and execute a manufacturing licence conferring
such rights on BIOGENETICS.
5.
PAYMENTS TO ASLAN
5.1
5.2
Initial Payment. In consideration of the licenses and rights granted to BIOGENETICS hereunder,
BIOGENETICS shall pay to ASLAN an initial payment of one million USD (US $1,000,000) (“the Initial
Payment”), to be paid no later than thirty (30) days of ASLAN’s invoice for the same, which may be issued to
BIOGENETICS any time from mutual signature of this Agreement. The Initial Payment shall consist of (a) an
upfront licence fee component, and (b) a reimbursement component, to cover ASLAN’s costs associated with the
development of the Product in the Territory up to the Effective Date. The Parties shall work in good faith to agree
the relative allocation of the different components of the Initial Payment in writing as soon as possible after the
Effective Date and in any event no later than 31st March 2019. The Parties acknowledge that BIOGENETICS
may be required to pay Korean withholding tax (“WHT”) at a rate of […***…] percent ([…***…] %) on all or
part of the Initial Payment, depending on the agreed allocation and the WHT treatment in Korea of the different
components, but that as of the Effective Date this issue has not been finally determined between the Parties. If a
suitably qualified tax expert agreeable to both Parties determines by 31st March 2019 the exact amount of WHT (if
any) required to be paid by BIOGENETICS to the Korean National Tax Service, then BIOGENETICS may make
payment in satisfaction of ASLAN’s invoice for the Initial Payment as above, net of such WHT, subject always to
Section 5.6.
Clinical Trial Costs Contribution. BIOGENETICS agrees to reimburse ASLAN for […***…] per cent ([…
***…] %) of its Clinical Trial Costs for Products designed for the treatment of acute myeloid leukemia, incurred
as from the Effective Date (“the Clinical Trial Costs Contribution”). ASLAN shall invoice BIOGENETICS for
the Clinical Trial Costs Contribution on an annual basis, and, subject to Section 3.3, BIOGENETICS shall pay
such invoice within thirty (30) days of receipt.
9
5.3
Milestone Payments. Upon achieving certain milestones as set out below, BIOGENETICS will make one-time
milestone payments to ASLAN:
MILESTONE PAYMENTS
5.3.1 Development milestones
First Complete Response in current Phase 2 study
USD$ […***…] ([…***…] dollars)
First indication – First Commercial Sale
USD$ […***…] ([…***…] dollars)
Second indication - First Commercial Sale
USD$ […***…] ([…***…] dollars)
5.3.2 Sales milestones
Annual Net Sales in Territory exceed $[…***…] ([…***…]
US dollars):
Annual Net Sales in Territory exceed $[…***…] ([…***…]
US dollars):
Annual Net Sales in Territory exceed $[…***…] ([…***…]
US dollars):
Annual Net Sales in Territory exceed $[…***…] ([…***…]
US dollars):
Annual Net Sales in Territory exceed $[…***…] ([…***…]
US dollars):
Annual Net Sales in Territory exceed $[…***…] ([…***…]
US dollars):
5.3.3 In relation to Section 5.3.2:
USD$ […***…] ([…***…] dollars)
USD$ […***…] ([…***…] dollars)
USD$ […***…] ([…***…] dollars)
USD$ […***…] ([…***…] dollars)
USD$ […***…] ([…***…] dollars)
USD$ […***…] ([…***…] dollars)
(a) The references to “Annual Net Sales” in Section 5.3.2 shall mean the aggregate of annual Net Sales of Products
covered by this Agreement plus annual Net Sales of Varlitinib Products. As from the Effective Date of this Agreement,
the Parties agree that Section 5.3 of the Varlitinib Agreement shall be deemed superseded by Section 5.3.2 above.
(b) Where the Product is approved in different indications, Net Sales for the different indications for that drug shall be
aggregated for the purposes of calculating whether Net Sales during any calendar year have reached milestones as set out
above.
5.4
Royalties. Royalties shall be paid by BIOGENETICS to ASLAN in accordance with this Section 5.4 on Net Sales
of the Products in the Territory in the Field, as follows:
For Net Sales up to the equivalent of US$[…***…] ([…***…]
US dollars) during any particular calendar year:
For Net Sales above the equivalent of US$[…***…] ([…***…]
US dollars) and up to US$[…***…] ([…***…] US dollars)
during any particular calendar year
For Net Sales above the equivalent of US$[…***…] ([…***…]
US dollars) during any particular calendar year
[…***…]% ([…***…] percent) on Net Sales
[…***…]% ([…***…] percent) on Net Sales
[…***…]% ([…***…] percent) on Net Sales
10
In relation to Section 5.4:
(a) The references to “Net Sales” shall mean the aggregate of annual Net Sales of Products covered by this Agreement
plus annual Net Sales of Varlitinib Products. As from the Effective Date of this Agreement, the Parties agree that Section
5.3A of the Varlitinib Agreement shall be deemed amended accordingly.
(b) Where the Product is approved in different indications, Net Sales for the different indications for that drug shall be
aggregated for the purposes of calculating royalties as set out above.
Payments to ASLAN shall be on a quarterly basis and in US dollars and shall be made within thirty (30) days
following the applicable calendar quarter.
Taxes. BIOGENETICS agrees to pay to ASLAN the full amount of all payments stated in this Agreement without
deductions, subject to compliance with applicable laws. For the avoidance of doubt, ASLAN shall bear ultimate
liability for any tax or duties arising as a result of such payments (whether in Singapore, the Territory or
otherwise). In the event that BIOGENETICS is required to withhold any taxes on amounts payable to ASLAN in
accordance with applicable laws, each Party agrees to provide the other with reasonable assistance including
provision of any tax forms, evidence of taxes withheld and such other information as may be reasonably necessary
in order for the paying Party not to withhold tax, to withhold tax at a reduced rate under an applicable bilateral
income tax treaty or for ASLAN to reclaim withheld tax. The foregoing provisions shall apply mutatis mutandis to
payments by ASLAN pursuant to Section 15.
5.5
5.6
5.7
Statement. At the time of each quarterly payment in accordance with Section 5.4, BIOGENETICS shall provide
ASLAN with a statement specifying:
5.7.1
copies of any notifications, reports or statements from any Third Party relating to the contribution);
the nature of and amount of the payment received that contributes to Licensing Revenue (including
5.7.2
any deductions made in calculating such revenue;
the calculation of Licensing Revenue based on such payment including details and amount of
5.7.3
5.7.4
5.7.5
details of any exchange rates used to convert any currencies;
details of the Net Sales for the period of the statement; and
a statement of the amount of payment due to ASLAN in respect of such Licensing Revenue;
upon receipt of such statement, ASLAN may issue an invoice to BIOGENETICS for such amount.
5.7.6
Within 30 days of receipt of such invoice, BIOGENETICS must remit payment to ASLAN to a bank account
nominated by ASLAN
in respect of the fourth quarter of each calendar year, where there has been over- or under-payment to
5.7.7
ASLAN over the previous calendar year based on the rates applicable for Net Sales in each calendar year, an
explanation of any relevant adjustments (up or down) in the payment for that fourth quarter.
11
5.8
5.9
5.10
Royalty Term. Royalties payable under this Section 5 shall be paid on a Product-by-Product basis with respect to
Net Sales made during the Licence Period.
Generics. From the time that the Licensed Patents have expired and one or more Third Parties is selling a
Generic Product in the Territory, then as from the next quarter year the royalty applicable under Section 5.4 shall
be discounted by […***…] ([…***…]%).
Interest. Where ASLAN does not receive payment of any sum required on or before the day on which such
payment is due, BIOGENETICS shall pay ASLAN interest on the past due amount as follows: interest shall accrue
thereafter on the sum due and owing to ASLAN at the lesser of seven percent (7%) over the LIBOR rate for a three
month deposit in US dollars on the last Business Day of the previous calendar month, or the maximum amount
allowed by law, with interest to accrue on a day to day basis without prejudice to ASLAN’s right to receive
payment on the due date.
5.11
Economic Viability. If any of the following apply:
(a)
(b)
(c)
sales of Generic Products in the Territory result in an erosion of 60% or more of the price of Products in the
Territory from the price at First Commercial Sale;
fluctuations in the exchange rate between the South Korean won and US dollar for a continuous period of more
than two (2) months, resulting in a differential of higher than twenty per cent (20%) in comparison to the
exchange rate in force on the date of signature of this Agreement; or
the official Korean reimbursement price for a Product as determined from time to time by the respective
governmental authority shows dramatic change (that is to say, at the end of any two month period there has
been a more than 10% aggregate increase or decrease),
the Parties shall meet together either face to face or by telephone conference to discuss how to proceed, including without
limitation adjusting NHIP with the consent of both Parties.
5.12
Almirall Head Licence Agreement. BIOGENETICS will take all reasonable steps to assist ASLAN in ensuring
that it complies with its obligations under the Almirall Head Licence Agreement.
6.
RECORDS AND ACCOUNTS
6.1.
BIOGENETICS must keep complete and accurate records of all matters connected with the Commercialization of
Products and must also keep proper accounts in relation to Licensing Revenue and other payments payable to
ASLAN under this Agreement containing all data necessary for the calculation of the amounts payable to ASLAN
pursuant to this Agreement. BIOGENETICS must keep those records and books of account for five (5) years
following the end of the year to which they relate.
12
6.2.
6.3.
6.4.
6.5.
Not more than once in any twelve (12) month period, BIOGENETICS must permit during business hours an
independent accountant nominated by ASLAN to inspect the records and accounts maintained under Section 6.1
for the purpose of verifying their accuracy with a prior notice of ten (10) Business Days, and confirming whether
all payments payable to ASLAN under this Agreement have been properly calculated and paid by BIOGENETICS.
BIOGENETICS must provide to the accountant such assistance as is reasonably required by that person in order to
verify the accuracy of those records and accounts and confirm whether all payments payable to ASLAN under this
Agreement have been properly calculated and paid by BIOGENETICS.
If ASLAN’s inspection reveals that any monies are outstanding then BIOGENETICS must, within 30 days after
receiving notice of the amount due, pay ASLAN the outstanding amount. If the inspection reveals there was an
overpayment then the amount of the overpayment may be credited against future payments due to ASLAN under
this Agreement.
ASLAN shall bear the cost of the independent accountant appointed under this Section 6 except if the inspection
reveals that any monies are outstanding by more than 5%, in which case BIOGENETICS must pay ASLAN’s
reasonable inspection costs.
7.
INTELLECTUAL PROPERTY
Patent Prosecution
7.1.
7.2.
7.3.
ASLAN shall have the right to control the preparation, filing, prosecution and maintenance of all the ASLAN
Patents. ASLAN shall give BIOGENETICS an opportunity to review and comment on the text of each patent
application for the Territory within the ASLAN Patents, as well as any other material submissions related to the
ASLAN Patents in the Territory before filing, and shall supply BIOGENETICS with a copy of such patent
application as filed, together with notice of its filing date and serial number. BIOGENETICS has a right to make
reasonable recommendations in relation to the filing, prosecution, maintenance, enforcement and defence of the
ASLAN Patents in the Territory and ASLAN shall and shall accept BIOGENETICS’s recommendations, in good
faith, unless such recommendations would adversely affects the ASLAN Patents in the Territory.
BIOGENETICS shall reimburse ASLAN for the amounts paid to Third Parties by ASLAN in connection with the
filing, prosecution and maintenance of the ASLAN Patents in the Territory as from the Effective Date, including
without limitation, amounts paid by ASLAN as filing and maintenance fees, translation fees and amounts paid to
outside patent counsel and foreign associates (“Patent Costs”). ASLAN shall provide BIOGENETICS with an
invoice for Patent Costs on a monthly basis, and payment shall be due within thirty (30) days thereafter.
If ASLAN, in its sole discretion, which discretion shall not be exercised unreasonably, decides to abandon the
preparation, filing, prosecution or maintenance of any patent or patent application in the ASLAN Patents in the
Territory, then ASLAN shall notify BIOGENETICS in writing thereof at least ninety (90) days prior to any due
date that requires action to avoid loss of rights in connection with the applicable patent and/or patent application,
and following the date of such notice BIOGENETICS shall have the
13
Enforcement
7.4.
7.5.
7.6.
7.7.
right, at its cost, to prosecute and maintain such patents and patent applications in ASLAN’s name, provided that
BIOGENETICS shall give ASLAN an opportunity to review and comment on the text of each patent application or
other material submissions related to the ASLAN Patents before filing, and shall supply ASLAN with a copy of
such patent application as filed, together with notice of its filing date and serial number.
In the event that either Party becomes aware of actual or threatened infringement of any ASLAN Patents in any
country in the Territory by the manufacture or sale or use of a Product or competing product in the Field
(“Infringing Product”), it shall provide the other Party with the available evidence, if any, of such infringement.
ASLAN , at its sole expense, shall have the initial right to initiate and control any enforcement of the ASLAN
Patents in the Territory with respect to an Infringing Product or to defend any declaratory judgments seeking to
invalidate or hold the ASLAN Patents unenforceable (each, an “Enforcement Action”), in each case in ASLAN’s
own name and, if necessary for standing purposes, in the name of BIOGENETICS or its nominee and shall protect,
in good faith, the interests of BIOGENETICS in taking such enforcement action. If ASLAN does not, within one
hundred twenty (120) days of receipt of notice from BIOGENETICS, take significant steps to abate the
infringement or file suit to enforce the ASLAN Patents against at least one infringing party in the Territory,
BIOGENETICS shall have the right to take whatever action it deems appropriate to enforce the ASLAN Patents.
To make it clear of the responsibilities on the costs and expenses for the afore-mentioned enforcement action taken
by BIOGENETICS, ASLAN shall fully reimburse the reasonable costs and expenses incurred to BIOGENETICS
unless BIOGENETICS has breached the terms and conditions of this Agreement. The Party controlling any such
enforcement action shall not settle the action or otherwise consent to an adverse judgment in such action that
diminishes the rights or interests of the non-controlling Party (including in the case of BIOGENETICS, entering
into any settlement admitting the invalidity of, or otherwise impairing, the ASLAN Patents) without the prior
written consent of the other Party. All monies recovered upon the final judgment or settlement of any such suit to
enforce the ASLAN Patents shall be shared, after reimbursement of expenses, as follows: (i) in the event that
ASLAN brought the claim, suit or action, any remaining amount shall be shared eighty percent (80%) to ASLAN,
20% to BIOGENETICS, and (ii) in the event that BIOGENETICS brought the claim, suit or action, any remaining
amount shall be retained by BIOGENETICS.
In any suit to enforce and/or defend the ASLAN Patents pursuant to this Section 7, the Party not in control of such
suit (a) shall, at the request and expense of the controlling Party, (b) reasonably cooperate and, to the extent
possible, have its employees testify when requested and make available relevant records, papers, information,
samples, specimens, and the like, and (c) further agrees to be named in and consents to join in any suit, action, or
proceeding as a party to the suit, action, or proceeding to the extent necessary to establish standing in the suit,
action, or proceeding.
If a Third Party asserts that a patent or other right owned by it is infringed by the manufacture, use, marketing, sale
or importation of any Product, the Party becoming aware of such a matter shall immediately notify the other of it.
ASLAN shall have the right to initiate, prosecute, defend and control legal action (whether by suit, proceedings,
counter-claim, oppositions, customs procedure or otherwise) in respect of any such assertion. BIOGENETICS shall
have the right actively to co-operate and join with ASLAN in any legal action if it (acting in good faith and
reasonably) considers it necessary or desirable, and ASLAN shall have the right to have BIOGENETICS and/or its
nominee joined as a passive party to any legal action if necessary, and in either
14
circumstance each party shall reasonably co-operate with the other in regard to the same. All costs and expenses
(including attorneys' fees) of any legal action brought in accordance with this Section 7.7, shall be borne by
ASLAN, provided that where ASLAN is bearing BIOGENETICS’s costs and expenses (including attorneys' fees)
if BIOGENETICS actively elects to be joined as a party to such action (as above), these shall be reasonable. Any
monetary recovery in connection with legal action shall be applied first to reimburse ASLAN for its out-of-pocket
costs and expenses (including management time and reasonable attorneys' fees) incurred in connection with any
legal action. The remainder shall be split between the Parties in proportion to the relative degree of their active
involvement in connection with the action, but if the Parties, acting in good faith, cannot agree such relative
proportions, then on the basis of 50% to BIOGENETICS and 50% to ASLAN.
Patent Marking. BIOGENETICS agrees to mark and have its Affiliates mark all patented Products they sell or
distribute pursuant to this Agreement in accordance with the applicable patent statutes or regulations in the
Territory.
Patent Term Extensions. The Parties will reasonably discuss patent term adjustment, patent term extension,
supplemental patent protection or related extension of rights with respect to ASLAN Patents in the Territory. To
the extent permitted by applicable law, ASLAN shall apply for and pursue any such adjustment, extension or
protection as directed by BIOGENETICS, at BIOGENETICS’ cost.
Improvements by ASLAN. If any Improvements are made by ASLAN or its Third Party collaborators during
the Licence Period, the Parties acknowledge that ASLAN will own such Improvements and the Intellectual
Property therein. ASLAN will promptly disclose such Improvements to BIOGENETICS and they will form part of
the Licensed Technology licensed hereunder.
Improvements by BIOGENETICS. All rights, title and interest in any Improvements made by or on behalf of
BIOGENETICS or its Affiliates during the Licence Period shall be owned by ASLAN; and BIOGENETICS
hereby assigns all of its rights, title and interest in and to such Improvements to ASLAN and agrees to do all such
other acts as appropriate to allow ASLAN to perfect such rights, title and interest. BIOGENETICS will promptly
disclose such BIOGENETICS Improvements to ASLAN if they are necessary or useful to the development or
Commercialization of Products.
7.8.
7.9.
7.10.
7.11.
8.
WARRANTIES
8.1.
Each of the Parties warrants that:
8.1.1
8.1.2
8.1.3
it has full power and authority to enter into and observe the obligations under this Agreement and,
for the avoidance of doubt ASLAN warrants that the Licensed Patents and the Licensed Know-how are
either owned or Controlled by it;
to the best of its actual knowledge as at the Effective Date, its entry into and performance under the terms
of this Agreement will not infringe the rights of any Third Party or cause it to be in breach of any
obligations to a Third Party;
all information, data and materials provided by it to the other pursuant to this Agreement will be, to the
best of its knowledge and belief, accurate and complete in all material respects.
8.2.
ASLAN warrants that, to the best of its actual knowledge as at the Effective Date:
15
8.2.1
8.2.2
the exercise by BIOGENETICS of the licence rights granted to BIOGENETICS under Section 2 does not
infringe the rights of any Third Party and any terms and conditions of Almirall Head Licence Agreement;
no Third Party has threatened or, so far as it is aware, is currently threatening proceedings in respect of
infringement of any the Licensed Patents and the Licensed Know-how, and none of the same is the
subject of any actual or, so far as it is aware, threatened challenge, opposition or revocation proceedings.
8.3.
8.4.
8.5.
Any condition, warranty or other term which is not expressly set out in this Agreement which might
otherwise be implied or incorporated into this Agreement, whether by statute, common law or otherwise, is,
insofar as it is lawful to do so, hereby excluded.
Compliance with Law. Each Party covenants to the other that it will comply with all applicable laws as
amended, in carrying out its obligations pursuant to this Agreement. Each Party covenants to the other that it
and any sub-contractor legitimately appointed by it currently holds or at the relevant time will hold any and all
consents, approvals, orders or authorizations necessary to comply with its obligations under this Agreement.
Disclaimers. Without prejudice to ASLAN's warranties set out in Sections 8.1 and 8.2, BIOGENETICS
acknowledges that ASLAN licences the Licensed Technology “as is”, that is, without any warranty of any
kind, express or implied, including, without limitation, warranty of its accuracy or completeness, of
merchantability, fitness for a particular purpose (including but not limited to manufacture the Product or conduct
the development), commercial value, and without any warranty of any kind, express or implied, of the
inexistence of adverse effects, of the safety or other quality, efficiency, stability, characteristics or usefulness
of, or merchantability, or fitness for a particular purpose of any Product.
9.
LIABILITY
9.1.
BIOGENETICS Indemnities. BIOGENETICS shall indemnify, keep indemnified and hold harmless ASLAN,
its Affiliates and their directors, officers and employees (“ASLAN Indemnitees”) from and against all
Liabilities incurred in connection with any Third Party claim arising out of or resulting from:
9.1.1
9.1.2
9.1.3
breach of any term of this Agreement by BIOGENETICS, or its Affiliates, contractors or sub-licensees;
the negligence, recklessness or wilful misconduct of BIOGENETICS, its Affiliates or its contractors or
sub-licensees;
the Commercialization of Products by BIOGENETICS or its Affiliates, sub-licensees or contractors
or any end-use of such Products in a manner and for a purpose authorised by any of them,
except to the extent that the Liabilities arise out of or result from, directly or indirectly, breach of any term of
this Agreement, negligence, or wilful misconduct of any ASLAN Indemnitees.
16
9.2.
ASLAN Indemnities. ASLAN shall indemnify, keep indemnified and hold harmless BIOGENETICS and its
Affiliates, directors, officers and employees (“BIOGENETICS Indemnitees”) from and against all Liabilities
incurred in connection with any Third Party claim arising out of or resulting from:
9.2.1
9.2.2
breach of any term of this Agreement by ASLAN, or its Affiliates, contractors or sub-licensees;
the negligence, recklessness or wilful misconduct of ASLAN or its Affiliates or contractors in the
performance of its obligations under this Agreement,
except to the extent that the Liabilities arise out of or result from, directly or indirectly, breach of any term of
this Agreement, negligence, or wilful misconduct of any BIOGENETICS Indemnitees.
9.3.
It is a condition of indemnification under this Agreement that:
9.3.1
9.3.2
9.3.3
the indemnified Party gives written notice to the indemnifying Party of the Claim in respect of
which indemnification is sought promptly on becoming aware of it and does not at any time admit
liability or otherwise attempt to settle or compromise such Claim without the indemnifying Party’s prior
written consent;
the indemnifying Party shall, at its cost, have sole conduct of the defence or compromise of any such
Claim and as between the indemnifying Party and the indemnified Party shall have the sole right to
any costs and damages awarded as a result of any such Claim; and
the indemnified Party provides the indemnifying Party such assistance and co-operation as it shall
reasonably require, at the indemnifying Party’s reasonable cost, in respect of the conduct of such
defence or compromise.
9.4.
9.5.
Insurance. During the Licence Period, each Party, at its own expense, shall maintain product liability and other
appropriate insurance or self-insure in an amount consistent with industry standards to a reasonably adequate level,
and upon request each Party shall provide proof of such coverage to the other Party.
Excluded Liabilities. Subject to this Section 9.5, the Parties agree that with respect to any claim by one
Party against the other arising out of the performance or failure of performance of the other Party under this
Agreement, a Party shall be liable to the other Party for direct damages only and shall not be liable for any
indirect or consequential loss or damage whatsoever arising under or in relation to the Agreement whether arising
from breach of contract (including under any indemnity), misrepresentation (whether tortuous or statutory), tort
(including negligence), breach of statutory duty, strict liability including but not limited to loss of profits, loss of
business, loss of goodwill or similar loss, regardless of whether arising from warranty, strict liability or otherwise
or any other legal theory howsoever arising, even if that Party was aware of the possibility that such loss or
damage might be incurred by the other, except as a result of a Party’s wilful misconduct. Nothing in this
Section 9.5 is intended to limit or restrict the rights or obligations of either Party under Section 8 [Warranties]
or to limit a Party’s liability in respect of wilful misconduct.
17
10.
CONFIDENTIALITY
10.1.
Confidentiality; Exceptions. In this Agreement, “Confidential Information” means any information and
materials disclosed or made available to one Party by or on behalf of the other Party in connection with this
Agreement, whether disclosed in writing, orally or by any other means and regardless of the date it was
disclosed, except to the extent that it can be established by the receiving Party that such Confidential
Information:
10.1.1
10.1.2
10.1.3
10.1.4
10.1.5
is in the lawful knowledge or possession of the receiving Party prior to the time it was disclosed
to, or learned by, the receiving Party;
is developed independently by the receiving Party by an employee with no knowledge of the
disclosure;
was generally available to the public or otherwise part of the public domain at the time of its
disclosure to the receiving Party;
became generally available to the public or otherwise part of the public domain after its disclosure and
other than through any act or omission of the receiving Party in breach of this Agreement; or
is disclosed to the receiving Party, other than under an obligation of confidentiality, by a Third Party
who has the lawful power to disclose such information to the receiving Party.
Confidential Information shall be deemed to include the terms of this Agreement.
10.2.
Authorized Use and Disclosure. Except as expressly provided otherwise in this Agreement or on receiving the
prior written consent of the other Party, each Party:
10.2.1
10.2.2
10.2.3
must keep the Confidential Information of the other Party confidential;
must not use any Confidential Information of the other Party except as reasonably necessary in
carrying out its obligations, or exercising its rights, under this Agreement (“Permitted Purpose”);
may only disclose any Confidential Information of the other Party as follows:
(i)
to its Affiliates, directors, employees, permitted sub- licensees, consultants and advisors
(and the directors, employees, consultants and advisors of its Affiliates)
(“Representatives”) to the extent necessary for the Permitted Purpose provided that the Party
must ensure that any such Representative complies with the obligations of confidence and
non-use set out in this Agreement;
the terms of this Agreement may be disclosed to its legal and financial advisors, who must
be bound by similar obligations of confidentiality as contained in this Agreement;
if required to be disclosed to a competent authority in accordance with applicable laws,
regulations or stock exchange rules (as applicable), in which case the disclosing Party shall
promptly notify the other Party of such disclosure requirement to enable the other Party to seek a
protective order or other form of confidential treatment for the Confidential Information, and
shall thereafter disclose only that portion of the Confidential Information which is required to be
disclosed in order to comply;
(ii)
(iii)
18
(iv)
(v)
with ASLAN’s prior written consent (not to be unreasonably withheld), BIOGENETICS
may disclose ASLAN’s Confidential Information to potential investors, or acquirers, on a need
to know basis, and who must be bound by similar obligations of confidentiality as contained
in this Agreement;
BIOGENETICS may disclose IP of ASLAN to the extent such disclosure is reasonably
necessary in prosecuting or defending litigation, or conducting preclinical or clinical trials.
10.3.
Term of confidentiality. The obligations of confidentiality set out in this Section 10 apply from the Effective
Date until five (5) years after the expiration or termination of this Agreement.
10.4.
Specific enforcement. Each Party acknowledges that:
10.4.1
10.4.2
10.4.3
the value of the other Party’s Confidential Information, which includes any jointly owned
Confidential Information, is unique and difficult to assess in monetary terms;
a breach by it of any of its obligations of confidentiality under this Agreement may irreparably harm the
Party disclosing such Confidential Information, and damages may not be an adequate remedy for any
such breach; and
therefore, if it actually breaches or threatens to breach the confidentiality obligations set forth in this
Agreement, the Party whose Confidential Information is the subject of such breach, or who is affected by
such breach, may seek to enforce this Agreement by way of injunctive relief or specific performance as
a remedy (in addition to any other available relief) without proof of actual or special damage.
10.5.
Publications. ASLAN and BIOGENETICS agree not to issue any press releases or public announcements
concerning the terms of this Agreement if the other Party (or its Affiliates or products) is named therein (directly or
by referencing items such as logotypes, corporate image, commercial brands, or trademarks) or such release or
announcement discloses Confidential Information of the other Party or discloses information which will or may
(assessed reasonably) cause harm to the commercial value or reputation of the other’s products containing
ASLAN003 (and to ensure that their respective Affiliates do not do so) without the prior written consent of the
other Party, subject to Section 10.2.3 (iii). The Party interested in issuing the publication shall submit the proposal
to the other Party, who shall have at least seven (7) Business Days for review, except as required by a
governmental authority and applicable Law, including disclosure required by any securities exchange; provided
that following agreement upon the content of such disclosure, subsequent releases which do not materially depart
from such agreed content may be made without prior written consent from the other Party.
11.
TERM AND TERMINATION
11.1.
Term. This Agreement shall become effective as of the Effective Date and, unless earlier terminated under this
Agreement, shall continue in full force and effect until the expiry of the Licence Period, subject to Section 11.2.
19
11.2.
11.3.
11.4.
11.5.
Automatic Renewal For One Further Year. If either Party wishes this Agreement to expire without automatic
renewal for a further year, then it must serve notice on the other to that effect at least ninety (90) days before expiry
of the Licence Period. In the absence of such notice, then this Agreement shall automatically renew for one (1)
further year at which point it shall definitively expire unless the Parties mutually agree in writing otherwise.
Termination For Breach. Either Party may terminate this Agreement in the event the other Party shall have
breached or defaulted in the performance of any of its material obligations hereunder, and such default shall
have continued for ninety (90) days after written notice thereof was provided to the breaching Party by the non-
breaching Party. Any termination shall become effective at the end of such ninety (90) day period unless the
breaching Party (or any other Party on its behalf) has cured any such breach or default prior to the expiration of
the ninety (90) day period.
Termination For Material Safety Risk. Either Party may terminate the Agreement at any time in the event of a
Material Safety Risk associated with the Product.
Termination on Insolvency. Either Party may terminate this Agreement by notice, if, at any time, the other Party
(i) suspends payment of its debts or is unable to pay its debts as they fall due or admits inability to pay its debts or
is deemed unable to pay its debts or (ii) a petition is filed, a notice is given, a resolution is passed, or an order is
made, for or in connection with the winding up of that Party (other than for the sole purpose of a scheme for a
solvent amalgamation of that Party with one or more other companies or the solvent reorganisation of that
Party); or (iii) an application is made to court, or an order is made, for the appointment of an administrator, or if
an administrator is appointed over that Party; or (iv) a receiver is appointed over all or any of the assets of that
Party; or (v) any similar insolvency event to any of the foregoing occurs in any jurisdiction; or (vi) that Party
suspends or ceases, or threatens to suspend or cease, to carry on all or a substantial part of its business.
12.
EFFECT OF TERMINATION.
12.1.
12.2.
Accrued Rights, Surviving Obligations. Termination or expiration of the Agreement for any reason shall be
without prejudice to any obligations which shall have accrued prior to such termination or expiration,
including, without limitation, any and all damages arising from any breach hereunder.
Upon any termination of the Agreement, the licence granted to BIOGENETICS in Section 2.1 shall terminate,
except and only for long as needed by BIOGENETICS to meet its obligations under this Section 12.
12.3.
Upon any termination of the Agreement for any reason:
a)
BIOGENETICS shall promptly assign and transfer to ASLAN all Regulatory Filings with respect to Products
in the Territory that are held or Controlled by or under authority of BIOGENETICS or its Affiliates (including
Regulatory Filings obtained by permitted sub-licensees to the extent such sub-licensees’ sublicense(s) do not
survive the
20
termination of this Agreement), and shall take such actions and execute such other instruments, assignments
and documents as may be necessary to effect the transfer of rights under such Regulatory Filings to
ASLAN. BIOGENETICS shall cause each of its Affiliates and all such sub-licensees whose sublicense(s) do
not survive the termination of this Agreement to transfer any such Regulatory Filings to ASLAN if this
Agreement terminates. If applicable laws, rules or regulations prevent or delay the transfer of ownership of a
Regulatory Filing to ASLAN, BIOGENETICS shall grant, and does hereby grant, to ASLAN an exclusive and
irrevocable right of access and reference to such Regulatory Filing for the Product(s), and shall cooperate fully
to make the benefits of such Regulatory Filings available to ASLAN and/or its designee(s). Within ninety (90)
days after notice of such termination, BIOGENETICS shall provide to ASLAN copies of all such Regulatory
Filings, and of all preclinical and clinical data (including raw data, original records, investigator reports, both
preliminary and final, statistical analyses, expert opinions and reports, safety and other electronic databases)
and other Know-How information pertaining to the Product, or the manufacture thereof. ASLAN shall be free
to use and disclose such Regulatory Filings and other items in connection with the exercise of its rights and
licences under this Section 12.3.
BIOGENETICS shall grant, and hereby does grant, effective upon the effective date of such termination: (i) an
exclusive, worldwide, irrevocable, fully paid-up licence to ASLAN to make, use, sell, offer for sale or import
Product(s), under any patent rights owned or Controlled by BIOGENETICS or its Affiliates that: (A) were
generated by BIOGENETICS or its Affiliates in connection with the Development or Commercialization of
the Product(s) prior to the effective date of such termination, or (B) were otherwise utilized by
BIOGENETICS, its Affiliates or permitted sub-licensees in the Development or Commercialization of the
Product(s); and (ii) a non-exclusive, worldwide, fully-paid licence to ASLAN under any know-How that: (A)
were generated by BIOGENETICS or, its Affiliates in connection with the development or Commercialization
of the Product(s) prior to the effective date of such termination, or (B) were otherwise utilized by
BIOGENETICS, its Affiliates or such sub-licensees in the development or Commercialization of the
Product(s), in case under the preceding sub-clauses (i) and (ii) solely to the extent reasonably necessary for
ASLAN to make, use, sell, offer for sale or import Product(s) in the Field; provided, however, if any such
patent rights or other Intellectual Property licensed to ASLAN hereunder is subject to payment obligations to a
Third Party, BIOGENETICS shall promptly disclose such obligations to ASLAN in writing and such patent
rights or other Intellectual Property shall be deemed to be Controlled by BIOGENETICS only if ASLAN
agrees in writing to reimburse all amounts owed to such Third Party as a result of ASLAN’s exercise of such
licence.
BIOGENETICS shall cause to be assigned, and hereby does assign, to ASLAN all rights in and to any and all
trademarks used in connection with the Commercialization of the Product by BIOGENETICS or its
Affiliates. It is understood that such assignment shall not include the name or trademark for BIOGENETICS’
company itself.
If there are any ongoing clinical trials with respect to the Product being conducted by or on behalf of
BIOGENETICS, its Affiliates at the time of notice of termination,
b)
c)
d)
21
12.4.
12.5.
12.6.
BIOGENETICS agrees to (i) promptly transition to ASLAN or its designee all of such clinical trials and the
activities related to or (ii) terminate such clinical trials; in each case as requested by ASLAN and subject to
compliance with applicable laws, rules and regulations.
For a) through d) in Section 12.3 above, ASLAN shall be responsible for the reasonable costs of such transition
except in the case of a termination of this Agreement by ASLAN pursuant to Section 11.3 or 11.5, in which case
BIOGENETICS shall be responsible for such costs.
(a) If requested by ASLAN, BIOGENETICS or its Affiliates shall continue to distribute and sell the Products in
the Territory, in accordance with the terms and conditions of this Agreement, for a period requested by ASLAN not
to exceed six (6) months following the effective date of termination (“Commercialization Wind-Down Period”)
provided that ASLAN may terminate this Commercialization Wind-Down Period upon thirty (30) days’ notice to
BIOGENETICS. Notwithstanding any other provision of this Agreement, during this Commercialization Wind-
Down Period, BIOGENETICS’ and its Affiliates’ rights with respect to the Products (including the licences
granted under Section 2.1) shall be non-exclusive, and ASLAN shall have the right to engage one or more other
partner(s) or distributor(s) of the Products in all or part of the Territory. The Products sold or disposed by
BIOGENETICS or its Affiliates during this Commercialization Wind-Down Period shall be subject to royalties
under Section 5.4 above. After the Commercialization Wind-Down Period, BIOGENETICS, and its Affiliates
shall not sell the Products or make any representation that, or implying that, they are a continuing licensee of or
distributor for ASLAN for the Products.
(b) If ASLAN wishes BIOGENETICS or its Affiliates terminate to distribute and sell the Products in the Territory
without the Wind-Down Period mentioned above, ASLAN or its designee(s) shall purchase all quantities of the
Product in BIOGENETICS’ or its Affiliates’ inventory at the price BIOGENETICS actually incurred to purchase
the quantities so provided to ASLAN within thirty (30) days after the effective date of termination.
BIOGENETICS agrees to fully cooperate with ASLAN and its designee(s) to facilitate a smooth, orderly and
prompt transition of the development and Commercialization of Products to ASLAN and/or its designee(s) during
the Commercialization Wind-Down Period. Without limiting the foregoing BIOGENETICS shall, subject to
applicable date privacy laws and its relevant contractual confidentiality obligations to Third Parties, promptly
provide ASLAN (i) copies of customer lists, customer data and other customer information relating to the Products
and (ii) (if applicable) manufacturing information (including protocols for the production, packaging, testing and
other manufacturing activities) relating to the Product in BIOGENETICS’ Control, which in each case ASLAN
shall have the right to use and disclose for any purpose during this Commercialization Wind-Down Period and
thereafter. Upon request by ASLAN, BIOGENETICS shall transfer to ASLAN all quantities of the Product in its
or its Affiliates’ Control (as requested by ASLAN), within thirty (30) days after the end of this Commercialization
Wind-Down Period; provided, however, that ASLAN shall reimburse BIOGENETICS for the costs that
BIOGENETICS actually incurred to manufacture or purchase the quantities so provided
22
to ASLAN, which in the case BIOGENETICS has manufactured such quantities of Product itself, shall be
BIOGENETICS’ fully-burdened manufacturing cost. If any Product was manufactured by any Third Party for
BIOGENETICS, or BIOGENETICS had contracts with vendors which contracts are necessary or reasonably
useful for ASLAN to take over responsibility for the Product in the Territory, then BIOGENETICS shall cooperate
to the extent reasonably possible and requested in writing by ASLAN, to assign all of the relevant Third-Party
contracts to ASLAN, and in any case, BIOGENETICS agrees to cooperate with ASLAN to ensure uninterrupted
supply of the Products. ASLAN shall be responsible for the reasonable costs of such assignment except in the case
of a termination of this Agreement by ASLAN pursuant to Section 11.3 or 11.5, in which case BIOGENETICS
shall be responsible for such costs. If BIOGENETICS or its Affiliate manufactured any Product at the time of
termination, then BIOGENETICS (or its Affiliate) shall continue to provide for manufacturing of such Product for
ASLAN, at its fully-burdened manufacturing costs therefor, from the date of notice of such termination until such
time as ASLAN is able, using diligent efforts to do so but no longer than the expiration of the Commercialization
Wind-Down Period, to secure an acceptable alternative commercial manufacturing source from which sufficient
quantities of the Product may be procured and legally sold in the Territory.
12.7.
Survival. Sections 5, 6, 7.11, 9, 10, 12 and 13.11 of this Agreement shall survive expiration or termination of this
Agreement for any reason. With respect to any termination or expiration of this Agreement, all rights and
obligations of the Parties under this Agreement shall terminate upon such expiration or termination, except to the
extent otherwise provided in this Article 12.
12.8.
Termination is not the sole remedy under this Agreement and, whether or not termination is effected, all other
remedies will remain available except as agreed to otherwise herein.
13.
GENERAL
13.1.
Assignment. This Agreement shall not be assignable by either Party to any Third Party hereto without the
written consent of the other Party hereto, not to be unreasonably withheld or delayed except to the extent
provided in Section 2.5 under this Agreement. If any permitted assignment would result in withholding or other
similar taxes becoming due on payments from the assigning Party to the other Party under this Agreement, the
assigning Party shall be responsible for all such taxes resulting from such assignment, and the amount of such
taxes shall not be withheld or otherwise deducted from any amounts payable to other Party. No assignment and
transfer shall be valid and effective unless and until the assignee/transferee agrees in writing to be bound by the
provisions of this Agreement. The terms and conditions shall be binding on and inure to the benefit of the
permitted successors and assigns of the Parties.
13.2.
Independent status of the Parties. The Parties to this Agreement are independent contractors and agree that the
relationship between the Parties shall not constitute a partnership, joint venture or agency. No Party shall have the
authority to make any statement, representation or commitment of any kind, or to take any action, which shall be
binding on the other Party, without the prior written consent of the other Party.
23
13.3.
13.4.
13.5.
13.6.
13.7.
Waiver. No delay or omission by a Party in exercising or availing itself of any right, power or privilege hereunder
shall preclude the later exercise of any such right, power or privilege by such Party. No waiver shall be effective
unless made in writing with specific reference to the relevant provision(s) of this Agreement and signed by a duly
authorized representative of the Party granting the waiver. Waiver by a Party of a breach hereunder by the other
Party shall not be construed as a waiver of any succeeding breach of the same or any other provision.
Force majeure. Neither Party shall be deemed to be in breach of this Agreement or otherwise liable to the other by
reasons of any delay in performance or non-performance of any of its obligations under this Agreement, to the
extent that such delay or non-performance is due to any event of force majeure, including without limitation any
wars, insurrections, strikes, acts of God, Governmental actions or controls or any other contingency beyond its
control. The Party whose performance of obligations has been delayed by force majeure shall use its best efforts to
overcome the effect of the force majeure event as soon as possible. The Party affected by the force majeure shall
notify immediately to the other Party the existence of the force majeure. The other Party shall have no right to
demand indemnity or damages as a result of the force majeure event. If the event of force majeure preventing
performance continues for more than six (6) months from the date of notice given pursuant thereto and such
suspension of performance would otherwise constitute a material breach under this Agreement, the non-force
majeure Party may terminate this Agreement, by giving written notice of termination to the other without liability to
any of the Parties, except the obligation to make any payments due up to such date under this Agreement.
Termination under this Section 13.4 shall be considered as termination under Section 11.3 provided that no Party
shall be entitled to damages or any other legal remedy in connection therewith.
Entire Agreement. This Agreement embodies all of the understandings and obligations between the Parties with
respect to the subject matter hereof, and supersedes, replaces and cancels all prior agreements or understandings
between the Parties with respect to the same.
Amendments. No amendments to this Agreement shall be valid unless executed in writing duly authorized
signatories of both Parties.
Notices. All notices, instructions and other communications hereunder or in connection herewith shall be in writing,
shall be sent to the address of the relevant Party set forth below and shall be (a) delivered personally, (b) sent via a
reputable international overnight courier service, or (c) sent by facsimile transmission with confirmation by
overnight courier. Any such notice, instruction or communication shall be deemed to be delivered by the sending
Party in the case of (a) actual receipt, (b) signature of the receipt by the receiving Party and (c) issuance of
electronic confirmation of receipt, if transmitted by facsimile (if such transmission is on a Business Day, or
otherwise, on the next Business Day following such transmission). Either Party may change its address by giving
notice to the other Party in the manner provided above. All notices shall be in English language. Additionally, all
information, documents and reports which ASLAN is required to provide or send to BIOGENETICS under this
Agreement, and which are not originally in English, shall be sent together with their applicable translation into
English.
24
(a)
If to ASLAN:
ASLAN Pharmaceuticals Pte Limited
83 Clemenceau Avenue
#12-03 UE Square
Singapore 239920
Attention: General Counsel
Fax No.: +65 6225 2419
If to BIOGENETICS:
(b)
BIOGENETICS CO., LTD
11th Liveplex Tower,
702 Eonju-ro,
Seoul,
Republic of Korea
Attention: Joohoon Ahn / CEO
Fax No.: + 82 2 2622 7799
13.8.
13.9.
13.10.
Severability. In the event any portion of this Agreement shall be held illegal, void or ineffective, the remaining
portion hereof shall remain in full force and effect and shall not be affected. If any of the terms or provisions of this
Agreement are in conflict with any applicable statute or rule of law, then such terms or provisions shall be deemed
inoperative to the extent they may conflict therewith and shall be deemed to be modified to conform to such statute
or rule of law. However, in case such invalidation or unenforceability injures the rights and interests of either Party,
the Parties hereto shall renegotiate the corresponding provisions of this Agreement in good faith.
Third-Party beneficiaries. None of the provisions of this Agreement shall be for the benefit of or enforceable by
any Third Party including, without limitation, any creditor of any Party hereto. No such Third Party shall obtain any
right under any provision of this Agreement or shall by reason of any such provision make any claim in respect of
any debt, liability or obligation (or otherwise) against any Party hereto.
Governing Law. This Agreement and any dispute arising from the performance or breach hereof shall be
governed, construed and enforced in accordance with the laws of Singapore, without regard or giving effect to the
conflicts of law principles thereof. The Parties expressly exclude application of the United Nations Convention for
the International Sale of Goods.
13.11.
Dispute Resolution.
(a)
Internal Resolution. Except as otherwise expressly provided herein, in the event of any controversy, claim or
other dispute arising out of or relating to any provision of this Agreement or the interpretation, enforceability,
performance, breach, termination or validity hereof (a “Dispute”), such Dispute shall be first referred to the Chief
Executive Officer (CEO) of each Party or the Person that each of them may delegate (such delegate being a senior
director or above), for resolution, prior to proceeding under the following provisions of this Section. For the
avoidance of doubt, this internal resolution proceeding shall not and cannot be used by any of the Parties as a way
to
25
modify the rights and obligations under the Agreement or as a way to modify the agreements already reached by
the Parties as they have been reflected in the Agreement. Any Parties’ resolution under this proceeding shall be
resolved in accordance with the terms and conditions of the Agreement and the rights and obligations of the
Parties as they are currently reflected in the Agreement. This internal resolution proceeding will be used as the
last resort for the Parties to avoid to enter into a dispute to be resolved by the arbitration proceeding below. A
Dispute shall be referred to such executives upon any Party providing the other Party with written notice that such
Dispute exists, and such executives, or their designees, shall attempt to resolve such Dispute through good faith
discussions, each Party acting reasonably, within sixty (60) Business Days of being referred to such executives.
(b) Arbitration. Except as otherwise agreed in writing, the Parties agree that any Dispute over any matter which has
not been resolved following the procedures set out in Section 13.11(a) must be finally resolved through a binding
arbitration which the Parties agree to accept in lieu of litigation or other legally available remedies (except for
injunctive relief where such relief is necessary to protect a Party from irreparable harm pending the outcome of
the arbitration). Any such arbitration shall be settled in Hong Kong International Arbitration Centre (“HKIAC”)
in accordance with its Rules of Arbitration by one (1) arbitrator chosen in accordance with said Rules. The
arbitration shall be conducted in English and will be held in Hong Kong. The award rendered by HKIAC shall be
binding and final upon the Parties.
13.12.
13.13.
13.14.
Use of Name. None of the Parties is entitled to use the corporate or commercial name of the other Party, for any
advertisement or promotional purposes without the prior written consent of the other Party.
Awareness. In this Agreement when a Party's liability for a statement is limited by the extent of its 'awareness', this
shall be construed to mean a level of awareness assuming reasonable enquiries have been made.
Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument.
14.
NEW COMMERCIAL ENTITY
14.1.
14.2.
The Parties acknowledge that ASLAN and BIOGENETICS may wish in the future to establish a new commercial
entity (the “Commercial JV Co”) intended to promote the introduction and Commercialization of oncology drugs
in the Territory.
If the Commercial JV Co is established, the financial and other terms and conditions set out in this Agreement
shall be reviewed and discussed by both parties and revised as mutually agreed. However the Parties agree to
negotiate in principle that:
(a) BIOGENETICS shall own a majority stake in the Commercial JV Co;
(b) ASLAN shall own a minority stake in the Commercial JV Co but shall have board representation; and
26
(c) ASLAN shall have a right (but not the obligation) to co-invest at each funding round for the Commercial JV Co at
a valuation per share (to be negotiated among ASLAN, BIOGENETICS and where relevant, other investors)
applying to other new investors in the Commercial JV in each funding round.
14.3.
Prior to establishing the Commercial JV, ASLAN and BIOGENETICS shall enter into a separate definitive
agreement setting forth among others, the ownership structure described in Section 14.2 above, the rights and
obligations of ASLAN and BIOGENETICS and other terms.
15.
BUY-BACK OPTION
15.1.
15.2.
15.3.
ASLAN reserves the right any time between the Effective Date and the date of first submission of an NDA to the
MFDS for Products in the Territory, to revoke the rights granted to BIOGENETICS pursuant to this Agreement
without any liability, subject to ASLAN complying with the terms set out below ("Buy-Back Option").
ASLAN may exercise the Buy-Back Option by giving thirty (30) days' written notice (or such shorter period as the
Parties may agree) to this effect ("Buy-Back Notice") to BIOGENETICS. The Buy-Back Notice shall specify: (i)
the effective date of the revocation effected by the Buy-Back Option, and (ii) the amount to be paid by ASLAN to
BIOGENETICS in accordance with Sections 15.3 or 15.4 (as applicable).
In the event ASLAN has agreed detailed terms with a Third Party for a major international licensing deal for
ASLAN003, in respect of which the territories covered by the licence include at least the USA, the European
Union and either or both of China or Japan) (“Global Deal”), then once the Buy-Back Option has been exercised
and the Global Deal has been entered into, ASLAN shall pay to BIOGENETICS the following sums:
(a)
(b)
a sum equal to the Total Amount Paid multiplied by a factor of one point two (1.2), the resulting amount
payable within thirty (30) days of the BIOGENETICS’s invoice for the same; and the “Total Amount Paid”
shall mean the aggregate of: accumulated Clinical Trial Costs Contributions, plus the Initial Payment pursuant
to Section 5.1, plus milestones paid pursuant to Section 5.3, all as actually paid by BIOGENETICS and
received by ASLAN, plus sums actually paid by BIOGENETICS in relation to Regulatory Filings, all as shall
have occurred between the Effective Date and the date of the Buy-Back Notice; and
a sum equal to two per cent (2%) of the upfront payment actually received by ASLAN from the Global Deal
(“the Share of Upfront”). ASLAN undertakes to inform BIOGENETICS within thirty (30) days of receipt of
such upfront payment that it has received the same, providing adequate details for the purposes of this Section,
and, upon receiving BIOGENETICS’s correct invoice for the Share of Upfront, to pay the Share of Upfront to
BIOGENETICS within thirty (30) days; and
(c)
thereafter, two per cent (2%) of all royalties and sales milestones actually received by ASLAN from the Global
Deal.
15.4.
In the absence of ASLAN agreeing the detailed terms of a Global Deal with a Third Party, then once the Buy-Back
Option has been exercised ASLAN shall pay to BIOGENETICS the following sum:
(a)
a sum equal to the Total Amount Paid (as defined in Section 15.3(a)) multiplied by a factor of one point five
(1.5), the resulting amount payable within thirty (30) days of the BIOGENETICS’s invoice for the same.
27
15.5.
Upon exercise by ASLAN of the Buy-Back Option in accordance with Section 15.2, and subject to any
Commercialization arrangements with Third Parties entered into with ASLAN's consent and approval: (i) all
licences granted to BIOGENETICS under Section 2 shall cease; (ii) BIOGENETICS shall cease all exploitation of
the Licensed Technology; (iii) BIOGENETICS shall promptly return to ASLAN, at ASLAN's expense or, if
ASLAN so elects, permanently delete, all records and copies (including electronic copies) of the Licensed
Technology, of technical material in its possession relating to the Products, and of any information (whether or not
technical) of a confidential nature communicated to it by ASLAN, either in contemplation or as a result of this
Agreement; and (iv) within ninety (90) days after the date of revocation specified in the Buy-Back Notice
BIOGENETICS shall promptly destroy or, if ASLAN shall so elect, deliver to ASLAN or any other person
designated by ASLAN, at ASLAN's expense, all Product(s) that BIOGENETICS has not disposed of within 90
days after the date of termination. BIOGENETICS agrees (at ASLAN's cost) to execute such documents and do
all such acts and things as ASLAN may deem desirable or necessary pursuant to its exercise of its rights under this
Section 15.5.
IN WITNESS WHEREOF, the Parties have executed this Agreement in duplicate originals by their duly authorized representatives as of the date
and year first above written.
Each person executing this Agreement on behalf of a Party represents and warrants his / her capacity and authority to do so.
ASLAN PHARMACEUTICALS PTE LTD
By:
Name:
Title:
/s/ Carl Firth
Carl Firth
CEO
Date: 11th March 2019
BIOGENETICS CO., LTD
By:
Name:
Title:
/s/ Joohoon Ahn
Joohoon Ahn
CEO
Date: 11th March 2019
28
[…***…]
Schedule 1
29
[…***…]
Schedule 2
30
Subsidiaries of ASLAN Pharmaceuticals Limited
Exhibit 8.1
Name of Subsidiary
ASLAN Pharmaceuticals Pte. Ltd.*
ASLAN Pharmaceuticals Taiwan Limited
((cid:0)(cid:0)(cid:0)(cid:0)(cid:0)(cid:0)(cid:0)(cid:0)(cid:0))**
ASLAN Pharmaceuticals Pty Ltd**
ASLAN Pharmaceuticals Hong Kong Limited
((cid:0)(cid:0)(cid:0)(cid:0)(cid:0)(cid:0)(cid:0)(cid:0)(cid:0)(cid:0)(cid:0))**
ASLAN Pharmaceuticals (Shanghai) Co. Ltd.
((cid:0)(cid:0)(cid:0)(cid:0)(cid:0)(cid:0)(cid:0) ((cid:0)(cid:0)) (cid:0)(cid:0)(cid:0)(cid:0))***
ASLAN Pharmaceuticals (USA) Inc.**
*
Wholly owned by ASLAN Pharmaceuticals Limited
** Wholly owned by ASLAN Pharmaceuticals Pte. Ltd.
*** Wholly owned by ASLAN Pharmaceuticals Hong Kong Limited
Jurisdiction of Incorporation or Organization
Singapore
Taiwan
Australia
Hong Kong
People’s Republic of China
United States
Exhibit 12.1
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Carl Firth, certify that:
1.
2.
3.
4.
I have reviewed this annual report on Form 20-F of ASLAN Pharmaceuticals Limited;
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;
The company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the company and have:
(a)
(b)
(c)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us
by others within those entities, particularly during the period in which this report is being prepared;
Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered
by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over
financial reporting; and
5.
The company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):
(a)
(b)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and
Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s
internal control over financial reporting.
Date: April 29, 2019
By:
/s/ Carl Firth, Ph.D.
Carl Firth, Ph.D.
Chief Executive Officer and Chairman
(Principal Executive Officer)
Exhibit 12.2
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Kiran Asarpota, certify that:
1.
2.
3.
4.
I have reviewed this annual report on Form 20-F of ASLAN Pharmaceuticals Limited;
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects
the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this report;
The company’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the company and have:
(a)
(b)
(c)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us
by others within those entities, particularly during the period in which this report is being prepared;
Evaluated the effectiveness of the company’s disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
Disclosed in this report any change in the company’s internal control over financial reporting that occurred during the period covered
by the annual report that has materially affected, or is reasonably likely to materially affect, the company’s internal control over
financial reporting; and
5.
The company’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
to the company’s auditors and the audit committee of the company’s board of directors (or persons performing the equivalent functions):
(a)
(b)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the company’s ability to record, process, summarize and report financial information; and
Any fraud, whether or not material, that involves management or other employees who have a significant role in the company’s
internal control over financial reporting.
Date: April 29, 2019
By:
/s/ Kiran Asarpota
Kiran Asarpota
Vice President of Finance
(Principal Financial Officer and
Principal Accounting Officer)
Exhibit 13.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter
63 of Title 18 of the United States Code (18 U.S.C. §1350), Carl Firth, Ph.D., Chief Executive Officer and Chairman of ASLAN Pharmaceuticals Limited (the
“Company”), hereby certifies that, to the best of his knowledge:
1.
2.
The Company’s Annual Report on Form 20-F for the year ended December 31, 2018, to which this Certification is attached as Exhibit 13.1 (the
“Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
Company.
Date: April 29, 2019
By:
/s/ Carl Firth, Ph.D.
Carl Firth, Ph.D.
Chief Executive Officer and Chairman
(Principal Executive Officer)
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter
63 of Title 18 of the United States Code (18 U.S.C. §1350), Kiran Asarpota, Vice President of Finance of ASLAN Pharmaceuticals Limited (the “Company”),
hereby certifies that, to the best of his knowledge:
1.
2.
The Company’s Annual Report on Form 20-F for the year ended December 31, 2018, to which this Certification is attached as Exhibit 13.2 (the
“Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the
Company.
Exhibit 13.2
Date: April 29, 2019
By:
/s/ Kiran Asarpota
Kiran Asarpota
Vice President of Finance
(Principal Financial Officer and
Principal Accounting Officer)